Ticker,Drug,Indication,Stage,Date,Catalyst,Shares_Millions,Market_Cap,Volatility,Share_Price_D-1,Share_Price_D1,Share_Price_D5,Perc_Return_D1,Perc_Return_D5,XBI_Return_D1,XBI_Return_D5,Short_Interest_Pct,Year_Beta,Daily_Volum_Traded,row_id,has_endpoint,has_pvalue,has_effect,has_safety,has_sample,has_phase,has_partner,has_regulatory,has_financial,has_enrollment,has_clinical,has_catalyst,pos_count,neg_count,neu_count,headline_sentiment,TARGET,input_ids,token_type_ids,attention_mask,labels
IONS,Zilganersen (ION373),Alexander diseaseÂ ,Phase 1,2024-10-01,"Fast track designation granted by FDA, noted October 1, 2024.",159.0,6154.51136,39.2138,40.06,39.07,37.8,-0.025023421,-0.058069228,0.00721218,0.017356229,6.73813,0.04177,65.97454,2087,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 13227  1854  7970  3609  1118 18762   117  2382  1357   122   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,2024-10-01,"FDA granted Breakthrough Therapy designation, noted October 1, 2024.",32.0,99.57133,92.2927,2.77,3.12,3.965,0.118985682,0.358658535,0.00721218,0.017356229,6.47174,0.12705,136.77682,2088,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  3609 15835  1582 14929 23789  7970   117  2382  1357   122
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-GBM),GliomaÂ ,Phase 2b,2024-10-01,"Phase 2b data from CNS reported a statistically significant reduction in tumor volume rate change was seen in tumors receiving > 100 Gy absorbed dose, noted October 1, 2024.",99.0,7.7242,86.8029,1.46,1.31,1.35,-0.108409299,-0.078331843,0.00721218,0.017356229,0.89364,0.1373,0.19353,2089,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  1830  2233  1121   140 12412  2103   170 11435  1193
  2418  7234  1107 14601  3884  2603  1849  1108  1562  1107 24309  4172
   135  1620   144  1183  8761 13753   117  2382  1357   122   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,2024-10-01,"Phase 2 data showed a complete 100% resolution of brain metastasis in the right temporal lobe after 8 and 11 months of treatment. The patient, who also experienced marked reduction of an orbital tumor",1.0,38.3468,135.2269,185.99991,121.49994,161.99992,-0.425832421,-0.138150348,0.00721218,0.017356229,0.0,0.0,32.54412,2090,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2799   170  2335  1620   110  6021  1104  3575
 27154  8419  4863  1107  1103  1268 18107 25163  1170   129  1105  1429
  1808  1104  3252   119  1109  5351   117  1150  1145  4531  3597  7234
  1104  1126 16488 14601   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,2024-10-01,"Phase 3 OnTarget trial showed statistical significance for crofelemer in a prespecified subgroup of breast cancer patients for the prophylaxis of cancer therapy-related diarrhea, noted October 1, 2024",2.0,11.36671,199.6915,33.75,30.75,32.25,-0.093090423,-0.045462374,0.00721218,0.017356229,4.01091,0.00141,0.81863,2091,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  1212  1942  1813 16609  3443  2799 11435  7467  1111
   172  2180  8124 14183  1200  1107   170  3073 20080 10294  6202 23470
  1104  7209  4182  4420  1111  1103 21146 18873  7897  1548  1104  4182
  7606   118  2272  4267  1813  1197 13836   117  2382  1357   122   117
 17881  1527   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATHE,ATH434-202 - (biomarker data),Multiple System Atrophy (MSA)Â ,Phase 2,2024-10-02,"Phase 2 interim data from MDS reported that at 6 months all participants exhibited brain volume declines consistent with MSA progression; however, the clinical responders maintained stable brain volum",15.0,21.28134,85.9902,1.375,1.43,1.31,0.039220713,-0.048426594,0.013668575,0.017089154,0.0,0.0,0.03376,2092,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 10572  2233  1121  9292  1708  2103  1115  1120   127
  1808  1155  6635  7799  3575  3884  6246  1116  8080  1114 10978  1592
 16147   132  1649   117  1103  7300  6297  1468  4441  6111  3575 10857
  1818   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PDSB,PDS0101 and chemoradiotherapy - (IMMUNOCERV),Cervical cancerÂ ,Phase 2,2024-10-02,"Phase 2 data presented at ASTRO showed 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in fully treated patients. Notably, 88% of patients achieved a complete metabolic r",46.0,151.32942,75.8709,3.65,4.11,3.4,0.118695861,-0.070951736,0.013668575,0.017089154,12.51734,0.18477,5.69641,2093,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101 12278   123  2233  2756  1120 15278 23313  2346  2799  1620   110
  3164   118  2370  2905  8115   113 11570   114  1105 16147   118  1714
  8115   113   153 17691   114  5600  1107  3106  5165  4420   119  1753
  5382   117  5385   110  1104  4420  3890   170  2335 25158   187   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RXRX,REC-1245 - (DAHLIA),Solid tumorsÂ ,IND-Enabling,2024-10-02,"IND cleared by the FDA, noted October 2, 2024.",434.0,1716.71617,71.2619,6.17,6.11,6.15,-0.009772065,-0.003246756,0.013668575,0.017089154,21.05662,0.21784,29.10744,2094,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1357   123   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATYR,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosisÂ ,Phase 1/2,2024-10-02,Additional Phase 1b/2a data from post hoc analysis emonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs su,97.0,134.91723,60.5118,1.72,1.78,2.11,0.034289073,0.204363657,0.013668575,0.017089154,0.90477,0.04272,0.84088,2095,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101  8154 12278   122  1830   120   123  1161  2233  1121  2112 16358
  1665  3622  9712  4199 18775  1181 11435  1193  2418  3719  1107  1159
   118  1106   118  1148   118  1231 16046  2217  1111  1884  3740 10658
  4648  7874  1329  1107 20340   113   124   119   121  1105   126   119
   121 17713   120  4023   174  2087  6112 14067 12013  1181   114  5016
 28117   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
URGN,UGN-103 - (UTOPIA),Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerÂ ,Phase 3,2024-10-02,"Phase 3 trial dosing initiated, noted October 2, 2024.",46.0,529.795,69.8373,12.48,12.58,11.89,0.007980888,-0.048429652,0.013668575,0.017089154,15.12399,0.09377,2.58367,2096,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124  3443 18463  1158  7087   117  2382  1357   123   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KZIA,Paxalisib (GDC-0084) with radiotherapy,Brain MetastasesÂ ,Phase 1,2024-10-02,"Phase 1 data at the 2024 ASTRO Annual Meeting showed a 67% partial response (PR) in patients treated with 45mg paxalisib combined with radiotherapy, noted October 2, 2024.",1.0,13.00182,239.1125,21.55,21.82,19.8,0.012451164,-0.084693879,0.013668575,0.017089154,5.3867,0.0021,0.77636,2097,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  1120  1103 17881  1527 15278 23313  2346  8451
 12505  2799   170  5486   110  7597  2593   113 11629   114  1107  4420
  5165  1114  2532  1306  1403   185  7897 14200 13292  3490  1114  2070
  8420 11478  1183   117  2382  1357   123   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMMX,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL AmyloidosisÂ ,Phase 1/2,2024-10-02,Phase 1b/2 data presented at ASGCT showed that study is now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed.Th,28.0,40.0777,78.1699,1.48,1.46,1.54,-0.013605652,0.039740329,0.013668575,0.017089154,1.74749,0.06936,0.4811,2098,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123  2233  2756  1120 15278 13478  1942
  2799  1115  2025  1110  1208 18463  1158  1120 13753  4298  1634  1104
 10181  1550   151  3190  1658   118 17365  8784  2069   116   157  3652
   119  1752  1884 13252  1204  1120  4214  1550  8784  2069   116   157
  3652  1640  4358  2063   119   157  1324   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BMY,Opdivo (nivolumab) - (CheckMate -77T),Non-metastatic non-small cell lung cancerÂ ,Approved,2024-10-03,"Approved October 3, 2024.",0.0,109884.8187,30.2519,53.76,54.2,52.4,0.008151212,-0.025623105,0.005930488,0.019248188,1.07488,0.01025,834.59556,2099,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357   124   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ABVX,Obefazimod,Ulcerative ColitisÂ ,Phase 2b,2024-10-03,"Phase 2b OLM data reported clinical remission and a safety profile consistent with prior studies of oral, once-daily obefazimod when administered at a reduced dose of 25mg for up to an additional two",77.0,573.34599,41.4843,9.3,9.06,8.17,-0.02614528,-0.129545491,0.005930488,0.019248188,0.0,0.17672,0.36258,2100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830   152 22074  2233  2103  7300  1231 11234  1105
   170  3429  6168  8080  1114  2988  2527  1104  9619   117  1517   118
  3828   184  3962  8057  5303  3702  1181  1165  8318  1120   170  3549
 13753  1104  1512  1306  1403  1111  1146  1106  1126  2509  1160   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RNA,del-desiran (AOC 1001) - (HARBOR),Myotonic dystrophy type 1 (DM1)Â ,Phase 3,2024-10-03,"Phase 3 partial clinical hold removed by the FDA, noted October 3, 2024.",128.0,5510.56173,70.8271,47.12,47.05,44.22,-0.001486673,-0.063520364,0.005930488,0.019248188,10.22823,0.10401,59.88924,2101,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1,neg,"[  101 12278   124  7597  7300  2080  2856  1118  1103 18762   117  2382
  1357   124   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PHVS,Bradykinin B2 receptor - (CHAPTER-1),Hereditary angioedema (HAE) attacksÂ ,Phase 2,2024-10-03,"Phase 2 OLE long term safety data to be presented on October 5, 2024.",54.0,966.19795,70.8477,18.32,17.89,17.83,-0.023751462,-0.027110927,0.005930488,0.019248188,1.19026,0.07182,0.40025,2102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   152 17516  1263  1858  3429  2233  1106  1129  2756
  1113  1357   126   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IONS,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE)Â ,Phase 2,2024-10-03,Phase 2 new 3 year OLE data that continues to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing,159.0,5956.02955,39.432,39.38,37.81,37.95,-0.040684455,-0.036988569,0.005930488,0.019248188,6.73813,0.04177,87.00032,2103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1207   124  1214   152 17516  2233  1115  3430  1106
 10541  1274 13293 18649  1179  3209  1106  7852  2418  1105  8505  7234
  1116  1107   145  1592  2036  3690  1146  1106  1210  1201  1114  7868
  1137  1451  1160   118  2370 18463  1158   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TOVX,SYN-004 (Ribaxamase),Allogeneic hematopoietic cell transplantation (HCT) for the prevention of acute graft-versus-host-disease (aGVHD)Â ,Phase 1/2,2024-10-03,"Phase 1b/2 DSMC positive review with 15 SAEs were reported among 10 patients, with the most common SAE being infections and infestations, including sepsis, noted October 3, 2024.",9.0,4.06771,153.5302,1.24,1.79,1.56,0.36710424,0.229574442,0.005930488,0.019248188,4.00376,0.02115,137.23093,2104,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123 18448 10044  3112  3189  1114  1405
 13411 27485  1127  2103  1621  1275  4420   117  1114  1103  1211  1887
 13411  2036  1217 16565  1105  1107 17695  6006   117  1259 14516 17990
   117  2382  1357   124   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMRN,"CampETEC HBC product, ProMilk 85, C. jejuni CG8421 Challenge strain","Campylobacter and Enterotoxigenic Escherichia coli (ETEC), Healthy VolunteersÂ ",Phase 2,2024-10-04,"Phase 2 data reported a 10.4% protective efficacy against moderate to severe campylobacteriosis following challenge with Campylobacter compared to the placebo group, noted October 4, 2024.",6.0,22.79984,70.533,2.7377,2.69,2.2,-0.017576958,-0.218660791,0.003212937,-0.020889557,0.0,0.0,0.0141,2105,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103   170  1275   119   125   110  9760 23891
  1222  8828  1106  5199  3227  7777 12809 11179  9866 11776  1378  4506
  1114  5503  7777 12809 11179  1200  3402  1106  1103  1282  4043  1372
   117  2382  1357   125   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMY,Neoadjuvant Opdivo (nivolumab) and Chemotherapy,Stage IIA to IIIB non-small cell lung cancer (NSCLC)Â ,Approved,2024-10-04,"Approved October 4, 2024.",0.0,109398.2438,30.1824,54.2,53.96,52.2,-0.004437877,-0.037598414,0.003212937,-0.020889557,1.07488,0.00876,692.40852,2106,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357   125   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RARE,UX701 - (Cyprus2+),Wilson DiseaseÂ ,Phase 1/2,2024-10-04,"Phase 1/2/3 data reported that six of the patients have completely tapered off of standard-of-care treatment with chelators and/or zinc therapy, and a seventh patient has begun to taper as of the data",96.0,4954.06583,44.6877,53.66,53.79,55.1,0.002419731,0.026481871,0.003212937,-0.020889557,3.92457,0.15955,41.9008,2107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123   120   124  2233  2103  1115  1565  1104
  1103  4420  1138  2423  6649  4359  1228  1104  2530   118  1104   118
  1920  3252  1114 22572  9945  5067  1105   120  1137 19159  7606   117
  1105   170  5001  5351  1144  4972  1106  6649  1197  1112  1104  1103
  2233   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BDRX,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM)Â ,Phase 1,2024-10-04,"Phase 1 open label data reported that Patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively, noted October 4, 2024.",0.0,3.22361,186.2313,60.075,55.5,52.5,-0.079210761,-0.134780612,0.003212937,-0.020889557,0.56046,0.09213,0.49811,2108,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1501  3107  2233  2103  1115  7195 24767   108   122
  1105   108   123  1138 10281  1114  2905  8115   113 11570   114  1290
  1838  1104  3252  1104  1367  1808  1105  1492  1808   117  3569   117
  2382  1357   125   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KZR,Zetomipzomib - (PALIZADE),Lupus nephritisÂ ,Phase 2b,2024-10-04,"Phase 2b IND placed on clinical hold, noted October 4, 2024.",7.0,58.18737,69.3725,8.256,7.975,8.476,-0.03462856,0.026298432,0.003212937,-0.020889557,1.18641,0.12323,1.04055,2109,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1,pos,"[  101 12278   123  1830 15969  2137  1973  1113  7300  2080   117  2382
  1357   125   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PHVS,Bradykinin B2 receptor - (CHAPTER-1),Hereditary angioedema (HAE) attacksÂ ,Phase 2,2024-10-05,Phase 2 OLE long term safety data reported that the attack rate remained low through >1.5 years. An early-onset reduction of attack rate in participants switching from placebo to deucrictibant 40 mg/d,54.0,982.94034,70.8888,18.2,18.2,19.73,0.0,0.080718726,0.01217514,-0.011927355,1.19026,0.07215,0.0,2110,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123   152 17516  1263  1858  3429  2233  2103  1115  1103
  2035  2603  1915  1822  1194   135   122   119   126  1201   119  1760
  1346   118 15415  7234  1104  2035  2603  1107  6635 12806  1121  1282
  4043  1106  1260 21977  4907  3121  7167  1204  1969 17713   120   173
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SRRK,Apitegromab - (SAPPHIRE),Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Â ,Phase 3,2024-10-07,"Phase 3 study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expande",96.0,2743.51832,225.1463,7.42,34.28,28.52,1.530383037,1.346426538,0.004213562,-0.015871734,20.76753,0.05797,1462.64992,2111,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2025  1899  1157  2425  1322  7587   117 15107   170
 11435  1193  2418  1105  7300  1193 17119  8331  1107  5968  3053   117
  1112  7140  1118  1103 14473 11195 16068 17264  8226 20334 16409 10224
  2007   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RARE,UX143 (setrusumab) - (Orbit),Osteogenesis ImperfectaÂ ,Phase 2/3,2024-10-07,"Breakthrough Therapy Designation granted by the FDA, noted October 7, 2024.",96.0,4828.80966,44.0932,53.79,52.43,56.19,-0.02560863,0.043651229,0.004213562,-0.015871734,3.92457,0.15955,34.70756,2112,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 15835  1582 14929 23789  4800  1891  3609  1118  1103 18762   117
  2382  1357   128   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,2024-10-07,"Preclinical data demonstrated improvements in motor and cognitive function, which persisted even after the treatment was discontinued, suggesting a lasting neuroprotective effect, noted October 7, 202",35.0,54.51821,111.962,1.82,2.135,2.35,0.159630146,0.255578827,0.004213562,-0.015871734,2.27244,0.03325,1.27708,2113,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  7160  8313  1107  5968  1105 12176
  3053   117  1134 20702  1256  1170  1103  3252  1108  8779   117  8783
   170  9810 24928 11955  1643 21020 13851  2629   117  2382  1357   128
   117 17881   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BFRI,Ameluz (aminolevulinic acid HCI) Topical Gel - (3 tubes),Actinic keratosis (AK)Â ,Approved,2024-10-07,"Approved October 7, 2024.",10.0,4.81732,113.2554,0.96,0.869,0.819,-0.099590159,-0.158849201,0.004213562,-0.015871734,2.42366,0.00138,2.25428,2114,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357   128   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VINC,VIP943 (anti-CD123),Hematologic malignanciesÂ ,Phase 1,2024-10-07,"Phase 1 data demonstrated a favorable safety profile with no dose-limiting toxicities, noted October 7, 2024.",5.0,21.55487,228.0176,14.6,13.96,8.1,-0.044825431,-0.589157467,0.004213562,-0.015871734,1.30491,0.02982,3.73196,2115,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  2233  7160   170 11169  3429  6168  1114  1185 13753
   118 15816 12844  4233   117  2382  1357   128   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BDTX,BDTX-4933,Brain tumors harboring all-class BRAF or RAS mutationsÂ ,Phase 1,2024-10-07,"Phase 1 deprioritized, looking for a partnership to continue program, noted October 7, 2024.",56.0,206.80792,88.4853,3.75,3.66,3.48,-0.024292693,-0.074723546,0.004213562,-0.015871734,10.36932,0.06589,2.33482,2116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1260  1643  8558  7729  2200   117  1702  1111   170
  5210  1106  2760  1788   117  2382  1357   128   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KRRO,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD)Â ,Preclinical,2024-10-07,"Preclinical data from the Oligonucleotide Therapeutics Society reported that treatment achieved AAT levels between MM and MZ in rodents as early as Week 1, noted October 7, 2024.",9.0,333.45551,81.835,33.59,35.86,39.25,0.065394065,0.155723041,0.004213562,-0.015871734,2.72114,0.05455,2.58773,2117,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  1121  1103   152  2646  7528 21977
 26918 23767  1109 14543 14272  7376  2015  2103  1115  3252  3890 10419
  1942  3001  1206   150  2107  1105   150  5301  1107  8335  5240  1112
  1346  1112  6237   122   117  2382  1357   128   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AZN,Airsupra (albuterol/budesonide) - (BATURA),Severe exacerbations in patients with intermittent or mild persistent asthmaÂ ,Phase 3,2024-10-07,"Phase 3 trial met primary endpoint, noted October 7, 2024.",0.0,183089.7991,18.289,117.38,118.1,119.36,0.006115188,0.016727601,0.004213562,-0.015871734,0.0,0.07857,144.0931,2118,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  1899  2425  1322  7587   117  2382  1357   128
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MRK,KEYTRUDA (pembrolizumab) - (KEYNOTE-689),Head and Neck Squamous Cell CarcinomaÂ ,Phase 3,2024-10-08,"Phase 3 trial met its primary endpoint, noted October 8, 2024.",0.0,275077.5065,23.1036,108.59,108.52,111.53,-0.000644834,0.026714291,0.000207641,-0.030466474,0.97893,0.0584,958.49368,2119,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  1899  1157  2425  1322  7587   117  2382  1357
   129   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SAGE,Dalzanemdor (SAGE-718) - (LIGHTWAVE),Mild cognitive impairment and mild dementia due to ADÂ ,Phase 2,2024-10-08,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n",62.0,104432.4708,84.6431,14.0,13.0,13.0,-0.074107972,-0.074107972,0.000207641,-0.030466474,0.0,1e-05,7.8585,2120,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   123  1499  2568  2233  2103  1115  1103  3443  1225  1136
 10541   170 11435  1193  2418  3719  1121  2259  2568  1107  6635  5165
  1114  5358  1233 14883  5521  8380  6055  1282  4043  1113  1103  2425
  1322  7587   117   183   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SUPN,Dalzanemdor (SAGE-718) - (LIGHTWAVE),Mild cognitive impairment and mild dementia due to ADÂ ,Phase 2,2024-10-08,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n",56.0,1790.92508,34.3581,32.06,32.5,33.52,0.013630942,0.044533128,0.000207641,-0.030466474,12.33641,0.07172,11.1073,2121,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   123  1499  2568  2233  2103  1115  1103  3443  1225  1136
 10541   170 11435  1193  2418  3719  1121  2259  2568  1107  6635  5165
  1114  5358  1233 14883  5521  8380  6055  1282  4043  1113  1103  2425
  1322  7587   117   183   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AVTX,AVTX-009 (anti-IL-1Î² mAb) - (LOTUS),Hidradenitis suppurativa (HS)Â ,Phase 2,2024-10-08,"Phase 2 patient dosing commenced, noted October 8, 2024",13.0,93.24126,97.2843,9.6325,9.63,9.69,-0.000259572,0.005951628,0.000207641,-0.030466474,0.61421,0.00251,0.19538,2122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  5351 18463  1158  8042   117  2382  1357   129   117
 17881  1527   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BIIB,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA)Â ,Phase 2/3,2024-10-08,"Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naÃ¯ve to nusinersen, noted October 8, 2024.",146.0,26554.11734,26.6596,183.34,182.3,191.55,-0.005688671,0.043806519,0.000207641,-0.030466474,2.51806,0.17802,220.16772,2123,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123   120   124  2686  2103  7300  6245  1104   170  2299
 13753  6716  1179  1104   183  1361 16167  3792   113  1851   120  1743
 17713   114  1107  1241  2833  2331  5165  1105  3252   118   100  1106
   183  1361 16167  3792   117  2382  1357   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IONS,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA)Â ,Phase 2/3,2024-10-08,"Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naÃ¯ve to nusinersen, noted October 8, 2024.",159.0,5954.4543,39.179,37.86,37.8,37.84,-0.001586043,-0.000528402,0.000207641,-0.030466474,6.73813,0.04269,54.99265,2124,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   120   124  2686  2103  7300  6245  1104   170  2299
 13753  6716  1179  1104   183  1361 16167  3792   113  1851   120  1743
 17713   114  1107  1241  2833  2331  5165  1105  3252   118   100  1106
   183  1361 16167  3792   117  2382  1357   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BPTH,BP1001-A (Prexigebersen-A),Obesity in Type 2 diabetes patientsÂ ,Phase 1,2024-10-08,"Phase 1 initiated, noted October 8, 2024.",8.0,3.03711,133.3564,0.8513,1.19,1.15,0.334943993,0.300752628,0.000207641,-0.030466474,0.64063,0.01153,78.14987,2125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  7087   117  2382  1357   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
OGEN,ONP-002,Moderate-to-severe concussion in the acute through subacute phasesÂ ,Phase 2,2024-10-08,"Phase 2 data reported that the drug spreads well in the areas of the nose where it can be quickly absorbed into the brain, noted October 8, 2024.",4.0,3.11726,180.0142,11.89622,10.80108,8.9559,-0.096574573,-0.28390817,0.000207641,-0.030466474,2.01454,0.03634,0.68377,2126,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1115  1103  3850 23237  1218  1107  1103
  1877  1104  1103  3678  1187  1122  1169  1129  1976  8761  1154  1103
  3575   117  2382  1357   129   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PHIO,INTASYL,Hematological malignanciesÂ ,Preclinical,2024-10-08,"Preclinical data shared at the Oligonucleotide Therapeutics Society (OTS) Meeting showed that compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-",5.0,2.41863,93.1654,2.89,2.81,2.76,-0.028072019,-0.046025822,0.000207641,-0.030466474,1.98194,0.07377,0.08766,2127,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  3416  1120  1103   152  2646  7528
 21977 26918 23767  1109 14543 14272  7376  2015   113   152 11365   114
 12505  2799  1115 10071  1145  4607  1103 16354  1105 13950  1104 11258
  2109  2765  1103 14543  1905  1216  1112   151  2428   117   157 17656
  1105  8784  2069   118   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PTCT,Vatiquinone - (MOVE-FA),Friedreich ataxiaÂ ,Phase 3,2024-10-08,"Phase 3 trial met pre-specified endpoint for two different FA long-term extension studie with highly statistically significant evidence of durable treatment benefit on disease progression, noted Octob",79.0,3136.19841,60.0343,34.99,40.77,37.56,0.15288421,0.070877348,0.000207641,-0.030466474,6.79174,0.15938,89.21964,2128,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   124  3443  1899  3073   118  9467  1322  7587  1111  1160
  1472  6820  1263   118  1858  4973 24084  1663  1114  3023 11435  1193
  2418  2554  1104  3840  9739  3252  5257  1113  3653 16147   117  2382
 14125 12809   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TVGN,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19Â ,Phase 1,2024-10-08,"Phase 1 data published at the Blood Advances Journal showed that all patients treated with TVGN 489 returned to baseline health within 14 days, with no evidence of reinfection or Long COVID during a s",196.0,53.56605,127.9916,0.3195,0.3139,1.37,-0.01768281,1.455808745,0.000207641,-0.030466474,0.40429,0.00038,0.47203,2129,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2233  1502  1120  1103  5657 25308  3603  2799  1115
  1155  4420  5165  1114  1794  2349  2249  3615  1580  1608  1106  2259
  2568  2332  1439  1489  1552   117  1114  1185  2554  1104  1231  1394
 11916  1988  1137  3261 18732 23314  2137  1219   170   188   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
INSM,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE)Â ,Phase 3,2024-10-08,"Phase 3 additional data presented at CHEST 2024 showed that treatment was well-tolerated, noted October 8, 2024.",211.0,12264.87048,117.6589,70.5,71.37,74.66,0.012264903,0.057331764,0.000207641,-0.030466474,7.10983,0.00027,73.75761,2130,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2509  2233  2756  1120 24890  9919  1942 17881  1527
  2799  1115  3252  1108  1218   118 21073  1181   117  2382  1357   129
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TEVA,Prolia (denosumab) biosimilar - (TVB-009P),OsteoporosisÂ ,Approved,2024-10-08,"FDA biosimilar approved on October 8, 2024.",0.0,19861.35672,34.1194,17.28,17.53,18.15,0.014363936,0.049120797,0.000207641,-0.030466474,2.67798,0.1971,80.28707,2131,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 18762 25128  5053  3080  5815  4092  1113  1357   129   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GSK,Arexvy (60+ at increased risk) - (AReSVi-006),"Respiratory Syncytial Virus Vaccine, AdjuvantedÂ ",Phase 3,2024-10-08,"Phase 3 data presented at CHEST showed that trial met primary endpoint, noted October 8, 2024.",0.0,59267.69295,22.3035,14.8,14.53,14.94,-0.018411703,0.009414999,0.000207641,-0.030466474,0.0,0.03746,111.95792,2132,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2233  2756  1120 24890  9919  1942  2799  1115  3443
  1899  2425  1322  7587   117  2382  1357   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CLSD,CLS-AX - (ODYSSEY),Neovascular age-related macular degeneration (wet AMD)Â ,Phase 2b,2024-10-09,"Phase 2b with topline data reported that the trial achieved both its primary and secondary outcomes. noted October 9, 2024.",5.0,97.91669,72.9885,22.19999,19.64999,16.79999,-0.122015009,-0.278713547,0.009104139,-0.031925691,0.34947,0.11206,24.17075,2133,0,0,0,0,0,1,0,0,1,0,1,0,3,0,0,1,neg,"[  101 12278   123  1830  1114  1499  2568  2233  2103  1115  1103  3443
  3890  1241  1157  2425  1105  3718 13950   119  2382  1357   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OCGN,OCU200,Diabetic macular edema (DME)Â ,IND-Enabling,2024-10-09,"Clinical hold lifted October 9, 2024.",292.0,273.14824,86.0978,0.9582,0.9489,0.9391,-0.009753105,-0.020134555,0.009104139,-0.031925691,17.58504,0.04027,2.29494,2134,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1,neg,"[  101 15961  2080  3358  1357   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KYMR,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Phase 1,2024-10-09,"IND cleared by the FDA, noted October 9, 2024.",71.0,2763.1658,62.0929,43.04,43.34,49.02,0.00694608,0.130098462,0.009104139,-0.031925691,13.8139,0.21627,16.09713,2135,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1357   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VKTX,VK0214,X-linked adrenoleukodystrophy (X-ALD)Â ,Phase 1b,2024-10-09,"Phase 1b results after 28 days of once-daily dosing, treatment shown to be safe and well-tolerated, with significant reductions in very long-chain fatty acids (VLCFAs), key biomarkers of X-ALD, noted",113.0,6940.27397,79.0965,66.68,62.64,65.85,-0.062501006,-0.01252563,0.009104139,-0.031925691,13.06707,0.07486,215.91006,2136,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  1830  2686  1170  1743  1552  1104  1517   118  3828
 18463  1158   117  3252  2602  1106  1129  2914  1105  1218   118 21073
  1181   117  1114  2418  7234  1116  1107  1304  1263   118  4129 24862
 13087   113   159 12674  8842  1116   114   117  2501 25128  8519  1468
  1104   161   118 18589  2137   117  2382   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALNY,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Â ,sNDA Filing,2024-10-09,"sNDA submitted to the FDA, noted October 9, 2024. Priority review voucher utilized to accelerate review period",131.0,34778.28097,53.6971,271.19,270.9,300.55,-0.001069933,0.102794447,0.009104139,-0.031925691,3.51078,0.04236,116.9329,2137,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101   188 16769  1592  7402  1106  1103 18762   117  2382  1357   130
   117 17881  1527   119  4602  1785  3189   191  6094  6072 12750  1106
 26872  3189  1669   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CANF,Namodenoson - (CF102-222PC),Pancreatic CancerÂ ,Phase 1,2024-10-09,"Orphan Drug Designation granted by the FDA, noted October 9, 2024.",10.0,55.18993,76.407,0.027,0.027,0.031,0.0,0.138150338,0.009104139,-0.031925691,0.0,1e-05,0.48204,2138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  2926 20695  1179 13982  4800  1891  3609  1118  1103 18762   117
  2382  1357   130   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BIIB,Felzartamab - (TRANSCEND),Antibody-mediated rejection (AMR) in kidney transplant recipientsÂ ,Phase 3,2024-10-09,"Breakthrough Therapy Designation granted by the FDA, noted October 9, 2024.",146.0,27058.10662,26.7766,182.3,185.76,189.0,0.018801836,0.036093333,0.009104139,-0.031925691,1.95592,0.17802,215.66179,2139,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 15835  1582 14929 23789  4800  1891  3609  1118  1103 18762   117
  2382  1357   130   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
DYN,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1)Â ,Phase 1/2,2024-10-09,"Phase 1/2 update presented at the World Muscle Society demonstrated robust muscle delivery and dose-dependent, consistent splicing correction while also showing improvement in myotonia, muscle strengt",142.0,3214.83355,80.529,33.13,32.02,35.4,-0.034078509,0.066272604,0.009104139,-0.031925691,8.84399,0.17346,15.06208,2140,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123 11984  2756  1120  1103  1291 19569  1116
 10536  2015  7160 17351  6484  6779  1105 13753   118  7449   117  8080
   188  1643 22548 22590  1229  1145  4000  8331  1107  1139 12355  5813
   117  6484   188  7877  2118  1204   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
DYN,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,2024-10-09,"Phase 1/2 update demonstrated dose dependent exon skipping and dystrophin expression and improvement in multiple functional endpoints in both cohorts, noted October 9, 2024.",142.0,3214.83355,80.529,33.13,32.02,35.4,-0.034078509,0.066272604,0.009104139,-0.031925691,8.84399,0.17346,15.06208,2141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123 11984  7160 13753  7449  4252  1320 19476
  2624  1105   173  6834  8005 27008  1179  2838  1105  8331  1107  2967
  8458  1322 21521  1107  1241  1884 13252  2145   117  2382  1357   130
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VTRS,EFFEXOR (venlafaxine) - (B2411367),Generalized anxiety disorder (GAD)Â ,Phase 3,2024-10-09,"Phase 3 study met primary and all secondary efficacy endpoints, noted October 9, 2024.",0.0,13618.06848,25.9718,11.32,11.41,11.82,0.007919091,0.043221939,0.009104139,-0.031925691,2.20444,0.02561,48.03867,2142,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1,pos,"[  101 12278   124  2025  1899  2425  1105  1155  3718 23891  1322 21521
   117  2382  1357   130   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TRDA,ENTR-601-44,Duchenne Muscular Dystrophy (DMD)Â ,Phase 1,2024-10-09,"Phase 1 interim data presented at the World Muscle Society reinforced its safety profile and supports the planned 4Q 2024 global regulatory filings for a Phase 2 clinical trial, noted October 9, 2024",38.0,568.97407,58.7978,16.39,16.17,17.66,-0.013513719,0.074630802,0.009104139,-0.031925691,5.78754,0.12834,3.45013,2143,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 10572  2233  2756  1120  1103  1291 19569  1116 10536
  2015 11331  1157  3429  6168  1105  6253  1103  2919   125  4880 17881
  1527  4265 12638 16504  1116  1111   170 12278   123  7300  3443   117
  2382  1357   130   117 17881  1527   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
UNCY,UNI-494,Acute kidney injury (AKI)Â ,Phase 1,2024-10-09,"Phase 1 study completed, noted October 9, 2024.",17.0,34.14751,121.1611,3.599,3.619,4.084,0.005541715,0.126420871,0.009104139,-0.031925691,1.05327,0.0182,0.40622,2144,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2025  2063   117  2382  1357   130   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PEPG,PGN-EDO51 - (CONNECT1),Duchenne muscular dystrophy (DMD)Â ,Phase 2,2024-10-09,"Phase 2 OLE 12-week data from WMS reported that all participants at 5 mg/kg demonstrated increased dystrophin production and exon skipping at just 3 months and after 4 doses, noted October 9, 2024.",32.0,310.25396,90.8617,9.76,9.52,8.99,-0.024897552,-0.082179552,0.009104139,-0.031925691,2.96251,0.04883,0.73007,2145,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   152 17516  1367   118  1989  2233  1121   160  7182
  2103  1115  1155  6635  1120   126 17713   120  4023  7160  2569   173
  6834  8005 27008  1179  1707  1105  4252  1320 19476  2624  1120  1198
   124  1808  1105  1170   125 24429   117  2382  1357   130   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMTX,"Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)",MelanomaÂ ,Phase 1b,2024-10-10,"Phase 1b cohorts data reported an cORR of 54% in both all melanoma patients and in cutaneous melanoma patients, noted October 10, 2024.",121.0,963.52469,52.7199,11.07,9.345,9.55,-0.169397306,-0.147697592,-0.024310136,-0.030573415,9.23177,0.1776,22.30681,2146,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  1884 13252  2145  2233  2103  1126   172  9565
  2069  1104  4335   110  1107  1241  1155  1143  4371  7903  4420  1105
  1107  2195 13064  1143  4371  7903  4420   117  2382  1357  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Phase 1,2024-10-10,"Phase 1 initial dosing completed, noted October 10, 2024.",0.0,12.59306,253.2526,499.79192,673.96602,553.47635,0.298987842,0.102027171,-0.024310136,-0.030573415,8.00983,0.01288,3.20875,2147,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  3288 18463  1158  2063   117  2382  1357  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JNJ,TREMFYA (Guselkumab) - (QUASAR),Crohn's diseaseÂ ,Approved,2024-10-10,"FDA Approved on October 10, 2024.",0.0,386386.681,16.8281,160.65,160.51,164.47,-0.00087184,0.023500097,-0.024310136,-0.030573415,0.82,0.05469,769.46712,2148,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762   138  8661 16011  1113  1357  1275   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVS,TREMFYA (Guselkumab) - (QUASAR),Crohn's diseaseÂ ,Approved,2024-10-10,"FDA Approved on October 10, 2024.",0.0,2178.09011,56.0008,7.15,7.0,7.65,-0.021202208,0.067593291,-0.024310136,-0.030573415,0.0,0.02199,0.092,2149,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762   138  8661 16011  1113  1357  1275   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
FHTX,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Phase 1,2024-10-10,"Phase 1 trial initiated, noted October 10, 2024.",56.0,390.6203,94.7007,7.26,7.06,7.74,-0.027934777,0.064021859,-0.024310136,-0.030573415,2.16044,0.07958,0.81319,2150,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  3443  7087   117  2382  1357  1275   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LLY,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Phase 1,2024-10-10,"Phase 1 trial initiated, noted October 10, 2024.",946.0,820008.7518,31.0409,919.74,910.69,917.12,-0.009888467,-0.002852696,-0.024310136,-0.030573415,0.64295,0.13326,1531.82885,2151,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  3443  7087   117  2382  1357  1275   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PFE,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 2,2024-10-10,"Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.",0.0,166260.8332,23.3265,30.19,29.34,29.27,-0.028558971,-0.030947643,-0.024310136,-0.030573415,1.19329,0.00487,1007.7624,2152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103   170  3324   110 23066  2069  1107  1103
  1476  1306  1403  1113  5242  6906  3121  1830 13753  1981  6055  3081
   110 23066  2069  1107  1103  1654  1981   117  2382  1382  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CRDF,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 2,2024-10-10,"Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.",66.0,117.30508,75.0582,2.52,2.52,2.79,0.0,0.101782694,-0.024310136,-0.030573415,14.66537,0.06302,1.105,2153,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2103   170  3324   110 23066  2069  1107  1103
  1476  1306  1403  1113  5242  6906  3121  1830 13753  1981  6055  3081
   110 23066  2069  1107  1103  1654  1981   117  2382  1382  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,2024-10-11,"Phase 2b study showed 36% of patients on denifanstat achieved MASH resolution without worsening fibrosis, and 52% had a â‰¥2-point NAS reduction. With secondary endpoints and a favorable safety profile,",32.0,137.54885,97.2211,4.14,4.31,5.41,0.040242116,0.267553305,-0.029189435,-0.036831503,6.17731,0.11696,2.93656,2154,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1,pos,"[  101 12278   123  1830  2025  2799  3164   110  1104  4420  1113 10552
  8914  5443 19756  3890  9960  1708  3048  6021  1443  4146  3381 20497
 12725  4863   117  1105  3882   110  1125   170   248   796   203  1477
   118  1553 25165  7234   119  1556  3718  1322 21521  1105   170 11169
  3429  6168   117   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CATX,212Pb-VMT01,MC1R-positive metastatic melanomaÂ ,Phase 1/2,2024-10-11,"Phase 1/2 safety and efficacy update reported that one patient experiencing a RECIST version 1.1 objective response after completion of treatment, and two patients experiencing stable disease at 9 and",74.0,853.63426,80.2064,13.25,12.66,12.65,-0.045550136,-0.046340337,-0.029189435,-0.036831503,14.22178,0.00116,65.61648,2155,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  3429  1105 23891 11984  2103  1115  1141
  5351 13992   170   155  8231  6258  1942  1683   122   119   122  7649
  2593  1170  6026  1104  3252   117  1105  1160  4420 13992  6111  3653
  1120   130  1105   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CAPR,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD)Â ,BLA Filing,2024-10-11,"Phase 3 OLE data presented at the 29th Annual Congress of the World Muscle Society, demonstrated sustained improvements in cardiac and skeletal muscle function over three years. Key outcomes included",45.0,627.94626,116.5046,17.14,17.77,18.86,0.036096729,0.095628364,-0.029189435,-0.036831503,14.82773,0.01283,81.63072,2156,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124   152 17516  2233  2756  1120  1103 17333  8451  2757
  1104  1103  1291 19569  1116 10536  2015   117  7160  8505  8313  1107
 17688  1105 23400  6484  3053  1166  1210  1201   119  7443 13950  1529
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BCAB,Evalstotug (BA3071),Oncology (various)Â ,Phase 2,2024-10-11,"Phase 2 data presented at SMR reported 1 cCR (cervical cancer) and 2 cPRs (melanoma and gastric), noted October 11, 2024.",58.0,100.05498,121.7066,1.93,2.07,1.94,0.070028604,0.00516797,-0.029189435,-0.036831503,9.24147,0.22892,1.71552,2157,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2756  1120 19293  2069  2103   122   172 23554
   113   172  1200 15901  1348  4182   114  1105   123   172 22861  1116
   113  1143  4371  7903  1105  3245 11048   114   117  2382  1357  1429
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PFE,Hympavzi (marstacimab-hncq),Hemophilia A or BÂ ,Approved,2024-10-11,"Approved October 11, 2024.",0.0,165240.8281,23.3471,29.34,29.16,29.22,-0.006153866,-0.004098366,-0.029189435,-0.036831503,1.19329,0.00529,863.64951,2158,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357  1429   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BNTC,BB-301,Oculopharyngeal muscular dystrophy (OPMD)Â ,Phase 1/2,2024-10-12,"Phase 1b/2a data from the Annual Congress of the World Muscle Society reported that Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-mont",26.0,194.32629,96.9333,10.86,10.86,11.48,0.0,0.055520076,-0.003944379,-0.011586448,0.29686,0.00415,0.0,2159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123  1161  2233  1121  1103  8451  2757
  1104  1103  1291 19569  1116 10536  2015  2103  1115 12859 16811   122
  1105 12859 16811   123  4531  3840  9739   117  7300  1193 17119  8313
  1107 24841  1120   130   118  1808  1105   127   118 19863  1204   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LLY,Mirikizumab - (VIVID-1),Crohn's diseaseÂ ,Phase 3,2024-10-14,"Phase 3 1-year data reported that a greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075), not",946.0,836954.7649,31.2654,932.06,929.51,906.13,-0.002739625,-0.028214407,-0.006363979,0.005385371,0.64295,0.14459,1441.09836,2160,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124   122   118  1214  2233  2103  1115   170  3407  1295
  1104  4420  1115  3890  1117  2430 13791  1596  2593  1127  4379  1114
  1940 10160  9368 10161  1830  1120  6237  3882  1107  1103  2905  1416
   113  4650   119   123   110  6055  3615   119   129   110   132   185
   134   121   119  3135 26253   114   117  1136   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GSK,Depemokimab - (ANCHOR 1/2),Chronic rhinosinusitis with nasal polypsÂ ,Phase 3,2024-10-14,"Phase 3 data reported that trial met primary endpoint, noted October 14, 2024.",0.0,60960.4729,22.9597,14.8,14.945,14.64,0.009749615,-0.010869672,-0.006363979,0.005385371,0.0,0.03646,124.65501,2161,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  2233  2103  1115  3443  1899  2425  1322  7587   117
  2382  1357  1489   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RPTX,RP-3467 - (POLAR),Solid tumorsÂ ,Phase 1,2024-10-14,"Phase 1 dosing commenced, noted October 14, 2024.",42.0,143.89036,66.4869,3.14,3.39,3.6,0.076607121,0.136711046,-0.006363979,0.005385371,1.67812,0.26281,0.2971,2162,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 18463  1158  8042   117  2382  1357  1489   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CMND,CMND-100,Alcohol use disorder (AUD)Â ,Phase 1/2,2024-10-14,"IRB approval on US clinical sites for part A of Phase 1/2a, noted October 14, 2024.",5.0,5.71943,92.4239,1.36,1.41,1.54,0.036105005,0.124297717,-0.006363979,0.005385371,4.96446,0.02251,0.46278,2163,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1,pos,"[  101   146 22672  5684  1113  1646  7300  3911  1111  1226   138  1104
 12278   122   120   123  1161   117  2382  1357  1489   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ENVB,EB-003 (EVM301 series),Mental health disordersÂ ,Preclinical,2024-10-15,"In vitro data showed no meaningful activity against hERG or 5-HT2B, targets related to cardiovascular adverse drug reactions (ADRs), noted October 15, 2024.",0.0,3.77312,77.6845,74.15999,76.13999,96.53399,0.026348833,0.263670388,-0.011840395,0.008107879,2.23068,6e-05,8.2401,2164,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  1130   191  2875  2180  2233  2799  1185 17119  3246  1222   177
  9637  2349  1137   126   118   145  1942  1477  2064   117  7539  2272
  1106  3621 25575 16798  3850  9535   113  5844  2069  1116   114   117
  2382  1357  1405   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AMGN,UPLIZNA (Inebilizumab) - (MINT),Myasthenia gravisÂ ,Phase 3,2024-10-15,"Phase 3 trial met its primary endpoint, noted October 15, 2024.",538.0,174680.3561,26.5173,324.62,325.09,319.66,0.0014468,-0.015397337,-0.011840395,0.008107879,1.82641,0.06745,635.94171,2165,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3443  1899  1157  2425  1322  7587   117  2382  1357
  1405   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,2024-10-15,"Phase 2 EoP2 meeting. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD",19.0,104.17106,200.3682,7.51,7.98,9.63,0.060702946,0.24864776,-0.011840395,0.008107879,9.26706,0.07295,11.92494,2166,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1,pos,"[  101 12278   123   142  1186  2101  1477  2309   119  1507  1103  2309
   117  1103 18762  3609 16443  1106 10980  1114 22927 12278   124  2527
   117  1359  1113  1103  1881   112   188 12278   123   120   124  7300
  2233  4000   188 17162  6451  7903  2941  8331  1107  1346  5844   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JNJ,Nipocalimab - (Vibrance-MG),Generalized myasthenia gravisÂ ,Phase 2/3,2024-10-15,"Phase 2/3 data reported sustained disease control over 24 weeks in antibody positive adolescents aged 12 â€“ 17 years, noted October 15, 2024.",0.0,395028.6858,16.8597,161.6,164.1,163.45,0.015351852,0.011382987,-0.011840395,0.008107879,0.82,0.05522,1730.92122,2167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123   120   124  2233  2103  8505  3653  1654  1166  1572
  2277  1107  2848 14637  3112 25506  1116  4079  1367   248 28731   789
  1542  1201   117  2382  1357  1405   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VTYX,Tamuzimod (VTX002),Ulcerative Colitis (UC)Â ,Phase 2,2024-10-15,"Phase 2 data reported that endoscopic remission occurred in 43.8% (14/32) and 46.4% (13/28) of patients who received tamuzimod 30 mg and 60 mg, respectively, compared to 18.2% (4/22) of patients who r",71.0,170.31261,110.3461,2.34,2.41,2.25,0.029475818,-0.039220713,-0.011840395,0.008107879,12.11676,0.01119,1.74632,2168,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1115  1322  2155 22258  1231 11234  3296
  1107  3887   119   129   110   113  1489   120  2724   114  1105  3993
   119   125   110   113  1492   120  1743   114  1104  4420  1150  1460
 27629 13601  5303  3702  1181  1476 17713  1105  2539 17713   117  3569
   117  3402  1106  1407   119   123   110   113   125   120  1659   114
  1104  4420  1150   187   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MGTX,AAV-GAD,Parkinson's DiseaseÂ ,Phase 1,2024-10-15,"Phase 1 met its primary endpoint, noted October 15, 2024.",80.0,412.53623,58.6081,4.64,5.33,5.98,0.138636872,0.253706202,-0.011840395,0.008107879,2.49991,0.14649,10.87835,2169,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   122  1899  1157  2425  1322  7587   117  2382  1357  1405
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVCR,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC)Â ,Approved,2024-10-15,"FDA approved by the FDA, noted October 15, 2024.",111.0,1924.10697,68.2641,16.06,17.78,16.15,0.101742522,0.005588341,-0.011840395,0.008107879,5.07193,0.10998,49.28344,2170,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  4092  1118  1103 18762   117  2382  1357  1405   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ZLAB,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC)Â ,Approved,2024-10-15,"FDA approved by the FDA, noted October 15, 2024.",109.0,2432.88599,61.1221,24.72,24.79,28.82,0.002827713,0.153456958,-0.011840395,0.008107879,4.95339,0.05973,18.47562,2171,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  4092  1118  1103 18762   117  2382  1357  1405   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GNPX,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC)Â ,Phase 1,2024-10-15,"Phase 1 portion to continue following review from safety review committee approval to advance to highest dose, noted October 15, 2024.",0.0,1.20802,103.5093,17.09,16.785,179.5,-0.018007867,2.351681711,-0.011840395,0.008107879,2.25149,0.05297,1.00577,2172,0,0,0,1,0,1,0,1,0,0,0,0,3,0,0,1,pos,"[  101 12278   122  3849  1106  2760  1378  3189  1121  3429  3189  3914
  5684  1106  4657  1106  2439 13753   117  2382  1357  1405   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JAZZ,Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq),"First-line, Small Cell Lung Cancer (SCLC)Â ",Phase 3,2024-10-15,"Phase 3 topline data demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review f",60.0,7242.45165,26.9647,111.03,117.28,113.1,0.054763803,0.018471948,-0.011840395,0.008107879,5.46908,0.03397,151.526,2173,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   124  1499  2568  2233  7160   170 11435  1193  2418  8331
  1107  1103  2425  1322 21521  1104  2905  8115   113 11570   114  1105
 16147   118  1714  8115   113   153 17691   114   117  1112 14758  1118
  1126  2457  3189   175   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LYRA,LYR-210 - (ENLIGHTEN II),Chronic rhinosinusitisÂ ,Phase 3,2024-10-15,"Phase 3 enrollment to be completed, noted Ocrtober 15, 2024",1.0,14.95031,295.1749,11.125,11.42,12.6,0.026171376,0.124501986,-0.011840395,0.008107879,4.36044,0.00613,0.19955,2174,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124 10803  1106  1129  2063   117  2382   152  1665  3740
 21367  1197  1405   117 17881  1527   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
QURE,AMT-162,SOD1-ALSÂ ,Phase 1/2,2024-10-15,"Phase 1/2 dosing commenced, noted October 15, 2024.",54.0,274.65457,118.6249,5.64,5.64,6.65,0.0,0.164732789,-0.011840395,0.008107879,10.79556,0.02051,2.85159,2175,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123 18463  1158  8042   117  2382  1357  1405
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
HCM,Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH),Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-10-16,"Phase 2 data demonstrated a high, clinically meaningful and durable objective response rate (ORR) for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)",174.0,2589.28664,50.2138,2.84,3.03,3.25,0.064758567,0.134850944,0.0001007,0.026943154,0.0,9e-05,0.652,2176,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  7160   170  1344   117  7300  1193 17119  1105
  3840  9739  7649  2593  2603   113 23066  2069   114  1111  4420  1114
   174 25786  1200  7435  3213  5318 10814   118   182 15012  1906   113
   142  2349  2271  2069  1306   114  1664   118  1353  2765 13093  4182
   113   151 10844 12674   114   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AZN,IVX-A12,RSV/human Metapneumovirus (hMPV)Â ,Phase 2,2024-10-16,"Phase 2 interim data from ID week reported that treatment was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age, noted October 16, 2024.",0.0,186407.4297,18.1325,118.5,120.24,118.28,0.014576785,-0.001858266,0.0001007,0.026943154,0.0,0.07853,161.07964,2177,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123 10572  2233  1121 10999  1989  2103  1115  3252  1108
  1218   118 21073  1181  1105 13280 13601  2728 19438  1222  1241 25591
  2559  1105   177 12347  2559  1107  2214  6323  2539  1106  4859  1201
  1104  1425   117  2382  1357  1479   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ACET,ADI-001,Idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS)Â ,IND-Enabling,2024-10-16,"IND Clearance by the FDA, noted October 16, 2024.",83.0,135.36098,76.6536,1.4,1.49,1.44,0.062303883,0.028170877,0.0001007,0.026943154,4.09374,0.04421,0.82838,2178,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 15969  2137 15458  3923  1118  1103 18762   117  2382  1357  1479
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CGEM,CLN-978,Systemic Lupus Erythematosus (SLE)Â ,IND-Enabling,2024-10-16,"IND Cleared by the FDA, noted October 16, 2024.",59.0,1020.96865,77.7335,16.24,17.61,15.61,0.080989588,-0.0395656,0.0001007,0.026943154,15.88336,0.07858,11.47589,2179,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 15969  2137 15458  1174  1118  1103 18762   117  2382  1357  1479
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVAX,NVX-CoV2373 - (COVID-19-Influenza Combination),"COVID-19, COVID-19 vaccine, InfluenzaÂ ",Phase 2,2024-10-16,"Phase 2 IND placed on hold October 16, 2024.",162.0,1624.95044,151.0699,12.6,10.15,10.0,-0.216223108,-0.231111721,0.0001007,0.026943154,21.16203,0.05963,328.1459,2180,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 15969  2137  1973  1113  2080  1357  1479   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
WVE,WVE-006 - (RestorAATion-2),"Healthy volunteers, AATD who have the homozygous PiZZ mutationÂ ",Phase 1/2,2024-10-16,"Phase 1b/2a data resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 d",159.0,2266.61615,119.7713,8.56,14.9,14.67,0.554261023,0.538704402,0.0001007,0.026943154,3.67571,0.04298,258.15888,2181,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123  1161  2233  3657  1107  1928 13441
  1703 10419  1942  3001  1104   199  1429 17599  3702  5815   117  1114
  1928  4098   118  2076   150   118 10419  1942  4311  1167  1190  2539
   110  1104  1703 10419  1942   132  3840  9739 10620  1114   150   118
 10419  1942  4592  4379  1194  4667   173   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GRI,GRI-0621,Idiopathic pulmonary fibrosis (IPF)Â ,Preclinical,2024-10-16,"Preclinical data reported an increase in IFN-Î³ producing NKT cells in IPF, compared to controls and confirmed iNKT cell phenotype in a second cohort, using an antibody against VÎ±24-JÎ±18 of the iNKT TC",2.0,1.35874,140.8494,6.29,7.8897,13.70201,0.226597041,0.778581467,0.0001007,0.026943154,5.7767,0.03016,7.35574,2182,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2103  1126  2773  1107 13729  2249
   118   236 19763  4411   151  2428  1942  3652  1107 14274  2271   117
  3402  1106  7451  1105  3659   178  2249  2428  1942  2765   185 10436
 27172  1107   170  1248  1884 13252  1204   117  1606  1126  2848 14637
  1222   159 28189 28168 19598   118   147 28189 28168 15292  1104  1103
   178  2249  2428  1942   157  1658   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
DRUG,BMB-201,PainÂ ,Preclinical,2024-10-16,"Preclinical data reported dose-dependent efficacy with similar efficacy to morphin, noted October 16, 2024.",7.0,175.38416,907.8615,44.11,39.29,64.21,-0.115716481,0.375472448,0.0001007,0.026943154,0.0,0.00982,5.76911,2183,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2103 13753   118  7449 23891  1114
  1861 23891  1106   182  1766 27008  1179   117  2382  1357  1479   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GKOS,Epioxa (Epi-on),Progressive keratoconusÂ ,Phase 3,2024-10-16,"Second Phase 3 trial met primary endpoint, noted October 16, 2024.",57.0,7041.05924,28.8321,127.61,128.2,129.94,0.004612807,0.018094068,0.0001007,0.026943154,5.74407,0.04178,31.0485,2184,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101  2307 12278   124  3443  1899  2425  1322  7587   117  2382  1357
  1479   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PHIO,INTASYL(PH-894),Solid tumorsÂ ,Preclinical,2024-10-16,"Preclinical data shared at ASGCT 2024 showed that treatment leads to potent and specific silencing of BRD4 in NK cells, without affecting cell viability., noted October 16, 2024.",5.0,2.79734,97.9183,2.76,3.25,2.93,0.163424317,0.059771743,0.0001007,0.026943154,5.6089,0.07068,3.52065,2185,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  3416  1120 15278 13478  1942 17881
  1527  2799  1115  3252  4501  1106 18106  1105  2747 27466  7836  4869
  1104 26660  2137  1527  1107   151  2428  3652   117  1443 12759  2765
  2258  5474   119   117  2382  1357  1479   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VSTM,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC)Â ,Phase 3,2024-10-17,"Phase 3 data reported overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or",61.0,107.04836,173.0224,3.33,2.66,3.29,-0.224646181,-0.012084739,0.004198327,0.030382084,5.83711,0.13491,11.75655,2186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  2905  2593  5600  4379   113  1955   110
  2905   117  3140   110  1107   148  9664  1708 21392   117  1542   110
  1107   148  9664  1708  4098   118  2076   114  1107  4420  2133  4182
  1125 12687  2693  2988  3252  1114 22572  5521 20939  1105   120  1137
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LGND,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,2024-10-17,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How",19.0,1934.49912,39.9459,107.16,105.89,110.99,-0.011922225,0.035117062,0.004198327,0.030382084,5.45261,0.1619,7.72584,2187,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2233  1120  1103 14056  1708  2799  1115  1103  3443
  1899  1141  1104  1157  1160  1884   118  2425  1322 21521   117  1114
  2908   110  1104  4420 11190 12342   172  5800  1891  1439  1476  1904
   119  4191   176  3906  1775 12805  1673  1145  2799  4946 12342   172
  5800  1891   119  1731   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MRNS,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,2024-10-17,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How",55.0,3222.63646,36.284,42.61,43.01,42.0,0.009343679,-0.014419349,0.004198327,0.030382084,0.0,0.0447,0.24972,2188,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  2233  1120  1103 14056  1708  2799  1115  1103  3443
  1899  1141  1104  1157  1160  1884   118  2425  1322 21521   117  1114
  2908   110  1104  4420 11190 12342   172  5800  1891  1439  1476  1904
   119  4191   176  3906  1775 12805  1673  1145  2799  4946 12342   172
  5800  1891   119  1731   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BDRX,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM)Â ,Phase 1,2024-10-17,"Phase 1 data reported that patient #3 has achieved 13 months OS to date, with six months progression free survival (PFS). Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to d",0.0,3.40947,207.3395,84.0,58.7,66.15,-0.358377072,-0.238891908,0.004198327,0.030382084,2.2857,0.09625,2.79688,2189,1,0,0,0,0,1,0,0,0,0,0,0,3,0,0,1,neg,"[  101 12278   122  2233  2103  1115  5351   108   124  1144  3890  1492
  1808 11570  1106  2236   117  1114  1565  1808 16147  1714  8115   113
   153 17691   114   119  7195  9080   108   125  1144  1136 12687  1105
  3890  1367  1808   153 17691  1105  1367  1808 11570  1106   173   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AVXL,ANAVEX 3-71 (AF710B),SchizophreniaÂ ,Phase 2,2024-10-17,"Phase 2 data reported that ANAVEX3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia, noted October 17, 2024.",85.0,466.79932,66.528,5.525,5.505,5.33,-0.003626477,-0.035932009,0.004198327,0.030382084,20.74988,0.11947,2.57239,2190,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1115 23096 26390 24654  1495   118  5729
 17798   170 13753   118  7449   185  7111  1918  2528 24662  2629  1113
  7649   142 17020 25128  8519  1468  1104   188  4313 26474   117  2382
  1357  1542   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ADTX,ATI-1701,Francisella tularensis vaccineÂ ,Preclinical,2024-10-17,"Preclinical data presented at IDweek reported full protection against lethal tularemia in animal models after one year, noted October 17, 2024.",4.0,4.55868,166.6362,277.5,270.0,198.75,-0.027398974,-0.33377318,0.004198327,0.030382084,0.13618,0.03385,2.9322,2191,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2756  1120 10999 21394  2103  1554
  3636  1222 14969   189  5552 20504  1107  3724  3584  1170  1141  1214
   117  2382  1357  1542   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KZR,Zetomipzomib (KZR-616-208) - (PORTOLA),Autoimmune Hepatitis (AIH)Â ,Phase 2a,2024-10-17,"Phase 2a IDMC ecommended that the trial may proceed without modification following its third scheduled meeting., noted October 17, 2024.",7.0,59.53717,72.5253,8.947,8.16,8.018,-0.092074112,-0.109629266,0.004198327,0.030382084,1.34714,0.12455,1.01234,2192,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1161 10999 10044   174  8178  2354  4902  1115  1103
  3443  1336 10980  1443 15156  1378  1157  1503  4533  2309   119   117
  2382  1357  1542   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMLX,AMX0035 - (HELIOS),Wolfram SyndromeÂ ,Phase 2,2024-10-17,"Phase 2 topline data from ISPAD reported improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the study's primary efficacy endpoint, noted Oc",89.0,266.88328,69.8215,4.08,3.92,4.9,-0.040005335,0.183138217,0.004198327,0.030382084,1.87972,0.03649,13.00308,2193,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1499  2568  2233  1121 19432 10147  2137  2103  8331
  1107 13316 13782  7698  3053   117  1112  7140  1118   140   118   185
 27105  2593  1170  1572  2277  1104  3252  1114  6586  3190  7629 19297
   117  1103  2025   112   188  2425 23891  1322  7587   117  2382   152
  1665   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AVDL,LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII),Pediatric narcolepsyÂ ,Approved,2024-10-17,"Approved October 17, 2024.",97.0,1340.08575,37.5078,13.24,13.92,13.0,0.050084104,-0.018293193,0.004198327,0.030382084,11.39087,0.01115,19.68777,2194,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357  1542   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AURA,Belzupacap sarotalocan (AU-011),Non-muscular invasive bladder cancer (NMIBC)Â ,Phase 1,2024-10-17,Phase 1 updated data reported that 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation and 2 out of 3 pat,62.0,510.44692,57.1882,10.25,10.29,11.24,0.003894844,0.092201139,0.004198327,0.030382084,2.31998,0.17466,2.56788,2195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  8054  2233  2103  1115   125  1149  1104   126  4420
  1114  1822  3654  3653  7160   170  7300  2335  2593  1114  1185 14601
  3652  2735  1113  1117  9870  9779  7542 10540  1105   123  1149  1104
   124 26227   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SUPN,SPN-820,Treatment-resistant depressionÂ ,Phase 2a,2024-10-17,"Phase 2a open label data reported a rapid and substantial decrease in depressive symptoms, noted October 17, 2024.",56.0,1864.7663,33.7194,33.98,33.84,33.8,-0.004128582,-0.005311314,0.004198327,0.030382084,12.64906,0.078,9.06638,2196,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1161  1501  3107  2233  2103   170  6099  1105  6432
  9711  1107  1260 16568  8006   117  2382  1357  1542   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RANI,RT-114,ObesityÂ ,Preclinical,2024-10-17,"Preclinical pharmacokinetic data provided further evidence of the RaniPill platform's potential to enable oral delivery of multiple obesity treatments, noted October 17, 2024.",71.0,84.92287,128.6731,2.6,2.63,2.39,0.011472401,-0.084218079,0.004198327,0.030382084,2.44221,0.00223,6.79806,2197,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867   185  7111  1918  2528  4314  9265  2233
  2136  1748  2554  1104  1103 24202  2101  7956  3482   112   188  3209
  1106  9396  9619  6779  1104  2967   184 27655 14115   117  2382  1357
  1542   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ABBV,VYALEV (foscarbidopa and foslevodopa),Parkinson's diseaseÂ ,Approved,2024-10-17,"Approved October 17, 2024.",0.0,333079.44,19.8322,190.46,188.57,189.65,-0.009972908,-0.004261931,0.004198327,0.030382084,0.84108,0.01275,833.29121,2198,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357  1542   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KZR,Zetomipzomib - (PALIZADE),Lupus nephritisÂ ,Phase 2b,2024-10-18,"Phase 2b IND placed on clinical hold, noted October 4, 2024. Phase 2b will be discontinued after clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 (fatal), no",7.0,60.10628,72.3561,8.16,8.238,7.857,0.009513427,-0.037839315,0.01164865,0.021889395,1.34714,0.12985,0.19613,2199,0,0,0,0,0,1,0,1,0,0,0,0,0,4,0,-1,neg,"[  101 12278   123  1830 15969  2137  1973  1113  7300  2080   117  2382
  1357   125   117 17881  1527   119 12278   123  1830  1209  1129  8779
  1170  7300  2080  1378  1103 13710  1104  1103 10999 10044  1170  1157
  8670  1104  1300  6318   126   113 11874   114   117  1185   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,ENFLONSIA (Clesrovimab) (MK-1654-004) - (CLEVER),Respiratory syncytial virus (RSV) infantsÂ ,Phase 2/3,2024-10-18,Phase 2b/3 data presented at IDweek reported that treatment reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpo,0.0,275533.7722,23.4135,109.75,108.7,103.98,-0.009613258,-0.054006479,0.01164865,0.021889395,1.07549,0.05257,1035.15412,2200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830   120   124  2233  2756  1120 10999 21394  2103
  1115  3252  3549 25591  2559   118  2628  2704 20412   113  3718  1322
  7587   114  1105 25591  2559   118  2628  2211 19192  8974  2704 20412
   113 16371  1322  5674   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PFE,VYLOY (zolbetuximab-clzb),Advanced Gastric and GEJ CancerÂ ,Approved,2024-10-18,"Approved October 18, 2024.",0.0,165580.8298,23.2633,29.27,29.22,28.45,-0.001709694,-0.02841494,0.01164865,0.021889395,1.19329,0.00078,708.43516,2201,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
REGN,EYLEA HD (aflibercept) - (PHOTON ext),Diabetic macular edema (DME)Â ,Phase 3,2024-10-21,"Phase 3 extension data reported that 88% of EYLEA HD patients had a last assigned dosing interval of â‰¥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 w",105.0,104534.5913,20.7683,990.68,968.5,928.61,-0.022643093,-0.064702732,0.015749947,0.013513719,1.6045,0.17293,769.2873,2202,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  4973  2233  2103  1115  5385   110  1104   142  3663
 17516  1592 10728  4420  1125   170  1314  3346 18463  1158 14235  1104
   248   796   203 11964  2277  1120  1989 17801   117  1229 26081  5173
  1105  1126 10024  7257  8313  3890  1107  1103  1148  5306   192   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,2024-10-21,"Phase 2b microbiome analysis presented at ID Week indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients, noted October 21, 2024",1.0,31.84036,61.8589,40.2,39.2,37.8,-0.025190249,-0.061557893,0.015749947,0.013513719,3.02701,0.03814,0.15033,2203,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830 17599 25959  3263  3622  2756  1120 10999  6237
  5057   170 11169  9691 16516  1513  5190  6168  1134  1336  8681  1106
   178  3962  3293 21341  2980   112   188 16250  2848   118  1231 10182
 21629  2629  1107  4420   117  2382  1357  1626   117 17881  1527   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ABBV,BOTOX (OnabotulinumtoxinA),Platysma prominence associated with platysma muscle activity (M21-310)Â ,Approved,2024-10-21,"Approved October 21, 2024.",0.0,329493.7622,19.9223,188.86,186.54,189.68,-0.012360307,0.004332442,0.015749947,0.013513719,0.84108,0.00815,838.79427,2204,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1357  1626   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NRIX,Bexobrutideg (NX-5948),Relapsed/Refractory Waldenstrom's MacroglobulinemiaÂ ,Phase 1/2,2024-10-21,"Phase 1a/1b data reported an objective responses observed in 7 of 9 (77.8%), noted October 21, 2024.",76.0,1804.90847,66.675,25.05,25.48,26.45,0.017020003,0.054382331,0.015749947,0.013513719,12.8151,0.14869,15.28466,2205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1161   120   122  1830  2233  2103  1126  7649 11317
  4379  1107   128  1104   130   113  5581   119   129   110   114   117
  2382  1357  1626   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PYPD,D-PLEX100 - (SHIELD I),Abdominal (soft tissue) sternal surgical site infectionsÂ ,Phase 3,2024-10-21,"Phase 3 data published at the Journal of Surgery trial showed that despite study did not meet its primary endpoint due to COVID-19-related impacts, pre-specified and post-hoc analyses indicated poten",10.0,22.45148,63.1965,3.59,3.3,3.4194,-0.084229734,-0.048687105,0.015749947,0.013513719,0.10689,0.01043,0.01221,2206,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   124  2233  1502  1120  1103  3603  1104 17910  3443  2799
  1115  2693  2025  1225  1136  2283  1157  2425  1322  7587  1496  1106
 18732 23314  2137   118  1627   118  2272 15791   117  3073   118  9467
  1105  2112   118 16358  1665 18460  4668  9814  1424   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ELAB,EL-32,ObesityÂ ,Preclinical,2024-10-21,"Preclinical data reported statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model, noted October 21, 2024.",0.0,4.88787,176.5658,456.19007,485.10008,485.10008,0.061445677,0.061445677,0.015749947,0.013513719,1.39023,0.00197,6.82584,2207,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2103 11435  1193  2418  6986  1107
  5688  3220   117  5968  3053  1105  1404  5239  1107  4079   140  1571
  1559 13360   120   127  4538 10322  2235   117  2382  1357  1626   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RGNX,ABBV-RGX-314,Wet age-related macular degeneration (wet AMD)Â ,Phase 2,2024-10-21,"Phase 2 data reported a 97% reduction in treatment burden at nine months after treatment, noted October 21, 2024.",50.0,512.51846,56.8657,11.1,10.37,9.38,-0.068028086,-0.168365345,0.015749947,0.013513719,10.74272,0.09524,7.9352,2208,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103   170  5311   110  7234  1107  3252 11904
  1120  2551  1808  1170  3252   117  2382  1357  1626   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MIRA,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSDÂ ",Preclinical,2024-10-21,"Preclinical data has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica), noted October 21, 2024.",19.0,17.07946,316.1708,1.1,1.05,1.57,-0.046520016,0.35576544,0.015749947,0.013513719,2.70652,0.00538,3.08175,2209,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  1144  2602  3407  2489  3893  3402
  1106 18762   118  4092 14115   144 19252 22083  1394   113   151  8816
  9921  1394   114  1105 11689  2571  7767  1394   113   149 23710  1161
   114   117  2382  1357  1626   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVO,Semaglutide - (SOUL),Major adverse cardiovascular events (MACE)Â ,Phase 3,2024-10-21,"Trial data reported that trial met its primary endpoint, noted October 21, 2024.",0.0,3579127.915,32.4007,118.09,117.33,112.36,-0.006456568,-0.049739043,0.015749947,0.013513719,0.0,0.0,379.04536,2210,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12819  2233  2103  1115  3443  1899  1157  2425  1322  7587   117
  2382  1357  1626   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,2024-10-21,"Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no",0.0,107430.3667,22.8712,86.72,86.29,88.76,-0.004970821,0.02325156,0.015749947,0.013513719,1.42451,0.03715,384.10069,2211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2103  1115  1103  4612  4441   170  1344  2603
   113   183   134  3927   132  5706   119   123   110   114  1104 14837
 18793   113  9622   118   122 13254   133  1851  4034   120   182  2162
   114  1107   191  9992  7810  1193 14336  6323   117   170  3718  1322
  7587  1104  1103  2025   117  1185   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MRK,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,2024-10-21,"Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no",0.0,269551.6222,23.6301,108.7,106.34,104.23,-0.021950286,-0.041991798,0.015749947,0.013513719,1.07549,0.05257,1217.04588,2212,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1115  1103  4612  4441   170  1344  2603
   113   183   134  3927   132  5706   119   123   110   114  1104 14837
 18793   113  9622   118   122 13254   133  1851  4034   120   182  2162
   114  1107   191  9992  7810  1193 14336  6323   117   170  3718  1322
  7587  1104  1103  2025   117  1185   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TARA,IV choline chloride - (THRIVE-3),Parenteral nutrition (PN)Â ,Phase 3,2024-10-21,"Fast Track Designation graned by the FDA, noted October 21, 2024.",38.0,41.46584,64.9737,1.91,2.01,2.4,0.05103148,0.228365495,0.015749947,0.013513719,10.39934,0.13773,1.34445,2213,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 13227  6563  4800  1891   176 18194  1181  1118  1103 18762   117
  2382  1357  1626   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AMRX,Pyridostigmine Bromide Extended-Release (PB ER) Tablets USP 105 mg,Lethal effects of soman nerve agent poisoningÂ ,Approved,2024-10-21,"NDA Approved by the FDA, noted October 21, 2024.",314.0,2621.82589,38.5766,8.58,8.47,8.54,-0.012903405,-0.004672906,0.015749947,0.013513719,1.46329,0.10454,6.74534,2214,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   151 11392   138  8661 16011  1118  1103 18762   117  2382  1357
  1626   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MDGL,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 3,2024-10-21,"Phase 3 enrollment completed, noted October 21, 2024.",22.0,4535.5611,48.8635,214.44,208.89,217.0,-0.026222181,0.011867375,0.015749947,0.013513719,17.78707,0.10631,34.50382,2215,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,pos,"[  101 12278   124 10803  2063   117  2382  1357  1626   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RGNX,RGX-314 - (ALTITUDE),Diabetic retinopathyÂ ,Phase 1/2,2024-10-21,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",50.0,512.51846,56.8657,11.1,10.37,9.38,-0.068028086,-0.168365345,0.015749947,0.013513719,10.74272,0.09524,7.9352,2216,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122   120   123  1161  1263   118  1858  2686  2103  1115
  3252  1108  1218   118 21073  1181  1114  5603   110  1104 14355  1116
 14546   118  1714  1105  5311   110  7234  1107  2848   118   159 17020
  2271  3252 11904   117  2382  1357  1626   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CLSD,RGX-314 - (ALTITUDE),Diabetic retinopathyÂ ,Phase 1/2,2024-10-21,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",5.0,98.66414,73.017,17.24999,19.79999,16.49999,0.137869869,-0.044451789,0.015749947,0.013513719,0.34947,0.09325,2.93165,2217,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122   120   123  1161  1263   118  1858  2686  2103  1115
  3252  1108  1218   118 21073  1181  1114  5603   110  1104 14355  1116
 14546   118  1714  1105  5311   110  7234  1107  2848   118   159 17020
  2271  3252 11904   117  2382  1357  1626   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ABBV,RGX-314 - (ALTITUDE),Diabetic retinopathyÂ ,Phase 1/2,2024-10-21,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",0.0,329493.7622,19.9223,188.86,186.54,189.68,-0.012360307,0.004332442,0.015749947,0.013513719,0.84108,0.00815,838.79427,2218,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   122   120   123  1161  1263   118  1858  2686  2103  1115
  3252  1108  1218   118 21073  1181  1114  5603   110  1104 14355  1116
 14546   118  1714  1105  5311   110  7234  1107  2848   118   159 17020
  2271  3252 11904   117  2382  1357  1626   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RVMD,Daraxonrasib (RMC-6236) - (RASolute 302),Metastatic pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 3,2024-10-21,"Phase 3 dosing commenced, noted October 21, 2024.",186.0,7976.10953,38.5656,50.43,47.75,47.75,-0.054607169,-0.054607169,0.015749947,0.013513719,9.78379,0.12358,52.75134,2219,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124 18463  1158  8042   117  2382  1357  1626   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OCGN,OCU410ST - (GARDian),"Stargardt, Retinitis Pigmentosa 19 (RP19), and Cone-rod dystrophy 3 (CORD3) diseasesÂ ",Phase 1/2,2024-10-21,"Phase 1/2 DSMB convened and approved enrollment for the second phase, noted October 21, 2024.",292.0,270.12573,83.1157,0.94,0.9384,1.01,-0.001703578,0.071825735,0.015749947,0.013513719,17.58504,0.03548,1.61805,2220,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   122   120   123 18448 20660 21419  1105  4092 10803  1111
  1103  1248  4065   117  2382  1357  1626   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMRN,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC)Â ,Phase 2,2024-10-22,"Phase 2 final results reported no SAEs and that all subjects challenged had ETEC negative stool at discharge, noted October 22, 2024.",6.0,17.6442,73.466,1.96,2.0019,1.92,0.021152256,-0.020619287,0.015193804,-0.004168579,0.0,0.0,0.00628,2221,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  1509  2686  2103  1185 13411 27485  1105  1115  1155
  5174  7964  1125 27269  8231  4366 15631  1120 12398   117  2382  1357
  1659   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TEVA,SELARSDI (ustekinumab-aekn) 130 mg/26 mL - (STELARA Biosimilar),Crohn's diseaseÂ ,Approved,2024-10-22,"FDA Biosimilar approval on October 22, 2024.",0.0,20824.40026,34.0056,18.18,18.38,18.43,0.010941028,0.013657683,0.015193804,-0.004168579,2.16174,0.17744,68.37176,2222,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762   139 10714  4060  8009  1197  5684  1113  1357  1659   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALVO,SELARSDI (ustekinumab-aekn) 130 mg/26 mL - (STELARA Biosimilar),Crohn's diseaseÂ ,Approved,2024-10-22,"FDA Biosimilar approval on October 22, 2024.",301.0,3740.34151,31.0267,12.25,12.4,12.96,0.012170536,0.056341754,0.015193804,-0.004168579,0.02659,0.02681,0.55904,2223,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762   139 10714  4060  8009  1197  5684  1113  1357  1659   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMUX,Vidofludimus Calcium - (ENSURE),Progressive Multiple SclerosisÂ ,Phase 3,2024-10-22,"Phase 3 trial had positive outcome of the non-binding, interim futility analysis, noted October 22, 2024.",98.0,126.11062,69.5859,1.55,1.4,1.31,-0.101782694,-0.168227794,0.015193804,-0.004168579,2.97726,0.11123,15.52777,2224,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1,neg,"[  101 12278   124  3443  1125  3112  9386  1104  1103  1664   118  7861
   117 10572   175 16065 11796  3622   117  2382  1357  1659   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MOLN,MP0712,Small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumorsÂ ,Preclinical,2024-10-22,"Preclinical data presented at EANM led to strong and dose-dependent efficacy in mice bearing established tumors with clinically-relevant levels of DLL3 expression and at a clinically-relevant dose, as",40.0,192.52542,86.4915,5.7,5.8,5.6,0.017391743,-0.017699577,0.015193804,-0.004168579,0.0,0.00011,1.28474,2225,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2756  1120 23616  2249  2107  1521
  1106  2012  1105 13753   118  7449 23891  1107 14105  7343  1628 24309
  1114  7300  1193   118  7503  3001  1104 26624  2162  1495  2838  1105
  1120   170  7300  1193   118  7503 13753   117  1112   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANNX,ANX007 - (ARCHER-II),Geographic atrophyÂ ,Phase 2,2024-10-22,"Phase 2 data from AAO reported that 0% (0/56) ANX007 monthly-treated patients with less advanced disease lost 15 letters, or three lines on an eye chart, vs. 17% (10/59) sham patients, and 6% (5/89) A",109.0,799.80049,78.8957,7.48,7.57,7.57,0.011960275,0.011960275,0.015193804,-0.004168579,8.22682,0.0773,5.10154,2226,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  1121 10419  2346  2103  1115   121   110   113
   121   120  4376   114 23096  3190  7629  1559  7868   118  5165  4420
  1114  1750  3682  3653  1575  1405  3784   117  1137  1210  2442  1113
  1126  2552  3481   117  5016   119  1542   110   113  1275   120  4589
   114   188  2522  4420   117  1105   127   110   113   126   120  5840
   114   138   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,2024-10-22,"Phase 2 new survival data showing a 55% one-year survival rate with the Bria-IMT regimen, surpassing current SoC, noted October 22, 2024.",1.0,44.43928,141.308,119.42994,130.82993,124.84494,0.091168312,0.044342564,0.015193804,-0.004168579,0.0,0.0,5.55766,2227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1207  8115  2233  4000   170  3731   110  1141   118
  1214  8115  2603  1114  1103   139  3464   118   146 13910  6716  1179
   117  8910 21793  1954  1573  1658   117  2382  1357  1659   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Phase 1,2024-10-22,"Phase 1 data presented at EANM reported favorable biodistribution, tumor uptake, and low off-target binding, noted October 22, 2024.",6.0,18.48192,128.1719,5.25,5.25,16.21,0.0,1.127400259,0.015193804,-0.004168579,3.19223,0.0236,0.20525,2228,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2233  2756  1120 23616  2249  2107  2103 11169 25128
 10396 14970   117 14601  1146 13482   117  1105  1822  1228   118  4010
  7861   117  2382  1357  1659   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GNLX,Olvimulogene Nanivacirepvec (Olvi-Vec) - (VIRO-25),Malignant pleural effusion (MPE) due to non-small cell lung cancer (NSCLC) or breast cancerÂ ,Phase 2,2024-10-22,"Phase 2 dosing commenced, noted October 22, 2024.",37.0,88.66556,128.1592,2.65,2.6,3.09,-0.019048195,0.153611451,0.015193804,-0.004168579,3.28066,0.01013,1.11352,2229,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123 18463  1158  8042   117  2382  1357  1659   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PFE,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD)Â ,Approved,2024-10-22,"FDA Approved on October 22, 2024.",0.0,163427.4857,23.0641,28.93,28.84,28.46,-0.003115807,-0.016379526,0.015193804,-0.004168579,1.19329,0.00078,837.40943,2230,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762   138  8661 16011  1113  1357  1659   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANRO,ALTO-100,Major depressive disorderÂ ,Phase 2b,2024-10-22,"Phase 2b study did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, noted October 22, 2024.",27.0,391.71388,82.8185,14.29,14.53,4.01,0.016655486,-1.270768751,0.015193804,-0.004168579,15.26856,0.08361,24.71915,2231,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830  2025  1225  1136 10541  8331  1107  1260 16568
  8006  3402  1106  1282  4043  1107  4420  1114   170  2962   118  1359
 12176 25128  8519  1200   117  2382  1357  1659   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RXRX,REC-3964,Difficile ColitisÂ ,Phase 2,2024-10-22,"Phase 2 dosing initiated, noted October 22, 2024.",434.0,1857.2003,71.7869,6.76,6.61,6.74,-0.022439236,-0.002962965,0.015193804,-0.004168579,22.27253,0.2161,18.79568,2232,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123 18463  1158  7087   117  2382  1357  1659   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GYRE,Hydronidone (F351),Chronic hepatitis B (CHB)-associated liver fibrosis in the PRCÂ ,Phase 3,2024-10-22,"Phase 3 last patient completed, noted October 22, 2024.",96.0,1307.00433,87.2488,14.15,13.99,14.97,-0.011371835,0.056333574,0.015193804,-0.004168579,0.48949,0.10156,0.13712,2233,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  1314  5351  2063   117  2382  1357  1659   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
OKYO,Urcosimod (OK-101),Neuropathic corneal pain (NCP)Â ,Phase 2,2024-10-23,"Phase 2 initiated, noted October 23, 2024.",33.0,41.61867,96.9286,1.03,1.23,1.165,0.177455367,0.123162285,0.01043381,-0.001525243,0.61964,0.08539,1.24299,2234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  7087   117  2382  1357  1695   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GLUE,MRT-50969,CCNE1-amplified solid tumorsÂ ,Preclinical,2024-10-23,"Preclinical data from EORTC-NCI-AACR reported that treatment induced robust tumor growth suppression and regression, noted October 23, 2024.",61.0,298.85977,91.8041,5.31,4.87,9.22,-0.086497898,0.551783202,0.01043381,-0.001525243,7.13245,0.11693,0.81293,2235,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  1121   142  9565  9481   118 14056
  2240   118 10419 23554  2103  1115  3252 10645 17351 14601  3213 18793
  1105  1231 24032   117  2382  1357  1695   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RPTX,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid TumorsÂ ,Phase 1,2024-10-23,"Phase 1 data reported that after 9 weeks on therapy, there was no observed impact on Progression Free Survival (PFS) in patients who started on or switched to the schedule of 2 weeks on / 1 week off o",42.0,145.58818,65.358,3.52,3.43,3.45,-0.025900728,-0.020086759,0.01043381,-0.001525243,1.67812,0.23552,0.26968,2236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1115  1170   130  2277  1113  7606   117
  1175  1108  1185  4379  3772  1113 12798  1988  4299 26849   113   153
 17691   114  1107  4420  1150  1408  1113  1137  6759  1106  1103  6030
  1104   123  2277  1113   120   122  1989  1228   184   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SDGR,SGR-3515,Solid tumorsÂ ,Preclinical,2024-10-23,"Preclinical data presented at EORTC-NCI-AACR reported superior anti-tumor activity of SGR-3515 compared to inhibitors of Wee1 or Myt1 alone due to strong target engagement of both Wee1 and Myt1, noted",73.0,1319.07318,52.5808,18.68,18.12,17.58,-0.030437132,-0.060691541,0.01043381,-0.001525243,12.07283,0.20089,16.02283,2237,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554  2103  7298  2848   118 14601  3246  1104
   156 27617   118  2588 16337  3402  1106 27558  1116  1104  1284  1162
  1475  1137  1422  1204  1475  2041  1496  1106  2012  4010  8164  1104
  1241  1284  1162  1475  1105  1422  1204  1475   117  2382   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RVMD,Daraxonrasib (RMC-6236),Advanced Solid TumorsÂ ,Phase 1,2024-10-23,"Updated Phase 1 data from AACR-NCI-EORTC reported progression-free survival (PFS) and overall survival (OS) at daily doses ranging from 160 mg to 300 mg, noted October 23, 2024.",186.0,8103.05913,38.643,47.13,48.51,50.5,0.028860221,0.069063595,0.01043381,-0.001525243,9.78379,0.12358,125.22323,2238,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 17451 12278   122  2233  1121 10419 23554   118 14056  2240   118
   142  9565  9481  2103 16147   118  1714  8115   113   153 17691   114
  1105  2905  8115   113 11570   114  1120  3828 24429  7032  1121  7690
 17713  1106  3127 17713   117  2382  1357  1695   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GANX,GT-03842,OncologyÂ ,Preclinical,2024-10-23,"Presentation at ENA reported that GT-03842 and its analogues were found to inhibit DDR2 phosphorylation in a dose-dependent manner, noted October 23, 2024.",35.0,68.43503,116.9268,2.69,2.68,2.18,-0.003724399,-0.210216317,0.01043381,-0.001525243,2.56222,0.02924,0.5884,2239,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 13653  1891  1120   142 11185  2103  1115 14965   118  5347  1604
 23117  1105  1157 26116  1116  1127  1276  1106  1107 23034 23232  2069
  1477   185 15342  7880  4649  6840  1107   170 13753   118  7449  4758
   117  2382  1357  1695   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
COGT,CGT6297,Solid tumorsÂ ,Preclinical,2024-10-23,"Preclinical data presented at EORTC-NCI-AACR 2024 demonstrated robust inhibition of downstream signaling and efficacy, noted October 23, 2024.",139.0,1346.2407,60.039,12.24,12.3,12.01,0.004889985,-0.018969641,0.01043381,-0.001525243,7.58192,0.00095,10.27425,2240,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554 17881  1527  7160 17351  1107 16485  1104
 14102 16085  1105 23891   117  2382  1357  1695   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OLMA,OP-3136,Breast CancerÂ ,Preclinical,2024-10-23,"Preclinical data presented at the EORTC-NCI-AACR demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND su",68.0,681.56173,71.605,12.46,11.91,11.63,-0.04514513,-0.068935547,0.01043381,-0.001525243,14.8728,0.04439,6.8005,2241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2756  1120  1103   142  9565  9481
   118 14056  2240   118 10419 23554  7160 17351  2848   118 14601  3246
  1112   170  1423  3677   117  1112  1218  1112   188 10941 17292  1105
  9927  2848   118 14601  3246  1107  4612  1114   185  5971 11846  4487
  2227   132 15969  2137 28117   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ORIC,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLCÂ ",Preclinical,2024-10-23,"Preclinical data presented at the EORTC-NCI-AACR 2024 demonstrated systemic and intracranial clinical responses in heavily pre-treated patients with EGFR and HER2 exon 20 insertion mutations, noted Oc",97.0,622.18464,71.0279,8.71,8.82,9.42,0.012550079,0.078363298,0.01043381,-0.001525243,17.38366,0.06252,7.75117,2242,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2756  1120  1103   142  9565  9481
   118 14056  2240   118 10419 23554 17881  1527  7160 27410  1105  1107
  4487  1665 23851  1348  7300 11317  1107  3777  3073   118  5165  4420
  1114   142  2349  2271  2069  1105   145  9637  1477  4252  1320  1406
 27914 17157   117  2382   152  1665   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
APRE,APR-1051 - (ACESOT-1051),Solid tumorsÂ ,Phase 1,2024-10-23,"Phase 1 clinical efficacy and safety from EORTC-NCI-AACR reported that one patient had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the thi",5.0,21.18442,71.4722,4.18,3.9,4.01,-0.069334693,-0.041520005,0.01043381,-0.001525243,0.24222,0.05931,0.07627,2243,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  7300 23891  1105  3429  1121   142  9565  9481   118
 14056  2240   118 10419 23554  2103  1115  1141  5351  1125  3653 16147
  1120  3927  1552   117   170  1248  6367  1378  3164  1552  1104  3252
  1105 18463  1158  1110  7173  1107  1103 24438  1182   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CATX,[203/212Pb]Pb-PSV359,Solid TumorsÂ ,Preclinical,2024-10-23,"Preclinical findings presented at EANM demonstrated that drug exhibits strong binding affinity and selectivity for hFAP, noted October 23, 2024.",74.0,788.22943,79.419,12.39,11.69,11.47,-0.05815592,-0.077154764,0.01043381,-0.001525243,14.22178,0.00241,6.71654,2244,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  9505  2756  1120 23616  2249  2107  7160
  1115  3850 10877  2012  7861 18859  1105  8247  6366  1111   177  8842
  2101   117  2382  1357  1695   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MAIA,MAIA-2021-020,Solid TumorsÂ ,Preclinical,2024-10-23,"Preclinical data shared at EORTC-NCI-AACR Symposium reported that MAIA-2022-12 and MAIA-2021-20 resulted in tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma",32.0,63.59318,91.3313,2.7501,2.66,2.8,-0.033311152,0.017982143,0.01043381,-0.001525243,2.90092,0.0147,0.11466,2245,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  3416  1120   142  9565  9481   118
 14056  2240   118 10419 23554 26520  2103  1115  9960  9984   118 17881
  1477   118  1367  1105  9960  9984   118 17881  1475   118  1406  3657
  1107 14601  3213  1107 16485  1107  3073  1665 21472  7867  3584  1104
 13093  4182   117  2942 10294  6163  1610 16430  7903   117  1143  4371
  7903   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Preclinical,2024-10-23,"Phase 1 progressed to Cohort 2. The Safety Review Committee approved the move after a favorable safety assessment of Cohort 1, with no significant safety issues or dose-limiting toxicities observed, n",0.0,11.61931,253.5245,563.64036,621.85239,465.69629,0.098286361,-0.190882705,0.01043381,-0.001525243,8.00983,0.01098,1.79467,2246,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   122 12687  1106  3291 13252  1204   123   119  1109  9218
  4960  2341  4092  1103  1815  1170   170 11169  3429  8670  1104  3291
 13252  1204   122   117  1114  1185  2418  3429  2492  1137 13753   118
 15816 12844  4233  4379   117   183   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ZLAB,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLCÂ ",Phase 1b,2024-10-24,"Phase 1a/1b trial preliminary data shared at the EORTC-NCI-AACR Symposium reported an objective response rate (ORR) of 74% across all tested dose levels, noted October 24, 2024.",109.0,3256.27903,63.2297,28.94,33.18,30.22,0.136722564,0.043279236,-0.004953059,-0.003717093,4.83903,0.05229,140.27718,2247,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1161   120   122  1830  3443  9889  2233  3416  1120
  1103   142  9565  9481   118 14056  2240   118 10419 23554 26520  2103
  1126  7649  2593  2603   113 23066  2069   114  1104  5692   110  1506
  1155  7289 13753  3001   117  2382  1357  1572   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTN,PL9643 - (MELODY-1),Dry eye disease (DED)Â ,Phase 3,2024-10-24,"Phase 3 data presentation reported that PL9643 has a positive effect across multiple regions of the eye in patients with moderate and severe dry eye disease (DED), with an excellent ocular safety/tole",46.0,104.79346,52.5033,0.064,0.064,0.069,0.0,0.075223421,-0.004953059,-0.003717093,0.0,0.05883,0.07627,2248,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  8685  2103  1115   153  2162  1580 22433  1495
  1144   170  3112  2629  1506  2967  4001  1104  1103  2552  1107  4420
  1114  8828  1105  5199  3712  2552  3653   113 18581  2137   114   117
  1114  1126  6548   184 11702  3429   120  1106  1513   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTN,PL9654,Retinal diseasesÂ ,Preclinical,2024-10-24,"Preclinical data reported that PL9654 0.05 mg/kg causes a reduction in microglia and negative enrichment of genes associated with immune-related pathways, noted October 24, 2024.",46.0,104.79346,52.5033,0.064,0.064,0.069,0.0,0.075223421,-0.004953059,-0.003717093,0.0,0.05883,0.07627,2249,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2103  1115   153  2162  1580 27677
  1527   121   119  4991 17713   120  4023  4680   170  7234  1107 17599
 22812  1105  4366  4035 10886  1880  1104  9077  2628  1114 11650   118
  2272 19530   117  2382  1357  1572   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BBIO,BBP-812 - (CANaspire),Canavan DiseaseÂ ,Phase 1/2,2024-10-24,"Phase 1/2 preliminary data showed significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose, noted",191.0,4544.75128,53.2306,24.45,24.17,23.41,-0.011518021,-0.043466934,-0.004953059,-0.003717093,9.4557,0.06292,40.50034,2250,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  9889  2233  2799  2418  1105  8505  7234
  1116  1107   151   118 20839  2340 25552  9349  2193   113   151 11189
   114  3001  1107 19968   117   172  9014 12725 20080 14196  8240   113
 24821  2271   114   117  1105  3575  1107  1155  6635  1150  1460  1822
 13753   117  2382   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KURA,Ziftomenib and imatinib - (KOMET-015),Gastrointestinal Stromal Tumors (GIST)Â ,Preclinical,2024-10-24,"Preclinical data showed robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models, noted October 24, 2024.",86.0,1362.56134,38.1766,17.02,17.78,16.72,0.043685107,-0.017783515,-0.004953059,-0.003717093,12.12585,0.28331,27.73337,2251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2799 17351  1105  3840  9739  2848
  8928  1766  3246  1107 13280 11745  2605  1830   118  7246   113   122
  2162   114  1105 13280 11745  2605  1830   118 13676   113   123  2162
   120   124  2162   114   144  6258  1942  3584   117  2382  1357  1572
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RCUS,Casdatifan (AB521) + volrustomig,Clear cell renal cell carcinoma (ccRCC)Â ,Phase 2,2024-10-24,"Phase 2 first clinical data presented at EORTC-NCI-AACR reported an objective response rate of 34%, noted October 24, 2024.",107.0,1630.15241,55.1185,17.33,17.83,15.3,0.028443328,-0.124586275,-0.004953059,-0.003717093,6.93216,0.20296,34.68643,2252,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1148  7300  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554  2103  1126  7649  2593  2603  1104  3236
   110   117  2382  1357  1572   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PRLD,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,2024-10-24,"Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d",56.0,117.57755,133.328,1.64,1.55,1.2,-0.056441311,-0.312374685,-0.004953059,-0.003717093,3.28459,0.02296,0.53687,2253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233 11984  3416  1120  1103   142  9565  9481   118
 14056  2240   118 10419 23554  2103  3659  7597 11317   113 11629  1116
   114  1127  4379  1107   125  4420   113   123 13936  4184 19911  1348
   117   123   151 10844 12674   114   117  1259   123  1104   130   151
 10844 12674  4420  1114  3659 11629  1116  1120   173   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,2024-10-24,"Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d",0.0,268385.61,23.5447,106.38,105.88,102.32,-0.004711212,-0.038912432,-0.004953059,-0.003717093,1.02737,0.05257,878.37339,2254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233 11984  3416  1120  1103   142  9565  9481   118
 14056  2240   118 10419 23554  2103  3659  7597 11317   113 11629  1116
   114  1127  4379  1107   125  4420   113   123 13936  4184 19911  1348
   117   123   151 10844 12674   114   117  1259   123  1104   130   151
 10844 12674  4420  1114  3659 11629  1116  1120   173   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VRCA,VP-315 (LTX-315),Basal cell carcinomaÂ ,Phase 2,2024-10-24,Phase 2 presented data at the Fall Clinical Dermatology Conference highlighting that approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual t,9.0,64.00283,116.8493,15.1,15.0,14.0,-0.006644543,-0.075637414,-0.004953059,-0.003717093,10.62455,0.05797,0.48753,2255,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  2756  2233  1120  1103  6760 15961  9682 21943  4807
  3047 23201  1115  2324  4062   110  1104 24309  5165  1107  4539   123
  3890  2335  1117  2430  7810 16443  1105  4420  1114 25399   189   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,2024-10-24,"Phase 2b data presented at the NEALS meeting reported a 2-fold reduction of several miRNAs following PrimeC treatment, noted October 24, 2024.",23.0,23.55992,90.2988,1.15,1.21,1.25,0.050858417,0.083381609,-0.004953059,-0.003717093,1.21061,0.08246,0.378,2256,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1830  2233  2756  1120  1103 26546 12507  1708  2309
  2103   170   123   118 11203  7234  1104  1317  1940 15654  1116  1378
  3460  1658  3252   117  2382  1357  1572   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LEXX,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),DiabetesÂ ,Preclinical,2024-10-24,"Preclinical data reported that of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, wh",19.0,47.64558,87.8908,2.7,2.73,2.15,0.011049836,-0.227783931,-0.004953059,-0.003717093,1.5796,0.01561,0.19022,2257,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101 11689  1665 21472  7867  2233  2103  1115  1104  1103  2022  8690
  2114  2103  1113  2052   117  3177  7889  7412 12880 23258   118 18893
  2137  1372   139  1105  1103  6753  3177  7889  7412 12880 23258   118
   181  5132  1403 25937  3269  1372   145  1127  1241  2265  1107  7914
  1892  6656  3001   117   192  1324   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ERAS,Naporafenib plus trametinib - (SEACRAFT-1),RAS Q61X solid tumorsÂ ,Phase 1b,2024-10-24,"Phase 1b data from EORTC-NCI-AACR reported that 40% (4/10) response rate observed in the melanoma cohort, including three confirmed partial responses (cPR) and one unconfirmed partial response (uPR),",283.0,728.54132,70.4049,2.58,2.58,2.59,0.0,0.003868477,-0.004953059,-0.003717093,11.93473,0.07876,3.14512,2258,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830  2233  1121   142  9565  9481   118 14056  2240
   118 10419 23554  2103  1115  1969   110   113   125   120  1275   114
  2593  2603  4379  1107  1103  1143  4371  7903  1884 13252  1204   117
  1259  1210  3659  7597 11317   113   172 22861   114  1105  1141  8362
  7235 22750  7597  2593   113   190 22861   114   117   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
APGE,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD)Â ",Phase 1,2024-10-24,"Phase 1 9 month data reported that MAD cohorts showed similar inhibition of pSTAT6 through available follow-up. Single doses of APG777 suppressed TARC, an inflammatory mediator and the most strongly c",59.0,2944.57566,54.7374,51.43,51.95,52.04,0.010060058,0.011790994,-0.004953059,-0.003717093,12.11178,0.06891,13.31546,2259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   130  2370  2233  2103  1115  9960  2137  1884 13252
  2145  2799  1861  1107 16485  1104   185  9272 13821  1545  1194  1907
  2812   118  1146   119  8353 24429  1104 10997  2349  1559  1559  1559
 14336   157 12426  1658   117  1126 22653  2394  2772  1105  1103  1211
  5473   172   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
REGN,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU)Â ,Phase 3,2024-10-24,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",105.0,100260.384,21.0086,941.39,928.9,838.2,-0.013356416,-0.116100771,-0.004953059,-0.003717093,1.58978,0.17293,486.20948,2260,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103  1115  3840  8508 25926  1204  5409  3549
  1122  1732  1105 20844  2707  3246  1121  2259  2568   132  3746   110
  1104  4420  3890  1218   118  4013  3653  2781   117  2382  1357  1572
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNY,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU)Â ,Phase 3,2024-10-24,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",0.0,122349.8341,22.4395,52.89,52.05,52.88,-0.01600949,-0.00018909,-0.004953059,-0.003717093,0.0,0.0,172.09349,2261,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103  1115  3840  8508 25926  1204  5409  3549
  1122  1732  1105 20844  2707  3246  1121  2259  2568   132  3746   110
  1104  4420  3890  1218   118  4013  3653  2781   117  2382  1357  1572
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GSK,Arexvy (60+ at increased risk) - (AReSVi-006),"Respiratory Syncytial Virus Vaccine, AdjuvantedÂ ",Phase 3,2024-10-24,"Additional Phase 3 data reported that a single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. noted October 24, 202",0.0,59369.66765,22.3779,14.48,14.555,13.925,0.00516619,-0.039082601,-0.004953059,-0.003717093,0.0,0.02581,95.3868,2262,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  8154 12278   124  2233  2103  1115   170  1423 13753  1104 20034
  8468 22308  1174 17351 11650  2593  1114 12095  3429  6168  1107  6323
  4079  1407   118  3927  1120  2569  3187  1111 25591  2559   118   149
 10460  2137   119  2382  1357  1572   117 17881   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PFE,"PREVNAR 20 + seasonal influenza vaccine (SIIV, Fluad Quadrivalent)",Pneumonia and influenza for >65 yrsÂ ,NDA Filing,2024-10-24,"ACIP voted to expand the recommendation, noted October 24, 2024.",0.0,162294.1466,23.0894,28.86,28.64,28.3,-0.007652211,-0.019594749,-0.004953059,-0.003717093,1.25195,0.00078,901.40353,2263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  9690 11410  4751  1106  7380  1103 13710   117  2382  1357  1572
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRNS,Ganaxolone - (TrustTSC),Tuberous Sclerosis ComplexÂ ,Phase 3,2024-10-24,"Phase 3 study did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency, noted October 24, 2024.",55.0,3146.95958,36.1322,42.0,42.0,42.47,0.0,0.011128326,-0.004953059,-0.003717093,0.0,0.05341,0.46145,2264,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,pos,"[  101 12278   124  2025  1225  1136  2283  1103  2425  1322  7587  1104
  3029  1849  1107  1743   118  1285   157 10844   118  2628 20752  5625
   117  2382  1357  1572   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LYEL,LYL845,Solid TumorsÂ ,Phase 1,2024-10-24,"Program discontinued, noted October 24, 2024.",19.0,279.04338,106.6589,23.0,21.8,19.206,-0.053584246,-0.180271486,-0.004953059,-0.003717093,4.20272,0.07407,3.21343,2265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  4659  8779   117  2382  1357  1572   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NTLA,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE)Â ,Phase 2,2024-10-24,Phase 2 data presentation at ACAAI showed that deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% comp,107.0,1610.03013,63.3847,19.94,15.85,14.22,-0.229558264,-0.33807834,-0.004953059,-0.003717093,16.10642,0.33781,180.36815,2266,0,0,1,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  2233  8685  1120  9690 11189  2240  2799  1115  1996
  2035  2603  7234  1116  3890  1107  1241 13753  3001  7289   132   170
  1423  1851 17713 13753  3657  1107   170  1928  7868  2035  2603  7234
  1104  5581   110  1105  5615   110  3254  1643   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PHVS,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,2024-10-24,"Phase 2 data presented at ACAAI provided further evidence on the long-term safety and efficacy of deucrictibant for prevention of HAE attacks , noted October 24, 2024.",54.0,1151.98448,68.0411,22.21,21.33,24.87,-0.040428105,0.11311962,-0.004953059,-0.003717093,0.24397,0.06274,1.56121,2267,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2756  1120  9690 11189  2240  2136  1748  2554
  1113  1103  1263   118  1858  3429  1105 23891  1104  1260 21977  4907
  3121  7167  1204  1111 13347  1104   145  1592  2036  3690   117  2382
  1357  1572   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
DTIL,PBGENE-PMM,Primary mitochondrial myopathiesÂ ,Preclinical,2024-10-24,"Preclinical data reported that targeted gene insertion can be achieved using ARCUS in greater than 85% of T cells and 39% of non-dividing primary human hepatocytes, noted October 24, 2024.",11.0,61.34229,44.8332,8.55,8.48,8.56,-0.008220833,0.001168907,-0.004953059,-0.003717093,2.96472,0.22886,0.72675,2268,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2103  1115  9271  5565 27914  1169
  1129  3890  1606 22133 23520  1708  1107  3407  1190  4859   110  1104
   157  3652  1105  3614   110  1104  1664   118 18699  2425  1769  1119
  4163  2430  3457  3052   117  2382  1357  1572   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PROK,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKDÂ ",Phase 2,2024-10-24,Phase 2 interim results presented at Kidney Week reported that six SAEs in 51 patients were related to the kidney biopsy procedure and one SAE was related to the injection procedure. No product relate,294.0,217.43864,121.6323,1.7,1.725,1.6,0.014598799,-0.060624622,-0.004953059,-0.003717093,8.51685,0.01285,0.43113,2269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 10572  2686  2756  1120  9847  4695  6237  2103  1115
  1565 13411 27485  1107  4062  4420  1127  2272  1106  1103 16042 25128
 12685  7791  1105  1141 13411  2036  1108  2272  1106  1103 14546  7791
   119  1302  3317 15123   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
EYPT,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD)Â ,Phase 3,2024-10-24,"Phase 3 trial dosing was initiated based on DAVIO-2 study results, noted October 24, 2024.",68.0,511.63409,108.4392,9.96,9.56,11.76,-0.040989345,0.166126871,-0.004953059,-0.003717093,17.13697,0.01884,2.68936,2270,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  3443 18463  1158  1108  7087  1359  1113   141 26390
 19368   118   123  2025  2686   117  2382  1357  1572   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RXRX,EXS73565 (â€˜565),Haematological cancersÂ ,Preclinical,2024-10-24,"Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining â€˜565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC-",434.0,1786.95824,71.8628,6.33,6.36,6.32,0.004728141,-0.001581028,-0.004953059,-0.003717093,21.15415,0.2161,18.66331,2271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  1121  1103   142  9565  9481   118
 14056  2240   118 10419 23554   113   142 11185   114  2103  1115 12459
   100  1114   195 19762  1107  3584  1104   139   118  2765 12477  2646
 12149  9885  2136  6353   117  1167  3840  9739 23891  1190  1719  3677
  2041   117  1259  1107  5254   118   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
EXAI,EXS73565 (â€˜565),Haematological cancersÂ ,Preclinical,2024-10-24,"Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining â€˜565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC-",125.0,134.68206,43.3627,1.366,1.384,1.346,0.013091096,-0.01474953,-0.004953059,-0.003717093,0.0,0.00404,0.13298,2272,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  1121  1103   142  9565  9481   118
 14056  2240   118 10419 23554   113   142 11185   114  2103  1115 12459
   100  1114   195 19762  1107  3584  1104   139   118  2765 12477  2646
 12149  9885  2136  6353   117  1167  3840  9739 23891  1190  1719  3677
  2041   117  1259  1107  5254   118   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,IDE397 + Trodelvy (sacituzumab-govitecan-hziy),MTAP-Deletion Bladder CancerÂ ,Phase 1,2024-10-25,"Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC",0.0,110804.2952,22.7336,88.78,89.0,89.51,0.00247497,0.008188951,-0.012670038,-0.020558428,1.32391,0.02712,510.41456,2273,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  3443  8685  1120   142  9565  9481   118 14056  2240
   118 10419 23554  2103  1126  3081   110 23066  2069  1118   155  8231
  6258  1942   122   119   122   131   122 15531   116   129 11629  1116
  1149  1104  1765   174  7501  6718  2165  3777  3073   118  5165   113
  3151   123   118   124  2988  2442   117  7032  1121   122   118   128
   114   150  9159  2101   118  3687 26883  1320 16991  1105   151 10844
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IDYA,IDE397 + Trodelvy (sacituzumab-govitecan-hziy),MTAP-Deletion Bladder CancerÂ ,Phase 1,2024-10-25,"Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC",87.0,2475.30777,48.5647,29.2,29.3,28.6,0.003418807,-0.020761991,-0.012670038,-0.020558428,11.37237,0.27874,29.71723,2274,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  3443  8685  1120   142  9565  9481   118 14056  2240
   118 10419 23554  2103  1126  3081   110 23066  2069  1118   155  8231
  6258  1942   122   119   122   131   122 15531   116   129 11629  1116
  1149  1104  1765   174  7501  6718  2165  3777  3073   118  5165   113
  3151   123   118   124  2988  2442   117  7032  1121   122   118   128
   114   150  9159  2101   118  3687 26883  1320 16991  1105   151 10844
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ZYME,ZW220,"NSCLC, ovarian and uterine cancerÂ ",Preclinical,2024-10-25,"Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity across a wide range of hepatocellular carcinoma (HCC) models, including those with lower and heterogenous GPC3 expres",75.0,918.64275,35.6041,12.92,12.93,13.28,0.000773694,0.027482646,-0.012670038,-0.020558428,5.86041,0.13112,3.28167,2275,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554  2103   170  2012  2848   118 14601  3246
  1506   170  2043  2079  1104  1119  4163  2430 18091  1610 16430  7903
   113 18315  1658   114  3584   117  1259  1343  1114  2211  1105  1119
 25710  4915  2285 15175  1658  1495  4252  1643  4894   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TYRA,TYRA-300 - (SURF301),Bladder and solid tumorsÂ ,Phase 1/2,2024-10-25,"Phase 1/2 trial dosing initiated, noted November 29, 2022. Phase 1/2 data presented at EORTC-NCI-AACR reported that 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response",53.0,1158.03858,70.4508,28.61,21.93,16.39,-0.265900745,-0.557084914,-0.012670038,-0.020558428,4.165,0.15915,54.44087,2276,0,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122   120   123  3443 18463  1158  7087   117  2382  1379
  1853   117 17881  1477   119 12278   122   120   123  2233  2756  1120
   142  9565  9481   118 14056  2240   118 10419 23554  2103  1115   127
  1149  1104  1429   113  4335   119   126   110   114  4420  1114   143
  2349  2271  2069  1495   116   182 21986  3890   170  3659  7597  2593
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PPBT,IM1240 - (CAPTN-3),CancerÂ ,Preclinical,2024-10-25,Preclinical data presented at EORTC-NCI-AACR reported sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arm,2.0,29.35465,90.8744,0.081,0.081,0.062,0.0,-0.26731477,-0.012670038,-0.020558428,0.0,0.00975,0.0,2277,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554  2103  8505 14601  1231 24032  1107   170
  9225  4366  7209  4182  1107   118   191 15435  2235   132   138 13753
  7449  3246  1105   170   188 10941 10805  5562  2629  1104  1103  8306
  1197  1981   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANIP,"Estradiol Gel, 0.06% - (generic version of EstroGel Gel, 0.06%)",Hot flashes and to treat moderate to severe menopausal changesÂ ,Approved,2024-10-25,"Approved October 25, 2025.",21.0,1138.29378,39.0383,59.28,58.32,58.19,-0.016326893,-0.018558462,-0.012670038,-0.020558428,10.49602,0.04312,9.06649,2278,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1357  1512   117 17881  1571   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AQST,Anaphylm (AQST-109) - (EPIPHAST II),Allergic reactions (anaphylaxis)Â ,Phase 2,2024-10-25,"Trial PK and PD data reported that 87.5% of subjects showing no change in film location between 1.5 to 3 minutes after administration of Anaphylm, noted October 25, 2024.",99.0,499.91808,70.8888,5.48,5.49,5.52,0.001823155,0.007272759,-0.012670038,-0.020558428,11.85041,0.00533,8.53072,2279,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12819   153  2428  1105 27802  2233  2103  1115  5966   119   126
   110  1104  5174  4000  1185  1849  1107  1273  2450  1206   122   119
   126  1106   124  1904  1170  3469  1104  9954 22192 13505   117  2382
  1357  1512   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JNJ,TREMFYA (guselkumab) - (SPECTREM),Plaque psoriasis (PsO)Â ,Phase 3,2024-10-25,"Phase 3b data reported statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement, noted October 25, 2024.",0.0,387338.3837,16.8296,163.67,160.88,160.13,-0.01719346,-0.02186622,-0.012670038,-0.020558428,0.77501,0.02418,1029.70424,2280,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  1830  2233  2103 11435  7467  1506  1155  2425  1105
  3718  1322 21521  1107  1822  1404  2473  1298 15604 16420  4863  1114
  1957  1751  6083   117  2382  1357  1512   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ITRM,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,Approved,2024-10-25,"Approved October 25, 2024.",44.0,42.68727,99.6782,1.17,1.88,1.22,0.474268028,0.04184711,-0.012670038,-0.020558428,0.94188,0.02634,196.53692,2281,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1357  1512   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,2024-10-25,"Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic",256.0,123295.4224,20.1374,471.91,477.7,471.12,0.012194631,-0.001675451,-0.012670038,-0.020558428,1.66269,0.19003,487.11165,2282,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830   120   123  1161  1207  2233  1113  2908 17713
  9314   154  1527  2277  1107   146  1403  1592 24928  7880 12736 23610
  2799  1928 19753 23554  7234  1121  2259  2568  1104  5046   110  4379
  1120  3615  2277   117  2628  1114  6111  1231  7050  3053   113   174
  2349  2271  2069   114  1105  5519   110 11190 12257   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,2024-10-25,"Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic",68.0,66.19524,20.4773,7.6,7.6,7.8,0.0,0.025975486,-0.012670038,-0.020558428,0.0,0.06131,0.0,2283,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123  1161  1207  2233  1113  2908 17713
  9314   154  1527  2277  1107   146  1403  1592 24928  7880 12736 23610
  2799  1928 19753 23554  7234  1121  2259  2568  1104  5046   110  4379
  1120  3615  2277   117  2628  1114  6111  1231  7050  3053   113   174
  2349  2271  2069   114  1105  5519   110 11190 12257   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IRON,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemiaÂ ,Phase 1/2,2024-10-25,"Phase 1b/2 data presented at ASN demonstrated that a single dose results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD",34.0,1367.68236,51.6969,46.0,46.01,47.13,0.000217368,0.024268344,-0.012670038,-0.020558428,4.97094,0.12263,18.8509,2284,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123  2233  2756  1120 15278  2249  7160
  1115   170  1423 13753  2686  1107  8505 18793  1104  1119  1643 16388
  1394  1105 13221 15100  1104  3926   117  1105  2569 14044 25669  8167
  4184  8136 16317  1105  3001  1104 23123  8032  2858  7939  1107   151
  2137  2137   118   140  2428  2137   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
KALV,Sebetralstat - (KONFIDENT-S),Hereditary angioedema (HAE)Â ,Phase 3,2024-10-25,"Phase 3 data presented at ACAAI reported that patients treated with sebetralstat 300mg (n=49, P=0.002) and sebetralstat 600mg (n=52, P=0.034) achieved a faster reduction in substantial symptom burden",50.0,504.75671,59.3354,12.07,11.68,10.61,-0.032845058,-0.128926082,-0.012670038,-0.020558428,15.75893,0.03311,1.39144,2285,0,1,0,0,1,1,0,0,0,0,0,0,3,0,0,1,neg,"[  101 12278   124  2233  2756  1120  9690 11189  2240  2103  1115  4420
  5165  1114 14516 16632 16179 19756  3127  1306  1403   113   183   134
  3927   117   153   134   121   119  3135  1477   114  1105 14516 16632
 16179 19756  4372  1306  1403   113   183   134  3882   117   153   134
   121   119  5347  1527   114  3890   170  4946  7234  1107  6432   188
 17162  6451  4165 11904   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVCT,NXP900,Non-small cell lung cancer (NSCLC)Â ,Phase 1,2024-10-25,"Data reported at AACR-NCI-EORT noted that NXP900 as a single agent potently inhibits cell proliferation of ALK fusion driven cell lines that are resistant to crizotinib, alectinib and lorlatinib, note",25.0,163.39755,70.0429,8.75,8.76,6.41,0.001142205,-0.311194429,-0.012670038,-0.020558428,5.61216,0.00286,0.79798,2286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  7154  2103  1120 10419 23554   118 14056  2240   118   142  9565
  1942  2382  1115   151  3190  2101 21500  1568  1112   170  1423  3677
 18106  1193  1107 23034  1116  2765 23766  1104 18589  2428 11970  4940
  2765  2442  1115  1132 13676  1106   172 28021  3329  4729  1830   117
 23280  5822  4729  1830  1105 25338 17670 11745  2605  1830   117  3805
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATXS,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteersÂ ",Phase 1/2,2024-10-25,Phase 1b/2 data presented at the ACAAI reported rapid inhibition of plasma kallikrein was associated with reductions in HAE attacks and with a favorable safety profile during the first 28 days of the,56.0,647.19799,58.7203,11.68,11.47,11.32,-0.018143046,-0.031306905,-0.012670038,-0.020558428,6.19255,0.08349,1.86798,2287,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  1830   120   123  2233  2756  1120  1103  9690 11189
  2240  2103  6099  1107 16485  1104 13441 24181  6473  1377  1874  1394
  1108  2628  1114  7234  1116  1107   145  1592  2036  3690  1105  1114
   170 11169  3429  6168  1219  1103  1148  1743  1552  1104  1103   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RVMD,RMC-9805,"Pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.Â ",Phase 1,2024-10-25,"Phase 1 preliminary safety data presented at AACR-NCI-EORTC reported acceptable tolerability and encouraging initial antitumor activity, with durability assessment pending longer follow-up, noted Octo",186.0,7753.94773,38.8185,47.25,46.42,55.09,-0.017722253,0.153515558,-0.012670038,-0.020558428,9.97546,0.07546,96.68061,2288,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   122  9889  3429  2233  2756  1120 10419 23554   118 14056
  2240   118   142  9565  9481  2103 12095  1106  2879  6328  1105 11653
  3288  2848  8928  1766  3246   117  1114  3840 17952 13378  8670 15498
  2039  2812   118  1146   117  2382 14125  1186   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
KURA,KO-2806 - (FIT-001),Solid TumorsÂ ,Preclinical,2024-10-25,"Preclinical and clinical data presented at EORTC-NCI-AACR showed improved tumor growth inhibition compared to the combinations with a SHP2 or SOS1 inhibitors, noted October 25, 2024.",86.0,1341.87003,38.1845,17.78,17.51,16.88,-0.015302084,-0.051944741,-0.012670038,-0.020558428,12.12585,0.26813,10.21596,2289,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  1105  7300  2233  2756  1120   142  9565
  9481   118 14056  2240   118 10419 23554  2799  4725 14601  3213  1107
 16485  3402  1106  1103 16058  1114   170 17730  2101  1477  1137   156
  9025  1475 27558  1116   117  2382  1357  1512   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ZYME,ZW251,Hepatocellular carcinomaÂ ,Preclinical,2024-10-25,"Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity in models with a breadth of NaPi2b expression, noted October 25, 2024.",75.0,918.64275,35.6041,12.92,12.93,13.28,0.000773694,0.027482646,-0.012670038,-0.020558428,5.86041,0.13112,3.28167,2290,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554  2103   170  2012  2848   118 14601  3246
  1107  3584  1114   170  8162  1582  1104 11896  2101  1182  1477  1830
  2838   117  2382  1357  1512   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1/2,2024-10-25,"Phase 1/2a data from WSC 2024 reported that treatment appears to cross the BBB to reduce neuroinflammation noted October 25, 2024.",124.0,14.37806,204.1598,0.3871,0.3992,0.2672,0.030779487,-0.370685616,-0.012670038,-0.020558428,1.19949,0.01037,0.39769,2291,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  1161  2233  1121   160 10844 17881  1527
  2103  1115  3252  2691  1106  2771  1103   139 20056  1106  4851 24928
 11955  1394  2087  7609 16059  2382  1357  1512   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VERA,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 2b,2024-10-26,"Phase 2b 96-week data presented at Kidney Week reported that -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and",63.0,2252.86876,47.246,41.09,41.09,43.82,0.0,0.064325551,-0.013698844,-0.021587235,11.28951,0.02891,0.0,2292,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1830  5306   118  1989  2233  2756  1120  9847  4695
  6237  2103  1115   118  5046   110  7234  1107 20003 11179  6787   118
 19353 26845   146  1403  1592  1475   113   144  1181   118   146  1403
  1592  1475   114   117  6021  1104 23123  2980 19700  1107  3453   110
  1104  6635   117   170   118  3882   110  7234  1107  4592 19700   117
  1105   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BIIB,Felzartamab - (PREVAIL),IgA nephropathy (IgAN)Â ,Phase 2,2024-10-26,"Phase 2 trial final results presented at ASN reported that patients maintained a mean reduction of approximately 50% in the UPCR through month 24, which was more than 18 months after the last dose was",146.0,26465.26374,25.918,181.69,181.69,173.79,0.0,-0.044454264,-0.013698844,-0.021587235,2.10575,0.14976,0.0,2293,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  3443  1509  2686  2756  1120 15278  2249  2103  1115
  4420  4441   170  1928  7234  1104  2324  1851   110  1107  1103 19753
 23554  1194  2370  1572   117  1134  1108  1167  1190  1407  1808  1170
  1103  1314 13753  1108   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CLDX,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU)Â ",Phase 2,2024-10-26,"Phase 2 efficacy and safety data from ACAAI reported that trial met all primary end secondary endpoints, noted October 26, 2024.",66.0,1786.45071,54.6283,26.95,26.95,25.68,0.0,-0.048270819,-0.013698844,-0.021587235,12.66806,0.0593,0.0,2294,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1,neg,"[  101 12278   123 23891  1105  3429  2233  1121  9690 11189  2240  2103
  1115  3443  1899  1155  2425  1322  3718  1322 21521   117  2382  1357
  1744   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
APLS,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGNÂ ,Phase 3,2024-10-26,"Phase 3 study results presented at ASN Kidney Week reported a statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4, noted Octo",126.0,3248.72563,54.6457,26.68,26.68,27.98,0.0,0.047575748,-0.013698844,-0.021587235,17.31847,0.00224,0.0,2295,0,1,1,0,0,1,0,0,0,0,0,0,3,0,0,1,pos,"[  101 12278   124  2025  2686  2756  1120 15278  2249  9847  4695  6237
  2103   170 11435  1193  2418  5599   110   113   185   133   121   119
  1288  1475   114  4592 19700  7234  3402  1106  1282  4043   117  1114
  7234  4379  1112  1346  1112  6237   125   117  2382 14125  1186   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LGVN,Laromestrocel (lomecel-B) - (ELPIS II),Hypoplastic Left Heart SyndromeÂ ,Phase 2b,2024-10-27,Phase 2b long term survival data shared at the Congenital Heart Surgeons' Society (CHSS) reported a 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this comp,15.0,31.73445,184.3703,2.21,2.21,2.03,0.0,-0.084956722,-0.013698844,-0.021587235,4.13603,0.01152,0.0,2296,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830  1263  1858  8115  2233  3416  1120  1103 16752
  4915 19058  4641 17078 27815   112  2015   113 24890 12480   114  2103
   170   126   118  1214  8115  1170  2016   123  9172  6059  1104  1620
   110  1114  3839  8753  1762 26965   132  1142  3254  1643   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
HUMA,ATEV - (V007),Acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease.Â ,Phase 3,2024-10-28,"Phase 3 detailed results presented at ASN showed superior patency and function over the standard autogenous fistula at six and 12 months, noted October 28, 2024.",158.0,677.67855,106.2968,5.59,5.42,5.07,-0.030883472,-0.09763847,-0.014409324,-0.021083431,13.33676,0.00213,14.72295,2297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  6448  2686  2756  1120 15278  2249  2799  7298 26227
  9517  1105  3053  1166  1103  2530 12365  4915  2285  7374  5886  1120
  1565  1105  1367  1808   117  2382  1357  1743   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
UNCY,UNI-494,Acute kidney injury (AKI)Â ,Preclinical,2024-10-28,"Preclinical data and Phase 1 presented at the American Society of Nephrology (ASN) Kidney Week indicated therapeutic administration of UNI-494 slows down and may even halt or reverse AKI progression,",17.0,47.08375,124.0451,4.15,4.99,4.799,0.184327576,0.145299229,-0.014409324,-0.021083431,1.10764,0.00667,2.01627,2298,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  1105 12278   122  2756  1120  1103
  1237  2015  1104   151  8043  8167  4807   113 15278  2249   114  9847
  4695  6237  4668 20340  3469  1104  7414  2240   118  3927  1527  3345
  1116  1205  1105  1336  1256  9700  1137  7936 25808  2240 16147   117
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
EYPT,EYP-1901 - (VERONA),Diabetic macular edema (DME)Â ,Phase 2,2024-10-28,"Phase 2 interim data demonstrated that the 2.7mg dose showed a +8.9-letter improvement in best-corrected visual acuity (BCVA) and a 68-micron reduction in CST, outperforming the aflibercept control. T",68.0,648.64071,113.9258,9.5,12.12,11.7,0.243565182,0.208297043,-0.014409324,-0.021083431,17.13697,0.01478,55.33904,2299,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123 10572  2233  7160  1115  1103   123   119   128  1306
  1403 13753  2799   170   116   129   119   130   118  2998  8331  1107
  1436   118 13808  5173   170 10182  1785   113  3823 12152   114  1105
   170  5599   118 17599  1179  7234  1107 24821  1942   117  1149  3365
 13199  1158  1103   170  2087  2646  3169  2093  6451  1654   119   157
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BCLI,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,2024-10-28,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared",10.0,10.73753,110.8521,1.9596,2.02,1.8,0.030357141,-0.084953706,-0.014409324,-0.021083431,3.12085,0.16001,0.21246,2300,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3631  2469  2233  2103   170 11435  1193  2418  3719
  1107  5010  1104  1260  2822  6801  8005 18389   113   149 10460   117
   185   134   121   119  5347  1559  1580   114  1114   170  3151  8115
  1159  1104  3993   119   127  1808  1111  1103  1260  2822  6801  8005
 18389  1372  3402   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PLUR,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,2024-10-28,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared",8.0,23.6311,67.3439,4.37,4.32,4.5601,-0.011507607,0.042581544,-0.014409324,-0.021083431,0.0421,0.01735,0.04834,2301,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3631  2469  2233  2103   170 11435  1193  2418  3719
  1107  5010  1104  1260  2822  6801  8005 18389   113   149 10460   117
   185   134   121   119  5347  1559  1580   114  1114   170  3151  8115
  1159  1104  3993   119   127  1808  1111  1103  1260  2822  6801  8005
 18389  1372  3402   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IRWD,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF)Â ,Phase 3,2024-10-28,"New Phase 3 data demonstrated a steady treatment effect across patient demographics and SBS characteristics. Safety results showed high treatment compliance and low rates of adverse events, noted Octo",162.0,662.91685,84.0106,3.96,4.15,4.19,0.046864309,0.056456709,-0.014409324,-0.021083431,7.46931,0.02384,4.37745,2302,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  1203 12278   124  2233  7160   170  6386  3252  2629  1506  5351
 17898  1116  1105 23798  5924   119  9218  2686  2799  1344  3252 14037
  1105  1822  5600  1104 16798  1958   117  2382 14125  1186   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TYRA,TYRA-300 - (BEACH301),AchondroplasiaÂ ,IND-Enabling,2024-10-28,"IND cleared by the FDA, noted October 28, 2024.",53.0,1050.31407,71.6683,21.93,19.89,16.42,-0.09763847,-0.289355458,-0.014409324,-0.021083431,4.165,0.15915,23.87096,2303,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1357  1743   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MIRA,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSDÂ ",Preclinical,2024-10-28,"Preclinical data reported that on Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provide",19.0,25.53785,317.831,1.29,1.57,1.85,0.196433401,0.360543421,-0.014409324,-0.021083431,2.10607,0.01088,36.56714,2304,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2103  1115  1113  2295   130   117
  1120  1103 17307 13753  1104  3127 17713   120  4023   117 26835 20284
  3161   118   123  1521  1106  1485   118  2335  2999  2734  1104  2489
 15750   117  1149  3365 13199  1158 18762   118  4092   176 19252 22083
  1394  1118  2539   110   117  1134  2194   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AGIO,Mitapivat (AG-348) - (RISE UP),Sickle cell diseaseÂ ,Phase 3,2024-10-28,"Phase 3 portion of the study enrollment completed, noted October 23, 2024.",58.0,2621.63543,55.03,45.09,46.08,44.83,0.021718524,-0.005782934,-0.014409324,-0.021083431,7.22073,0.09075,23.18082,2305,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,neg,"[  101 12278   124  3849  1104  1103  2025 10803  2063   117  2382  1357
  1695   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CADL,CAN-3110,GliomaÂ ,Phase 1b,2024-10-28,"Phase 1b data presented at IOVC showed improved survival and immune activation, with 3 out of 6 patients surviving over a year post-treatment, noted October 28, 2024.",54.0,176.78712,101.8016,5.6,5.51,5.19,-0.016201975,-0.076032901,-0.014409324,-0.021083431,5.11279,0.00548,2.31203,2306,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  2233  2756  1120   146  2346 19076  2799  4725
  8115  1105 11650 14915   117  1114   124  1149  1104   127  4420  5932
  1166   170  1214  2112   118  3252   117  2382  1357  1743   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,TREMFYA (guselkumab),Ulcerative Colitis Subcutaneous Induction (ASTRO) Crohn's Disease Subcutaneous InductionÂ ,Phase 3,2024-10-28,Phase 3 results reported that a greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI stu,0.0,389071.8723,16.8802,160.88,161.6,158.24,0.004465401,-0.016545878,-0.014409324,-0.021083431,0.77501,0.02418,782.57273,2307,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2686  2103  1115   170  3407  1295  1104  4420  5165
  1114  4841 12734 13064   157 16941 18586  3663  1592 18293  1105  5972
  3890  7300  1105  1322  2155 22258  1231 11234  1120  3615  2277  1107
  1103 12278   124   144  9664 23314 21669   188  7926   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LLY,Mirikizumab - (LUCENT-3),Ulcerative colitis (UC)Â ,Phase 3,2024-10-28,"Phase 3 data reported that 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission, noted October 28, 2024.",946.0,806412.3225,30.9302,892.7,895.59,806.14,0.003232141,-0.101993153,-0.014409324,-0.021083431,0.64267,0.11018,1866.50091,2308,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103  1115  5615   110  1104  4420  4441  1263
   118  1858  7300  1231 11234  1105  5787   110  3890  1263   118  1858
  1322  2155 22258  1231 11234   117  2382  1357  1743   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LLY,Mirikizumab - (VIVID-2),Crohn's diseaseÂ ,Phase 2,2024-10-28,"Phase 2 data reported that 96% of patients had clinical response as measured by the Crohn's Disease Activity Index (CDAI) and 87% were in clinical remission as measured by CDAI, noted October 28, 2024",946.0,806412.3225,30.9302,892.7,895.59,806.14,0.003232141,-0.101993153,-0.014409324,-0.021083431,0.64267,0.11018,1866.50091,2309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1115  5306   110  1104  4420  1125  7300
  2593  1112  7140  1118  1103   140  2180  7272   112   188 20012  2173
  6366 10146   113  2891  1592  2240   114  1105  5966   110  1127  1107
  7300  1231 11234  1112  7140  1118  2891  1592  2240   117  2382  1357
  1743   117 17881  1527   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVS,Fabhalta (iptacopan),C3 glomerulopathy (C3G)Â ,Phase 3,2024-10-28,"Phase 3 data reported that Fabhalta sustained proteinuria reduction at 12 months, noted October 28, 2024.",0.0,2455.01871,52.4511,7.81,7.89,7.62,0.010191171,-0.024628594,-0.014409324,-0.021083431,0.0,0.01853,0.58903,2310,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115   143  6639 24537  1161  8505  4592
 19700  7234  1120  1367  1808   117  2382  1357  1743   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SHPH,Ropidoxuridine,GlioblastomaÂ ,Phase 2,2024-10-28,"Phase 2 study engaged all six of the planned clinical trial site locations to administer the clinical trial, noted October 28, 2024.",1.0,2.96184,99.7177,31.25,33.25,40.0,0.062035391,0.246860078,-0.014409324,-0.021083431,1.51333,0.01135,10.60695,2311,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2025  4349  1155  1565  1104  1103  2919  7300  3443
  1751  4541  1106 23972  1103  7300  3443   117  2382  1357  1743   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GNPX,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC)Â ,Preclinical,2024-10-28,"Preclinical data presented at EORTC-NCI-AACR demonstrated Reqorsaâ€™s potential effectiveness across these challenging cancer types, expanding its applicability beyond KRAS G12C mutant lung cancer, not",0.0,9.85989,254.9033,99.0,137.0,101.0,0.324861076,0.020000667,-0.014409324,-0.021083431,2.36815,0.00533,51.54255,2312,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2756  1120   142  9565  9481   118
 14056  2240   118 10419 23554  7160   100  3209 12949  1506  1292 10467
  4182  3322   117  9147  1157 12647  9538  5474  2894   148  9664  1708
   144 11964  1658 21392 13093  4182   117  1136   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
THAR,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,2024-10-28,"Phase 1 results presented at ACG Meeting showed no opioid withdrawal effects, reinforcing safety profile, noted October 28, 2024.",4.0,2.27455,105.8588,1.95,1.98,2.95,0.015267472,0.413975798,-0.014409324,-0.021083431,1.54053,0.00056,0.08174,2313,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1,pos,"[  101 12278   122  2686  2756  1120  9690  2349 12505  2799  1185 11769
  2660  2386 10602  3154   117  1231  1394 20586  3429  6168   117  2382
  1357  1743   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BCDA,CardiAMP (Heart Failure II),Ischemic heart failure of reduced ejection fraction (HFrEF)Â ,Phase 3,2024-10-28,"Phase 3 completed, noted October 28, 2024.",5.0,9.20991,138.9315,2.42,2.63,2.38,0.083216306,-0.016667052,-0.014409324,-0.021083431,1.42655,0.12702,0.59182,2314,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2063   117  2382  1357  1743   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
COYA,Low Dose Interleukin-2 (LD IL-2) - (COYA 301),Alzheimerâ€™s Disease (AD)Â ,Phase 2,2024-10-29,"Phase 2 trial met primary and secondary endpoints, noted October 29, 2024.",16.0,112.18104,84.5166,10.19,7.37,6.74,-0.323989141,-0.413346922,0.000710985,-0.021396025,1.22253,0.05633,6.70266,2315,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1,neg,"[  101 12278   123  3443  1899  2425  1105  3718  1322 21521   117  2382
  1357  1853   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ZLAB,Xanomeline-Trospium (KarXT) (ZL-2701-001) - (China Bridging Trial),SchizophreniaÂ ,Phase 3,2024-10-29,"Phase 3 trial demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo, noted October 29, 2024.",109.0,3084.53435,63.614,32.54,31.43,30.92,-0.034707251,-0.051066878,0.000710985,-0.021396025,4.83903,0.03065,25.07881,2316,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  3443  7160   170 11435  1193  2418   130   119   123
   118  1553  7234  1107  8544 12412  1708  8653  2794  1121  2259  2568
  1120  6237   126  3402  1106  1282  4043   117  2382  1357  1853   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ABEO,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB)Â ,BLA Filing,2024-10-29,"BLA resubmitted on October 29, 2024.",51.0,284.57559,60.6035,6.39,6.57,6.21,0.027779564,-0.028573372,0.000710985,-0.021396025,6.39391,0.00224,3.28917,2317,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   139 10783  1231  6385  1830  9084  1906  1113  1357  1853   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,2024-10-29,"Phase 2b completed and Phase 3 expected to commenced by year end 2024, noted October 29, 2024.",32.0,186.05796,99.3698,5.99,5.83,5.81,-0.027074412,-0.030510841,0.000710985,-0.021396025,12.47934,0.09099,3.38002,2318,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830  2063  1105 12278   124  2637  1106  8042  1118
  1214  1322 17881  1527   117  2382  1357  1853   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,2024-10-29,"Phase 3 study following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional",120.0,108.32253,107.8005,1.04,0.9069,0.9235,-0.136943802,-0.118805192,0.000710985,-0.021396025,5.97937,0.04539,0.90449,2319,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2025  1378  2012  3636   113  5731   110  5236  3187
  7234  6055  1282  4043   114  7160  1194  2370   127  1114   185  5521
 11083 26648  3740   117  8784  2249 17195  3663  7300  3443  6635  1127
  1723  1111  1126  2509   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1/2,2024-10-29,Phase 1/2a study Six-month interim data shared at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) newly analyzed biomarker data from the initial dose-escalation Phase 1 AD tri,124.0,11.19774,203.5084,0.35,0.3109,0.259,-0.118461837,-0.301105093,0.000710985,-0.021396025,1.19949,0.01037,0.90128,2320,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  1161  2025  4995   118  2370 10572  2233
  3416  1120  1103  4815  8451 15961 21373  1113 24278   112   188 20012
  3047   113 16899 14569   114  3599 17689 25128  8519  1200  2233  1121
  1103  3288 13753   118 13936  7867  1891 12278   122  5844   189  2047
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMNM,IM-1021,Advanced B-cell lymphomas and advanced solid tumorsÂ ,Preclinical,2024-10-29,"Preclinical data reported that IM-1021 showed superior efficacy compared to zilovertamab vedotin in both the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 triple negative breast cancer model, n",87.0,737.85154,63.0289,12.43,12.2,12.97,-0.018676954,0.042526093,0.000710985,-0.021396025,18.06291,0.06285,4.64836,2321,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2103  1115   146  2107   118  9081
  1475  2799  7298 23891  3402  1106   195 24755 12986  7363  1830  1396
  2572  6105  1107  1241  1103 27901  2718   118   122 19435  2765   181
 25698  7903  2235  1105  1103  9292  1592   118 19443   118  3993  1604
  9225  4366  7209  4182  2235   117   183   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LGVN,Laromestrocel (lomecel-B) - (CLEAR MIND),Alzheimer's DiseaseÂ ,Phase 2a,2024-10-29,Phase 2a data presented at CTAD in late breaking presentation showed that that Lomecel-B's ability to inhibit MMP14 activity correlates with improved clinical and biomarker outcomes in Alzheimer's pat,15.0,31.44726,184.2027,2.18,2.19,2.25,0.004576667,0.031605339,0.000710985,-0.021396025,4.13603,0.01152,2.1277,2322,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  1161  2233  2756  1120 16899 14569  1107  1523  4440
  8685  2799  1115  1115 10605  3263 18389   118   139   112   188  2912
  1106  1107 23034   150 12347 17175  3246  1884 18337  5430  1114  4725
  7300  1105 25128  8519  1200 13950  1107 24278   112   188 26227   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,2024-10-29,"Additional data from pilot study on functional diarrhea, crofelemer significantly improved stool consistency and reduced abdominal pain without causing constipation, marking it as a potentially effect",2.0,9.98052,176.2322,28.25,27.0,26.0,-0.045256592,-0.08299692,0.000710985,-0.021396025,1.50858,0.00077,0.62324,2323,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  8154  2233  1121  3955  2025  1113  8458  4267  1813  1197 13836
   117   172  2180  8124 14183  1200  5409  4725 15631 20904  1105  3549
 24716  2489  1443  3989 14255  2050  9717  1891   117 10079  1122  1112
   170  9046  2629   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVS,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML)Â ,Approved,2024-10-29,"FDA Approved on October 29, 2024.",0.0,2473.68805,52.2424,7.89,7.95,7.79,0.007575794,-0.012755275,0.000710985,-0.021396025,0.0,0.01853,0.42098,2324,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762   138  8661 16011  1113  1357  1853   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CGTX,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's DiseaseÂ ,Phase 2,2024-10-29,"Phase 2 results presented at CTAD showed a significant slowdown in cognitive decline, particularly in participants with lower plasma p-tau217 levels, an Alzheimerâ€™s biomarker, noted October 29, 2024.",73.0,22.87579,129.5554,0.5421,0.57,0.4882,0.050185875,-0.104725328,0.000710985,-0.021396025,1.22267,0.09294,0.54111,2325,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2686  2756  1120 16899 14569  2799   170  2418  3345
  5455  1107 12176  6246   117  2521  1107  6635  1114  2211 13441   185
   118 27629  1358 18202  1559  3001   117  1126   100 25128  8519  1200
   117  2382  1357  1853   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SPRO,SPR720,Nontuberculous mycobacterial (NTM) pulmonary disease (PD)Â ,Phase 2,2024-10-29,"Phase 2 study did not meet its primary endpoint, based on the planned interim analysis of 16 patients; current development was suspended, noted on October 29, 2024.",56.0,70.80437,40.9831,1.29,1.31,1.31,0.015384919,0.015384919,0.000710985,-0.021396025,0.71614,0.09637,1.18046,2326,1,0,0,0,1,1,0,0,0,0,0,0,0,3,0,-1,pos,"[  101 12278   123  2025  1225  1136  2283  1157  2425  1322  7587   117
  1359  1113  1103  2919 10572  3622  1104  1479  4420   132  1954  1718
  1108  6232   117  2382  1113  1357  1853   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CALC,Auxora - (CARPO),Acute PancreatitisÂ ,Phase 2b,2024-10-30,Phase 2 full results presented at ACG showed high and medium doses of Auxora led to a 100% reduction in severe respiratory failure and a 64.2% reduction in persistent respiratory failure compared to l,13.0,51.60075,104.4896,3.93,4.8,3.5,0.199976492,-0.115876457,0.015645291,-0.038611762,0.31774,2e-05,1.41437,2327,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1554  2686  2756  1120  9690  2349  2799  1344  1105
  5143 24429  1104 27758  1775  6533  1521  1106   170  1620   110  7234
  1107  5199 19192  4290  1105   170  3324   119   123   110  7234  1107
 15970 19192  4290  3402  1106   181   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LXEO,LX1001 - (LEAD),Alzheimerâ€™s diseaseÂ ,Phase 1/2,2024-10-30,"Phase 1/2 interim data from CTAD reported a dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months, noted October 30, 2024.",54.0,273.57981,90.9439,9.97,8.275,8.2,-0.186341663,-0.19544643,0.015645291,-0.038611762,6.22649,0.03627,9.50734,2328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123 10572  2233  1121 16899 14569  2103   170
 13753   118  7449  2773  1107 24928 11955  1643 21020 13851 10997 19825
  1477  2838  1107  1155  6635  1114  7173  3840 17952 13378  1120  1367
  1808   117  2382  1357  1476   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PMN,PMN310 - (PRECISE-AD),Alzheimer's disease (AD)Â ,Phase 1a,2024-10-30,"Phase 1a topline data from 5 cohorts reported that generally well tolerated and achieved concentrations in the cerebrospinal fluid indicating its potential for target engagement in AD patients, noted",53.0,32.57514,89.8893,1.03,1.09,1.03,0.056618894,0.0,0.015645291,-0.038611762,0.46099,0.02003,0.32653,2329,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  1161  1499  2568  2233  1121   126  1884 13252  2145
  2103  1115  2412  1218 21073  1181  1105  3890 14759  1107  1103   172
  9014 12725 20080 14196  8240  7713  1157  3209  1111  4010  8164  1107
  5844  4420   117  2382   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MLYS,Lorundrostat - (Launch-HTN),Uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).Â ,Phase 3,2024-10-30,"Phase 3 enrollment completed, noted October 30, 2024.",66.0,685.23358,59.4571,13.96,13.78,14.95,-0.012977832,0.068515203,0.015645291,-0.038611762,3.24408,0.12272,5.6081,2330,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,pos,"[  101 12278   124 10803  2063   117  2382  1357  1476   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TLSA,Foralumab + Ozempic (semaglutide),ObesityÂ ,Preclinical,2024-10-30,"Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob",111.0,122.51084,106.7601,1.02,1.18,0.898,0.145711811,-0.127387838,0.015645291,-0.038611762,0.05176,0.05447,3.60078,2331,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115 21447  2848   118  2891
  1495  1107  4612  1114 14516  1918  1403 25937  3269  7160   188 10941
 10805  5562  3154  1107  7495 11911  1313 15540 14229  1107  3073  1665
 21472  7867  3584  1104 10211   118 10645   184 27655   117  2382 14125
 12809   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVO,Foralumab + Ozempic (semaglutide),ObesityÂ ,Preclinical,2024-10-30,"Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob",0.0,3418959.512,32.026,111.98,113.24,105.36,0.011189176,-0.060937226,0.015645291,-0.038611762,0.0,0.0,1258.01056,2332,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115 21447  2848   118  2891
  1495  1107  4612  1114 14516  1918  1403 25937  3269  7160   188 10941
 10805  5562  3154  1107  7495 11911  1313 15540 14229  1107  3073  1665
 21472  7867  3584  1104 10211   118 10645   184 27655   117  2382 14125
 12809   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMEA,Icovamenib (BMF-219) with a GLP-1-Based Therapy - (COVALENT-211),Diabetes and obesityÂ ,Preclinical,2024-10-30,"Preclinical data reported that pretreatment improved insulin secretion, approximately doubling the effect-size depending on the dose, noted October 30, 2024.",59.0,374.70802,164.6503,12.06,10.34,8.88,-0.153874322,-0.306092634,0.015645291,-0.038611762,22.59277,0.00573,9.44104,2333,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115  3073  7877  2980  1880
  4725 26825  3318  1988   117  2324 21756  1103  2629   118  2060  5763
  1113  1103 13753   117  2382  1357  1476   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMEA,BMF-650,ObesityÂ ,Preclinical,2024-10-30,"Preclinical data reported a higher bioavailability and a less variable pharmacokinetic profile, with significant improvements in glucose stimulated insulin secretion, noted October 30, 2024.",59.0,374.70802,164.6503,12.06,10.34,8.88,-0.153874322,-0.306092634,0.015645291,-0.038611762,22.59277,0.00573,9.44104,2334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103   170  2299 25128 15677  8009
  5474  1105   170  1750  7898   185  7111  1918  2528  4314  9265  6168
   117  1114  2418  8313  1107 20636 26225  1181 26825  3318  1988   117
  2382  1357  1476   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CORT,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,2024-10-30,"Phase 3 data reported statistically significant improvements in mean SBP at 22 weeks, noted October 30, 2024.",105.0,4912.90617,44.1976,48.21,46.89,54.23,-0.027762035,0.117667792,0.015645291,-0.038611762,19.73326,0.03215,66.88432,2335,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   124  2233  2103 11435  1193  2418  8313  1107  1928   156
  2064  2101  1120  1659  2277   117  2382  1357  1476   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NRIX,NX-5948,B-cell malignancies / graft-versus-host diseaseÂ ,Preclinical,2024-10-30,"Preclinical data reported that clinical activity in patients with CLL with 69.2% ORR and all responses ongoing as of April 17, 2024:, noted October 30, 2024.",76.0,1705.02931,65.1398,25.2,24.07,27.0,-0.045877743,0.068992871,0.015645291,-0.038611762,13.04496,0.13259,18.34252,2336,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2103  1115  7300  3246  1107  4420
  1114   140 23955  1114  5691   119   123   110 23066  2069  1105  1155
 11317  7173  1112  1104  1364  1542   117 17881  1527   131   117  2382
  1357  1476   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VINC,VIP236,Solid tumorsÂ ,Phase 1,2024-10-31,"Phase 1 data reported a 45% disease control rate, noted October 2024.",5.0,10.77743,105.7118,7.0,6.98,6.444,-0.002861232,-0.082760684,-0.008599375,-0.045582035,2.71133,0.02236,0.10462,2337,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103   170  2532   110  3653  1654  2603   117
  2382  1357 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MTNB,MAT2203 - (ORALTO),Invasive aspergillosisÂ ,Phase 3,2024-10-31,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n",5.0,3.11012,181.0056,1.93,0.62,0.555,-1.135555804,-1.246307168,-0.008599375,-0.045582035,1.60345,0.09104,1.92383,2338,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,-1,neg,"[  101 12819  1718  6445  1112  1419  1664   118 19520  1858   118  6837
 12830  1378  1136  5783  1121  1103 19916  3547   117  1419  1702  1111
  3209 13274  4688  1106  3644  3223   118  1205  1137 13679   117   183
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MTNB,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitisÂ ,Phase 3,2024-10-31,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n",5.0,3.11012,181.0056,1.93,0.62,0.555,-1.135555804,-1.246307168,-0.008599375,-0.045582035,1.60345,0.09104,1.92383,2339,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,-1,neg,"[  101 12819  1718  6445  1112  1419  1664   118 19520  1858   118  6837
 12830  1378  1136  5783  1121  1103 19916  3547   117  1419  1702  1111
  3209 13274  4688  1106  3644  3223   118  1205  1137 13679   117   183
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KYMR,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Phase 1,2024-10-31,"Phase 1 clinical trial initiated, noted October 31, 2024.",71.0,2990.2127,61.4842,47.67,46.17,49.86,-0.031972033,0.044916809,-0.008599375,-0.045582035,13.99943,0.19531,34.5269,2340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  7300  3443  7087   117  2382  1357  1955   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AVXL,Blarcamesine (ANAVEX2-73-AD-004) - (ATTENTION-AD),Mild to moderate Alzheimerâ€™s diseaseÂ ,Phase 2/3,2024-10-31,"Phase 2b/3 data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis, noted October 31, 2024.",85.0,561.34632,69.1954,5.71,6.62,7.635,0.147876346,0.290523915,-0.008599375,-0.045582035,21.11591,0.11109,38.73158,2341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1830   120   124  2233  3659  1103  6978  1104  2168
   113 12556  1592   114  1118  3073   118  9467   156 23413  8271  2069
  1475  5565  3622   117  2382  1357  1955   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Phase 1,2024-10-31,"Additional data reported a sustained 80%+ drug release over a 7-day period and minimal variation in key physical properties, noted October 31, 2024.",9.0,5.06744,185.0233,1.13,1.13,1.28,0.0,0.124642445,-0.008599375,-0.045582035,2.88298,0.00688,1.04957,2342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  8154  2233  2103   170  8505  2908   110   116  3850  1836  1166
   170   128   118  1285  1669  1105 10298  8516  1107  2501  2952  4625
   117  2382  1357  1955   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ABOS,ACU193 - (ALTITUDE-AD),Early Alzheimer's diseaseÂ ,Phase 2,2024-10-31,Phase 2 data at CTAD highlighted the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures f,60.0,173.02976,75.2922,3.03,2.88,3.17,-0.050772325,0.045168968,-0.008599375,-0.045582035,2.11165,0.0601,0.45543,2343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  1120 16899 14569 11634  1103   185  1942  3984
 18202  1559  3919  4164  1112  1126  3903  1105  7856  6806  1106  3251
  6635  1111 18589 21669 27074 20427   118  5844  1115 13822 14924  1821
  7777  7874   153 11943 14884  1116  1105   181 25509  1197 23609 26405
  5332  8826   175   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ATOS,(Z)-Endoxifen - (I-SPY 2),Locally advanced breast cancerÂ ,Phase 2,2024-10-31,"Phase 2 study met the primary endpoint at 10mg once daily, noted October 31, 2024.",129.0,173.54523,58.5575,1.41,1.38,1.5,-0.021506205,0.061875404,-0.008599375,-0.045582035,10.37847,0.10099,0.87853,2344,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  2025  1899  1103  2425  1322  7587  1120  1275  1306
  1403  1517  3828   117  2382  1357  1955   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,2024-10-31,"Preclinical data reported a high conversion rate of 90.1% at 24 hours with significant inhibition of TNFÎ± production in human whole blood, with an IC50 of 0.022 Î¼M, indicating strong potency, noted Oc",9.0,3.22181,72.4588,3.1,2.72,2.54,-0.130770231,-0.19923803,-0.008599375,-0.045582035,1.4077,0.06541,6.65242,2345,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103   170  1344  7497  2603  1104
  3078   119   122   110  1120  1572  2005  1114  2418  1107 16485  1104
   157 28047 28189 28168  1707  1107  1769  2006  1892   117  1114  1126
   146  1658 11049  1104   121   119  5507  1477   236 28176  2107   117
  7713  2012  9814  9517   117  2382   152  1665   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INTS,INT230-6 - (INVINCIBLE-4),Triple Negative Breast CancerÂ ,Phase 2,2024-10-31,"Phase 2 trial dosing intiated, noted October 31, 2024",47.0,44.75852,48.6627,3.05,3.25,3.22,0.063513406,0.054239769,-0.008599375,-0.045582035,0.29861,0.0016,0.07883,2346,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  3443 18463  1158  1107 10691  1906   117  2382  1357
  1955   117 17881  1527   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BFRI,Ameluz (BF-200 ALA),Basal cell carcinomaÂ ,Phase 3,2024-10-31,"Phase 3 data reported primary and secondary endpoints were all highly statistically significant, noted October 31, 2024.",10.0,6.81853,111.4276,0.9339,1.23,0.88,0.275400082,-0.059447459,-0.008599375,-0.045582035,8.54625,0.0052,163.38872,2347,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1,neg,"[  101 12278   124  2233  2103  2425  1105  3718  1322 21521  1127  1155
  3023 11435  1193  2418   117  2382  1357  1955   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VCNX,Pepinemab - (SIGNAL-AD),Alzheimerâ€™s Disease (AD)Â ,Phase 1/2,2024-10-31,"Phase 1/2 data presented at CTAD reported that the expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment, no",2.0,7.79859,141.6353,4.03,2.79,3.3,-0.36772478,-0.199843907,-0.008599375,-0.045582035,1.2343,0.00023,1.26711,2348,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122   120   123  2233  2756  1120 16899 14569  2103  1115
  1103  2838  1104 13441   144  8842  2101  1105   185   118 27629  1358
 22196 25128  8519  1468  2691  1106  2773  8941  1219 12029  2240  1105
  1115  1142  1110  1107 23034  1174  1118   185  8043  2042  1918  1830
  3252   117  1185   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SUPN,SPN-820,Treatment-resistant depressionÂ ,Phase 2a,2024-10-31,"Phase 2a data reported that suicidal ideation decreased by 80%, noted October 31, 2024.",56.0,1877.44054,33.3288,34.87,34.07,36.4,-0.023209629,0.042941914,-0.008599375,-0.045582035,12.28528,0.06478,12.86804,2349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1161  2233  2103  1115 28117 27804  1911  2116 10558
  1118  2908   110   117  2382  1357  1955   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LXRX,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,NDA Filing,2024-11-01,"Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.",363.0,441.0206,99.5074,1.95,1.22,1.27,-0.468978514,-0.428812472,-0.022319398,-0.071099963,7.64887,0.05349,25.61995,2350,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  9433  2341  4751  1429  1106   124  1115  1103  6245  1104   163
  5730 19854  1161  1202  1136  1149 24078  5084  1103 11040  1107  6323
  1114   157  1475  2137  1105   140  2428  2137   117  2382  1379   122
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNXP,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infectionÂ ",Preclinical,2024-11-01,"Preclinical data showed tolerability and no evidence of spreading to blood or tissues, noted November 1, 2024.",8.0,24.87678,169.9867,14.53,13.93,14.1,-0.04217069,-0.03004068,-0.022319398,-0.071099963,3.05917,0.06023,1.74121,2351,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2799  1106  2879  6328  1105  1185
  2554  1104  9243  1106  1892  1137 14749   117  2382  1379   122   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVO,Wegovy (semaglutide) injection - (ESSENCE),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 3,2024-11-01,"Phase 3 trial met its primary endpoint, noted November 1, 2024.",0.0,3407437.419,31.9137,111.95,111.94,107.2,-8.93296e-05,-0.043356094,-0.022319398,-0.071099963,0.0,0.0,509.85636,2352,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3443  1899  1157  2425  1322  7587   117  2382  1379
   122   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TEVA,Olanzapine LAI (44749) - (SOLARIS),SchizophreniaÂ ,Phase 3,2024-11-01,"Phase 3 data reported no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date, noted November 1, 2024.",0.0,20903.70973,33.5945,18.44,18.45,17.11,0.000542152,-0.07485913,-0.022319398,-0.071099963,1.75723,0.10489,130.99751,2353,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1185 15299  1104  3799   118  1130 26857
  9352 17262  1818   120 22087 13759   156  5730 12743   113 27802 12480
   114  1958  1106  2236   117  2382  1379   122   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VKTX,VK2735 - (VENTURE),ObesityÂ ,Phase 2a,2024-11-03,"Phase 2a 13 week data presented at Obesity week demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%, noted November 3, 2024.",113.0,8121.48367,82.7473,72.88,72.88,68.48,0.0,-0.062272521,0.000503804,-0.048276762,12.91659,0.05732,0.0,2354,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1161  1492  1989  2233  2756  1120   152 27655  1989
  7160  7234  1116  1107  1928  1404  2841  5236  1106  1282  4043   117
  7032  1146  1106   127   119   129   110   117  2382  1379   124   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SUPN,SPN-817,Treatment-resisted seizuresÂ ,Phase 2,2024-11-04,Phase 2 data reported that treatment was safe and had acceptable tolerability with 2 subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenan,56.0,1916.10877,33.4885,33.97,34.7,36.61,0.021261905,0.074843645,-0.013507634,-0.042018015,12.25994,0.05608,15.63676,2355,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2103  1115  3252  1108  2914  1105  1125 12095
  1106  2879  6328  1114   123  5174 19959 26728 21490  1272  1104  3252
  2272 16798  1958  1149  1104  1103  1744  5174  1150  2242  1103  1514
  5208  1389   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
FBIO,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,Approved,2024-11-04,"FDA approved on November 4, 2024.",29.0,47.68485,70.6674,1.9,1.73,1.76,-0.093732478,-0.076540077,-0.013507634,-0.042018015,9.33219,0.03554,2.89286,2356,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762  4092  1113  1379   125   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
DERM,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,Approved,2024-11-04,"FDA approved on November 4, 2024.",24.0,110.2689,72.4383,6.17,5.32,5.58,-0.148225535,-0.100510062,-0.013507634,-0.042018015,0.37,0.02988,4.7599,2357,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762  4092  1113  1379   125   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CRBP,CRB-913,ObesityÂ ,Preclinical,2024-11-04,"Preclinical results presented at Obesity Week suggest CRB-913's clinical potential as a standalone therapy, in combination with incretin analogs, or as a maintenance therapy , noted November 4, 2024.",12.0,220.52454,157.279,16.92,18.31,18.59,0.078951005,0.094127448,-0.013507634,-0.042018015,22.82851,0.00623,10.25298,2358,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2686  2756  1120   152 27655  6237  5996
 15531  2064   118  5539  1495   112   188  7300  3209  1112   170  2484
 20717  1673  7606   117  1107  4612  1114  1107 13782  6105 13022  1116
   117  1137  1112   170  5972  7606   117  2382  1379   125   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
XNCR,XmAb942 - (XENITH-UC),Inflammatory bowel diseases (IBD)Â ,Phase 1,2024-11-04,"Phase 1 dosing commenced, noted November 4, 2024. Phase",71.0,1504.83425,53.4678,21.26,21.52,23.31,0.012155362,0.09205508,-0.013507634,-0.042018015,6.8399,0.12325,8.22804,2359,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 18463  1158  8042   117  2382  1379   125   117 17881
  1527   119 12278   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTN,PL7737,Obesity Due to Leptin Receptor DeficiencyÂ ,Preclinical,2024-11-04,"Preclinical data reported that L7737 significantly decreased food intake and body weight in DIO mice, but not in MC4R-KO mice, noted November 4, 2024.",46.0,109.70565,53.6164,0.068,0.067,0.063,-0.014815086,-0.076372979,-0.013507634,-0.042018015,0.0,0.02421,0.05177,2360,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115   149  1559  1559 26303
  5409 10558  2094 14741  1105  1404  2841  1107   141 19368 14105   117
  1133  1136  1107 12029  1527  2069   118   148  2346 14105   117  2382
  1379   125   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,2024-11-04,Phase 2 additional new data demonstrated significant improvements in both progression-free survival (PFS) and overall survival (OS) when treated with CM24 in combination with nivolumab and chemotherap,2.0,21.79054,92.0001,0.062,0.06,0.053,-0.032789823,-0.156842471,-0.013507634,-0.042018015,0.0,0.00216,0.21333,2361,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2509  1207  2233  7160  2418  8313  1107  1241 16147
   118  1714  8115   113   153 17691   114  1105  2905  8115   113 11570
   114  1165  5165  1114   140  2107 19598  1107  4612  1114 11437  6005
  7776  6639  1105 22572  5521 12858  5970  1643   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IRON,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,2024-11-04,End of Phase 2 meeting with the FDA resulted in positive feedback to initiate its Phase 3 APOLLO trial by mid-2025.,34.0,1731.5257,59.3196,47.13,58.25,66.57,0.211834352,0.345344285,-0.013507634,-0.042018015,4.97094,0.0925,121.54037,2362,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  5135  1104 12278   123  2309  1114  1103 18762  3657  1107  3112
 13032  1106 19687  1157 12278   124 10997 13901  2162  2346  3443  1118
  2286   118 17881  1571   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRVO,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2a,2024-11-04,Phase 2a data presented at CTAD confirmed recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB. Nef,9.0,102.92415,101.0269,12.81,12.47,12.14,-0.026900356,-0.05372033,-0.013507634,-0.042018015,15.38266,0.06144,0.79845,2363,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  1161  2233  2756  1120 16899 14569  3659  2793  3812
  3783  7713  1115 13441   176 25737 20497 27647 12576  1183  5190  4592
   113   144  8842  2101   114  1110   170 17351  4929  1104 24928 11955
  2007 27054 15306  3653  3246  1107 26624  2064   119   151 11470   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SKYE,Nimacimab - (CBeyond),ObesityÂ ,Preclinical,2024-11-04,"Preclinical preliminary data from a diet-induced obesity (DIO) model in mice, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven",30.0,165.0403,127.5362,5.56,5.44,5.5,-0.021819047,-0.010850016,-0.013507634,-0.042018015,4.67158,3e-05,1.28775,2364,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101 11689  1665 21472  7867  9889  2233  1121   170 10211   118 10645
   184 27655   113   141 19368   114  2235  1107 14105   117  3890  2418
 13753   118  7449  2841  2445  1104  1146  1106  1479   110  3402  1106
  3686   117 23201   170  2281 17963  1193   118  4940   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SRRK,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Preclinical,2024-11-04,"Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin, noted November 4, 2024.",96.0,2542.62483,225.6886,28.42,27.67,28.15,-0.026744329,-0.009545768,-0.013507634,-0.042018015,16.2457,0.02021,27.73071,2365,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  1437  1115  5833  2428   118  3887
  1580  2569  8290  3367  1105  6069  7930  3367  4361  1107 14105  4172
  1899 13199  1394   117  2382  1379   125   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CYDY,Leronlimab with trifluridine plus tipiracil (TAS-102) and bevacizumab,"CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC)Â ",Phase 2,2024-11-04,"The FDA cleared the Phase 2 trial, noted on November 4, 2024.",0.0,150.32293,94.2406,0.127,0.123,0.1265,-0.032002731,-0.003944778,-0.013507634,-0.042018015,1.07839,0.02152,0.6143,2366,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1,neg,"[  101  1109 18762  5323  1103 12278   123  3443   117  2382  1113  1379
   125   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATOS,Z-Endoxifen - (Karisma),"Mammographic breast density (MBD), breast cancerÂ ",Phase 2,2024-11-04,"Phase 2 data reported that the relative significant density change was -19.3 percent and -26.5 percent for the 1 and 2 mg arms, respectively, using the placebo arm as a reference. No significant diffe",129.0,177.31796,57.5519,1.42,1.41,1.62,-0.007067167,0.131769278,-0.013507634,-0.042018015,10.37847,0.11019,0.95434,2367,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2103  1115  1103  5236  2418  3476  1849  1108
   118  1627   119   124  3029  1105   118  1744   119   126  3029  1111
  1103   122  1105   123 17713  1739   117  3569   117  1606  1103  1282
  4043  1981  1112   170  3835   119  1302  2418  4267 15475   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GUTS,Revita - (REVITALIZE-1),Type 2 DiabetesÂ ,Phase 1,2024-11-04,"Phase 1 data showed that a single Revita procedure led to sustained, clinically meaningful weight loss in the majority of patients with T2D, noted November 4, 2024.",50.0,122.69367,102.7788,2.84,2.56,2.51,-0.103796794,-0.123521299,-0.013507634,-0.042018015,3.95964,0.13667,1.06111,2368,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2799  1115   170  1423  6750  5168  7791  1521
  1106  8505   117  7300  1193 17119  2841  2445  1107  1103  2656  1104
  4420  1114   157  1477  2137   117  2382  1379   125   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GPCR,GSBR-1290 -(ACCESS and ACCESS II ),"Type 2 Diabetes, obesityÂ ",Phase 2a,2024-11-04,"Poster presented at Obesity week reported a 6.8% placebo-adjusted weight loss at 60 and 120 mg, respectively, with QD dosing at 12 weeks, noted November 4, 2024.",57.0,2272.98971,85.5317,41.14,39.74,38.7,-0.034622647,-0.061141284,-0.013507634,-0.042018015,18.88962,0.05536,32.76778,2369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  3799  1200  2756  1120   152 27655  1989  2103   170   127   119
   129   110  1282  4043   118 10491  2841  2445  1120  2539  1105  5356
 17713   117  3569   117  1114   154  2137 18463  1158  1120  1367  2277
   117  2382  1379   125   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GUTS,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D)Â ,Preclinical,2024-11-05,"Preclinical study 13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model, noted Novemb",50.0,115.02531,103.057,2.56,2.4,2.43,-0.064538521,-0.052116001,-0.031937654,-0.012917618,3.95964,0.13667,1.41871,2370,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2025  1492   118  1989  2812   118  1146
  5149  1103  6119  2233  1106   118  2236 15107  3840  9739 23891  1104
   155  4538 12152   118  3135  1475  1113  2841  1105  1892  6656  1107
  1103 10211   118 10645   184 27655   113   141 19368   114 10322  2235
   117  2382 14152  5521  1830   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RCUS,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC)Â ,Phase 3,2024-11-05,"Phase 3 data presented reported results from Part 1 of its ARC-10 study, showing that treatment led to greater PFS, overall survival, and objective response rates compared to zimberelimab alone or che",107.0,1397.92655,56.0577,15.56,15.29,16.77,-0.017504499,0.074888057,-0.031937654,-0.012917618,6.93216,0.15679,8.21104,2371,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  2756  2103  2686  1121  4539   122  1104  1157
 22133  1658   118  1275  2025   117  4000  1115  3252  1521  1106  3407
   153 17691   117  2905  8115   117  1105  7649  2593  5600  3402  1106
   195  4060  3169 21091  1918  1830  2041  1137 22572  1162   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NXTC,LNCB74,B7-H4 expressing cancersÂ ,Preclinical,2024-11-05,Preclinical data presented at SITC demonstrated strong anti-tumor activity in multiple CDX and PDX tumor models. A single dose of 3 mg/kg resulted in durable tumor regression in multiple tumor models,2.0,36.64835,64.6132,15.72001,15.72001,18.48001,0.0,0.161755184,-0.031937654,-0.012917618,0.26371,0.03547,0.00704,2372,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2756  1120   156 12150  1658  7160
  2012  2848   118 14601  3246  1107  2967  2891  3190  1105 27802  3190
 14601  3584   119   138  1423 13753  1104   124 17713   120  4023  3657
  1107  3840  9739 14601  1231 24032  1107  2967 14601  3584   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RYTM,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevanceÂ ,Phase 2,2024-11-05,"Phase 2 trial showed that patients with acquired hypothalamic obesity who were on therapy for more than one year achieved a mean overall percent reduction in fat mass of 29.6%, versus a reduction in l",66.0,3455.78912,49.0453,52.99,56.25,64.06,0.059702825,0.189716928,-0.031937654,-0.012917618,13.77088,0.12492,49.56126,2373,0,0,0,0,0,1,1,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  3443  2799  1115  4420  1114  2888   177  1183 11439
 19456  7257   184 27655  1150  1127  1113  7606  1111  1167  1190  1141
  1214  3890   170  1928  2905  3029  7234  1107  7930  3367  1104  1853
   119   127   110   117  6055   170  7234  1107   181   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JNJ,CAPLYTA (Lumateperone) 42mg - (Study 304),Prevention of relapse in schizophreniaÂ ,Phase 3,2024-11-05,"Phase 3 study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo, noted November 5, 2024.",0.0,381247.0976,15.5711,158.24,158.35,152.64,0.000694905,-0.03603066,-0.031937654,-0.012917618,0.77501,0.00373,1036.72917,2374,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  2025  7160   170 11435  1193  2418   113   185   134
   121   119  1288  1477   114  2039  1159  1106  1231 16046  2217  1107
   188  4313 26474  4420  5165  1114   181 10161 21747 28032  1162  3402
  1106  1282  4043   117  2382  1379   126   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SANA,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemiasÂ ",Phase 1,2024-11-05,"Sana is halting enrollment and further internal investment in the Phase 1 ARDENT trial. It is actively seeking a licensing partner to support advancement, noted November 2024.",237.0,754.15952,79.4633,3.76,3.39,2.84,-0.103589036,-0.280614905,-0.031937654,-0.012917618,14.9594,0.04651,12.38173,2375,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  1727  1161  1110  9700  1158 10803  1105  1748  4422  5151  1107
  1103 12278   122 22133 20427 15681  3443   119  1135  1110  8525  5788
   170 15469  3547  1106  1619 19024   117  2382  1379 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NXTC,NC410 in combination w/ pembrolizumab - (LAIR-2),Solid TumorsÂ ,Phase 1/2,2024-11-06,"Phase 1/2 data presented at SITC reported a disease control rates were 86% and 47% for the 200 mg and 100 mg NC410 doses, respectively, noted November 6, 2024.",2.0,36.50847,63.7025,15.72001,15.66001,16.92001,-0.003824094,0.073562522,-0.023475026,0.006080864,0.26371,0.03547,0.04892,2376,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122   120   123  2233  2756  1120   156 12150  1658  2103
   170  3653  1654  5600  1127  5942   110  1105  3862   110  1111  1103
  2363 17713  1105  1620 17713 14056 25892  1568 24429   117  3569   117
  2382  1379   127   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
HCM,HMPL-523 - (ESLIM-01),Primary immune thrombocytopenia (ITP)Â ,Phase 3,2024-11-06,"Phase 3 data presented at ESMO Asia with an overall response was achieved by 81%, noted November 6, 2024.",174.0,2427.18405,50.1253,2.86,2.84,2.68,-0.007017573,-0.06500483,-0.023475026,0.006080864,0.0,0.00119,0.38506,2377,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124  2233  2756  1120   142 16450  2346  3165  1114  1126
  2905  2593  1108  3890  1118  5615   110   117  2382  1379   127   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNGX,TNG462 with daraxonrasib or zoldonrasib,Solid TumorsÂ ,Phase 1/2,2024-11-06,"Phase 1/2 data demonstrated durable clinical activity across multiple tumor types, noted November 6, 2024.",111.0,348.03373,96.7372,5.18,3.24,3.56,-0.469231726,-0.375044511,-0.023475026,0.006080864,8.28978,0.11029,48.38103,2378,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  7160  3840  9739  7300  3246  1506
  2967 14601  3322   117  2382  1379   127   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNGX,TNG908,MTAP-deleted tumorsÂ ,Phase 1/2,2024-11-06,"TNG908 enrollment being stopped to fully resource TNG462 and TNG456, noted November 6, 2024.",111.0,348.03373,96.7372,5.18,3.24,3.56,-0.469231726,-0.375044511,-0.023475026,0.006080864,8.28978,0.11029,48.38103,2379,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101   157 11780 21500  1604 10803  1217  2141  1106  3106  9100   157
 11780 23435  1477  1105   157 11780 21336  1545   117  2382  1379   127
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CCCC,CFT8919,Non-Small Cell Lung Cancer (NSCLC)Â ,Phase 1,2024-11-06,"Phase 1 dosing commenced, noted November 6, 2024.",71.0,421.41609,80.5495,6.09,5.97,5.13,-0.019901154,-0.171542423,-0.023475026,0.006080864,9.42186,0.05108,5.7369,2380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 18463  1158  8042   117  2382  1379   127   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IONS,ION582 - (REVEAL),Angelman SyndromeÂ ,Phase 3,2024-11-06,"Phase 2 EoP2 discussion with FDA went well, including alignment on Phase 3 design, noted November 6, 2024.",159.0,6164.31008,39.3024,38.8,39.04,37.78,0.006166515,-0.026640385,-0.023475026,0.006080864,6.2508,0.00759,67.48127,2381,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   142  1186  2101  1477  6145  1114 18762  1355  1218
   117  1259 12793  1113 12278   124  1902   117  2382  1379   127   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VINC,OQY-3258 (ESG401),Unresectable recurrent or metastatic triple-negative breast cancerÂ ,Phase 3,2024-11-06,"Phase 3 garnered Breakthrough Designation from China's National Medical Products Administration (NMPA) on November 6, 2024.",5.0,10.09805,105.0904,6.92,6.54,6.48,-0.056478604,-0.065695259,-0.023475026,0.006080864,2.71133,0.02415,0.13967,2382,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124 13331 15835  1582 14929  4800  1891  1121  1975   112
   188  1305  3875 16818  4918   113   151 12347  1592   114  1113  1379
   127   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
DVAX,CpG 1018 adjuvant with rF1V vaccine - (DoD Trial),Recombinant plague vaccineÂ ,Phase 2,2024-11-07,"Based on the results from a randomized, active-controlled Phase 2 clinical trial of the two-dose plague vaccine adjuvanted with CpG 1018, Dynavax has submitted a proposal to the DoD regarding addition",117.0,1580.08382,33.351,12.29,12.02,13.39,-0.022213994,0.085722236,-0.016842911,0.054978739,12.97771,0.00047,26.68119,2383,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  7457  1113  1103  2686  1121   170  7091  2200   117  2327   118
  4013 12278   123  7300  3443  1104  1103  1160   118 13753 13824 20034
  8050  9380 14194  1174  1114   140  1643  2349  7393  1604   117   141
 21880  2497  1775  1144  7402   170  5835  1106  1103  2091  2137  4423
  1901   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
HOWL,WTX-330,Solid tumorsÂ ,Phase 1,2024-11-07,"Phase 1 data presented at SITC revealed the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signal, noted November 7, 2024",45.0,99.82146,114.9551,2.44,2.24,1.93,-0.085522173,-0.234478036,-0.016842911,0.054978739,1.74132,2e-05,1.88764,2384,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  2233  2756  1120   156 12150  1658  3090  1103  7300
  3209  1104  1103 14601   118  9618 15393   118  1367  5250 23632  9610
   160  1942  3190   118 14747   117  1114 11169  1106  2879  6328  6168
  1105 11653 23891  4344   117  2382  1379   128   117 17881  1527   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INDP,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumorsÂ ,Phase 1,2024-11-07,"Phase 1 data from SITC reported that confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's ""pulse"" approach, noted November 7, 2024.",1.0,12.13427,97.9041,32.47999,33.31999,31.49999,0.02553331,-0.030636979,-0.016842911,0.054978739,0.30333,0.09814,0.03139,2385,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  1121   156 12150  1658  2103  1115  3659  1115
 13063  7341 10973  1976  4712  1121  1103  1892 14765  1170  3469   117
  4374  1103  1881   112   188   107  8561   107  3136   117  2382  1379
   128   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INKT,AGENT-797,Solid TumorsÂ ,Preclinical,2024-11-07,"Preclinical data presented at SITC reported durable disease control in majority of heavily pretreated patients, noted November 7, 2024.",4.0,29.06957,55.2893,7.323,7.352,7.5,0.003952305,0.02388294,-0.016842911,0.054978739,0.16526,0.00506,0.02951,2386,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2756  1120   156 12150  1658  2103
  3840  9739  3653  1654  1107  2656  1104  3777  3073  7877  2913  4420
   117  2382  1379   128   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IOBT,IO102-IO103 in combination with pembrolizumab - (IOB-022),Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-07,"Phase 2 data presented at SITC reported an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 mont",65.0,81.03352,113.6823,1.16,1.23,0.89,0.058594164,-0.264953821,-0.016842911,0.054978739,0.42053,0.07535,0.23723,2387,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2233  2756  1120   156 12150  1658  2103  1126  2905
  2593  2603  1104  3731   110  8362  7235 22750   120  3615   110  3659
   117  3653  1654  2603  1104  5615   110   117  1105  2324  1851   110
  1104  4420  1443  3653 16147  1120  1367 19863  1204   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BOLT,BDC-4182,"gastric/gastroesophageal junction cancer, pancreatic cancerÂ ",Preclinical,2024-11-07,"Preclinical data from SITC reported that treatment demonstrated anti-tumor activity in a wide range of tumor models and elicits immunological memory, noted November 7, 2024.",1.0,24.92189,73.8091,12.952,13.026,12.448,0.005697144,-0.039690249,-0.016842911,0.054978739,0.31216,0.00437,0.04275,2388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  1121   156 12150  1658  2103  1115
  3252  7160  2848   118 14601  3246  1107   170  2043  2079  1104 14601
  3584  1105  8468 22308  1116 13280 13601 22176  2962   117  2382  1379
   128   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BOLT,Trastuzumab imbotolimod (BDC-1001) with Opdivo,"HER2-Expressing Solid Tumors, gastric cancer, including gastroesophageal junction cancerÂ ",Phase 1,2024-11-07,"Phase 1 data reported pharmacodynamic changes were observed in HER2 IHC3+ and HER2 IHC2+, with both the greatest increase and statistical significance in patients with HER2 IHC 3+ tumors, noted Novemb",1.0,24.92189,73.8091,12.952,13.026,12.448,0.005697144,-0.039690249,-0.016842911,0.054978739,0.31216,0.00437,0.04275,2389,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103   185  7111  1918  2528 24662  2607  1127
  4379  1107   145  9637  1477   146 15779  1495   116  1105   145  9637
  1477   146 15779  1477   116   117  1114  1241  1103  4459  2773  1105
 11435  7467  1107  4420  1114   145  9637  1477   146 15779   124   116
 24309   117  2382 14152  5521  1830   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALLO,ALLO-316 - (TRAVERSE),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,2024-11-07,"Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2",221.0,668.85397,82.1433,3.22,3.19,2.46,-0.009360443,-0.26922001,-0.016842911,0.054978739,18.75238,0.06465,8.02628,2390,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 11984  2756  1120   156 12150  1658  2103  1126  8007
 24187 24442  1104  1851   110  1105 16752 22750 24187 24442  1104  3081
   110  1107  7195 24767  1114  2891 20829 17037 26271  5096  4342  1988
 18417   113   157 10197   114  1104  6752  1190  1851   110   117  2382
  1379   128   117   123   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CLLS,ALLO-316 - (TRAVERSE),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,2024-11-07,"Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2",72.0,121.46094,48.4651,1.77,1.75,1.91,-0.011363759,0.076123695,-0.016842911,0.054978739,0.0,0.0,0.12991,2391,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 11984  2756  1120   156 12150  1658  2103  1126  8007
 24187 24442  1104  1851   110  1105 16752 22750 24187 24442  1104  3081
   110  1107  7195 24767  1114  2891 20829 17037 26271  5096  4342  1988
 18417   113   157 10197   114  1104  6752  1190  1851   110   117  2382
  1379   128   117   123   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NKTR,NKTR-255,Locally advanced non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-07,Phase 2 data reported at SITC demonstrated statistically significant superiority of the eight-week absolute lymphocyte count with NKTR-255 post chemoradiation and in combination with durvalumab versus,19.0,252.18887,73.3585,20.84999,20.54999,17.54999,-0.014493014,-0.172300089,-0.016842911,0.054978739,3.27964,0.08952,2.55556,2392,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  2233  2103  1120   156 12150  1658  7160 11435  1193
  2418 21378  1104  1103  2022   118  1989  7846   181 25698 13335 14300
  5099  1114   151  2428 23313   118 22589  2112 22572  5521  6533 25971
  1105  1107  4612  1114  3840 13461  7776  6639  6055   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Phase 1,2024-11-07,"Phase 1 clinical study commenced, noted November 7, 2024.",9.0,3.0086,67.464,2.55,2.54,2.62,-0.003929278,0.027080959,-0.016842911,0.054978739,1.4077,0.07293,0.11516,2393,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  7300  2025  8042   117  2382  1379   128   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NKTX,NKX019,Non-Hodgkin lymphoma (NHL)Â ,Phase 1,2024-11-07,"No further NKX019 development in lymphoma planned, noted November 7, 2024.",71.0,230.75983,78.2158,3.35,3.27,2.7,-0.024170361,-0.215708573,-0.016842911,0.054978739,14.76544,0.04234,1.94662,2394,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  1302  1748   151  2428  3190 24400  1580  1718  1107   181 25698
  7903  2919   117  2382  1379   128   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MOLN,MP0317,Solid TumorsÂ ,Preclinical,2024-11-07,"Preclnical PoC data presented at SITC supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only, November 7, 2024.",40.0,191.68809,91.8199,5.54,5.2,4.85,-0.063335875,-0.133015796,-0.016842911,0.054978739,0.0,0.03184,0.08763,2395,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101 11689  1665 21615  4571 18959  1658  2233  2756  1120   156 12150
  1658  6253  1103  3209  1104  2891  1495   156 18548   118   141 12426
  2101  1394  3482  1106 23162  1105 14112   157  3652  1107  1103  2915
  1104 14601  7539  1178   117  1379   128   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AVIR,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19Â ,Phase 3,2024-11-07,"Phase 3 trial did not meet primary endpoint, noted November 7, 2024.",79.0,290.55292,48.2548,3.58,3.44,3.31,-0.039891329,-0.078414611,-0.016842911,0.054978739,3.11325,0.13189,0.97043,2396,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   124  3443  1225  1136  2283  2425  1322  7587   117  2382
  1379   128   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMNN,IMNN-001 - (OVATION 2),Ovarian cancerÂ ,Phase 2,2024-11-08,"Phase 2 data presented at SITC reported a 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone, noted November 8, 2024.",2.0,11.59909,206.3528,10.71521,10.43347,9.39913,-0.02664532,-0.131047096,-0.005035355,0.114887029,2.32795,0.02656,0.23232,2397,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2233  2756  1120   156 12150  1658  2103   170  2588
   110  8331  1107  2905  8115  1105  1512   110  8331  1107 16147   118
  1714  8115  6055  2530   118  1104   118  1920  2041   117  2382  1379
   129   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MURA,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 1/2,2024-11-08,"Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.",17.0,59.97373,43.0133,3.38,3.52,3.45,0.04058528,0.020498522,-0.005035355,0.114887029,2.30539,0.00594,0.34225,2398,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123 17599  1424 25740  1320  1880   185  7111
  1918  2528 24662  2233  3416  1120   156 12150  1658  7160 14601   118
  1751   118  2747   185  7111  1918  2528 24662  3246  1105 11650 14915
   117  2382  1379   129   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALKS,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 1/2,2024-11-08,"Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.",165.0,4669.62038,32.8276,28.97,28.86,28.19,-0.003804258,-0.027293507,-0.005035355,0.114887029,9.77951,0.05223,53.02026,2399,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123 17599  1424 25740  1320  1880   185  7111
  1918  2528 24662  2233  3416  1120   156 12150  1658  7160 14601   118
  1751   118  2747   185  7111  1918  2528 24662  3246  1105 11650 14915
   117  2382  1379   129   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ELTX,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 1a,2024-11-08,"Phase 1a data presented at SITC reported that the highest three quartiles of T cell responders have not yet reached mDFS, whereas the lowest quartile achieved a mDFS of 3.1 months, noted November 8, 2",16.0,54.66141,109.5539,4.61,5.08,5.48,0.097083405,0.172877244,-0.005035355,0.114887029,0.37098,0.0141,0.0629,2400,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,pos,"[  101 12278   122  1161  2233  2756  1120   156 12150  1658  2103  1115
  1103  2439  1210   186  6718  3740 12846  1104   157  2765  6297  1468
  1138  1136  1870  1680   182 16395  1708   117  6142  1103  6905   186
  6718  3740  4759  3890   170   182 16395  1708  1104   124   119   122
  1808   117  2382  1379   129   117   123   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AMGN,TEZSPIRE (tezepelumab-ekko),Chronic Rhinosinusitis with Nasal Polyps (CRwNP)Â ,Phase 3,2024-11-08,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",538.0,174848.6441,20.1769,321.91,325.28,283.61,0.010414347,-0.126671948,-0.005035355,0.114887029,1.74354,0.03195,643.45133,2401,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103   170 11435  1193  2418  1105  7300  1193
 17119  7234  1107 21447   185 23415  1643  2060  1105  3549 21447 22860
  3402  1106  1282  4043   117  2382  1379   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,TEZSPIRE (tezepelumab-ekko),Chronic Rhinosinusitis with Nasal Polyps (CRwNP)Â ,Phase 3,2024-11-08,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",0.0,153524.9558,20.6939,97.25,99.03,99.78,0.018137852,0.02568278,-0.005035355,0.114887029,0.0,0.05065,402.29858,2402,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   124  2233  2103   170 11435  1193  2418  1105  7300  1193
 17119  7234  1107 21447   185 23415  1643  2060  1105  3549 21447 22860
  3402  1106  1282  4043   117  2382  1379   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AMGN,Tezepelumab - (WAYPOINT),Chronic Rhinosinusitis With Nasal PolypsÂ ,Phase 3,2024-11-08,"Phase 3 trial had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo, noted November 8, 2024.",538.0,174848.6441,20.1769,321.91,325.28,283.61,0.010414347,-0.126671948,-0.005035355,0.114887029,1.74354,0.03195,643.45133,2403,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  3443  1125   170 11435  1193  2418  1105  7300  1193
 17119  7234  1107  1103  2060  1104 21447   185 23415  3491  1105  3549
 21447 22860  3402  1106  1282  4043   117  2382  1379   129   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IPHA,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL)Â ,Preclinical,2024-11-08,"Preclinical data reported that IPH6501 targets on NK cells and show effective IPH6501-induced killing of CD20+ B-NHL target cells, noted November 8, 2024.",92.0,130.33076,65.9952,1.8447,1.8413,1.44,-0.001844819,-0.247673549,-0.005035355,0.114887029,0.0,0.0,0.01303,2404,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115 14274  3048 27677 24400
  7539  1113   151  2428  3652  1105  1437  3903 14274  3048 27677 24400
   118 10645  3646  1104  2891 10973   116   139   118  6521  4010  3652
   117  2382  1379   129   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IOVA,LN-145 and KEYTRUDA (pembrolizumab) - (IOV-COM-202),Solid TumorsÂ ,Phase 2,2024-11-08,"Phase 2 updated cohort 1a data at ASCO noted that 30% confirmed complete response rate, noted November 8, 2024",361.0,3226.10466,75.6164,12.28,10.585,8.18,-0.148534018,-0.406279772,-0.005035355,0.114887029,19.79727,0.07329,288.97813,2405,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  8054  1884 13252  1204   122  1161  2233  1120 15278
 15678  2382  1115  1476   110  3659  2335  2593  2603   117  2382  1379
   129   117 17881  1527   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CARM,CAR-M therapy,Hepatocellular carcinoma (HCC)Â ,Preclinical,2024-11-08,"Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.",41.0,42.16761,86.0282,1.03,1.01,0.8832,-0.019608471,-0.153762406,-0.005035355,0.114887029,2.50483,0.05521,0.85874,2406,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1103  3252  1666  5250   118
 22653   172 25669 21420  3965  1105  3399  1126 22653   117  9618 23639
 12736 19911   185 10436 27172  1852  2848  4915  8164   117  2382  1379
   129   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRNA,CAR-M therapy,Hepatocellular carcinoma (HCC)Â ,Preclinical,2024-11-08,"Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.",389.0,18021.01809,61.7213,50.28,46.83,36.85,-0.071083361,-0.310751765,-0.005035355,0.114887029,8.64321,0.00507,635.08683,2407,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1103  3252  1666  5250   118
 22653   172 25669 21420  3965  1105  3399  1126 22653   117  9618 23639
 12736 19911   185 10436 27172  1852  2848  4915  8164   117  2382  1379
   129   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VTYX,VTX958,Crohn's diseaseÂ ,Phase 2,2024-11-08,"The company does not plan to commit significant internal resources to further development of VTX958, noted November 8, 2024.",71.0,155.56347,106.5292,2.24,2.2,1.87,-0.018018506,-0.180537435,-0.005035355,0.114887029,11.84596,0.01515,1.95322,2408,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  1109  1419  1674  1136  2197  1106 10836  2418  4422  3979  1106
  1748  1718  1104   159  1942  3190  1580  1571  1604   117  2382  1379
   129   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CMPX,CTX-471 (CD137 agonist),Solid tumorsÂ ,Phase 1,2024-11-08,Phase 1 new data presented at SITC showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471,138.0,247.66051,84.2921,1.84,1.8,1.38,-0.021978907,-0.287682072,-0.005035355,0.114887029,1.60388,0.02468,1.00988,2409,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  1207  2233  2756  1120   156 12150  1658  2799   170
 18741  1206  1103  3001  1104 18250  2765  8050 23746 14730   113 14056
 10964  1137  2891  1571  1545   114  2838  1105  2593  1105  3653  1654
  1107  4420  5165  1114 16899  3190   118  3862  1475   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANIX,Î±-lactalbumin,Breast cancer vaccineÂ ,Phase 1a,2024-11-08,"Phase 1a additional data presented at SITC showed that vaccine was safe and well tolerated by participants in all 3 cohorts, noted November 8, 2024.",32.0,110.69745,68.5234,3.62,3.44,3.08,-0.051002554,-0.161544429,-0.005035355,0.114887029,1.84503,0.00455,1.60485,2410,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  1161  2509  2233  2756  1120   156 12150  1658  2799
  1115 20034  1108  2914  1105  1218 21073  1181  1118  6635  1107  1155
   124  1884 13252  2145   117  2382  1379   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CUE,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,2024-11-08,"Phase 1 presented at SITC showed an objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months, noted November 8, 2024.",76.0,103.55727,136.2531,1.78,1.72,1.245,-0.034289073,-0.357477834,-0.005035355,0.114887029,3.23451,0.00454,0.96089,2411,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2756  1120   156 12150  1658  2799  1126  7649  2593
  2603   113 23066  2069   114  1104  3993   110   117  1367   118  2370
  2905  8115   113 11570   114  1104  5539   119   124   110  1105   170
  3151  2905  8115   113   182  9025   114  1104  1626   119   129  1808
   117  2382  1379   129   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AUTL,AUCATZYL (obecabtagene autoleucel) - (FELIX),B-Cell Acute Lymphoblastic LeukemiaÂ ,Approved,2024-11-08,"FDA Approved on November 8, 2024.",266.0,992.53233,69.5938,4.04,3.73,3.08,-0.079836458,-0.271315095,-0.005035355,0.114887029,3.28712,0.08637,17.38236,2412,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762   138  8661 16011  1113  1379   129   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CADL,CAN-3110,MelanomaÂ ,Preclinical,2024-11-08,"Data presented in a poster at SITC reported that CAN-3110 demonstrated potent antitumor activity both in vitro and in vivo, highlighting its potential as a promising therapeutic agent for treating me",54.0,154.96947,95.798,5.09,4.83,3.8,-0.052431363,-0.292276764,-0.005035355,0.114887029,5.11279,0.00223,2.01545,2413,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  7154  2756  1107   170 14525  1120   156 12150  1658  2103  1115
  8784  2249   118 26277  1568  7160 18106  2848  8928  1766  3246  1241
  1107   191  2875  2180  1105  1107   191 15435   117 23201  1157  3209
  1112   170 10480 20340  3677  1111 12770  1143   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-08,"Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.",105.0,89129.31927,23.9985,824.48,828.42,756.81,0.004767388,-0.085640653,-0.005035355,0.114887029,1.59488,0.11222,466.88509,2414,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 11984  2756  1120   156 12150  1658  2103  1126 23066
  2069  1107  1103   124  2162  3545  1114  1103  7967 17713 13753  1110
  3383   110   113   124   120   129   114   117  2382  1379   129   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-08,"Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.",32.0,72.8856,89.3786,3.32,2.91,2.26,-0.131811702,-0.38459997,-0.005035355,0.114887029,2.78053,0.00155,0.94841,2415,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 11984  2756  1120   156 12150  1658  2103  1126 23066
  2069  1107  1103   124  2162  3545  1114  1103  7967 17713 13753  1110
  3383   110   113   124   120   129   114   117  2382  1379   129   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CGEN,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancerÂ ",Phase 1,2024-11-08,"Report initial findings at SITC reported a Confirmed ORR of 17.4%, noted November 8, 2024.",93.0,159.37485,72.364,1.81,1.78,1.41,-0.016713481,-0.249737141,-0.005035355,0.114887029,1.72927,0.01783,0.37774,2416,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  7178  3288  9505  1120   156 12150  1658  2103   170 16752 22750
 23066  2069  1104  1542   119   125   110   117  2382  1379   129   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Preclinical,2024-11-08,"Preclinical data reported that the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone, n",9.0,5.7401,185.6937,1.28,1.28,1.13,0.0,-0.124642445,-0.005035355,0.114887029,2.88298,0.00845,0.20922,2417,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101 11689  1665 21472  7867  2233  2103  1115  1103  3490  3252  7160
  2418  8331  1107 18560 13950  2272  1106  5199  6600   118 10645  2975
  1112  3402  1106  1606  1719  3677  2041   117   183   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ADAG,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumorsÂ ,Phase 1/2,2024-11-09,"Phase 1/2 data presented at SITC showed a three-fold increased active (e.g., cleaved) drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while",47.0,116.87487,92.8619,2.64,2.64,2.16,0.0,-0.200670695,0.006258747,0.126181131,0.04823,0.00706,0.0,2418,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122   120   123  2233  2756  1120   156 12150  1658  2799
   170  1210   118 11203  2569  2327   113   174   119   176   119   117
   172 19094  5790   114  3850  7401  1107 16358  3702  4915  2200 14601
  7918  8025  1120  1275 17713   120  4023  6055   170  1423 13753  1104
   178  8508 24891 10161  1830  1120   122 17713   120  4023  1229   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,2024-11-09,"Phase 1b additional data shared at SITC reported one complete response and one partial response, noted November 9, 2024.",5.0,2.53913,93.6034,2.95,2.95,2.21,0.0,-0.288812655,0.006258747,0.126181131,2.47943,0.0488,0.0,2419,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  2509  2233  3416  1120   156 12150  1658  2103
  1141  2335  2593  1105  1141  7597  2593   117  2382  1379   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
REPL,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)Â ,Phase 3,2024-11-09,"Phase 3 data presented at SITC reported that the median overall survival for the trial has not been reached, however, one-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8%, respective",78.0,849.91817,76.7232,12.44,12.44,10.8,0.0,-0.141370953,0.006258747,0.126181131,10.48438,0.03269,0.0,2420,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124  2233  2756  1120   156 12150  1658  2103  1115  1103
  3151  2905  8115  1111  1103  3443  1144  1136  1151  1680   117  1649
   117  1141   118   117  1160   118   117  1105  1210   118  1214  8115
  5600  1127  3453   119   124   110   117  5519   119   124   110   117
  1105  4335   119   129   110   117  7514   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SRRK,SRK-181 - (DRAGON),Solid TumorsÂ ,Phase 1,2024-11-09,"Phase 1 data presented at SITC demonstrated durable antitumor activity in heavily pretreated patients with antiâ€“PD-1â€“resistant cancer across multiple cancer types , noted November 9, 2024.",96.0,2672.19118,224.8285,29.08,29.08,26.49,0.0,-0.093283349,0.006258747,0.126181131,16.2457,0.01866,0.0,2421,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  2233  2756  1120   156 12150  1658  7160  3840  9739
  2848  8928  1766  3246  1107  3777  3073  7877  2913  4420  1114  2848
 28198 28731   789 27802   118   122 28198 28731   789 13676  4182  1506
  2967  4182  3322   117  2382  1379   130   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CUE,CUE-102,Wilms' Tumor (WT1)-expressing cancersÂ ,Phase 1,2024-11-09,Phase 1 trial presentation SITC reported that patients with HPV16+ R/M HNSCC refractory to platinum-based treatments and checkpoint inhibitors (2L+) receiving CUE-101 4 mg/kg monotherapy exhibit an,76.0,103.55727,136.2531,1.72,1.72,1.245,0.0,-0.323188761,0.006258747,0.126181131,3.23451,0.00454,0.0,2422,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  3443  8685   156 12150  1658  2103  1115  4420  1114
 18444  2559 16229   116   155   120   150   145 12412 12096  1231 27476
  9363  1183  1106 11980   118  1359 14115  1105  4031  7587 27558  1116
   113   123  2162   116   114  4172   140 24846   118  7393   125 17713
   120  4023 19863 20939  8245  1126   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMAB,Givastomig (TJ033721 / ABL111),"First-line metastatic gastric cancers, solid tumorsÂ ",Phase 1,2024-11-09,"Phase 1 data presented at SITC 2024 reported that a dose range between 8-12 mg/kg Q2W was identified as the preferred dose range for heavily pre-treated GEC patients., noted November 9, 2024.",81.0,89.57815,73.2636,1.1,1.1,1.04,0.0,-0.056089467,0.006258747,0.126181131,0.60365,0.06287,0.0,2423,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  2233  2756  1120   156 12150  1658 17881  1527  2103
  1115   170 13753  2079  1206   129   118  1367 17713   120  4023   154
  1477  2924  1108  3626  1112  1103  6349 13753  2079  1111  3777  3073
   118  5165 25075  1658  4420   119   117  2382  1379   130   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RCUS,Etrumadenant (AB928) and zimberelimab - (ARC-9),Colorectal CancerÂ ,Phase 1/2,2024-11-09,"Phase 1b/2 data presented at SITC reported that OS was greater with zim than with chemo, noted November 9, 2024.",107.0,1633.48222,57.2752,17.85,17.85,15.7,0.0,-0.128342796,0.006258747,0.126181131,6.92579,0.2319,0.0,2424,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  1830   120   123  2233  2756  1120   156 12150  1658
  2103  1115 11570  1108  3407  1114   195  4060  1190  1114 22572  5521
  1186   117  2382  1379   130   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
XAIR,Beyond Cancer (UNO),Solid tumorsÂ ,Preclinical,2024-11-11,"Preclinical efficacy data from Low Volume UNO (LV UNO, < 100 mL) presented at SITC showed that LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibi",5.0,36.82291,148.0278,9.478,10.202,10.176,0.073610456,0.071058683,0.035862947,0.124766472,2.01308,0.01643,0.6718,2425,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867 23891  2233  1121  8274  6849  7414  2346
   113   149  2559  7414  2346   117   133  1620   182  2162   114  2756
  1120   156 12150  1658  2799  1115   149  2559  7414  2346  1107  4612
  1114  2848   118   187 15481   118   149  1475  3657  1107 16639  8115
  1105 11590  1103 14601  3213  1107  3031  5567   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CANF,Namodenoson - (CF102-222PC),Pancreatic CancerÂ ,Phase 2a,2024-11-11,"Phase 2a dosing initiated, noted November 11, 2024.",10.0,57.234,79.6862,0.028,0.028,0.026,0.0,-0.074107972,0.035862947,0.124766472,0.0,0.00877,0.1082,2426,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  1161 18463  1158  7087   117  2382  1379  1429   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NCNA,NUC-3373 in Combination with Pembrolizumab or Docetaxel - NuTide: 303),Non Small Cell Lung Cancer (NSCLC)Â ,Phase 1/2,2024-11-11,"Phase 1b/2 commenced, noted October 26, 2022. Phase 1b/2 initial data showed that among patients who had exhausted all other treatment options, including prior PD-(L)1 therapy, a 22% objective respons",1.0,3.50438,246.7668,301.0,312.0,288.0,0.035892923,-0.044149785,0.035862947,0.124766472,2.82826,0.0391,0.79123,2427,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830   120   123  8042   117  2382  1357  1744   117
 17881  1477   119 12278   122  1830   120   123  3288  2233  2799  1115
  1621  4420  1150  1125  8984  1155  1168  3252  6665   117  1259  2988
 27802   118   113   149   114   122  7606   117   170  1659   110  7649
  1231 20080  4199   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-11,"Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.",0.0,254810.1985,23.5922,102.92,100.73,96.56,-0.021508317,-0.063787411,0.035862947,0.124766472,1.03685,0.08711,1014.88064,2428,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1126  2905  2593  2603   113 23066  2069
   114  1104  1367   119   129   110  1105  3151   153 17691   113   182
  2101 17691   114  1104   124   119   128  1808   117  2382  1379  1429
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BYSI,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-11,"Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.",40.0,79.79469,73.7823,1.94,1.98,1.72,0.020408872,-0.120363682,0.035862947,0.124766472,5.17658,0.01866,0.03971,2429,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1126  2905  2593  2603   113 23066  2069
   114  1104  1367   119   129   110  1105  3151   153 17691   113   182
  2101 17691   114  1104   124   119   128  1808   117  2382  1379  1429
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CERO,CER-1236,"Solid tumors, non-small cell lung cancer (NSCLC) and ovarian cancerÂ ",Preclinical,2024-11-11,"Preclinical study presented ar SITC highlighted CER-1236's ability to increase TIM-4-L expression in ovarian cancer cells, resulting in tumor cell death while sparing healthy cells, noted November 11,",1.0,29.45998,216.7077,140.0,392.0,479.4,1.029619417,1.230892899,0.035862947,0.124766472,1.06563,5e-05,283.5677,2430,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2025  2756   170  1197   156 12150  1658
 11634  9855  2069   118 13414  1545   112   188  2912  1106  2773   157
 13371   118   125   118   149  2838  1107   184  8997  1811  4182  3652
   117  3694  1107 14601  2765  1473  1229 22620  3384  8071  3652   117
  2382  1379  1429   117   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVAX,NVX-CoV2373 - (COVID-19-Influenza Combination),"COVID-19, COVID-19 vaccine, InfluenzaÂ ",Phase 2,2024-11-11,"Phase 2 hold removed, FDA cleared study to begin enrolling in planned Phase 3 trial, noted November 11, 2024.",162.0,1442.44369,116.0066,8.91,9.01,7.83,0.01116083,-0.129211731,0.035862947,0.124766472,24.97341,0.03918,132.08874,2431,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  2080  2856   117 18762  5323  2025  1106  3295  4035
 10747  1158  1107  2919 12278   124  3443   117  2382  1379  1429   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CTXR,LYMPHIR (denileukin diftitox),B-cell lymphomasÂ ,Phase 1,2024-11-11,"Phase 1 preliminary efficacy results strongly suggests that LYMPHIR may have the ability to improve and prolong the anti-tumor activity of immune checkpoint inhibitors. To date, this unique regimen ha",17.0,81.18185,87.8718,10.2875,11.23,5.605,0.087659203,-0.607270509,0.035862947,0.124766472,6.5224,0.00132,1.96114,2432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  9889 23891  2686  5473  5401  1115   149  3663 12347
  3048 18172  1336  1138  1103  2912  1106  4607  1105  5250  9851  1103
  2848   118 14601  3246  1104 11650  4031  7587 27558  1116   119  1706
  2236   117  1142  3527  6716  1179  5871   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ABBV,Emraclidine (CVL-231) - (EMPOWER-1),SchizophreniaÂ ,Phase 2,2024-11-11,"Phase 2 trial did not meet their primary endpoint, noted November 11, 2024.",0.0,308242.2865,27.953,199.5,174.43,166.28,-0.134290721,-0.182141122,0.035862947,0.124766472,1.02568,0.0105,3621.21041,2433,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123  3443  1225  1136  2283  1147  2425  1322  7587   117
  2382  1379  1429   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
APVO,ALG.APV-527,Solid tumorsÂ ,Phase 1,2024-11-11,"Phase 1 data presented at SITC indicated that trial endpoints of adequate exposure, safety, tolerability and biological activity were met, noted November 11, 2024.",3.0,5.33142,180.0901,204.6842,213.12021,159.61816,0.040388069,-0.248683841,0.035862947,0.124766472,6.49236,0.01935,1.1306,2434,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  2233  2756  1120   156 12150  1658  4668  1115  3443
  1322 21521  1104 12373  7401   117  3429   117  1106  2879  6328  1105
  7269  3246  1127  1899   117  2382  1379  1429   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AIMD,VELDONA,SjÃ¶gren's syndromeÂ ,Phase 3,2024-11-11,"IRB approval on track as scheduled, company plans new phase of treatment evaluation expected 1Q 2025, noted November 11, 2024.",4.0,6.91803,100.0734,2.399,2.4995,2.155,0.041038728,-0.10726126,0.035862947,0.124766472,1.0351,0.0089,0.12946,2435,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   146 22672  5684  1113  1854  1112  4533   117  1419  2714  1207
  4065  1104  3252 10540  2637   122  4880 17881  1571   117  2382  1379
  1429   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CRVS,Ciforadenant,Metastatic castration resistant prostate cancer (mCRPC)Â ,Phase 1/2,2024-11-11,"Phase 1/2 data reported that 5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions >30%, compared to 1 of 11 (9%) receiving monotherapy, noted November 11, 20",74.0,597.99025,78.736,9.45,9.56,8.34,0.011572986,-0.124951525,0.035862947,0.124766472,4.67621,0.00423,5.49273,2436,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2103  1115   126  1104  1572   113
  1626   110   114  4172  4612  7606  1125 12727  1592  7597 11317  3393
  1112 12727  1592  7234  1116   135  1476   110   117  3402  1106   122
  1104  1429   113   130   110   114  4172 19863 20939   117  2382  1379
  1429   117  1406   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
FATE,FT825/ONO-8250,Solid TumorsÂ ,Phase 1,2024-11-11,"Phase 1 data reported that treatment was well-tolerated with no DLTs and no events of any grade of CRS, ICANS, or GvHD, noted November 11, 2024.",115.0,291.52738,80.1622,2.42,2.56,2.27,0.056239718,-0.063987709,0.035862947,0.124766472,13.96433,0.06567,3.06839,2437,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0,neg,"[  101 12278   122  2233  2103  1115  3252  1108  1218   118 21073  1181
  1114  1185 26624  1942  1116  1105  1185  1958  1104  1251  3654  1104
 15531  1708   117   146 11356 12412   117  1137   144  1964 23527   117
  2382  1379  1429   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RARE,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 1/2,2024-11-11,"Phase 1/2 data reported statistically significant separation between the GTX-102 and sham arms, noted November 11, 2024.",96.0,4681.12825,39.8352,50.36,50.73,43.78,0.007320242,-0.140020117,0.035862947,0.124766472,3.4458,0.09183,53.80591,2438,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   122   120   123  2233  2103 11435  1193  2418  8865  1206
  1103 14965  3190   118  9081  1105   188  2522  1739   117  2382  1379
  1429   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMTX,"Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)",MelanomaÂ ,Phase 1b,2024-11-11,"Phase 1b data reported a 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses, noted November 11, 2024.",121.0,1078.97739,51.5293,9.25,9.04,7.82,-0.022964377,-0.167938997,0.035862947,0.124766472,5.60642,0.01629,4.57316,2439,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  2233  2103   170  4335   110   172  9565  2069
   117  1367   119   122  1808   182  2137  9565  1105   127  1808   182
  2101 17691  1107  3777  3073  7877  2913 27154 27372  1143  4371  7903
  4420  1105   135   122   118  1214   182  2101 17691  1107  4420  1114
  1996 11317   117  2382  1379  1429   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
FATE,FT836,Solid TumorsÂ ,Preclinical,2024-11-11,"Preclinical data presented at SITC showed robust antigen-mediated expansion, functional persistence, and durable anti-tumor activity in the presence of alloreactive T cells, noted November 11, 2024.",115.0,291.52738,80.1622,2.42,2.56,2.27,0.056239718,-0.063987709,0.035862947,0.124766472,13.96433,0.06567,3.06839,2440,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101 11689  1665 21472  7867  2233  2756  1120   156 12150  1658  2799
 17351  2848  4915   118 22060  4298   117  8458  1679 19031   117  1105
  3840  9739  2848   118 14601  3246  1107  1103  2915  1104  1155  4474
 19667   157  3652   117  2382  1379  1429   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NGNE,NGN-101,CLN5 Batten DiseaseÂ ,Phase 1/2,2024-11-11,"Phase 1/2 was discontinued due to RMAT application denial by the FDA, noted November 11, 2024.",14.0,1060.69069,92.9267,68.21,71.53,19.82,0.04752576,-1.235899653,0.035862947,0.124766472,6.16501,0.1759,30.42715,2441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  1108  8779  1496  1106   155  8271  1942
  4048 16926  1118  1103 18762   117  2382  1379  1429   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NGNE,NGN-401 - (Embolden),Rett SyndromeÂ ,Phase 1/2,2024-11-11,"Phase 1/2 data showed that all four participants in the low-dose cohort showed consistent and durable improvements across key clinical domains, including hand function, language, and ambulation, with",14.0,1060.69069,92.9267,68.21,71.53,19.82,0.04752576,-1.235899653,0.035862947,0.124766472,6.16501,0.1759,30.42715,2442,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2799  1115  1155  1300  6635  1107
  1103  1822   118 13753  1884 13252  1204  2799  8080  1105  3840  9739
  8313  1506  2501  7300 13770   117  1259  1289  3053   117  1846   117
  1105  1821 23601  2116   117  1114   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ZVRA,Arimoclomol (EAP),Niemann-Pick disease type C (NPC)Â ,Phase 3,2024-11-11,Additional data presented at the 53rd Child Neurology Society Annual Meeting showed that the NPCCSS swallow score reflects the patient's level of dysfunction. Study indicates that a change in score re,56.0,471.45539,73.4186,9.0,8.96,8.6,-0.00445435,-0.045462374,0.035862947,0.124766472,7.4833,0.02666,5.19676,2443,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  8154  2233  2756  1120  1103  4389  2956  6405   151  8816  4807
  2015  8451 12505  2799  1115  1103   151 15270 12122  1708 11692  2794
 11363  1103  5351   112   188  1634  1104   173  6834 26420   119  8690
  6653  1115   170  1849  1107  2794  1231   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ARCT,"ARCT-2304 - (LUNAR-H5N1, BARDA)",Influenza disease caused by H5N1 virusÂ ,IND-Enabling,2024-11-11,"IND cleared after receiving ""Study May Proceed"" notification by the FDA, noted November 11, 2024",27.0,551.7695,80.4531,19.625,20.37,16.27,0.037258967,-0.187481342,0.035862947,0.124766472,16.90918,0.20481,13.69392,2444,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 15969  2137  5323  1170  4172   107  8690  1318  5096  2093  1174
   107  1136  5783  1118  1103 18762   117  2382  1379  1429   117 17881
  1527   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNDX,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,2024-11-12,"Phase 2 topline results showed that the trial met its primary endpoint. Revumenib demonstrated a favorable safety profile with only 5% treatment-related discontinuation, noted November 12, 2024.",86.0,1383.64791,59.8841,21.78,16.21,15.77,-0.295363782,-0.322882717,0.034591245,0.105435644,12.48581,0.2245,135.72931,2445,1,0,0,1,0,1,0,0,0,0,1,0,4,0,0,1,neg,"[  101 12278   123  1499  2568  2686  2799  1115  1103  3443  1899  1157
  2425  1322  7587   119  6750 15447  2605  1830  7160   170 11169  3429
  6168  1114  1178   126   110  3252   118  2272 19959 26728 10255   117
  2382  1379  1367   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,2024-11-12,"Phase 3 data from long-term follow-up from months 7-12 after cessation of drug noted a 64% relative risk reduction in symptomatic disease versus placebo, noted November 12, 2024.",120.0,119.44264,107.1633,0.9775,1.0,0.7674,0.022756987,-0.241990114,0.034591245,0.105435644,6.9255,0.0651,0.42698,2446,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  1121  1263   118  1858  2812   118  1146  1121
  1808   128   118  1367  1170   172  5800  1891  1104  3850  2382   170
  3324   110  5236  3187  7234  1107   188 17162  6451  7903  2941  3653
  6055  1282  4043   117  2382  1379  1367   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
EQ,EQ302 - (IL-15 and IL-21),Solid TumorsÂ ,Preclinical,2024-11-12,Preclinical data shared at SITC reported a modest effect on reversing the phenotype and function of terminally exhausted CD8+ T cells as shown by the increase in the percentage of TCF-1 positive cells,59.0,30.10719,122.0497,0.7505,0.8499,0.7,0.124379044,-0.069659316,0.034591245,0.105435644,0.33186,0.01086,0.32161,2447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  3416  1120   156 12150  1658  2103
   170 11263  2629  1113  1231 27563  1103   185 10436 27172  1105  3053
  1104  6020  1193  8984  2891  1604   116   157  3652  1112  2602  1118
  1103  2773  1107  1103  6556  1104   157 27783   118   122  3112  3652
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,KOSELUGO (selumetinib) - (KOMET),Neurofibromatosis Type 1-Plexiform Neurofibromas (NF1-PN) in AdultsÂ ,Phase 3,2024-11-12,"Phase 3 results showed reduction in tumor volume, building on the established safety and efficacy profile of KOSELUGO in certain children and has the potential to support expanded use in certain adult",0.0,154873.7058,20.7857,99.85,99.9,100.24,0.000500626,0.003898251,0.034591245,0.105435644,0.0,0.05065,356.36448,2448,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2686  2799  7234  1107 14601  3884   117  1459  1113
  1103  1628  3429  1105 23891  6168  1104   148  9025 21678  2591  2349
  2346  1107  2218  1482  1105  1144  1103  3209  1106  1619  3631  1329
  1107  2218  4457   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
EVAX,EVX-V1,Cytomegalovirus (CMV) vaccineÂ ,Preclinical,2024-11-12,"Preclinical data reported successfully induced a specific immune response comparable to that of the conventional gB antigen, noted November 12, 2024.",6.0,13.27576,79.1834,12.1,11.9,7.7995,-0.016667052,-0.439145824,0.034591245,0.105435644,0.94205,0.01404,0.15274,2449,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  4358 10645   170  2747 11650
  2593 12763  1106  1115  1104  1103  7228   176  2064  2848  4915   117
  2382  1379  1367   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,BLA Filing,2024-11-12,"Voluntarily withdrawn November 12, 2024.",0.0,154873.7058,20.7857,99.85,99.9,100.24,0.000500626,0.003898251,0.034591245,0.105435644,0.0,0.05065,356.36448,2450,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-1,pos,"[  101  5713 19529 11486  9512  1379  1367   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AZN,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC)Â ,BLA Filing,2024-11-12,"BLA submitted November 12, 2024.",0.0,154873.7058,20.7857,99.85,99.9,100.24,0.000500626,0.003898251,0.034591245,0.105435644,0.0,0.05065,356.36448,2451,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101   139 10783  7402  1379  1367   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RVPH,Brilaroxazine - (RECOVER),SchizophreniaÂ ,Phase 3,2024-11-12,"108 patients have completed 1-year of treatment which is generally well tolerated to date in patients with acute and stable schizophrenia, noted November 12, 2024.",68.0,44.14238,125.4839,1.0,1.32,1.26,0.277631737,0.231111721,0.034591245,0.105435644,15.84101,0.00786,5.27589,2452,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,1,pos,"[  101 10601  4420  1138  2063   122   118  1214  1104  3252  1134  1110
  2412  1218 21073  1181  1106  2236  1107  4420  1114 12104  1105  6111
   188  4313 26474   117  2382  1379  1367   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
XBIO,DNase,Pancreatic carcinomaÂ ,Phase 1,2024-11-12,"Phase 1 data reported that treatment demonstrated beneficial effects of targeting NETs with systemic DNase I in models of primary tumor and metastatic CRC, improving the efficacy of CTLA-4 immune chec",1.0,6.36903,78.6174,3.95,4.13,3.9,0.044561828,-0.012739026,0.034591245,0.105435644,0.96178,0.00289,0.4268,2453,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1115  3252  7160 16250  3154  1104 15141
 26546  1942  1116  1114 27410   141  2249  6530   146  1107  3584  1104
  2425 14601  1105 27154 27372 15531  1658   117  9248  1103 23891  1104
 16899 10783   118   125 11650 22572 10294   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SYRE,SPY001,Inflammatory Bowel Disease (IBD)Â ,Phase 1,2024-11-12,"Phase 1 interim data showed a favorable safety profile and strong pharmacokinetics with a half-life over 90 daysâ€”four times longer than vedolizumab, noted November 12, 2024.",60.0,1842.2663,69.8942,39.35,35.82,26.9,-0.093989578,-0.380369688,0.034591245,0.105435644,16.04199,0.01556,43.71122,2454,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122 10572  2233  2799   170 11169  3429  6168  1105  2012
   185  7111  1918  2528  4314 22259  1114   170  1544   118  1297  1166
  3078  1552 28198 28731   790  1300  1551  2039  1190  1396  2572  2646
 10337  1918  1830   117  2382  1379  1367   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,Lenacapavir - (PURPOSE 2),HIV PrePÂ ,Phase 3,2024-11-13,"Phase 3 data reported that results demonstrated superiority of twice-yearly lenacapavir over bHIV, with 96% relative risk reduction, noted November 13, 2024.",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  2686  7160 21378  1104  3059   118
 13502  5837 22636 26519 25740  1166   171  3048  2240  2559   117  1114
  5306   110  5236  3187  7234   117  2382  1379  1492   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMGN,AMG 133 (maridebart cafraglutide) - (MariTide),Obesity and without diabetesÂ ,Phase 1,2024-11-13,"Phase 1 data reported that the company did not see an association between the administration of MariTide and bone mineral density changes, noted November 13, 2024.",538.0,162033.864,22.6024,298.84,301.44,287.87,0.008662678,-0.037399324,0.035958703,0.066856065,1.64135,0.03195,1123.04366,2456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1115  1103  1419  1225  1136  1267  1126
  3852  1206  1103  3469  1104 17978  1942  3269  1105  6028 10956  3476
  2607   117  2382  1379  1492   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LYRA,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitisÂ ,Phase 3,2024-11-13,"Phase 3 52 week extension data indicated that LYR-210 was generally well tolerated over the extended treatment period, including among patients who received repeat dosing for a total of 12 months. No",1.0,12.94097,80.306,13.75,9.885,8.9,-0.330020367,-0.434987547,0.035958703,0.066856065,3.11784,0.00063,1.47529,2457,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3882  1989  4973  2233  4668  1115   149  3663  2069
   118 13075  1108  2412  1218 21073  1181  1166  1103  2925  3252  1669
   117  1259  1621  4420  1150  1460  9488 18463  1158  1111   170  1703
  1104  1367  1808   119  1302   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INO,INO-3107,HPV 6 and HPV 11-associated Recurrent respiratory papillomatosisÂ ,Phase 1/2,2024-11-13,"New immunology on Phase 1/2 data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment, noted November 13, 2024.",53.0,128.52313,61.3909,5.15,4.95,3.97,-0.039609138,-0.26023062,0.035958703,0.066856065,13.49834,0.03159,3.03012,2458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  1203 13280 13601 16658  1113 12278   122   120   123  2233  2196
 15969  2346   118 18333  1559 10645  1126  4298  1104  1207   172  4934
  1348   157  3652  1107  1892  1115  1127  1136 11552  1895  2988  1106
  3252   117  2382  1379  1492   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BRTX,BRTX-100,Chronic lumbar disc diseaseÂ ,Phase 2,2024-11-13,"Phase 2 blinded preliminary data presented demonstrate a positive trend and clear signal in Primary and Secondary endpoints November 13, 2024.",7.0,10.65668,90.3289,1.64,1.54,1.4,-0.062913825,-0.158224005,0.035958703,0.066856065,0.63928,0.03657,0.16541,2459,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 24255  9889  2233  2756 10541   170  3112 10209  1105
  2330  4344  1107  6933  1105  7934  1322 21521  1379  1492   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GSK,Lete-cel - (IGNYTE-ESO),SarcomaÂ ,Phase 2,2024-11-13,"Phase 2 data reported six complete responses (6/64); twenty-one partial responses (21/64) noted November 13, 2024.",0.0,55576.40593,22.585,13.695,13.62,13.0,-0.005491502,-0.052081445,0.035958703,0.066856065,0.0,0.05556,168.22552,2460,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1565  2335 11317   113   127   120  3324
   114   132  2570   118  1141  7597 11317   113  1626   120  3324   114
  2382  1379  1492   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RNA,AOC1086,PLN CardiomyopathyÂ ,Preclinical,2024-11-13,"Preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA, noted November 13, 2024.",128.0,6263.73914,71.2177,46.73,52.5,43.65,0.116426813,-0.068183074,0.035958703,0.066856065,12.28701,0.08359,168.966,2461,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  7160 17351 27466 15654  6779  1106
  1103  1762  1105  9271  7466  5455  1114 18106  7234  1104  2324  2908
   110  1107 17688   153  2162  2249   182 15654   117  2382  1379  1492
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,Biktarvy - (ALLIANCE),HIV/HBV CoinfectionÂ ,Phase 3,2024-11-13,"Phase 3 data reported that after 3 years of treatment, Biktarvy maintained high rates of HIV-1 and HBV virologic suppression, defined as HIV RNA <50 copies/ mL and HBV RNA <29 IU/ mL, respectively, no",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2462,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  1170   124  1201  1104  3252   117
   139  4847  6817  7170  4441  1344  5600  1104  9622   118   122  1105
   145  2064  2559   191  9992 13791  1596 18793   117  3393  1112  9622
 13254   133  1851  4034   120   182  2162  1105   145  2064  2559 13254
   133  1853   146  2591   120   182  2162   117  3569   117  1185   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,Bictegravir and Lenacapavir - (ARTISTRY-1),HIVÂ ,Phase 2/3,2024-11-13,"Phase 2/3 data reported that at Week 48, fasting lipid parameters generally improved from baseline in both BIC+LEN groups (BIC 75 mg +LEN 25 mg and BIC 75 mg +LEN 50 mg) versus the complex antiretrovi",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   120   124  2233  2103  1115  1120  6237  3615   117
  2698  1158  4764  2386 11934  2412  4725  1121  2259  2568  1107  1241
   139  9741   116   149 11680  2114   113   139  9741  3453 17713   116
   149 11680  1512 17713  1105   139  9741  3453 17713   116   149 11680
  1851 17713   114  6055  1103  2703  2848  8127 12316  1182   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,Lenacapavir (GS-6207),HIVÂ ,Phase 1b,2024-11-13,"Phase 1b data reported that at Week 26, 21% (n=3) of participants who received LEN + TAB and the low dose of ZAB and 0% (n=0) participants who received LEN +TAB and the high dose of ZAB had an HIV vir",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  2233  2103  1115  1120  6237  1744   117  1626
   110   113   183   134   124   114  1104  6635  1150  1460   149 11680
   116   157 19985  1105  1103  1822 13753  1104   163 19985  1105   121
   110   113   183   134   121   114  6635  1150  1460   149 11680   116
   157 19985  1105  1103  1344 13753  1104   163 19985  1125  1126  9622
   191  3161   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CLPT,Upstaza (PTC-AADC),AADC deficiencyÂ ,Approved,2024-11-13,"Approved November 13, 2024.",28.0,302.05245,79.5392,11.12,10.95,10.96,-0.015405833,-0.014493007,0.035958703,0.066856065,2.49255,0.07398,2.75022,2465,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1379  1492   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PTCT,Upstaza (PTC-AADC),AADC deficiencyÂ ,Approved,2024-11-13,"Approved November 13, 2024.",79.0,3395.82005,57.0918,44.62,44.03,41.96,-0.013310969,-0.061465405,0.035958703,0.066856065,6.33617,0.21341,28.55504,2466,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1379  1492   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GSK,Blenrep,Multiple myelomaÂ ,Phase 3,2024-11-14,"Additional Phase 3 data reported that the trial met the key secondary endpoint of overall survival (OS), noted November 14, 2024.",0.0,55229.56345,22.5897,13.62,13.535,13.095,-0.006260378,-0.039308823,0.085331139,0.058788991,0.0,0.05556,117.33072,2467,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1,neg,"[  101  8154 12278   124  2233  2103  1115  1103  3443  1899  1103  2501
  3718  1322  7587  1104  2905  8115   113 11570   114   117  2382  1379
  1489   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ACIU,ACI-7104.056 - (VacSYn),Parkinson's disease (PD)Â ,Phase 2,2024-11-14,"Phase 2 interim safety and immunogenicity data reported that 100% of patients receiving ACI-7104.056 responded against the target antigen, noted November 14, 2024.",100.0,351.23802,64.8741,3.13,3.55,3.29,0.125914599,0.04985456,0.085331139,0.058788991,0.99501,0.03435,2.69418,2468,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123 10572  3429  1105 13280 13601  2728 19438  1785  2233
  2103  1115  1620   110  1104  4420  4172  9690  2240   118  5729  1568
  1527   119  4991  1545  5133  1222  1103  4010  2848  4915   117  2382
  1379  1489   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LLY,Tirzepatide - (SURMOUNT-1),Pre-diabetes and obesity or overweightÂ ,Phase 3,2024-11-14,"Phase 3 data reported a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years, noted November 14, 2024.",946.0,707946.686,31.7667,811.81,786.23,749.92,-0.032016952,-0.079299788,0.085331139,0.058788991,0.73572,0.13891,3144.01348,2469,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103   170  5706   110  7234  1107  3187  1104
 16147  1106  2076   123 17972  1506  1155  4528  1174 24429  1104   189
  3161  3171  4163 23767  3402  1106  1282  4043  1166  1210  1201   117
  2382  1379  1489   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMMP,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcomaÂ ,Phase 2,2024-11-14,"Phase 2 data presented at CTOS demonstrated a greater than three-fold increase in tumor hyalinization/fibrosis (median 50%), compared to the historical median of 15% with radiotherapy alone, November",147.0,494.55307,85.6898,1.87,2.09,1.84,0.111225635,-0.016172859,0.085331139,0.058788991,0.0,0.0,0.87482,2470,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2756  1120 16899  9025  7160   170  3407  1190
  1210   118 11203  2773  1107 14601   177 18543  4729  8569   120 20497
 12725  4863   113  3151  1851   110   114   117  3402  1106  1103  3009
  3151  1104  1405   110  1114  2070  8420 11478  1183  2041   117  1379
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMMP,Eftilagimod alpha + chemo+ anti-PD-1 - (INSIGHT-003),Solid tumorsÂ ,Phase 1,2024-11-14,"Phase 1 data update data in patients with a minimum follow-up of 22 months with a median overall survival is 32.9 months, with median progression free survival reaching 12.7 months, and a 24-month ove",147.0,494.55307,85.6898,1.87,2.09,1.84,0.111225635,-0.016172859,0.085331139,0.058788991,0.0,0.0,0.87482,2471,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233 11984  2233  1107  4420  1114   170  5867  2812
   118  1146  1104  1659  1808  1114   170  3151  2905  8115  1110  2724
   119   130  1808   117  1114  3151 16147  1714  8115  3634  1367   119
   128  1808   117  1105   170  1572   118  2370   184  2707   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ADIL,AD04 - (ONWARD),Alcohol use disorderÂ ,Phase 3,2024-11-14,Phase 3 topline results demonstrated that AD04 delivers lower ondansetron PK exposure compared to the marketed 4mg ondansetron tablet and can be taken in both fed and fasted states. Adial plans to eng,21.0,7.30259,76.9983,0.991,1.14,1.02,0.140069007,0.028843372,0.085331139,0.058788991,1.23142,0.00033,2.14036,2472,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  1499  2568  2686  7160  1115  5844  1568  1527 19603
  2211  1113  6778  9388  3484   153  2428  7401  3402  1106  1103 11777
   125  1306  1403  1113  6778  9388  3484 16048  1105  1169  1129  1678
  1107  1241  7672  1105  2698  1174  2231   119 24930  2916  2714  1106
  4035  1403   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 3,2024-11-14,"Phase 3 protocol amended with preliminary data now expected on 2H 2025, noted November 14, 2024.",30.0,9.27586,94.2375,2.51,3.09,2.83,0.207888338,0.119993959,0.085331139,0.058788991,4.07676,0.05143,1.64759,2473,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124 11309 13848  1114  9889  2233  1208  2637  1113   123
  3048 17881  1571   117  2382  1379  1489   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ANTX,Epetraborole - (EBO-103),"Mycobacterium avium complex (MAC) lung disease, Chronic non-tuberculous mycobacterial (NTM) lung diseaseÂ ",Phase 2,2024-11-14,"Phase 2 data reported nominally statistically significant improvements in MACrO2 measured from baseline to month 6 in post-hoc analysis, noted November 14, 2024.",27.0,29.87889,143.112,1.01,1.0,1.23,-0.009950331,0.197063839,0.085331139,0.058788991,0.44705,0.05553,0.69798,2474,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   123  2233  2103 27937 11435  1193  2418  8313  1107 25424
  1197  2346  1477  7140  1121  2259  2568  1106  2370   127  1107  2112
   118 16358  1665  3622   117  2382  1379  1489   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRVS,Soquelitinib - (CPI-818),Systemic sclerosisÂ ,Preclinical,2024-11-14,"Preclinical findings showed a reduced Th2 helper T cell infiltration and pulmonary fibrosis. These data support the broader application of ITK inhibitors in immune-mediated fibrotic diseases, noted No",74.0,547.47178,79.7685,8.87,8.52,8.94,-0.040258455,0.007860793,0.085331139,0.058788991,4.55206,0.00423,10.38646,2475,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  9505  2799   170  3549   157  1324  1477
  1494  1200   157  2765  1107  8702 21875  1105 26600 20497 12725  4863
   119  1636  2233  1619  1103 12594  4048  1104  9686  2428 27558  1116
  1107 11650   118 22060 20497 12725  2941  8131   117  2382  1302   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
DTIL,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV)Â ,Preclinical,2024-11-15,"Preclinical data reinforced safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study, noted November 15, 2024.",11.0,58.45347,43.3074,7.7,7.62,7.26,-0.010443959,-0.0588405,0.052944822,0.007453451,2.79685,0.06083,0.54792,2476,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233 11331  3429  6168  1105  3209  1106
  7852   170  8458 11200  1111 13306  1119  4163 27659   139   117  4374
 19024  1154  1148   118  1107   118  1769  7300  2025   117  2382  1379
  1405   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ETNB,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 2b,2024-11-15,"Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.",148.0,932.42701,64.8267,8.75,7.93,8.76,-0.098400665,0.001142205,0.052944822,0.007453451,4.57728,0.05644,11.37091,2477,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  1830  2233  2756  1120 10419 13726  2137  2103  1115
  3252  4725  4420   112  6820  9272  7432  1133  1145  3890  1241  9960
  1708  3048  6021  1105 20497 12725  4863  8331   117  2382  1379  1405
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CERO,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignanciesÂ ",IND-Enabling,2024-11-15,"IND cleared by the FDA, noted November 15, 2024.",1.0,42.8823,231.4044,374.4,570.6,436.2,0.421363694,0.152776109,0.052944822,0.007453451,1.06563,0.04062,334.57759,2478,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1379  1405   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ABUS,Imdusiran (AB-729 w/ NA therapy and Peginterferon alfa-2a) - (IM-PROVE II),Chronic Hepatitis BÂ ,Phase 2a,2024-11-15,"Phase 2a data presented at AASLD reported that 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1, noted November 15, 2024.",191.0,689.74973,42.0883,3.63,3.64,3.51,0.002751033,-0.033616611,0.052944822,0.007453451,3.45311,0.01583,6.5201,2479,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  1161  2233  2756  1120 10419 13726  2137  2103  1115
  1851   110  1104  4420  1150  1125  2259  2568   145  2064  1116  1592
  1403  3001  1750  1190  6087   146  2591   120   182  2162  3890  8458
 11200  1107  3291 13252  1204 18967   117  2382  1379  1405   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC)Â ,Phase 3,2024-11-15,"Phase 3 data reported that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with LivdelziÂ® (seladelpar) achieved a composite biochemical response, noted November 15, 2",0.0,110169.9018,25.2492,92.11,88.4,90.19,-0.041111545,-0.021064959,0.052944822,0.007453451,1.42383,0.0648,1012.57939,2480,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103  1115  5615   110   113  1476  1149  1104
  3413   114  1104  6635  1114  2425 16516  4567  1616 22572  5326  2118
 10721   113   153  9428   114  5165  1114 26997  6738  5303 28181 28167
   113 14516 21414  1233 17482   114  3890   170 14752 25128 16710  2593
   117  2382  1379  1405   117   123   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AVIR,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV)Â ,Phase 2,2024-11-15,"Phase 2 results from AASLD reported a SVR12 rate of 97%, noted November 15, 2024.",79.0,271.97105,47.5923,3.31,3.22,3.37,-0.02756683,0.017964555,0.052944822,0.007453451,3.06702,0.19011,1.01051,2481,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2686  1121 10419 13726  2137  2103   170 21479  2069
 11964  2603  1104  5311   110   117  2382  1379  1405   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALT,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 1b,2024-11-15,"Phase 1b data presented at AASLD reported that treatment reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after",88.0,541.2584,85.9033,8.455,7.61,8.68,-0.10529481,0.026263546,0.052944822,0.007453451,32.2486,0.10046,41.19094,2482,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122  1830  2233  2756  1120 10419 13726  2137  2103  1115
  3252  3549   149 12323  5236  1106  2259  2568  1118  1146  1106  5599
   119   126   110  1105 10558  1703 22572  9016  4648  4063  1105   189
 17305  1193 14840  8959  1118  1146  1106  1367   119   123   110  1105
  3140   119   127   110   117  3569   117  1170   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALNY,ALN-HBV02 (VIR-2218) and VIR-3434 - (MARCH),Hepatitis BÂ ,Phase 2,2024-11-15,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in",131.0,30382.74481,56.4135,257.91,235.56,244.89,-0.090645029,-0.051801557,0.052944822,0.007453451,2.86639,0.03543,414.89112,2483,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  2233  2103  1115  3614   110  1104  6635  1114  1822
  2259  2568  1124  4163 27659   139  2473  2848  4915   113   145  2064
  1116  1592  1403   114  3890   145  2064  1116  1592  1403  2445  1114
  1106  3962  5086  6824  1204   116  8468 15581 19496  1389   117  1105
  3993   110  1114  1106  3962  5086  6824  1204   116  8468 15581 19496
  1389   116   185 12606 22948  1906  1107   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VIR,ALN-HBV02 (VIR-2218) and VIR-3434 - (MARCH),Hepatitis BÂ ,Phase 2,2024-11-15,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in",138.0,1103.13816,63.5539,8.64,8.01,7.12,-0.075711822,-0.193494857,0.052944822,0.007453451,4.15466,0.0282,11.86062,2484,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  2233  2103  1115  3614   110  1104  6635  1114  1822
  2259  2568  1124  4163 27659   139  2473  2848  4915   113   145  2064
  1116  1592  1403   114  3890   145  2064  1116  1592  1403  2445  1114
  1106  3962  5086  6824  1204   116  8468 15581 19496  1389   117  1105
  3993   110  1114  1106  3962  5086  6824  1204   116  8468 15581 19496
  1389   116   185 12606 22948  1906  1107   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNDX,Revuforj (revumenib),Adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemiaÂ ,Approved,2024-11-15,"FDA approved on November 15, 2024.",86.0,1351.212,60.0912,16.79,15.83,16.09,-0.058876597,-0.04258551,0.052944822,0.007453451,12.48581,0.24298,79.9381,2485,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762  4092  1113  1379  1405   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMGN,UPLIZNA (INEBILIZUMAB-CDON),Immunoglobulin G4-related disease (IgG4-RD)Â ,Phase 3,2024-11-15,"Phase 3 data presented at ACR Convergence with statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, noted November 15, 2024.",538.0,152449.6556,23.189,295.93,283.61,294.53,-0.042522885,-0.004742074,0.052944822,0.007453451,1.64135,0.06958,1510.2604,2486,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2756  1120  9690  2069 16752  4121 12329  1114
 11435  1193  2418  5966   110  7234  1107  1103  3187  1104   146  1403
  2349  1527   118   155  2137 20646  3402  1106  1282  4043   117  2382
  1379  1405   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
REGN,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR)Â ,Phase 1,2024-11-16,"Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.",105.0,81424.83296,24.6737,756.81,756.81,738.0,0.0,-0.025168407,-0.001414658,-0.04690603,1.72212,0.14752,0.0,2487,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 10572  2233  2756  1120   138 11612  2103  1115   170
  1325  4420  1114  5883 11612  3699  2684  1120  2259  2568   113   183
   134  1407   114  2799  8331  1137  1185  1849  1107  1147  5883 11612
  3699  1120  2370  1367   117  2382  1379  1479   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NTLA,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR)Â ,Phase 1,2024-11-16,"Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.",107.0,1422.82455,64.316,13.97,13.97,14.3,0.0,0.023347364,-0.001414658,-0.04690603,15.85826,0.3262,0.0,2488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 10572  2233  2756  1120   138 11612  2103  1115   170
  1325  4420  1114  5883 11612  3699  2684  1120  2259  2568   113   183
   134  1407   114  2799  8331  1137  1185  1849  1107  1147  5883 11612
  3699  1120  2370  1367   117  2382  1379  1479   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,2024-11-17,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of",0.0,3146282.727,32.1382,101.74,101.74,105.06,0.0,0.032111076,-0.001414658,-0.04690603,0.0,0.0,0.0,2489,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  1830  2509  5306   118  6237  2233  2756  1120 10419
 13726  2137  2103  1126  1166  1969   110  1104  6635  5165  1114   142
  2271  3190  1851  1306  1403  1111  5306  2277   117  3402  1114   121
   110  1111  1282  4043   117  2799  1231 24032  1104 11911 20497 12725
  4863  1118  1155  1104   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AKRO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,2024-11-17,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of",79.0,1960.65807,51.6748,28.09,28.09,32.73,0.0,0.152878447,-0.001414658,-0.04690603,5.47423,0.07967,0.0,2490,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  1830  2509  5306   118  6237  2233  2756  1120 10419
 13726  2137  2103  1126  1166  1969   110  1104  6635  5165  1114   142
  2271  3190  1851  1306  1403  1111  5306  2277   117  3402  1114   121
   110  1111  1282  4043   117  2799  1231 24032  1104 11911 20497 12725
  4863  1118  1155  1104   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,2024-11-17,"Additional data shared at AASLD reported that denifanstat treatment improved fibrosis by â‰¥ 1 stage in more than 50% of F3 patients as follows, noted November 17, 2024.",32.0,152.28398,101.5518,4.73,4.73,4.76,0.0,0.006322466,-0.001414658,-0.04690603,12.956,0.12618,0.0,2491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  8154  2233  3416  1120 10419 13726  2137  2103  1115 10552  8914
  5443 19756  3252  4725 20497 12725  4863  1118   248   796   203   122
  2016  1107  1167  1190  1851   110  1104   143  1495  4420  1112  3226
   117  2382  1379  1542   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALNY,Nucresiran (ALN-TTRsc04) - (TRITON-CM),ATTR amyloidosisÂ ,Phase 1,2024-11-17,"Phase 1 additional data from AHA reported mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180, noted November 17, 2024.",131.0,30382.74481,56.4135,235.56,235.56,244.89,0.0,0.038843472,-0.001414658,-0.04690603,2.86639,0.03543,0.0,2492,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   122  2509  2233  1121   138 11612  2103  1928  7234  1116
  1104  3407  1190  3078   110  1121  2259  2568  3890  1120  2295  1405
  1105  8505  1194  1120  1655  2295  7967   117  2382  1379  1542   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CYTK,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM)Â ,Phase 3,2024-11-17,"Phase 3 data shared at AHA reported shortened times for VO2Rec to decline by 12.5% (VO2Rec T12.5%), 25% (VO2Rec T25%) and 50% (VO2Rec T50%) of peak VO2, corresponding to absolute reductions relative t",119.0,5926.67513,47.82,50.22,50.22,49.1,0.0,-0.022554319,-0.001414658,-0.04690603,13.29487,0.01014,0.0,2493,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  3416  1120   138 11612  2103 12898  1551  1111
   159  2346  1477  2069 10294  1106  6246  1118  1367   119   126   110
   113   159  2346  1477  2069 10294   157 11964   119   126   110   114
   117  1512   110   113   159  2346  1477  2069 10294   157 17600   110
   114  1105  1851   110   113   159  2346  1477  2069 10294   157 11049
   110   114  1104  4709   159  2346  1477   117  7671  1106  7846  7234
  1116  5236   189   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CYTK,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM)Â ,Phase 3,2024-11-17,"Phase 3 data shared at AHA reported that treatment rapidly improved the symptom and LVOT gradient criteria used to define guidelineeligibility in 97% of patients, noted November 17, 2024.",119.0,5926.67513,47.82,50.22,50.22,49.1,0.0,-0.022554319,-0.001414658,-0.04690603,13.29487,0.01014,0.0,2494,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  3416  1120   138 11612  2103  1115  3252  5223
  4725  1103   188 17162  6451  4165  1105   149 21049  1942 19848  9173
  1215  1106  9410  6388  2568 21091  5389  5474  1107  5311   110  1104
  4420   117  2382  1379  1542   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IVA,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D)Â ",Phase 2a,2024-11-18,"Phase 2a data presented at AASLD reported that 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin, no",95.0,223.35429,85.3009,2.505,2.565,2.435,0.023669744,-0.028341978,-0.01448674,-0.061245782,0.0,0.00805,0.057,2495,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  1161  2233  2756  1120 10419 13726  2137  2103  1115
  1851   110  3029  1104  4420  1486  1147   145  1830  1592  1475  1665
  3001  2071   127   119   126   110  1120  1989  1572  1378  3252  1114
  2495  2605  8702  6766 13523  2041  1137  1107  4612  1114  9712  4163
 23655  2087  2858 17817   117  1185   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NGNE,NGN-401 - (Embolden),Rett SyndromeÂ ,Phase 1/2,2024-11-18,"Phase 1/2 discontinuation of 3E15 vg dose announced November 18, 2024.",14.0,293.90311,147.1629,34.515,19.82,22.315,-0.554702483,-0.436134914,-0.01448674,-0.061245782,6.16501,0.21487,39.62561,2496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123 19959 26728 10255  1104   124  2036 16337
   191  1403 13753  1717  1379  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ACET,ADI-001,Lupus nephritis and Systemic Lupus Erythematosus (SLE)Â ,Phase 1,2024-11-18,"Phase 1 clinical trial initiated, noted November 18, 2024.",83.0,87.93013,66.1944,0.9469,0.9679,0.904,0.021935285,-0.046364131,-0.01448674,-0.061245782,3.78912,0.03864,0.66685,2497,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  7300  3443  7087   117  2382  1379  1407   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ADVM,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD)Â ,Phase 2,2024-11-18,"Phase 2 52-week data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec, The therapy reduced injection burden by 80%-90%, ac",20.0,142.49687,59.7718,6.86,6.85,6.15,-0.001458789,-0.10925536,-0.01448674,-0.061245782,7.71421,0.02835,2.82995,2498,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  3882   118  1989  2233  3490  1114  2812   118  1146
  1121   152  2101 21669  1658  1120   125  1201  2760  1106  1619  1263
   118  1858  3209  1436   118  1107   118  1705  3317  6168  1104   146
  1775  1186   118  1396  1665   117  1109  7606  3549 14546 11904  1118
  2908   110   118  3078   110   117   170  1665   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,Phase 3,2024-11-18,"Phase 3 data presented at ACR Convergence demonstrated statistically significant improvement in the primary endpoint of fibromyalgia neoplastic pain and in all six key secondary endpoints, including s",8.0,24.85693,168.687,13.11,13.3,19.2,0.014388737,0.381534981,-0.01448674,-0.061245782,4.10413,0.05779,1.20408,2499,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,pos,"[  101 12278   124  2233  2756  1120  9690  2069 16752  4121 12329  7160
 11435  1193  2418  8331  1107  1103  2425  1322  7587  1104 20497 12725
  4527  1348  9037 15242  1643 20519  2489  1105  1107  1155  1565  2501
  3718  1322 21521   117  1259   188   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RGNX,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,2024-11-18,"Phase 1/2 data showed functional improvements in all patients, with dose-dependent performance exceeding natural history benchmarks. Biomarker data confirmed robust microdystrophin expression, and th",50.0,502.88247,67.4751,9.63,10.15,9.58,0.05259048,-0.005205634,-0.01448674,-0.061245782,9.90886,0.15488,31.19794,2500,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2799  8458  8313  1107  1155  4420
   117  1114 13753   118  7449  2099 18291  2379  1607  6757 22328   119
   139  2660  8519  1200  2233  3659 17351 17599  3810 21216 27008  1179
  2838   117  1105 24438   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMTX,IMA402,Solid TumorsÂ ,Phase 1/2,2024-11-18,"Phase 1/2 initial clinical data demonstrated a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melan",121.0,933.36319,51.7965,8.17,7.82,7.59,-0.043784354,-0.073637317,-0.01448674,-0.061245782,5.60642,0.04155,9.28618,2501,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  3288  7300  2233  7160   170 11169  1106
  2879  6328  6168  1105  5300  1104 13753   118  7449  1105 11629 10964
  2036  2838   118  7449  7300  3246   117  1259  1148  7649 11317  1107
  1143  4371   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CYBN,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD)Â ,Phase 2,2024-11-18,"Phase 2 12-month data showed that 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses, noted November 18, 2024.",23.0,212.0149,61.9506,11.6,10.6,10.64,-0.090151097,-0.086384614,-0.01448674,-0.061245782,3.04843,0.02947,31.55966,2502,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1367   118  2370  2233  2799  1115  1620   110  1104
  6635  1127  1231 20080  4199  2109  1106  3252  1105  5729   110  1104
  6635  1127  1107  1231 11234  1120  1367  1808  1170  1198  1160  1479
 17713 24429   117  2382  1379  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,2024-11-18,"Phase 2 data presented at ICAR demonstrated alignment between FXN levels and disease progression, reinforcing the drug's potential efficacy, noted November 18, 2024.",85.0,393.04883,86.9184,6.69,6.16,6.33,-0.082537097,-0.055313638,-0.01448674,-0.061245782,4.26987,0.03392,6.89329,2503,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2756  1120   146 11356  2069  7160 12793  1206
 27649  2249  3001  1105  3653 16147   117  1231  1394 20586  1103  3850
   112   188  3209 23891   117  2382  1379  1407   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CABA,CABA-201 - (RESET-SLE),Systemic Lupus ErythematosusÂ ,Phase 1/2,2024-11-18,"Phase 1/2 additional data to presented at ACR showed that demonstrated compelling efficacy, including 100% B cell depletion within one month and early naÃ¯ve B cell repopulation, indicating potential i",91.0,131.96834,109.7389,3.03,2.7,2.29,-0.115310847,-0.280010802,-0.01448674,-0.061245782,7.58212,0.24846,8.3672,2504,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2509  2233  1106  2756  1120  9690  2069
  2799  1115  7160 18397 23891   117  1259  1620   110   139  2765  1260
  7136  2116  1439  1141  2370  1105  1346   100   139  2765  1231 18299
  6856   117  7713  3209   178   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CABA,rese-cel (resecabtagene autoleucel (CABA-201) - (RESET-Myositis),"Active idiopathic inflammatory myopathy (IIM, or myositis)Â ",Phase 1/2,2024-11-18,"Phase 1/2 data presented at ACR showed a safety profile was favorable, with low-grade CRS in three patients and no additional ICANS events reported, noted November 18, 2024.",91.0,131.96834,109.7389,3.03,2.7,2.29,-0.115310847,-0.280010802,-0.01448674,-0.061245782,7.58212,0.24846,8.3672,2505,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2756  1120  9690  2069  2799   170
  3429  6168  1108 11169   117  1114  1822   118  3654 15531  1708  1107
  1210  4420  1105  1185  2509   146 11356 12412  1958  2103   117  2382
  1379  1407   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CABA,CABA-201 - (RESET-SSc),Systemic sclerosis (SSc)Â ,Phase 1/2,2024-11-18,"Phase 1/2 initial data presented at ACR showed that first SSc patient demonstrated an emerging, drug-free clinical response, noted November 18, 2024.",91.0,131.96834,109.7389,3.03,2.7,2.29,-0.115310847,-0.280010802,-0.01448674,-0.061245782,7.58212,0.24846,8.3672,2506,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  3288  2233  2756  1120  9690  2069  2799
  1115  1148  6663  1665  5351  7160  1126  8999   117  3850   118  1714
  7300  2593   117  2382  1379  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
THAR,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,2024-11-18,"Phase 1 results at AASLD demonstrated a significant correlation between blood levels of TH104 and reductions in pruritus, measured by the Worst-Itch Numerical Rating Scale (WI-NRS). Patients experienc",4.0,3.52191,133.845,2.17,2.37,2.45,0.088162788,0.121360857,-0.01448674,-0.061245782,33.43584,0.01279,20.79411,2507,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2686  1120 10419 13726  2137  7160   170  2418 18741
  1206  1892  3001  1104   157 27012  1568  1527  1105  7234  1116  1107
   185  5082  7729  1361   117  7140  1118  1103 25120   118  1135  1732
   151 15447 17211 21632  1158 20334   113   160  2240   118   151  8900
   114   119  7195 24767  4252  3365  8584  1665   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CTNM,PIPE-791,Osteoarthritis and low back painÂ ,IND-Enabling,2024-11-18,"IND cleared by the FDA, noted November 18, 2024.",28.0,408.06246,75.4187,17.21,15.83,15.36,-0.083583736,-0.113723883,-0.01448674,-0.061245782,4.34308,0.35228,0.83475,2508,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1379  1407   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MBRX,Annamycin and Ara-C,Acute myeloid leukemia (AML)Â ,Phase 1/2,2024-11-18,"Phase 1/2 data demonstrated median overall survival (""OS"") of 9.1 months for subjects with a wide range of (0-6) prior lines of therapy (n=22) and 11.6 months (n=10) for subjects with 1 prior line of",30.0,7.56478,96.6266,2.71,2.52,2.65,-0.072689733,-0.022388995,-0.01448674,-0.061245782,4.07676,0.03438,0.12899,2509,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  7160  3151  2905  8115   113   107
 11570   107   114  1104   130   119   122  1808  1111  5174  1114   170
  2043  2079  1104   113   121   118   127   114  2988  2442  1104  7606
   113   183   134  1659   114  1105  1429   119   127  1808   113   183
   134  1275   114  1111  5174  1114   122  2988  1413  1104   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INTS,INT230-6 (VINblastine CIsplatin) - (INVINCIBLE-3),Early-stage presurgical breast cancerÂ ,Phase 3,2024-11-18,"Phase 3 data reported a median overall survival (""mOS"") of 21.3 months versus a synthetic control of 6.7 months, noted November 18, 2024.",47.0,43.54457,45.4989,3.15,3.14,2.86,-0.003179653,-0.096580828,-0.01448674,-0.061245782,0.31928,0.00802,0.02857,2510,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103   170  3151  2905  8115   113   107   182
  9025   107   114  1104  1626   119   124  1808  6055   170 13922  1654
  1104   127   119   128  1808   117  2382  1379  1407   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CLDI,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancerÂ ,Phase 1,2024-11-18,"Phase 1 data reported that treatment successfully kills and transforms tumor microenvironments and can additionally induce expression of engineered payloads in the tumor cells, noted November 18, 2024",3.0,45.39395,171.5978,26.28105,28.20113,24.24097,0.070513901,-0.08080397,-0.01448674,-0.061245782,3.03173,0.00284,4.44842,2511,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1115  3252  4358  8567  1105 24573 14601
 17599  1424 25740  1320  4385  1105  1169 19148 21497  2838  1104 16419
 21586  1116  1107  1103 14601  3652   117  2382  1379  1407   117 17881
  1527   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALLR,Stenoparib,Advanced ovarian cancer (AOC)Â ,Phase 2,2024-11-18,"Phase 2 update reported that two patients exceed 14 months on treatment, noted November 18, 2024.",14.0,5.36464,132.822,1.32,1.21,1.28,-0.087011377,-0.030771659,-0.01448674,-0.061245782,4.0472,0.05005,0.72138,2512,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 11984  2103  1115  1160  4420 13908  1489  1808  1113
  3252   117  2382  1379  1407   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMEA,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetesÂ ",Phase 2,2024-11-18,"Phase 2 trial data presented at ATTD-ASIA reported that 83% of patients with insulin deficiency responded to icovamenib, and showed a greater mean HbA1c reduction at Week 26 compared to baseline, than",59.0,233.01476,164.5143,6.53,6.43,6.93,-0.015432405,0.05945287,-0.01448674,-0.061245782,23.39179,0.01892,5.46661,2513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  3443  2233  2756  1120 13020  1942  2137   118 15278
  9984  2103  1115  6032   110  1104  4420  1114 26825 21344  5133  1106
   178  2528  2497  2354 13292   117  1105  2799   170  3407  1928   145
  1830  1592  1475  1665  7234  1120  6237  1744  3402  1106  2259  2568
   117  1190   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ARWR,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), HypertriglyceridemiaÂ ",NDA Filing,2024-11-18,"NDA submitted November 18, 2024.",138.0,2364.47651,50.8131,18.57,19.02,18.79,0.023943682,0.011777438,-0.01448674,-0.061245782,7.5522,0.11889,24.63497,2514,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101   151 11392  7402  1379  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ARWR,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),HypertriglyceridemiaÂ ,Phase 2b,2024-11-18,"Additional Phase 2b data reported that 10, 25, or 50 mg of plozasiran in the blinded portion of the studies produced mean reductions up to -74% at 24 weeks, noted November 18, 2024.",138.0,2364.47651,50.8131,18.57,19.02,18.79,0.023943682,0.011777438,-0.01448674,-0.061245782,7.5522,0.11889,24.63497,2515,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  8154 12278   123  1830  2233  2103  1115  1275   117  1512   117
  1137  1851 17713  1104   185  2858 23538  5132  1179  1107  1103 24255
  3849  1104  1103  2527  1666  1928  7234  1116  1146  1106   118  5692
   110  1120  1572  2277   117  2382  1379  1407   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LLY,Tirzepatide - (SUMMIT),Heart failure with preserved ejection fraction (HFpEF) and obesityÂ ,Phase 3,2024-11-18,"Phase 3 data showed a 38% reduction in the risk of heart failure outcomes, noted November 18, 2024.",946.0,654794.1824,32.5319,746.2,727.2,755.0,-0.025792118,0.011724088,-0.01448674,-0.061245782,0.73572,0.18443,6657.04405,2516,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  2799   170  3383   110  7234  1107  1103  3187
  1104  1762  4290 13950   117  2382  1379  1407   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CYTK,Omecamtiv mecarbil - (GALACTIC-HF),Heart failure with reduced ejection fraction (HFrEF)Â ,Phase 3,2024-11-18,"Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.",119.0,6129.65963,48.2405,50.22,51.94,50.25,0.033675853,0.000597193,-0.01448674,-0.061245782,13.29487,0.01014,66.94225,2517,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  3416  1120   138 11612  2103  1115  1175  1108
   170  5409  2299  3187  1104  1103  2425  1322  7587  1104  3621 25575
  1473  1137  1762  4290  1958  1105  1155   118  2612 14471   117  2382
  1379  1407   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AMGN,Omecamtiv mecarbil - (GALACTIC-HF),Heart failure with reduced ejection fraction (HFrEF)Â ,Phase 3,2024-11-18,"Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.",538.0,149842.6219,23.3091,283.61,278.76,294.0,-0.017248858,0.035979712,-0.01448674,-0.061245782,1.64135,0.06958,885.30803,2518,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  3416  1120   138 11612  2103  1115  1175  1108
   170  5409  2299  3187  1104  1103  2425  1322  7587  1104  3621 25575
  1473  1137  1762  4290  1958  1105  1155   118  2612 14471   117  2382
  1379  1407   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ACET,ADI-001,Non-Hodgkinâ€™s lymphomaÂ ,Phase 1,2024-11-18,"Phase 1 clinical update presented at ACR reported tissue trafficking and activation, complete depletion of CD19+ B cells within analyzed lymph node tissue was also observed, noted November 18, 2024.",83.0,87.93013,66.1944,0.9469,0.9679,0.904,0.021935285,-0.046364131,-0.01448674,-0.061245782,3.78912,0.03864,0.66685,2519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  7300 11984  2756  1120  9690  2069  2103  7918 12589
  1105 14915   117  2335  1260  7136  2116  1104  2891 16382   116   139
  3652  1439 17689   181 25698 14372  7918  1108  1145  4379   117  2382
  1379  1407   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALGS,Pevifoscorvir (ALG-000184) - (CAM-2),HBeAg-positive chronic hepatitis B (CHB)Â ,Phase 1b,2024-11-18,Phase 1a/1b data presented at the Liver Meeting reported that treatment decreased serum total cholesterol in young healthy dogs maintained on a normal diet in the 2-week study at â‰¥50 Âµg/kg/day (up to,6.0,74.67709,137.48,19.17,20.12,20.46,0.048367788,0.065125203,-0.01448674,-0.061245782,3.26801,0.00023,7.84308,2520,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1161   120   122  1830  2233  2756  1120  1103  3374
  1197 12505  2103  1115  3252 10558 23651  1703 22572  9016  4648  4063
  1107  1685  8071  6363  4441  1113   170  2999 10211  1107  1103   123
   118  1989  2025  1120   248   796   203 11049   228 28170  1403   120
  4023   120  1285   113  1146  1106   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NAMS,Obicetrapib - (BROOKLYN),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 3,2024-11-18,"Phase 3 data presented at AHA showed that the trial met its primary endpoint with an LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365, noted November 18, 2024.",112.0,2278.2356,48.903,24.9,24.66,21.05,-0.009685306,-0.167967243,-0.01448674,-0.061245782,0.77722,0.11049,28.16256,2521,1,0,1,0,0,1,0,0,0,0,0,0,3,0,0,1,neg,"[  101 12278   124  2233  2756  1120   138 11612  2799  1115  1103  3443
  1899  1157  2425  1322  7587  1114  1126   149  2137  2162   118   140
  1928  7234  6055  1282  4043  1104  3164   119   124   110  1120  1285
  5731  1105  3746   119   126   110  1120  1285 21033   117  2382  1379
  1407   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NKTR,NKTR-422,Autoimmune diseasesÂ ,Preclinical,2024-11-18,"Preclinical study presented at ACR 2024 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions, noted November 18, 2024.",19.0,189.99203,73.5103,16.04999,15.44999,16.34999,-0.03809987,0.018519059,-0.01448674,-0.061245782,2.83326,0.14903,1.43246,2522,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2025  2756  1120  9690  2069 17881  1527
  7160 24970  6021  1105  7918  6949  1107  2967  3073  1665 21472  7867
  3584  1104 13306 22653  2975   117  2382  1379  1407   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JNJ,Icotrokinra (JNJ-2113) - (ICONIC-LEAD),Moderate-to-severe psoriasisÂ ,Phase 3,2024-11-18,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.",0.0,372627.8074,15.8383,154.0,154.77,155.78,0.004987542,0.011492153,-0.01448674,-0.061245782,0.75208,0.0,1162.96917,2523,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2025  1899  1157  1884   118  2425  1322 21521  1107
  4420  1114  8828  1106  5199 12592 15604 16420  4863   117  2382  1379
  1407   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTGX,Icotrokinra (JNJ-2113) - (ICONIC-LEAD),Moderate-to-severe psoriasisÂ ,Phase 3,2024-11-18,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.",62.0,2407.16395,46.2957,41.11,40.39,45.53,-0.017669171,0.102120048,-0.01448674,-0.061245782,5.5069,0.1537,19.78609,2524,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2025  1899  1157  1884   118  2425  1322 21521  1107
  4420  1114  8828  1106  5199 12592 15604 16420  4863   117  2382  1379
  1407   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JNJ,Icotrokinra (JNJ-2113) - (ICONIC-TOTAL),Moderate-to-severe psoriasisÂ ,Phase 3,2024-11-18,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.",0.0,372627.8074,15.8383,154.0,154.77,155.78,0.004987542,0.011492153,-0.01448674,-0.061245782,0.75208,0.0,1162.96917,2525,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2025  2799  1517  3828   178 18982 24830  1394  1611
  1899  1103  2425  1322  7587  1104   146 10583  1104   121   120   122
  1120  1989  1479  3402  1106  1282  4043   117  2382  1379  1407   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTGX,Icotrokinra (JNJ-2113) - (ICONIC-TOTAL),Moderate-to-severe psoriasisÂ ,Phase 3,2024-11-18,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.",62.0,2407.16395,46.2957,41.11,40.39,45.53,-0.017669171,0.102120048,-0.01448674,-0.061245782,5.5069,0.1537,19.78609,2526,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2025  2799  1517  3828   178 18982 24830  1394  1611
  1899  1103  2425  1322  7587  1104   146 10583  1104   121   120   122
  1120  1989  1479  3402  1106  1282  4043   117  2382  1379  1407   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
INCY,MRGPRX2 (INCB000262),Spontaneous urticaria (CSU)Â ,Phase 2,2024-11-18,"Phase 2 enrollment paused, noted November 18, 2024.",196.0,14828.28967,30.5255,75.87,76.97,73.52,0.014394386,-0.031463871,-0.01448674,-0.061245782,3.85109,0.09206,141.90066,2527,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1,neg,"[  101 12278   123 10803  5162   117  2382  1379  1407   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INCY,MRGPRX4 (INCB000547),Cholestatic pruritus (CP)Â ,Phase 2,2024-11-18,"Phase 2 study data does not support further development, noted November 18, 2024.",196.0,14828.28967,30.5255,75.87,76.97,73.52,0.014394386,-0.031463871,-0.01448674,-0.061245782,3.85109,0.09206,141.90066,2528,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2025  2233  1674  1136  1619  1748  1718   117  2382
  1379  1407   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SLN,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia veraÂ ,Phase 2,2024-11-18,"Phase 2 data presented at AHA showed significant time-averaged Lp(a) reductions, with effects persisting 60 weeks following the first dose, noted November 18, 2024.",46.0,520.30742,53.2338,12.7,11.02,7.21,-0.14189019,-0.566133042,-0.01448674,-0.061245782,0.74832,0.0302,8.83399,2529,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2756  1120   138 11612  2799  2418  1159   118
 11445   149  1643   113   170   114  7234  1116   117  1114  3154  1679
 22398  1158  2539  2277  1378  1103  1148 13753   117  2382  1379  1407
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,2024-11-18,"Phase 2a data presented at AASLD reported a stable ELF score from Week 12 to Week 24, with a reduction in participants with an ELF score of >9.8 at baseline, noted November 18, 2024.",61.0,749.71664,56.7218,12.43,12.32,13.46,-0.008888947,0.079609419,-0.01448674,-0.061245782,11.85768,0.06371,16.99721,2530,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  1161  2233  2756  1120 10419 13726  2137  2103   170
  6111   142 25470  2794  1121  6237  1367  1106  6237  1572   117  1114
   170  7234  1107  6635  1114  1126   142 25470  2794  1104   135   130
   119   129  1120  2259  2568   117  2382  1379  1407   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALLO,ALLO-329 - (RESOLUTION),Autoimmune Disease (AID)Â ,Preclinical,2024-11-18,"Preclinical data shared at ACR demonstrated that ALLO-329 could be effective in treating autoimmune diseases with reduced or no lymphodepleting chemotherapy, noted November 18, 2024.",221.0,450.795,84.1403,2.27,2.15,2.28,-0.054311989,0.004395611,-0.01448674,-0.061245782,17.66607,0.13102,6.286,2531,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  3416  1120  9690  2069  7160  1115
 18589  2162  2346   118  2724  1580  1180  1129  3903  1107 12770 12365
  4060 13601  1673  8131  1114  3549  1137  1185   181 25698 13040  7136
  1916 22572  5521 20939   117  2382  1379  1407   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALNY,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV)Â ,Phase 2,2024-11-18,"Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.",131.0,29958.39759,56.5637,235.56,232.27,250.98,-0.01406517,0.063407597,-0.01448674,-0.061245782,2.86639,0.03543,362.7493,2532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123   117  1572   118  1989  2233  1121 10419 13726  2137
  2103  1620   110   191  9992 13791  1596 18793   117  2382  1379  1407
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VIR,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV)Â ,Phase 2,2024-11-18,"Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.",138.0,968.17244,66.2608,8.01,7.03,7.44,-0.130504055,-0.073819912,-0.01448674,-0.061245782,4.15466,0.0282,15.82726,2533,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   117  1572   118  1989  2233  1121 10419 13726  2137
  2103  1620   110   191  9992 13791  1596 18793   117  2382  1379  1407
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MIRM,Volixibat - (VANTAGE),Pruritus associated with primary biliary cholangitisÂ ,Phase 2b,2024-11-18,"Phase 2b data presented at AASLD reported rapid and statistically significant reductions in cholestatic pruritus were observed after treatment, noted November 18, 2024.",50.0,1988.34979,60.7189,44.5,41.42,44.27,-0.071725333,-0.005181942,-0.01448674,-0.061245782,14.25961,0.01405,24.67704,2534,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  1830  2233  2756  1120 10419 13726  2137  2103  6099
  1105 11435  1193  2418  7234  1116  1107 22572  9016 27372   185  5082
  7729  1361  1127  4379  1170  3252   117  2382  1379  1407   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ADVM,"Lxo-vec (ixoberogene soroparvovec, ADVM-022) - (OPTIC)",Wet age-related macular degeneration (Wet-AMD)Â ,Phase 2,2024-11-18,"Phase 2 long term data reported that 78% of patients who were injection free through year 1 remained injection free through year 4, noted November 18, 2024.",20.0,142.49687,59.7718,6.86,6.85,6.15,-0.001458789,-0.10925536,-0.01448674,-0.061245782,7.71421,0.02835,2.82995,2535,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1263  1858  2233  2103  1115  5603   110  1104  4420
  1150  1127 14546  1714  1194  1214   122  1915 14546  1714  1194  1214
   125   117  2382  1379  1407   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LLY,Muvalaplin,Heart diseaseÂ ,Phase 2,2024-11-18,"Phase 2 study met at the 12-week its primary endpoint, noted November 18, 2024.",946.0,654794.1824,32.5319,746.2,727.2,755.0,-0.025792118,0.011724088,-0.01448674,-0.061245782,0.73572,0.18443,6657.04405,2536,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  2025  1899  1120  1103  1367   118  1989  1157  2425
  1322  7587   117  2382  1379  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RCKT,RP-A501,Danon diseaseÂ ,Phase 2,2024-11-18,Phase 2 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 expression and â‰¥10% reduction in LV mass index at 12 months and sustained through most recent follow up (,107.0,1245.20578,57.0254,13.98,13.66,14.1,-0.023155883,0.008547061,-0.01448674,-0.061245782,13.05165,0.14621,20.29291,2537,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  7160  3429  1105 17119 23891   132  1155   174  7501
  6718  2165  4420  1437 17688 10722 12347  1477  2838  1105   248   796
   203 10424   110  7234  1107   149  2559  3367  7448  1120  1367  1808
  1105  8505  1194  1211  2793  2812  1146   113   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
FATE,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,2024-11-18,"Phase 1b data presenteed at ACR showed patient treated with fludarabine-free conditioning and single-dose FT819; favorable safety profile with no grade â‰¥3 adverse events and no events of CRS, ICANS, o",115.0,258.54014,83.1726,2.02,2.27,2.42,0.11668232,0.180670029,-0.01448674,-0.061245782,13.96232,0.0712,56.18804,2538,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   122  1830  2233  1675 11394  1120  9690  2069  2799  5351
  5165  1114 23896  7858 23156  1673   118  1714 15851  1105  1423   118
 13753   143  1942  1604 16382   132 11169  3429  6168  1114  1185  3654
   248   796   203  1495 16798  1958  1105  1185  1958  1104 15531  1708
   117   146 11356 12412   117   184   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
FATE,FT522,LupusÂ ,Phase 1,2024-11-18,"Phase 1 initial data showed a favorable safety profile, complete responses, and persistence of FT522 live cells, noted November 18, 2024.",115.0,258.54014,83.1726,2.02,2.27,2.42,0.11668232,0.180670029,-0.01448674,-0.061245782,13.96232,0.0712,56.18804,2539,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   122  3288  2233  2799   170 11169  3429  6168   117  2335
 11317   117  1105  1679 19031  1104   143  1942  1571 20581  1686  3652
   117  2382  1379  1407   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CMMB,nebokitug (CM-101) - (SPRING),Primary Sclerosing CholangitisÂ ,Phase 2,2024-11-19,"Phase 2 data presented at AASLD met the trial's primary endpoint, demonstrating a favorable safety profile over the 15-week treatment period on November 19, 2024.",5.0,30.54771,110.4505,6.6,6.48,6.36,-0.018349139,-0.037041272,-0.02204746,-0.07224985,0.86389,0.02463,0.16479,2540,1,0,0,1,0,1,0,0,0,0,1,0,4,0,0,1,neg,"[  101 12278   123  2233  2756  1120 10419 13726  2137  1899  1103  3443
   112   188  2425  1322  7587   117 15107   170 11169  3429  6168  1166
  1103  1405   118  1989  3252  1669  1113  1379  1627   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph),Solid tumorsÂ ,Phase 3,2024-11-19,"Phase 3 data reported that the trial met its primary endpoint, noted November 19, 2024.",0.0,244211.0252,23.608,96.56,96.54,101.62,-0.000207147,0.051075789,-0.02204746,-0.07224985,1.03685,0.11705,1264.00488,2541,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2233  2103  1115  1103  3443  1899  1157  2425  1322
  7587   117  2382  1379  1627   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,2024-11-19,"Phase 1b 2nd cohort completion, noted November 19, 2024.",5.0,2.69292,94.4509,2.27,2.552,2.51,0.117097534,0.100502922,-0.02204746,-0.07224985,4.87965,0.07484,0.69783,2542,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830  2518  1884 13252  1204  6026   117  2382  1379
  1627   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GSK,Linerixibat - (GLISTEN),Primary biliary cholangitis (PBC)Â ,Phase 3,2024-11-19,"Phase 3 trial met primary endpoint, noted November 19, 2024.",0.0,53189.3136,23.2159,13.1,13.035,13.38,-0.004974183,0.021148824,-0.02204746,-0.07224985,0.0,0.0807,211.86151,2543,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  1899  2425  1322  7587   117  2382  1379  1627
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BIIB,Dapirolizumab pegol (anti-CD40L),Systemic lupus erythematosusÂ ,Phase 3,2024-11-19,Phase 3 data reported that a greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on s,146.0,22649.15702,25.2903,157.94,155.43,157.69,-0.016019745,-0.001584134,-0.02204746,-0.07224985,2.14149,0.15644,201.57064,2544,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115   170  3407  2593  1108  4379  1506
  2967  7300  1322 21521  1621  6635  5165  1114   141  5301  2101  1259
  1851   110  1750  5199  3653 20646  1116  3402  1106  6635  1113   188
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALGS,Pevifoscorvir (ALG-000184) - (CAM-2),HBeAg-positive chronic hepatitis B (CHB)Â ,Phase 1b,2024-11-19,"Phase 1a/1b data presented at AALSD from â‰¤84 weeks demonstrated sustained HBV DNA suppression in 7/7 (100%) HBeAg-positive CHB subjects, noted November 19, 2024.",6.0,68.66432,137.948,20.12,18.5,21.35,-0.083943613,0.059337394,-0.02204746,-0.07224985,3.26801,0.00023,28.21659,2545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1161   120   122  1830  2233  2756  1120 10419 15928
  2137  1121   248   796   100  2277  7160  8505   145  2064  2559  5394
 18793  1107   128   120   128   113  1620   110   114   145  2064  1162
  1592  1403   118  3112 24890  2064  5174   117  2382  1379  1627   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVO,Icosema - (COMBINE 3),Type 2 diabetesÂ ,Phase 3,2024-11-19,"Phase 3a data reported that treatment had safe and well-tolerated profile, noted November 19, 2024.",0.0,3207922.258,32.5572,99.81,102.63,106.13,0.027861909,0.061396379,-0.02204746,-0.07224985,0.0,0.0,593.07044,2546,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   124  1161  2233  2103  1115  3252  1125  2914  1105  1218
   118 21073  1181  6168   117  2382  1379  1627   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GOVX,COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine,"COVID-19 Infection, Chronic Lymphocytic LeukemiaÂ ",Phase 2,2024-11-19,"Phase 2 DSMB review of interim data completed, the DSMB determined that, while the mRNA control arm of the study failed to meet the predetermined primary endpoint, the study should continue enrollment",25.0,27.45896,223.9857,3.03,2.91,2.7,-0.040409538,-0.115310847,-0.02204746,-0.07224985,3.19011,0.07303,4.53699,2547,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123 18448 20660  3189  1104 10572  2233  2063   117  1103
 18448 20660  3552  1115   117  1229  1103   182 15654  1654  1981  1104
  1103  2025  2604  1106  2283  1103  3073 26514 26486  2425  1322  7587
   117  1103  2025  1431  2760 10803   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NXTC,NC605,Osteogenesis Imperfecta (OI)Â ,Preclinical,2024-11-19,"Preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, noted November 19,",2.0,36.68875,66.1865,15.48001,15.72001,14.04001,0.015384909,-0.097638403,-0.02204746,-0.07224985,0.23608,0.01757,0.04935,2548,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233 15107  1115  3252  1114 14056 16480
  1571   117   170  2281  2848   118 14159  6415  1665   118  1405   113
   156 16337   114  2848 14637   117  3657  1107  9927  3964  1104  3068
  6028  1114  1618  6676  4625   117  2382  1379  1627   117   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LTRN,LP-300 - (Harmonic),Non-small cell lung cancer (NSCLC)Â ,Phase 2,2024-11-19,"Phase 2 additional expansion cohort dosing initiated, noted November 19, 2024.",10.0,33.21695,72.9822,3.16,3.08,3.072,-0.025642431,-0.028243212,-0.02204746,-0.07224985,1.53517,0.07001,0.14762,2549,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2509  4298  1884 13252  1204 18463  1158  7087   117
  2382  1379  1627   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,2024-11-19,"Phase 1/2 preliminary data showed an considerably slower lesion growth (21.4%) from baseline in treated vs. untreated fellow eyes that followed the natural history of the disease, noted November 19, 2",292.0,254.4974,74.1017,0.9112,0.8736,0.9086,-0.042139807,-0.002857459,-0.02204746,-0.07224985,17.38472,0.03,5.12646,2550,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  9889  2233  2799  1126  9627 12741  8241
  1988  3213   113  1626   119   125   110   114  1121  2259  2568  1107
  5165  5016   119  8362  7877  2913  3235  1257  1115  1723  1103  2379
  1607  1104  1103  3653   117  2382  1379  1627   117   123   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SGMO,ST-503,Chronic neuropathic painÂ ,Phase 1/2,2024-11-19,"IND Clearance by the FDA, noted November 19, 2024.",301.0,408.94787,151.6628,1.9,1.96,2.14,0.031090587,0.118951943,-0.02204746,-0.07224985,9.09599,0.001,12.56473,2551,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 15969  2137 15458  3923  1118  1103 18762   117  2382  1379  1627
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VKTX,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosisÂ ,Phase 2b,2024-11-19,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.",113.0,5740.08814,85.4305,49.11,51.51,53.42,0.047713284,0.084122528,-0.02204746,-0.07224985,11.91762,0.05502,284.05679,2552,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,pos,"[  101 12278   123  1830  3882  1989  2233  2756  1120 10419 13726  2137
 25172  2686  1259  2265  8337  1104  2025   112   188  2425  1105  3718
  1322 21521   117  2382  1379  1627   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LGND,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosisÂ ,Phase 2b,2024-11-19,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.",19.0,2112.5027,40.8582,111.67,111.8,124.33,0.001163467,0.107391228,-0.02204746,-0.07224985,4.86165,0.13992,10.97697,2553,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,pos,"[  101 12278   123  1830  3882  1989  2233  2756  1120 10419 13726  2137
 25172  2686  1259  2265  8337  1104  2025   112   188  2425  1105  3718
  1322 21521   117  2382  1379  1627   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRDL,CardiolRx - (MAvERIC-Pilot),Recurrent PericarditisÂ ,Phase 2,2024-11-19,"The phase 2 study marked rapid reductions in pericarditis pain and inflammation throughout the 26-week study. Episodes of pericarditis per year substantially reduced, noted November 18, 2024.",83.0,13.42958,52.1823,0.0625,0.0625,0.0675,0.0,0.076961041,-0.02204746,-0.07224985,0.0,0.04607,0.00526,2554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  1109  4065   123  2025  3597  6099  7234  1116  1107  1679  4578
 16936  6620  2489  1105 24970  2032  1103  1744   118  1989  2025   119
  8112  1116  1104  1679  4578 16936  6620  1679  1214 12613  3549   117
  2382  1379  1407   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SAGE,Dalzanemdor (SAGE-718) - (DIMENSION),Huntington's disease (HD)Â ,Phase 2,2024-11-20,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.",62.0,104432.4764,89.7992,13.0,13.0,14.0,0.0,0.074107972,-0.012055408,-0.070744405,0.0,9e-05,23.764,2555,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1,pos,"[  101 12278   123  1499  2568  2233  2103  1115  1103  3443  1225  1136
  2283  1157  2425  1322  7587   117  2382  1379  1406   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SUPN,Dalzanemdor (SAGE-718) - (DIMENSION),Huntington's disease (HD)Â ,Phase 2,2024-11-20,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.",56.0,1994.52014,35.1361,35.53,36.12,36.99,0.016469319,0.040270196,-0.012055408,-0.070744405,12.32065,0.08592,7.36545,2556,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1,pos,"[  101 12278   123  1499  2568  2233  2103  1115  1103  3443  1225  1136
  2283  1157  2425  1322  7587   117  2382  1379  1406   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ARGX,Efgartigimod - (ALKIVIA),"Myositis subsets (Immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM))Â ",Phase 2/3,2024-11-20,"Phase 2/3 data reported that the trial met its primary endpoint, noted November 20, 2024.",60.0,33419.53104,30.8338,532.2,553.6,582.4,0.039423046,0.090138138,-0.012055408,-0.070744405,0.0,0.00017,54.10886,2557,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123   120   124  2233  2103  1115  1103  3443  1899  1157
  2425  1322  7587   117  2382  1379  1406   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CLDX,CDX-622,Chronic inflammationÂ ,Phase 1a,2024-11-20,"Phase 1a dosing commenced, noted November 20, 2024.",66.0,1751.48783,57.9298,24.98,26.4,27.89,0.055288505,0.110192697,-0.012055408,-0.070744405,12.41981,0.03867,29.65401,2558,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1161 18463  1158  8042   117  2382  1379  1406   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PRFX,PRF-110,BunionectomyÂ ,Phase 3,2024-11-20,"Phase 3 partial topline data indicated that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, noted November 20, 202",1.0,2.31551,192.2712,5.6,4.16,2.75,-0.297251523,-0.711165686,-0.012055408,-0.070744405,5.43807,0.0191,5.29806,2559,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124  7597  1499  2568  2233  4668  1115 11629  2271   118
  6745  7160 11435  1193  2418 21378  1166  1282  4043  1107  7914  2489
  1219  1103  1148  3615  2005  1378  6059   117  2382  1379  1406   117
 17881   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VYGR,VY1706,Alzheimer's diseaseÂ ,Preclinical,2024-11-20,"Preclinical candidate VY1706 demonstrated significant reductions of tau at low doses in NHP study, noted November 20, 2024. I",55.0,292.79314,67.6886,5.27,5.36,5.78,0.016933613,0.09237332,-0.012055408,-0.070744405,5.40482,0.0681,2.489,2560,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  3234   159  3663 16770  1568  1545  7160
  2418  7234  1116  1104 27629  1358  1120  1822 24429  1107 20576  2101
  2025   117  2382  1379  1406   117 17881  1527   119   146   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NAMS,Obicetrapib & ezetimibe - (TANDEM),Cardiovascular diseaseÂ ,Phase 3,2024-11-20,"Phase 3 study achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg mon",112.0,1848.6413,54.4671,23.68,20.01,20.8,-0.168398661,-0.129677823,-0.012055408,-0.070744405,0.77722,0.11049,60.28489,2561,1,0,1,0,0,1,0,0,0,0,0,0,3,0,0,1,neg,"[  101 12278   124  2025  3890  1155  1884   118  2425  1322 21521  1104
   149  1708  1928  7234  1107   149  2137  2162   118   140  1113  1499
  1104 12477 23984  1193 21073  1181  4764  2386   118 22015  1158  1103
 14543  1905  6055  1296  1104  1282  4043   117   174  3171  3121  3080
  3962  1275 17713   117  1105   184 15421  2105 14543 13292  1275 17713
 19863   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,2024-11-20,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",256.0,116204.9415,23.5953,448.01,451.23,464.56,0.007161634,0.036275167,-0.012055408,-0.070744405,1.7492,0.31655,745.06376,2562,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   122  1830   120   123  1161  2025  3890   170  3078   110
  7234  1107  5837 16140  7257  9232  1116  1439  1103  1148  1476  1552
  1104  3252   117  5542  1103  2905 23891 10209  1562  1107  2988  2527
   117  2382  1379  1406   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,2024-11-20,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",68.0,64.45326,21.4893,7.4,7.4,7.4,0.0,0.0,-0.012055408,-0.070744405,0.0,0.00879,0.0,2563,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   122  1830   120   123  1161  2025  3890   170  3078   110
  7234  1107  5837 16140  7257  9232  1116  1439  1103  1148  1476  1552
  1104  3252   117  5542  1103  2905 23891 10209  1562  1107  2988  2527
   117  2382  1379  1406   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PBYI,PUMA-ALI-1201 - (ALISCA-Breast1),HER-2 Recurrent or metastatic breast cancerÂ ,Phase 2,2024-11-20,"Phase 2 was initiated, noted November 20, 2024.",50.0,139.40902,81.4824,2.74,2.84,3.23,0.035846132,0.164524217,-0.012055408,-0.070744405,6.49624,0.00077,0.76897,2564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1108  7087   117  2382  1379  1406   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RXRX,REC-4881,AXIN1 or APC Mutant CancersÂ ,Phase 2,2024-11-20,"Phase 2 was deprioritized as part of a disciplined strategic portfolio prioritization, noted November 20, 2024.",434.0,1732.50295,73.066,6.27,6.04,6.38,-0.037372343,0.017391743,-0.012055408,-0.070744405,21.76405,0.21578,102.70556,2565,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1108  1260  1643  8558  7729  2200  1112  1226  1104
   170  9360  1181  7061 12256  2988 17030  8569   117  2382  1379  1406
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PYXS,PYX-201-101,Pancreatic CancerÂ ,Phase 1,2024-11-20,"Phase 1 preliminary clinical data achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six h",62.0,227.15909,67.4071,4.16,3.82,1.83,-0.085264652,-0.821199107,-0.012055408,-0.070744405,9.84749,0.01513,20.84633,2566,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  9889  7300  2233  3890   170  3659  1851   110  7649
  2593  2603   113 23066  2069   114  1359  1113   155  8231  6258  1942
   122   119   122  9173   117  1259  1141  2335  2593  1105   170  3653
  1654  2603   113  5227  2069   114  1104  1620   110  1107  1565   177
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KTTA,PAS-004,Neurofibromatosis Type 1 (NF1) and solid tumorsÂ ,Phase 1,2024-11-20,"Phase 1 external Safety Review Committee recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities (DLT's),",7.0,4.0399,114.1835,3.15,3.19,2.9,0.012618464,-0.082691716,-0.012055408,-0.070744405,0.91446,0.00249,2.39119,2567,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1,neg,"[  101 12278   122  6298  9218  4960  2341  6315 20793  1106  1884 13252
  1204   125   117  1405  1306  1403 21749   117  1443 13334   119  1188
 13710  1108  1359  1113  1103  5884  1104  1251 13753 15816 12844  4233
   113 26624  1942   112   188   114   117   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,2024-11-21,"Preclinical data reported that treatment reduced key intracellular markers of inflammation and fibrosis in the colon, including PDE4B expression, while increasing cAMP levels, noted November 21, 2024.",9.0,3.24402,69.6191,2.44,2.44,2.42,0.0,-0.008230499,-0.023443912,-0.061769026,3.24268,0.03854,0.2343,2568,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115  3252  3549  2501  1107
  4487 18091 18004  1104 24970  1105 20497 12725  4863  1107  1103  1884
  4934   117  1259 27802  2036  1527  2064  2838   117  1229  4138   172
 10964  2101  3001   117  2382  1379  1626   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
XBIO,DNase I,Melanoma Lung MetastasisÂ ,Preclinical,2024-11-21,"Preclinical data demonstrated to significantly suppress metastatic tumor burden, decreases the number of metastatic foci, and substantially prolongs survival compared to the CAR T cell monotherapy gro",1.0,6.18799,78.7628,3.99,4.0126,4.2,0.005648179,0.051293294,-0.023443912,-0.061769026,0.96178,0.00404,0.02083,2569,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  7160  1106  5409 17203 27154 27372
 14601 11904   117 19377  1103  1295  1104 27154 27372   175 13335  1182
   117  1105 12613  5250  9851  1116  8115  3402  1106  1103  8784  2069
   157  2765 19863 20939   176  2180   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,2024-11-21,"Preclinical results confirmed the efficacy of Telomir-1 to turn back the biological clock and support longevity effectively, noted November 21, 2024.",32.0,132.35587,127.1046,4.2,4.47,4.28,0.062303883,0.018868484,-0.023443912,-0.061769026,1.84515,0.00134,0.98046,2570,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2686  3659  1103 23891  1104 11341 18882
  1197   118   122  1106  1885  1171  1103  7269  4705  1105  1619  1263
 25769  5877   117  2382  1379  1626   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
QURE,AMT-260 - (GenTLE),Refractory Temporal Lobe Epilepsy (rTLE)Â ,Phase 1/2,2024-11-21,"Phase 1/2a trial dosing commenced, noted November 21, 2024.",54.0,284.90365,125.7432,5.7,5.845,6.02,0.02512042,0.054621084,-0.023443912,-0.061769026,6.87183,0.04256,4.01419,2571,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123  1161  3443 18463  1158  8042   117  2382
  1379  1626   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ONC,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Approved,2024-11-21,"Approved November 21, 2024.",110.0,20671.25951,40.0755,194.26,194.56,206.16,0.001543131,0.059455098,-0.023443912,-0.061769026,1.02502,0.1016,43.08959,2572,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1379  1626   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JAZZ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Approved,2024-11-21,"Approved November 21, 2024.",60.0,7562.86946,29.9989,119.24,125.1,122.64,0.047975149,0.028114966,-0.023443912,-0.061769026,5.94397,0.0876,122.61526,2573,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1379  1626   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ZYME,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Approved,2024-11-21,"Approved November 21, 2024.",75.0,942.24456,42.0978,14.55,13.68,14.42,-0.061656081,-0.008974862,-0.023443912,-0.061769026,6.82389,0.17287,9.76781,2574,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1379  1626   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMRX,Brekiya (dihydroergotamine mesylate) injection,Migraine with or without aura and cluster headache in adultsÂ ,NDA Filing,2024-11-21,"Resubmitted NDA November 21, 2024.",314.0,2577.90566,34.7202,8.41,8.32,8.35,-0.010759219,-0.007159935,-0.023443912,-0.061769026,1.12998,0.09121,6.63007,2575,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11336  6385  1830  9084  1906   151 11392  1379  1626   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CATX,[212Pb]VMT-Î±-NET,Neuroendocrine tumors (NETs)Â ,Phase 1,2024-11-22,"Phase 1 data reported that eight of nine patients had durable control of disease, noted November 22, 2024.",74.0,234.52876,131.5792,3.0,3.47,4.35,0.145542305,0.371563556,-0.034703634,-0.054881758,11.86921,1e-05,33.5004,2576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2233  2103  1115  2022  1104  2551  4420  1125  3840
  9739  1654  1104  3653   117  2382  1379  1659   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PSTV,CNSide - (FORESEE),Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM)Â ,Phase 2,2024-11-22,"Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.",99.0,6.95767,88.6054,1.2,1.18,1.28,-0.016807118,0.064538521,-0.034703634,-0.054881758,0.88765,0.03272,0.54641,2577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  8154  3443  2233  7160  9927 15750  1107 11552  1158 14601  3652
   113  2908   110   114  5016   119 24821  2271   172 25669  4807   113
  1853   110   114  1107  4420  1114   149  2107   117  2382  1379  1659
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VRPX,Probudur,Pain ReliefÂ ,Preclinical,2024-11-22,"Preclinical data results from a minipig Dose Range Finding (DRF) study for Probudur demonstrated positive tolerance to it, and no adverse effects were reported, noted November 22, 2024.",1.0,4.58566,180.8744,14.7425,14.175,11.5275,-0.039254629,-0.245998994,-0.034703634,-0.054881758,4.33821,0.00035,90.88677,2578,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2686  1121   170  8715  8508  1403
  2091  2217  7389 18036   113 22219  2271   114  2025  1111  5096  7925
  7641  1197  7160  3112 15745  1106  1122   117  1105  1185 16798  3154
  1127  2103   117  2382  1379  1659   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Approved,2024-11-22,"FDA approved on November 22, 2024.",0.0,162377.0965,21.9968,100.62,104.74,106.12,0.040130044,0.053219484,-0.034703634,-0.054881758,0.0,0.03667,300.46334,2579,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  4092  1113  1379  1659   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BBIO,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Approved,2024-11-22,"FDA approved on November 22, 2024.",191.0,4426.14116,54.7944,23.24,23.42,27.09,0.007715426,0.153289724,-0.034703634,-0.054881758,9.10073,0.03495,48.91122,2580,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  4092  1113  1379  1659   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CNSP,Berubicin,Glioblastoma (GBM) (adult)Â ,Phase 2,2024-11-22,"Phase 2 update reported a slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, wh",0.0,7.15134,207.9387,78.00003,74.64003,67.20003,-0.044032253,-0.149035517,-0.034703634,-0.054881758,1.97895,0.01626,1.23044,2581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 11984  2103   170  2776  3407  6556  1104  4420  1114
  1155  7093  1137 26439   124   118   126  1114  1126  5024  8191   117
 16320   117  1105  9711  1107 24928  3818 12736 20473 10664  1127  2602
  1107  4420  4172  4108  5082 15421  1394   117   192  1324   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,2024-11-22,"Phase 1 data presented at SNO reported 86% (12/14 patients), with 2 responses and 10 stable cases, noted on November 22, 2024.",99.0,6.95767,88.6054,1.2,1.18,1.28,-0.016807118,0.064538521,-0.034703634,-0.054881758,0.88765,0.03272,0.54641,2582,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2233  2756  1120   156  2249  2346  2103  5942   110
   113  1367   120  1489  4420   114   117  1114   123 11317  1105  1275
  6111  2740   117  2382  1113  1379  1659   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MRK,WINREVAIR (sotatercept-csrk) - (ZENITH),"Pulmonary arterial hypertension (PAH, WHO* Group 1)Â ",Phase 3,2024-11-25,"Phase 3 trial met primary endpoint, noted November 25, 2024.",0.0,255897.9419,24.1139,99.18,101.16,100.61,0.019767041,0.014315275,-0.026758478,-0.031401199,1.03685,0.12301,3506.11365,2583,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  1899  2425  1322  7587   117  2382  1379  1512
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AZN,Truqap - (CAPItello-281),Dephosphorylated Phosphatase and Tensin Homolog (dPTEN) Hormone-Sensitive Prostate Cancer (HSPC)Â ,Phase 3,2024-11-25,"Phase 3 trial data demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS), noted November 25, 2024.",0.0,162377.0965,22.0474,104.74,104.74,105.54,0.0,0.007608939,-0.026758478,-0.031401199,0.0,0.03667,577.06136,2584,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  2233  7160   170 11435  1193  2418  1105  7300
  1193 17119  8331  1107  1103  2425  1322  7587  1104  2070 11293 16147
   118  1714  8115   113   187  2101 17691   114   117  2382  1379  1512
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
INAB,INB-200,GlioblastomaÂ ,Phase 1,2024-11-25,Phase 1 study presented at SNO reported that 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median OS from standard-of-care Stupp regimen while,4.0,22.02041,153.7152,9.52801,9.11401,11.04001,-0.044423092,0.147290065,-0.026758478,-0.031401199,1.38458,0.09331,0.09844,2585,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2025  2756  1120   156  2249  2346  2103  1115  1851
   110  1104  4420  1150  1460  4892 24429   113   183   134  1275   114
  1915  3534  1105  1107  1231 11234  2894  1103  2637  3151 11570  1121
  2530   118  1104   118  1920  1457  4455  1643  6716  1179  1229   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CGTX,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's DiseaseÂ ,Phase 2,2024-11-25,"Phase 2 additional analysis demonstrated that individuals who entered the study with plasma p-tau217 below the median experienced a normalization of several key indicators, such as the neuroinflammato",73.0,16.91003,131.4638,0.4277,0.407,0.4,-0.04960883,-0.066957468,-0.026758478,-0.031401199,1.96326,0.14858,19.23975,2586,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2509  3622  7160  1115  2833  1150  2242  1103  2025
  1114 13441   185   118 27629  1358 18202  1559  2071  1103  3151  4531
   170  2999  2734  1104  1317  2501 24091   117  1216  1112  1103 24928
 11955  1394  2087  7609 21943  1186   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SAVA,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimerâ€™s diseaseÂ ,Phase 3,2024-11-25,"Phase 3 trial did not meet primary endpoint, noted November 25, 2024.",48.0,206.63449,291.0718,26.48,4.295,3.445,-1.818938176,-2.039465827,-0.026758478,-0.031401199,38.60158,2e-05,406.82366,2587,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   124  3443  1225  1136  2283  2425  1322  7587   117  2382
  1379  1512   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CTXR,Mino-Lok,Catheter related blood stream infection (CRBSI)Â ,Phase 3,2024-11-25,"Phase 3 EoP Type C Meeting with the FDA resulted in clear, constructive, and actionable guidance underscoring a pathway to support a future NDA submission, noted November 25, 2024.",17.0,25.78948,122.8829,3.345,3.3375,3.22,-0.00224467,-0.038085334,-0.026758478,-0.031401199,6.1019,0.00254,19.71713,2588,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1,neg,"[  101 12278   124   142  1186  2101  6902   140 12505  1114  1103 18762
  3657  1107  2330   117  9417  2109   117  1105  2168  1895  8815  1223
 11428  3384   170 13548  1106  1619   170  2174   151 11392 13455   117
  2382  1379  1512   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMY,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA)Â ,Phase 3,2024-11-25,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically,0.0,119216.2249,32.075,58.87,58.78,59.94,-0.001529962,0.018012439,-0.026758478,-0.031401199,1.15479,0.00308,829.95744,2589,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  1499  2568  2686  2103  7300  1193 17119  8313  1107
  5968  3053  1120  1155  1159 21521  1113  1103  8226 16068  5796  2508
  2225  3313  1880   118  2724  3418   113   150 17938   118  2724   114
  1133  1103  3252  1981  1225  1136 11435  1193   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PFE,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA)Â ,Phase 3,2024-11-25,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically,0.0,148305.1292,22.0616,25.65,26.17,25.82,0.020070145,0.006605814,-0.026758478,-0.031401199,1.09175,0.00092,1510.20912,2590,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  1499  2568  2686  2103  7300  1193 17119  8313  1107
  5968  3053  1120  1155  1159 21521  1113  1103  8226 16068  5796  2508
  2225  3313  1880   118  2724  3418   113   150 17938   118  2724   114
  1133  1103  3252  1981  1225  1136 11435  1193   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BHVN,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA)Â ,Phase 3,2024-11-25,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically,105.0,4573.75919,55.43,45.59,45.23,44.74,-0.007927811,-0.018820438,-0.026758478,-0.031401199,9.05087,0.14194,104.78249,2591,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  1499  2568  2686  2103  7300  1193 17119  8313  1107
  5968  3053  1120  1155  1159 21521  1113  1103  8226 16068  5796  2508
  2225  3313  1880   118  2724  3418   113   150 17938   118  2724   114
  1133  1103  3252  1981  1225  1136 11435  1193   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNYA,TN-401 - (RIDGE-1),Arrhythmogenic Right Ventricular CardiomyopathyÂ ,Phase 1b,2024-11-25,"Phase 1b dosing commenced, noted on November 25, 2024.",162.0,234.49273,101.8143,2.38,2.96,3.58,0.218088781,0.408262313,-0.026758478,-0.031401199,6.61994,0.15058,22.12231,2592,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830 18463  1158  8042   117  2382  1113  1379  1512
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ABBV,AL002 - (INVOKE-2),Alzheimerâ€™s diseaseÂ ,Phase 2,2024-11-25,"Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.",0.0,312889.8656,28.4921,176.95,177.06,181.77,0.000621451,0.026874945,-0.026758478,-0.031401199,1.02568,0.00927,2207.04653,2593,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1,pos,"[  101 12278   123  2604  1106  2283  2425  1105  3718  1322 21521   119
  7457  1852  1103  2686   117  9596  2772  1110  7202  1103  1263   118
  1858  4973  2025   117  2382  1379  1512   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALEC,AL002 - (INVOKE-2),Alzheimerâ€™s diseaseÂ ,Phase 2,2024-11-25,"Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.",101.0,387.81312,76.4022,3.94,3.96,2.51,0.005063302,-0.45089797,-0.026758478,-0.031401199,4.80274,0.20933,11.20239,2594,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1,neg,"[  101 12278   123  2604  1106  2283  2425  1105  3718  1322 21521   119
  7457  1852  1103  2686   117  9596  2772  1110  7202  1103  1263   118
  1858  4973  2025   117  2382  1379  1512   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALEC,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,2024-11-25,"Phase 2 study reached a third of target enrollment, noted November 25, 2024.",101.0,387.81312,76.4022,3.94,3.96,2.51,0.005063302,-0.45089797,-0.026758478,-0.031401199,4.80274,0.20933,11.20239,2595,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2025  1680   170  1503  1104  4010 10803   117  2382
  1379  1512   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GSK,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,2024-11-25,"Phase 2 study reached a third of target enrollment, noted November 25, 2024.",0.0,54943.92847,23.355,13.42,13.465,13.415,0.003347595,-0.000372648,-0.026758478,-0.031401199,0.0,0.07581,161.82049,2596,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2025  1680   170  1503  1104  4010 10803   117  2382
  1379  1512   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMGN,AMG 133 (maridebart cafraglutide) - (MariTide),Obesity and without diabetesÂ ,Phase 2,2024-11-26,"Phase 2 52-week data demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks, noted November 26, 2024.",538.0,150514.5378,24.4523,294.0,280.01,278.32,-0.048754451,-0.054808236,-0.023985363,-0.000614376,1.82413,0.0746,4763.06306,2597,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  3882   118  1989  2233  7160  1146  1106   199  1406
   110  1903  2841  2445  1120  1989  3882  1443   170  2841  2445 14404
   117  7713  1103  3209  1111  1748  2841  2445  2894  3882  2277   117
  2382  1379  1744   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PTCT,PTC857 - (CardinALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,2024-11-26,"Phase 2 study failed to meet primary and secondary efficacy endpoints. Due to the lack of efficacy and biomarker signal, further development is not planned at this time, noted November 26, 2024.",79.0,3548.52783,51.8645,42.99,46.01,50.29,0.067891234,0.15683872,-0.023985363,-0.000614376,6.05902,0.23631,69.56063,2598,0,0,0,0,0,1,0,0,1,0,0,0,0,2,0,-1,pos,"[  101 12278   123  2025  2604  1106  2283  2425  1105  3718 23891  1322
 21521   119  4187  1106  1103  2960  1104 23891  1105 25128  8519  1200
  4344   117  1748  1718  1110  1136  2919  1120  1142  1159   117  2382
  1379  1744   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VALN,IXCHIQ (VLA1553-303),Chikungunya vaccineÂ ,BLA Filing,2024-11-26,"BLA submitted, noted November 26, 2024.",81.0,307.20344,49.0216,4.2971,4.0,3.89,-0.071646015,-0.099531219,-0.023985363,-0.000614376,0.0,0.0,0.11678,2599,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   139 10783  7402   117  2382  1379  1744   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LTRN,LP-184 (STAR-001),Solid tumorsÂ ,Preclinical,2024-11-26,"Preclinical data, including previously published research by Lantern Pharma, demonstrate an up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone, noted November 26",10.0,33.13068,72.4146,3.13,3.072,3.19,-0.018704189,0.018987912,-0.023985363,-0.000614376,1.49148,0.06314,0.22743,2600,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233   117  1259  2331  1502  1844  1118
 23999  7642 24275   117 10541  1126  1146  1106   127   118 11203  2773
  1107 17909  2107  2765 15750  1165  6400   118 21421  1110  3490  1114
   188  8508  3484  5326 26176  1162   117  2382  1379  1744   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LXRX,Pilavapadin (LX9211) - (PROGRESS),Diabetic Peripheral Neuropathic Pain (DPNP)Â ,Phase 2b,2024-11-26,"Phase 2b enrollment completed, noted November 26, 2024.",363.0,296.49598,102.7487,0.8132,0.8202,0.7129,0.008571131,-0.131635924,-0.023985363,-0.000614376,8.6802,0.07675,2.40466,2601,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,neg,"[  101 12278   123  1830 10803  2063   117  2382  1379  1744   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OTLK,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD)Â ,Phase 3,2024-11-27,"NORSE EIGHT trial did not meet the SPA primary endpoint, noted November 27, 2024.",44.0,40.21458,160.7117,4.89,1.7,1.66,-1.056564052,-1.080374701,-0.011566636,0.000607165,14.36845,0.00329,105.86973,2602,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-1,neg,"[  101 24819  8900  2036   142 23413 18784  3443  1225  1136  2283  1103
 16625  1592  2425  1322  7587   117  2382  1379  1765   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CRVO,Neflamapimod - (RewinD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2b,2024-11-27,"Phase 2b Orphan Drug Designation granted on November 27, 2024.",9.0,75.563,101.1676,7.98,9.155,9.7,0.137361767,0.195187474,-0.011566636,0.000607165,20.2242,0.05823,5.37073,2603,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1830  2926 20695  1179 13982  4800  1891  3609  1113
  1379  1765   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Preclinical,2024-11-27,"Preclinical data reported CRC MSI-H, ASXL1 mutations were observed in 7/12 (58%) of PDCs, aligning with predicted frequency of ~55%, noted November 27, 2024.",105.0,82.34692,61.6802,1.2,1.17,1.11,-0.025317808,-0.077961541,-0.011566636,0.000607165,12.45421,0.01769,1.68917,2604,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103 15531  1658 10978  2240   118
   145   117 15278  3190  2162  1475 17157  1127  4379  1107   128   120
  1367   113  4650   110   114  1104 27802 18363   117  2393 11368  1158
  1114 10035  5625  1104   199  3731   110   117  2382  1379  1765   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
APLT,Govorestat (AT-007) - (ACTION-Galactosemia kids),GalactosemiaÂ ,CRL,2024-11-27,"CRL announced November 27, 2024.",144.0,997.17498,100.4877,10.21,8.57,1.38,-0.1750999,-2.001284133,-0.011566636,0.000607165,11.65558,0.01947,131.41225,2605,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1,neg,"[  101 15531  2162  1717  1379  1765   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,2024-12-02,"Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.",75.0,3322.54244,38.1149,44.84,48.53,43.74,0.079081565,-0.024837583,0.019563748,0.013949483,12.79469,0.08617,47.59847,2606,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2509  2233  1121   142 16450  2346  3165  2757  2103
   122  2335  2593   117   124 11629  1116   117  1105   122  8362  7235
 22750 11629   117  2382  1382   123   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,2024-12-02,"Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.",661.0,98541.38453,24.3227,1526.0,1551.5,1561.5,0.016572272,0.022996965,0.019563748,0.013949483,0.0,0.06278,166.74436,2607,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2509  2233  1121   142 16450  2346  3165  2757  2103
   122  2335  2593   117   124 11629  1116   117  1105   122  8362  7235
 22750 11629   117  2382  1382   123   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
APGE,APG808,"Healthy volunteer, asthma, COPDÂ ",Phase 1,2024-12-02,"Phase 1 PK data reported that treatment was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of bi",59.0,2625.50027,56.6364,45.15,46.14,49.07,0.021689973,0.08325757,0.019563748,0.013949483,11.63953,0.0616,52.6695,2608,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   122   153  2428  2233  2103  1115  3252  1108  1218   118
 21073  1181  1114  1544   118  1297  1104  2324  3731  1552   117  4374
  3209  1111   123   118  1106   124   118  2370 18463  1158  1105 15107
  1996  1105  8505  1107 16485  1104 16516   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SNTI,SENTI-202,Acute Myeloid Leukemia (AML)Â ,Phase 1,2024-12-02,"Phase 1 initial data reported that 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile, noted December 2,",26.0,45.88645,243.1554,2.16,10.0,6.52,1.532476871,1.104766154,0.019563748,0.013949483,1.26349,0.06642,1306.54257,2609,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1,pos,"[  101 12278   122  3288  2233  2103  1115   123  1104   124  4420  3890
 25827  2137  4366 15531  1107  1103  1148 13753  1634 17428  1107  1103
  3443  1114   170  2412  1218   118 21073  1181  9889  3429  6168   117
  2382  1382   123   117   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVCR,Tumor Treating Fields (TTFields) - (PANOVA-3),Pancreatic cancerÂ ,Phase 3,2024-12-02,"Phase 3 final data showed that study met its primary endpoint with a statistically significant improvement in overall survival for patients, noted December 2, 2024.",111.0,3229.81281,86.9563,20.04,29.85,28.65,0.398454564,0.357423167,0.019563748,0.013949483,5.23957,0.13259,364.61065,2610,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   124  1509  2233  2799  1115  2025  1899  1157  2425  1322
  7587  1114   170 11435  1193  2418  8331  1107  2905  8115  1111  4420
   117  2382  1382   123   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,2024-12-02,"Phase 2 Final data demonstrated that combination showed clear and consistent improvement across all efficacy endpoints, noted December 2, 2024.",2.0,47.36839,143.3966,0.068,0.129,0.079,0.640304699,0.149940147,0.019563748,0.013949483,0.0,0.00362,4.3785,2611,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  3788  2233  7160  1115  4612  2799  2330  1105  8080
  8331  1506  1155 23891  1322 21521   117  2382  1382   123   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SNGX,HyBryte (synthetic hypericin) - (HPN-CTCL-04),Cutaneous T-Cell LymphomaÂ ,Phase 1,2024-12-02,"Trial data reported a statistically significantly improved compared to the Valchlor treated plaques (63%, [10/16] treatment success with HyBryteâ„¢ vs. 17%, [2/12] with Valchlor, p=0.02), noted December",4.0,8.33154,218.1972,3.35,3.32,3.49,-0.008995563,0.04094139,0.019563748,0.013949483,1.83228,0.00362,0.93694,2612,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12819  2233  2103   170 11435  1193  5409  4725  3402  1106  1103
 12226  1732 10885  5165 12592  1116   113  5519   110   117   164  1275
   120  1479   166  3252  2244  1114   145  1183  2064  1616  1566 28198
   791   201  5016   119  1542   110   117   164   123   120  1367   166
  1114 12226  1732 10885   117   185   134   121   119  5507   114   117
  2382  1382   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RVMD,Daraxonrasib (RMC-6236) - (RASolute 302),Metastatic pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 1,2024-12-02,"Phase 1 data reported an objective response rate (ORR) of 36% and 27% in patients with PDAC harboring a KRAS G12X mutation and patients with PDAC harboring any RAS mutation, respectively, noted Decemb",186.0,8713.76445,42.8441,57.85,51.8,47.04,-0.110463304,-0.20685515,0.019563748,0.013949483,9.72012,0.02775,221.45795,2613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1126  7649  2593  2603   113 23066  2069
   114  1104  3164   110  1105  1765   110  1107  4420  1114 27802  8101
 12397  1158   170   148  9664  1708   144 11964  3190 17895  1105  4420
  1114 27802  8101 12397  1158  1251 26547  1708 17895   117  3569   117
  2382 13063  5521  1830   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RVMD,Elironrasib (RMC-6291),Solid TumorsÂ ,Phase 1b,2024-12-02,"Phase 1b data reported an ORR of 25%, in the cohort of RMC-6291 in combination RMC-6236, noted December 2, 2024.",186.0,8713.76445,42.8441,57.85,51.8,47.04,-0.110463304,-0.20685515,0.019563748,0.013949483,9.72012,0.02775,221.45795,2614,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  2233  2103  1126 23066  2069  1104  1512   110
   117  1107  1103  1884 13252  1204  1104   155 10044   118  5073  1580
  1475  1107  4612   155 10044   118  5073 22997   117  2382  1382   123
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RIGL,R289,Myeloid dysplastic syndrome (MDS)Â ,Phase 1/2,2024-12-02,"FDA Fast track designation granted by the FDA, noted December 2, 2024.",17.0,476.48683,93.1133,27.61,27.05,23.16,-0.020491021,-0.175751373,0.019563748,0.013949483,2.62655,0.14312,8.85255,2615,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762 13227  1854  7970  3609  1118  1103 18762   117  2382  1382
   123   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,TREMFYA (guselkumab),Pediatric Juvenile Psoriatic ArthritisÂ ,BLA Filing,2024-12-02,"BLA submission on December 2, 2024.",0.0,372700.0361,14.8042,155.01,154.8,149.6,-0.00135567,-0.035524565,0.019563748,0.013949483,0.7259,7e-05,1075.31727,2616,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   139 10783 13455  1113  1382   123   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JANX,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC)Â ,Phase 1,2024-12-02,"Phase 1a interim update achieved 100% PSA50 declines, 63% PSA90 declines, and 31% PSA99 declines, with durable responses observed at â‰¥12 weeks. Anti-tumor activity showed a 50% objective response rat",60.0,2108.63583,59.5156,45.21,40.18,61.65,-0.117948942,0.310154928,0.019563748,0.013949483,7.9757,0.01162,120.79603,2617,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101 12278   122  1161 10572 11984  3890  1620   110 12727  1592 11049
  6246  1116   117  5519   110 12727  1592 21500  6246  1116   117  1105
  1955   110 12727  1592  1580  1580  6246  1116   117  1114  3840  9739
 11317  4379  1120   248   796   203 11964  2277   119  8329   118 14601
  3246  2799   170  1851   110  7649  2593 11631   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JSPR,Briquilimab - (ETESIAN),AsthmaÂ ,Phase 1/2,2024-12-02,"Phase 1b/2a dosing initiated, noted December 2, 2024.",16.0,359.58243,71.4532,22.81,23.97,22.4,0.049604012,-0.018138077,0.019563748,0.013949483,12.92303,0.13074,8.63867,2618,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  1830   120   123  1161 18463  1158  7087   117  2382
  1382   123   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,2024-12-02,"Phase 3 DSMB recommended continuation of the study, noted December 3, 2024.",1.0,56.44569,144.6552,147.35993,166.49992,178.49991,0.122116731,0.19171,0.019563748,0.013949483,0.0,0.0,3.55561,2619,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124 18448 20660  6315 14961  1104  1103  2025   117  2382
  1382   124   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SYRE,SPY002,Inflammatory Bowel Disease (IBD)Â ,Phase 1,2024-12-02,"Phase 1 dosing initiated, noted December 2, 2024.",60.0,1623.22698,69.9338,28.43,27.65,26.81,-0.027819198,-0.058669973,0.019563748,0.013949483,13.69623,0.04064,16.31107,2620,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122 18463  1158  7087   117  2382  1382   123   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD)Â ,sNDA Filing,2024-12-03,"sNDA submitted December 3, 2024.",0.0,366825.436,14.9212,154.8,152.36,149.23,-0.01588782,-0.036645221,0.005249886,0.019214743,0.7259,7e-05,1321.63387,2621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101   188 16769  1592  7402  1382   124   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,2024-12-03,"Preclinical results reported success demonstrating age reversal, longevity, and increased healthspan, noted December 3, 2024.",32.0,144.49589,127.4635,4.25,4.88,5.58,0.138226237,0.272269793,0.005249886,0.019214743,2.20944,0.00194,2.40139,2622,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2686  2103  2244 15107  1425 27183   117
  1263 25769   117  1105  2569  2332 27894   117  2382  1382   124   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRBP,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,2024-12-03,"Fast Track Designation granted by the FDA, noted December 3, 2024.",12.0,204.00632,155.1477,17.84,16.75,16.04,-0.063044869,-0.106357525,0.005249886,0.019214743,19.71872,0.00677,5.09143,2623,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 13227  6563  4800  1891  3609  1118  1103 18762   117  2382  1382
   124   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TERN,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML)Â ,Phase 1,2024-12-03,"Phase 1 study showed a safety profile with no dose-limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts, noted December 3, 202",87.0,540.21112,81.7559,6.15,6.36,6.92,0.033576296,0.117963688,0.005249886,0.019214743,4.68187,0.08389,16.17872,2624,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  2025  2799   170  3429  6168  1114  1185 13753   118
 15816 12844  4233   117 16798  1856   118  2272  3252 19959 26728 24176
   117  1137 13753  7234  1116  1506  1210 13753 13936  7867  1891  1884
 13252  2145   117  2382  1382   124   117 17881   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ROIV,Namilumab - (RESOLVE-Lung),SarcoidosisÂ ,Phase 2,2024-12-03,"Phase 2 data did not meet its primary endpoints. Further development of namilumab for the treatment of sarcoidosis will be discontinued, as noted on December 3, 2024.",682.0,8822.7509,27.5751,12.48,12.12,12.09,-0.029270382,-0.031748698,0.005249886,0.019214743,5.95494,0.07453,62.97632,2625,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123  2233  1225  1136  2283  1157  2425  1322 21521   119
  6940  1718  1104  9468  3080  7776  6639  1111  1103  3252  1104 21718
 19878  7874 11776  1209  1129  8779   117  1112  2382  1113  1382   124
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Phase 1,2024-12-03,"Phase 1 data reported no treatment related adverse events, noted December 3, 2024.",9.0,3.0313,68.895,2.4,2.28,1.44,-0.051293294,-0.510825624,0.005249886,0.019214743,8.62585,0.03807,0.49669,2626,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1185  3252  2272 16798  1958   117  2382
  1382   124   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TRVI,Haduvio - (Human Abuse Potential trial),Abuse Potential studyÂ ,Phase 1,2024-12-03,"The phase 1 study showed statistically significant lower ""Drug Liking"" scores for clinical doses of oral nalbuphine (81mg and 162mg) compared to IV butorphanol (6mg), supporting its low abuse potentia",121.0,213.68668,63.9492,2.86,2.78,2.68,-0.028370697,-0.06500483,0.005249886,0.019214743,2.28044,0.00815,0.82804,2627,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101  1109  4065   122  2025  2799 11435  1193  2418  2211   107 13982
  5255  4419   107  7432  1111  7300 24429  1104  9619  9468  1233  7925
 21587   113  5615  1306  1403  1105 19163  1306  1403   114  3402  1106
  4191  1133  1766 20695  2728  1233   113   127  1306  1403   114   117
  4374  1157  1822  6704 18106  1465   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LTRN,LP-184,Triple Negative Breast Cancer (TNBC)Â ,Phase 1a,2024-12-03,"FDA granted Fast Track Designation on December 3, 2024.",10.0,34.40327,71.9387,3.16,3.19,3.98,0.009448889,0.230709792,0.005249886,0.019214743,1.49148,0.06456,0.17926,2628,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  3609 13227  6563  4800  1891  1113  1382   124   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ENLV,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA)Â ,Phase 1/2,2024-12-03,"Phase 1/2 treatment showed significant improvements in pain (50% reduction, p<0.0007), functionality (42%, p<0.0008), and stiffness (37%, p<0.003) at three months, with no serious adverse reactions, n",23.0,28.5864,74.6487,1.08,1.3,1.25,0.185403223,0.14618251,0.005249886,0.019214743,0.45127,0.00585,5.927,2629,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123  3252  2799  2418  8313  1107  2489   113
  1851   110  7234   117   185   133   121   119  1288  1559   114   117
 16354   113  3565   110   117   185   133   121   119  1288  1604   114
   117  1105 11111  1757   113  3413   110   117   185   133   121   119
  3135  1495   114  1120  1210  1808   117  1114  1185  3021 16798  9535
   117   183   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RXRX,REC-1245 - (DAHLIA),Solid tumorsÂ ,Phase 1,2024-12-03,"Phase 1 dosing initiated, noted December 3, 2024.",434.0,2033.68309,76.1413,7.58,7.09,7.46,-0.066827859,-0.015957785,0.005249886,0.019214743,22.5121,0.19816,82.3796,2630,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122 18463  1158  7087   117  2382  1382   124   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ELTX,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 2,2024-12-03,"Phase 2 enrollment completed, noted December 3, 2024",16.0,53.88436,107.3356,5.2,5.0,5.59,-0.039220713,0.072320662,0.005249886,0.019214743,0.5522,0.00799,0.10514,2631,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,pos,"[  101 12278   123 10803  2063   117  2382  1382   124   117 17881  1527
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TEVA,AJOVY (fremanezumab-vfrm),Episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or moreÂ ,Phase 3,2024-12-04,"Phase 3 data reported a significant reduction in monthly migraine & headaches days (MMD) vs placebo, noted December 4, 2024.",0.0,20195.74467,30.9239,17.53,17.8,17.45,0.015284758,-0.00457405,0.003691933,0.007397547,1.86774,0.04847,167.39364,2632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103   170  2418  7234  1107  7868  1940 14867
  2042   111 16320  1116  1552   113   150 18219   114  5016  1282  4043
   117  2382  1382   125   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LLY,Zepbound (tirzepatide) - (SURMOUNT-5),ObesityÂ ,Phase 3,2024-12-04,"Phase 3 data reported that participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg), noted December 4, 2024.",946.0,747214.5274,33.3494,813.33,829.84,796.03,0.02009598,-0.021500058,0.003691933,0.007397547,0.72669,0.18572,3212.38533,2633,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  6635  1606   163  8043  8346  1575
  1851   119   124 24119   113  1659   119   129  4023   114  1105  6635
  1113  1284  2758  7170  1575  3081   119   122 24119   113  1405   119
   121  4023   114   117  2382  1382   125   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AVIR,SVR12 in combination of bemnifosbuvir and ruzasvir,Hepatitis C virus (HCV)Â ,Phase 2,2024-12-04,"Phase 2 data met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12), noted December 4, 2024.",79.0,263.10243,49.3837,3.48,3.115,2.96,-0.110803142,-0.161843025,0.003691933,0.007397547,3.12156,0.2113,2.03499,2634,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1,neg,"[  101 12278   123  2233  1899  1157  2425  1322 21521  1104  3429  1105
  8505   191  9992 13791  1596  2593  1120  1367  2277  2112   118  3252
   113 21479  2069 11964   114   117  2382  1382   125   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RLMD,REL-1017 - (RELIANCE II),Major depressive disorder (MDD)Â ,Phase 3,2024-12-04,"Phase 3 pre-planned interim analysis conducted by IDMC indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance, note",33.0,19.00975,225.9606,2.77,0.63,0.4175,-1.48088278,-1.892318055,0.003691933,0.007397547,3.82226,0.11561,11.3327,2635,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  3073   118  2919 10572  3622  3303  1118 10999 10044
  4668  1115  1103 11336 20541  1563 12278   124  2025  1110   175 26555
  1105  1110  9803  1106  2283  1103  2425 23891  1322  7587  1114 11435
  7467   117  3805   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
APVO,APVO442 (PSMA x CD3),PSMA-expressing prostate tumor cellsÂ ,Preclinical,2024-12-04,"Preclinical study showed that the molecule readily localizes to solid tumors by avoiding unwanted binding to immune cells circulating in the bloodstream, noted December 4, 2024.",3.0,5.0032,189.4932,173.90017,200.0,200.2,0.139835968,0.140835468,0.003691933,0.007397547,3.9689,0.03056,1.4286,2636,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2025  2799  1115  1103 14730 12337  1469
  9534  1106  4600 24309  1118 10101 20194  7861  1106 11650  3652 25655
  1107  1103  1892 14765   117  2382  1382   125   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,2024-12-04,Phase 2b 18-month data showed statistically significant results. Participants on PrimeC throughout the study showed a 33% slower disease progression and a 58% improvement in survival rates compared to,23.0,22.15915,92.5741,1.13,1.07,0.9102,-0.054558984,-0.216308556,0.003691933,0.007397547,1.2464,0.07386,0.25808,2637,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  1830  1407   118  2370  2233  2799 11435  1193  2418
  2686   119  4539 27989 21868  1113  3460  1658  2032  1103  2025  2799
   170  3081   110 12741  3653 16147  1105   170  4650   110  8331  1107
  8115  5600  3402  1106   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CGON,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in SituÂ ,Phase 3,2024-12-05,"Phase 3 data presented at SUO showed a 74.5% CR rate at any time, a median response duration exceeding 27 months, and 97.3% PFS at 12 months with no Grade 3+ adverse events, noted December 5, 2024.",76.0,2269.65189,46.4001,35.91,33.56,28.87,-0.067680927,-0.218212815,-0.003536608,0.047576203,7.97934,0.05874,63.88804,2638,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2756  1120   156  2591  2346  2799   170  5692
   119   126   110 15531  2603  1120  1251  1159   117   170  3151  2593
  9355 18291  1765  1808   117  1105  5311   119   124   110   153 17691
  1120  1367  1808  1114  1185  6318   124   116 16798  1958   117  2382
  1382   126   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited diseaseÂ ,Approved,2024-12-05,"Approved December 5, 2024.",0.0,164612.6791,22.1913,104.8,106.18,105.68,0.013081995,0.008361888,-0.003536608,0.047576203,0.0,0.03876,394.48153,2639,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382   126   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GLUE,MRT-2359,MYC-driven solid tumorsÂ ,Phase 2,2024-12-05,"Phase 2 initial data demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients, no",61.0,542.4809,131.312,9.24,8.83,7.79,-0.045386871,-0.170701026,-0.003536608,0.047576203,18.15252,0.02003,5.45722,2640,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  3288  2233  7160   170 11169  3429  6168  1105  9271
  3001  1104   144 15735  1942  1475 18126  1606   170  1626  1552  1113
   117   128  1552  1228  3850 18463  1158  6030  1107  3777  3073  7877
  2913  4600 14601  4420   117  1185   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
HEPA,P2B001,Early-stage Parkinson's disease (PD)Â ,Phase 3,2024-12-05,"Phase 3 data reported that treatment had significantly greater effect on the UPDRS Part II (Activities of Daily Living, or ADL), Part III (Motor), and Total (Parts II and III) scores versus placebo, n",11.0,4.38376,81.8429,31.4,31.5,31.0,0.003179653,-0.012820688,-0.003536608,0.047576203,0.92466,0.0094,0.0264,2641,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  3252  1125  5409  3407  2629  1113
  1103 19753 17308  1708  4539  1563   113 21966  1104  5732  7932   117
  1137  5844  2162   114   117  4539  2684   113  8226   114   117  1105
  8653   113 16633  1563  1105  2684   114  7432  6055  1282  4043   117
   183   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
URGN,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC)Â ,Phase 3,2024-12-05,"Phase 3 data from SUO reported a 79.6% complete response rate at 3 months in patients treated with UGN-102, noted December 5, 2024.",46.0,515.25485,69.461,12.46,12.21,11.47,-0.020268225,-0.082788582,-0.003536608,0.047576203,15.26575,0.06739,5.85979,2642,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  1121   156  2591  2346  2103   170  5899   119
   127   110  2335  2593  2603  1120   124  1808  1107  4420  5165  1114
   158  2349  2249   118  9081   117  2382  1382   126   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRUS,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,Approved,2024-12-05,"Approved December 5, 2024.",75.0,3002.81705,37.8872,45.485,43.86,41.45,-0.036379858,-0.09289472,-0.003536608,0.047576203,12.79469,0.08617,23.0708,2643,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1382   126   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GMAB,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,Approved,2024-12-05,"Approved December 5, 2024.",661.0,98557.45032,24.2784,1528.5,1551.5,1488.0,0.014935343,-0.026853926,-0.003536608,0.047576203,0.0,0.06278,120.7579,2644,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1382   126   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TARA,TARA-002 - (ADVANCED-2),High-grade non-muscle invasive bladder cancer (NMIBC) patients with Bacillus Calmette-GuÃ©rin (BCG)-naÃ¯ve and BCG-unresponsive carcinoma in situ (CIS)Â ,Phase 1/2,2024-12-05,"Phase 1b/2 OLE data presented at the Annual Meeting of the SUO included a 72% six-month CR rate, 100% CR rate in BCG-unresponsive patients, and no Grade 2+ treatment-related AE. Durable responses wer",38.0,124.19123,106.3901,3.54,6.02,6.25,0.530960532,0.568454737,-0.003536608,0.047576203,13.20959,0.0748,669.83229,2645,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123   152 17516  2233  2756  1120  1103
  8451 12505  1104  1103   156  2591  2346  1529   170  5117   110  1565
   118  2370 15531  2603   117  1620   110 15531  2603  1107  3823  2349
   118  8362  4894  5674  2316  2109  4420   117  1105  1185  6318   123
   116  3252   118  2272   138  2036   119 12786  9739 11317  1195  1197
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NVS,Fabhalta - (APPULSE-PNH),Paroxysmal nocturnal hemoglobinuria (PNH)Â ,Phase 3,2024-12-06,"Phase 3b data reported that treatment improved the average hemoglobin (Hb) level versus baseline, noted December 6, 2024.",0.0,2181.20167,51.4898,7.01,7.01,6.72,0.0,-0.042249547,-0.009306198,0.041215921,0.0,0.00714,0.0,2646,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  1830  2233  2103  1115  3252  4725  1103  1903 23123
  8032  2858  7939   113   145  1830   114  1634  6055  2259  2568   117
  2382  1382   127   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BNTX,BNT324/DB-1311,Solid tumorsÂ ,Phase 1/2,2024-12-06,"Phase 1/2 data reported that the patients with SCLC with at least one post-baseline tumor assessment and who had received prior immunotherapy but no prior topoisomerase 1 inhibitor, the unconfirmed ob",239.0,29181.12261,47.3931,118.84,121.72,120.38,0.023945274,0.012875356,-0.009306198,0.041215921,1.03101,0.06375,120.80053,2647,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123  2233  2103  1115  1103  4420  1114  9314
 12674  1114  1120  1655  1141  2112   118  2259  2568 14601  8670  1105
  1150  1125  1460  2988 13280 13601 12512  4679 11478  1183  1133  1185
  2988  1499  8586 23806  6530   122 27558   117  1103  8362  7235 22750
   184  1830   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AZN,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC)Â ,Phase 3,2024-12-06,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",0.0,165170.7933,22.1786,106.18,106.54,104.68,0.003384734,-0.014227689,-0.009306198,0.041215921,0.0,0.03907,250.55129,2648,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103   170  3659  7649  2593  2603   113 23066
  2069   114  1104  3565   119   128   110   117  2382  1382   127   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,2024-12-06,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",0.0,165170.7933,22.1786,106.18,106.54,104.68,0.003384734,-0.014227689,-0.009306198,0.041215921,0.0,0.03907,250.55129,2649,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103   170  3659  7649  2593  2603   113 23066
  2069   114  1104  3565   119   128   110   117  2382  1382   127   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PFE,BHV-7000,Focal EpilepsyÂ ,Phase 1,2024-12-06,"Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so",0.0,145811.6536,21.5683,25.7,25.73,25.58,0.001166634,-0.004680196,-0.009306198,0.041215921,1.66828,0.00061,819.00461,2650,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  7160  6548  1106  2879  6328  1120  1155 24429
 17428  1443  2129  5604  1449   113   140 12412   114 16798  3154  3417
  2628  1114  1168  2848   118 20752 23897   113 15278 25866   114   117
  1216  1112  1177   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BHVN,BHV-7000,Focal EpilepsyÂ ,Phase 1,2024-12-06,"Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so",105.0,4530.27662,52.3468,43.49,44.8,38.47,0.029677113,-0.12265231,-0.009306198,0.041215921,7.73803,0.14004,32.07801,2651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  7160  6548  1106  2879  6328  1120  1155 24429
 17428  1443  2129  5604  1449   113   140 12412   114 16798  3154  3417
  2628  1114  1168  2848   118 20752 23897   113 15278 25866   114   117
  1216  1112  1177   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MNOV,Ibudilast (MN-166) - (COMBAT-ALS),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2/3,2024-12-06,"Phase 2b/3 trial update from International Symposium on ALS / MND reported positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70),",49.0,114.76822,92.3765,2.26,2.34,2.1,0.034786116,-0.073427469,-0.009306198,0.041215921,0.71717,0.10035,0.15347,2652,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830   120   124  3443 11984  1121  1570 26520  1113
 18589  1708   120   150 16769  2103  3112 18741  1116  1127  4379  1206
  1103   127   118  2370  1105  1367   118  2370  2233  1111  8784 17691
  2794   113   121   119  5729   114   117  5847  8784 17691  2794   113
   121   119  3102   114   117   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
XENE,Azetukalner (XEN1101) - (X-TOLE2),Adult Focal EpilepsyÂ ,Phase 3,2024-12-06,Phase 3 OLE long-term safety and efficacy data presented at AES showed that drug achieved 85% sustained monthly seizure reduction at 36 months and one-year seizure freedom in 33% of patients. The drug,77.0,3256.9558,34.1431,41.41,42.72,40.05,0.031144797,-0.033393724,-0.009306198,0.041215921,3.85542,0.127,15.33302,2653,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124   152 17516  1263   118  1858  3429  1105 23891  2233
  2756  1120   138  9919  2799  1115  3850  3890  4859   110  8505  7868
 20752  7234  1120  3164  1808  1105  1141   118  1214 20752  4438  1107
  3081   110  1104  4420   119  1109  3850   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RAPP,RAP-219 - (PET),Drug-resistant focal epilepsyÂ ,Phase 2a,2024-12-06,Phase 2a Pk data presented at the American Epilepsy Society Annual Meeting showed 30% reduction in long episodes associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis,36.0,748.35431,0.0,20.27,20.46,18.77,0.0093298,-0.07688211,-0.009306198,0.041215921,4.75103,0.21156,1.89044,2654,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1161   153  1377  2233  2756  1120  1103  1237   142
 24898 12685  2015  8451 12505  2799  1476   110  7234  1107  1263  3426
  2628  1114   170  1851   110  1137  3407  7234  1107  7300 20752  1116
  1107   170  2112   118 16358  1665  3622   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
STOK,Zorevunersen (STK-001),Dravet SyndromeÂ ,Phase 1/2,2024-12-06,"Phase 1/2 data presented at AES showed substantial and durable seizure reductions and cognitive and behavioral improvements. In studies, patients treated for over two years experienced an 87% median r",54.0,702.87179,63.3973,12.57,13.27,12.06,0.054192826,-0.041418831,-0.009306198,0.041215921,12.08914,0.00737,12.34731,2655,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2756  1120   138  9919  2799  6432
  1105  3840  9739 20752  7234  1116  1105 12176  1105 18560  8313   119
  1130  2527   117  4420  5165  1111  1166  1160  1201  4531  1126  5966
   110  3151   187   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALT,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,2024-12-06,"Phase 2 data presentation reported a mean weight loss of 15.6% with pemvidutide 2.4 mg at Week 48, noted December 6, 2024.",88.0,647.94533,86.5326,9.14,9.11,9.03,-0.003287674,-0.012108018,-0.009306198,0.041215921,32.10813,0.21878,30.27424,2656,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  8685  2103   170  1928  2841  2445  1104  1405
   119   127   110  1114   185  5521 18312 16065  2007   123   119   125
 17713  1120  6237  3615   117  2382  1382   127   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IPHA,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, SÃ©zary SyndromeÂ ",Phase 2,2024-12-07,"Phase 2 data presented at ASH reported a clinically significant 2-point decrease on the VAS scale to mild by Week 13 (VAS<4), in SÃ©zary Syndrome Patients, and improvement in Itch intensity from Week 5",92.0,119.96906,74.342,1.47,1.47,3.02,0.0,0.719994431,0.009119528,0.059641647,0.0,0.0,0.0,2657,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  2233  2756  1120 15278  3048  2103   170  7300  1193
  2418   123   118  1553  9711  1113  1103 19497  1708  3418  1106 10496
  1118  6237  1492   113 19497  1708   133   125   114   117  1107   100
   156  5730 12743  7195 24767   117  1105  8331  1107  1135  1732  7657
  1121  6237   126   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BEAM,BEAM-101 - (BEACON),Sickle cell diseaseÂ ,Phase 1/2,2024-12-07,"Phase 1/2 data presented at ASH reported that all seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction of >60%, noted December 7, 2024.",101.0,2125.90929,67.3565,26.71,26.71,27.93,0.0,0.044663353,0.009119528,0.059641647,15.03485,0.17503,0.0,2658,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122   120   123  2233  2756  1120 15278  3048  2103  1115
  1155  1978  4420  5165  1114   139 12420  2107   118  7393  3890 23123
  8032  2858  7939   143   113   145  1830  2271   114 18293  1104   135
  2539   110   117  2382  1382   128   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AGIO,PYRUKYND (Mitapivat) - (ENERGIZE),ThalassemiaÂ ,sNDA Filing,2024-12-08,"sNDA filing submitted on December 8, 2024.",58.0,3515.34122,41.8654,61.64,61.64,38.965,0.0,-0.458647203,0.009119528,0.059641647,7.98079,0.16471,0.0,2659,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101   188 16769  1592 16504  7402  1113  1382   129   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CCCC,Cemsidomide (CFT7455),Hematologic malignanciesÂ ,Phase 1/2,2024-12-08,"Phase 1/2 escalation data from ASH reported that across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate, and in patients with PTCL, cemsidomide achieved a 44 pe",71.0,312.0032,84.7554,4.42,4.42,4.38,0.0,-0.009090972,0.009119528,0.059641647,10.485,0.05449,0.0,2660,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122   120   123 13936  7867  1891  2233  1121 15278  3048
  2103  1115  1506  1155 13753  3001 10581   117   172 14587 12894  3080
  2007  3890   170  3383  3029 23066  2069  1105  1627  3029   140 21148
  2603   117  1105  1107  4420  1114 22216 26351   117   172 14587 12894
  3080  2007  3890   170  3140   185  1162   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IRON,DISC-0974,Myelofibrosis (MF) patients with anemiaÂ ,Phase 1b,2024-12-08,"Phase 1b data presented at ASH reported that 68% of baseline nTD patients achieved a hemoglobin increase of â‰¥1.5 g/dL during study period and 50% had sustained increases for â‰¥12 weeks, noted December",34.0,1928.89619,61.1474,64.82,64.82,64.89,0.0,0.001079331,0.009119528,0.059641647,5.52203,0.18755,0.0,2661,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122  1830  2233  2756  1120 15278  3048  2103  1115  5599
   110  1104  2259  2568   183  1942  2137  4420  3890   170 23123  8032
  2858  7939  2773  1104   248   796   203  1475   119   126   176   120
   173  2162  1219  2025  1669  1105  1851   110  1125  8505  6986  1111
   248   796   203 11964  2277   117  2382  1382   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BEAM,BEAM-103 - (ESCAPE),Sickle Cell Disease (SCD)Â ,Preclinical,2024-12-08,"Preclinical data presented at ASH reported that all NHPs achieved >40% Î³-globin, a key constituent of HbF, post-transplant, noted December 8, 2024.",101.0,2125.90929,67.3565,26.71,26.71,27.93,0.0,0.044663353,0.009119528,0.059641647,15.03485,0.17503,0.0,2662,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2756  1120 15278  3048  2103  1115
  1155 20576 17598  3890   135  1969   110   236 19763   118   176  2858
  7939   117   170  2501 17962  1104   145  1830  2271   117  2112   118
 26965   117  2382  1382   129   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
AGIO,Mitapivat - (ENERGIZE-T),Transfusion-dependent thalassemiaÂ ,Phase 3,2024-12-08,"Phase 3 data presented at ASH reported that TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm, noted December 8, 2024.",58.0,3515.34122,41.8654,61.64,61.64,38.965,0.0,-0.458647203,0.009119528,0.059641647,7.98079,0.16471,0.0,2663,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2103  1115   157  2069
  2069  1108  3890  1118  1476   119   125   110   113   183   134  3882
   120 19619   114  1104  4420  1107  1103 26410 11478 12416  1204  1981
  3402  1106  1367   119   127   110   113   183   134  1429   120  5966
   114  1104  4420  1107  1103  1282  4043  1981   117  2382  1382   129
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
COGT,Bezuclastinib - (APEX),Advanced Systemic MastocytosisÂ ,Phase 2,2024-12-08,"Phase 2 presentation due at ASH reported 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID, noted December 8, 2024.",139.0,982.00477,55.0885,8.89,8.89,8.15,0.0,-0.086909122,0.009119528,0.059641647,6.98495,0.00641,0.0,2664,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  8685  1496  1120 15278  3048  2103  3882   110 23066
  2069  1679   182  2240  2924  2349  9173   117  1259  6032   110 23066
  2069  1111  4420  4172  1620 17713   139  9949   117  2382  1382   129
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2a,2024-12-08,Phase 2a presented at ASH showed that Median Overall Survival (mOS) in the 30 mg BIW cohort for relapsed/refractory AML patients exceeds 7.7 months. Acute Myeloid Leukemia with Myelodysplasia-Related,105.0,80.23546,62.3459,1.14,1.14,0.8721,0.0,-0.267879445,0.009119528,0.059641647,12.45421,0.0168,0.0,2665,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1161  2756  1120 15278  3048  2799  1115  3957  1179
  8007 26849   113   182  9025   114  1107  1103  1476 17713   139  2240
  2924  1884 13252  1204  1111  1231 16046  5591   120  1231 27476  9363
  1183  6586  2162  4420 26553   128   119   128  1808   119   138 23987
  1422 19773  2386  3180 16140  8191  1114  1422 19773  3810 20080 22992
   118 11336  6951   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ACLX,CART-ddBCMA - (iMMagine-1),Multiple MyelomaÂ ,Phase 2,2024-12-09,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted",55.0,4485.49388,52.2535,84.55,82.95,83.42,-0.019105059,-0.013454987,0.017501464,0.045185613,8.23435,0.26116,73.51875,2666,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2233  2756  1120 15278  3048  2103  1476   119   123
   118  2370  3151 16147   118  1714  8115  1114   170  3151  2812   118
  1146  1104  3383   119   122  1808  1107  1103 12278   122  2025  1104
  1126  8383   118   172  1883   132  3151  2905  8115  1136  1680   117
  2382   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,CART-ddBCMA - (iMMagine-1),Multiple MyelomaÂ ,Phase 2,2024-12-09,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted",0.0,112899.224,25.2113,92.13,90.59,92.05,-0.016856791,-0.000868715,0.017501464,0.045185613,1.44908,0.06896,670.03671,2667,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2233  2756  1120 15278  3048  2103  1476   119   123
   118  2370  3151 16147   118  1714  8115  1114   170  3151  2812   118
  1146  1104  3383   119   122  1808  1107  1103 12278   122  2025  1104
  1126  8383   118   172  1883   132  3151  2905  8115  1136  1680   117
  2382   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MCRB,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)Â ",Phase 1b,2024-12-09,"Breakthrough Therapy designation (BTD) granted by the FDA, noted December 9, 2024.",8.0,145.99812,114.2689,16.466,17.102,17.8,0.037897767,0.077900808,0.017501464,0.045185613,9.5089,0.00771,11.91195,2668,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 15835  1582 14929 23789  7970   113 27378  2137   114  3609  1118
  1103 18762   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
OLMA,OP-3136,Breast CancerÂ ,IND-Enabling,2024-12-09,"IND granted by the FDA, noted December 9, 2024.",68.0,696.35451,67.2743,10.45,9.44,6.44,-0.101645998,-0.484073438,0.017501464,0.045185613,11.60747,0.07652,5.93886,2669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 15969  2137  3609  1118  1103 18762   117  2382  1382   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KURA,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML)Â ,Phase 1a,2024-12-09,"Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.",86.0,818.85229,75.3191,10.67,10.53,9.975,-0.013207739,-0.067354103,0.017501464,0.045185613,14.19024,0.12336,18.17982,2670,1,0,0,0,0,0,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  1161 10572  2233  2756  1120 15278  3048  2799  1620
   110 15531  2603  1107   151 14808  1475   118   182  1105  6032   110
 15531  2603  1107   148 13910  1477  1592   118   187   122  2162 16798
  3187  6586  2162  1114   128   116   124   117  2382  1382   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,KEYTRUDA (pembrolizumab) plus chemotherapy - (KEYLYNK-001),Advanced Epithelial Ovarian CancerÂ ,Phase 3,2024-12-09,"Phase 3 data reported that trial met its primary endpoint, noted December 9, 2024.",0.0,262550.8836,24.0934,103.09,103.79,100.06,0.006767234,-0.029832387,0.017501464,0.045185613,1.04058,0.12559,1988.87245,2671,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  2233  2103  1115  3443  1899  1157  2425  1322  7587
   117  2382  1382   130   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ENTA,Zelicapavir (EDP-323) - (RSVPED),Respiratory Syncytial Virus RSV-A and RSV-BÂ ,Phase 2,2024-12-09,"Phase 2 data reported an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2, noted Dece",21.0,189.47727,53.2132,8.0,8.94,6.31,0.111094048,-0.237305865,0.017501464,0.045185613,15.94146,0.03258,8.92268,2672,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1126  2848 25740  1348  2629  1111  1103
  2425  1105  3718   191  9992  6360  1322 21521  1107  1103  2905  1416
   117  1114   170 14837  6829  6246  1104   122   119   125  9366  1120
  1103  1322  1104  3252  1107  4539   123   117  2382 13063  1162   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
COGT,Bezuclastinib - (SUMMIT),Non-Advanced Systemic MastocytosisÂ ,Phase 2,2024-12-09,"Phase 2 data presented at ASH included a 56% mean improvement in Total Symptom Score (TSS) at 24 weeks, with 76% of patients achieving a â‰¥50% TSS reduction and 95% of patients with elevated serum tryp",139.0,1068.16492,56.4482,8.89,9.67,8.26,0.08410126,-0.073502462,0.017501464,0.045185613,6.98495,0.00641,62.63744,2673,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  2233  2756  1120 15278  3048  1529   170  4376   110
  1928  8331  1107  8653   156 17162  6451  4165 18417   113   157 12480
   114  1120  1572  2277   117  1114  5465   110  1104  4420 11190   170
   248   796   203 11049   110   157 12480  7234  1105  4573   110  1104
  4420  1114  8208 23651  2222  1643   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VTVT,Azeliragon combined with stereotactic radiosurgery - (RAGE),Brain metastasis from breast cancerÂ ,Phase 2,2024-12-09,"Orphan drug designation granted on December 9, 2024.",3.0,115.59474,90.2214,17.92,17.56,15.44,-0.020293819,-0.148955863,0.017501464,0.045185613,0.41306,0.00748,0.28732,2674,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  2926 20695  1179  3850  7970  3609  1113  1382   130   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VOR,Trem-cel + Mylotarg (VBP101),Acute myeloid leukemia (AML)Â ,Phase 1/2,2024-12-09,"Phase 1/2 preliminary data presented at ASH suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant, noted",6.0,71.42054,81.7449,16.392,20.8,20.4,0.238159576,0.21874149,0.017501464,0.045185613,2.25309,0.10455,3.12909,2675,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122   120   123  9889  2233  2756  1120 15278  3048  5401
  4725  1231 16046  2217   118  1714  8115  3402  1106  1502  2114  1104
 12104  1139 19773  2386  5837 16140  8191   113  6586  2162   114  4420
  1120  1344  3187  1104  1231 16046  2217  2112   118 26965   117  2382
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PRTC,LYT-200,Relapsed/refractory AML and MDSÂ ,Phase 1b,2024-12-09,"Phase 1b data reported LYT-200 demonstrates clinical benefit as a single agent, with two partial responses and 59% of evaluable patients achieving stable disease or better, and in combination, two com",24.0,413.72003,31.9295,1.66,1.728,1.7,0.040147068,0.023810649,0.017501464,0.045185613,0.0,0.04923,2.1972,2676,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830  2233  2103   149  3663  1942   118  2363 17798
  7300  5257  1112   170  1423  3677   117  1114  1160  7597 11317  1105
  4589   110  1104   174  7501  6718  2165  4420 11190  6111  3653  1137
  1618   117  1105  1107  4612   117  1160  3254   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RLMD,REL-1017 - (RELIANCE II),Major depressive disorder (MDD)Â ,Phase 3,2024-12-09,"Phase 3 study discontinued, noted December 9, 2024.",33.0,14.51379,231.3254,0.4575,0.481,0.3888,0.050090385,-0.162711812,0.017501464,0.045185613,3.82226,0.0526,1.19218,2677,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2025  8779   117  2382  1382   130   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RLMD,REL-1017 - (Relight),Major Depressive Disorder (MDD)Â ,Phase 3,2024-12-09,"Phase 3 discontinued after recent data monitoring committee (DMC), noted December 9, 2024.",33.0,14.51379,231.3254,0.4575,0.481,0.3888,0.050090385,-0.162711812,0.017501464,0.045185613,3.82226,0.0526,1.19218,2678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  8779  1170  2793  2233  9437  3914   113   141 10044
   114   117  2382  1382   130   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNDX,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,2024-12-09,"Phase 2 data presented at ASH from subgroup analyses (N=64) showed responses across all major subgroups, including heavily pretreated patients, noted December 9, 2024.",86.0,1328.16542,61.5775,17.01,15.56,13.79,-0.089097888,-0.209857715,0.017501464,0.045185613,12.4228,0.24649,40.12986,2679,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   123  2233  2756  1120 15278  3048  1121 23470 18460   113
   151   134  3324   114  2799 11317  1506  1155  1558 23470  1116   117
  1259  3777  3073  7877  2913  4420   117  2382  1382   130   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ADCT,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL)Â ,Phase 2,2024-12-09,"Additional Phase 2 data presented at ASH showed best ORR of 97% and CR rate of 77% with 12-month PFS of 95%, data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of",112.0,310.37367,112.419,3.13,3.21,2.0,0.025237933,-0.447885824,0.017501464,0.045185613,3.2728,0.05734,10.22024,2680,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101  8154 12278   123  2233  2756  1120 15278  3048  2799  1436 23066
  2069  1104  5311   110  1105 15531  2603  1104  5581   110  1114  1367
   118  2370   153 17691  1104  4573   110   117  2233  1145  2756  1120
 15278  3048  1113   163  3663 20734 11414  9159 19863 20939  1107 16404
  4834   181 25698  7903  2196 23066  2069  1104   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MGTX,AAV2-hAQP1 - (AQUAx2),XerostomiaÂ ,Phase 1,2024-12-09,"Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA, noted December 9, 2024.",80.0,506.43404,63.0226,6.14,6.48,6.28,0.053895768,0.022545238,0.017501464,0.045185613,1.91062,0.05377,1.67435,2681,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 23287 24475  5838  5734  8445 23789   113   155  8271  1942   114
  7970  3609  1118  1103 18762   117  2382  1382   130   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SONN,SON-1010 with Trabectedin - (SB101),Solid tumorsÂ ,Phase 1,2024-12-09,"Phase 1 topline data in 21 evaluable patients, 48% achieved stable disease at four months, including one partial response with a 45% tumor reduction at the MTD. SON-1010 demonstrated favorable safety,",6.0,1.65857,115.0263,2.1,1.98,1.81,-0.0588405,-0.148610499,0.017501464,0.045185613,4.20171,0.00716,98.7371,2682,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  1499  2568  2233  1107  1626   174  7501  6718  2165
  4420   117  3615   110  3890  6111  3653  1120  1300  1808   117  1259
  1141  7597  2593  1114   170  2532   110 14601  7234  1120  1103   150
  1942  2137   119   156 11414   118  7393  1568  7160 11169  3429   117
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,"DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) - (CEPHEUS)",Newly diagnosed multiple myeloma (NDMM)Â ,Phase 3,2024-12-09,"Phase 3 data reported that 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPROÂ® were progression free at 4.5 years, noted December 9, 2024.",0.0,360180.3966,14.9939,149.31,149.6,143.85,0.001940384,-0.037253592,0.017501464,0.045185613,0.7259,0.00046,1258.18133,2683,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103  1115  4859  3029  1104  4420  1150  3890
 25827  2137 24928 25524  6366   113  1275   118   127   114  1114   141
 12426  5301 12507 24654  6820 15735 21564 28181 28167  1127 16147  1714
  1120   125   119   126  1201   117  2382  1382   130   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GILD,"YESCARTA (Axicabtagene Ciloleucel), KTE-C19 and utomilumab - (ZUMA-7)",Refractory Large B-cell LymphomaÂ ,Phase 1,2024-12-09,"Phase 1 data from ASH reported that 71% overall survival rate, noted December 9, 2024.",0.0,112899.224,25.2113,92.13,90.59,92.05,-0.016856791,-0.000868715,0.017501464,0.045185613,1.44908,0.06896,670.03671,2684,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  1121 15278  3048  2103  1115  5729   110  2905
  8115  2603   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MOLN,MP0621,Acute myeloid leukemia (AML)Â ,Preclinical,2024-12-09,"Additional preclinical data presented at ASH reported that treatment demonstrated intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti",40.0,183.76253,93.5512,5.06,4.985,4.62,-0.01493308,-0.090971778,0.017501464,0.045185613,0.0,0.01896,0.04371,2685,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101  8154  3073  1665 21472  7867  2233  2756  1120 15278  3048  2103
  1115  3252  7160  3005  6978  1107   191 15435   117 11190  3646  1104
   172  2428  2875   116  3652  1229  7914  1228   118  4010  3154  1562
  1114 27410  2848   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - (AQUILA),Active multiple myelomaÂ ,Phase 3,2024-12-09,"Phase 3 data reported that overall survival was also extended with DARZALEX FASPROÂ®, with 5-year survival rates of 93 percent versus 86.9 percent for active monitoring, noted December 9, 2024.",0.0,360180.3966,14.9939,149.31,149.6,143.85,0.001940384,-0.037253592,0.017501464,0.045185613,0.7259,0.00046,1258.18133,2686,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  2905  8115  1108  1145  2925  1114
   141 12426  5301 12507 24654  6820 15735 21564 28181 28167   117  1114
   126   118  1214  8115  5600  1104  5429  3029  6055  5942   119   130
  3029  1111  2327  9437   117  2382  1382   130   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,Calquence (acalabrutinib) - (AMPLIFY),Chronic lymphocytic leukaemia (CLL)Â ,Phase 3,2024-12-09,"Phase 3 data presented at ASH reported that treatment reduced the risk of disease progression or death by 58% versus standard of care, noted December 9, 2024.",0.0,165914.9456,22.2688,106.54,107.02,105.24,0.004495231,-0.012277045,0.017501464,0.045185613,0.0,0.03907,282.50958,2687,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2103  1115  3252  3549
  1103  3187  1104  3653 16147  1137  1473  1118  4650   110  6055  2530
  1104  1920   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GMAB,EPCORE (Epcoritamab) - (EPCORE NHL-2),Non-Hodgkin lymphoma (NHL)Â ,Phase 1b,2024-12-09,Phase 1b/2 overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) w,661.0,99192.69009,24.3986,1549.0,1561.5,1442.5,0.008037336,-0.071231842,0.017501464,0.045185613,0.0,0.06831,132.89146,2688,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830   120   123  2905  2593  2603   113 23066  2069
   114  1104  5391  3029  1105  2335  2593   113 15531   114  2603  1104
  3614  3029  1107  3777  3073  7877  2913  4420  1114  1231 16046  5591
  1137  1231 27476  9363  1183   113   155   120   155   114 13306   181
 25698 13335 23894  5837 16140  8191   113   140 23955   114   192   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
REGN,Pozelimab + Cemdisiran - (ACCESS-1),Paroxysmal Nocturnal Hemoglobinuria (PNH)Â ,Phase 3,2024-12-09,"Phase 3 data reported that 96% achieved adequate LDH control (â‰¤1.5 x ULN) across study visits, noted December 9, 2024.",105.0,84780.55043,25.314,778.0,788.0,724.87,0.012771566,-0.070734196,0.017501464,0.045185613,1.6599,0.14535,809.59278,2689,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   124  2233  2103  1115  5306   110  3890 12373   149  2137
  3048  1654   113   248   796   100   119   126   193   158  2162  2249
   114  1506  2025  7508   117  2382  1382   130   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GLPG,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL)Â ,Phase 1/2,2024-12-09,"Phase 1/2 data presented at ASH reported that all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%), noted December 9, 2024.",65.0,1690.91884,33.2324,25.66,25.66,25.7,0.0,0.001557633,0.017501464,0.045185613,0.0,0.08066,2.78077,2690,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   122   120   123  2233  2756  1120 15278  3048  2103  1115
  1155   129  1104   129 23891   118   174  7501  6718  2165  4420  5133
  1106  3252   113 23066  2069  1105 15531  2069  1620   110   114   117
  2382  1382   130   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MRK,NKTR-255 with BAVENCIO (avelumab) - (JAVELIN),Locally advanced or metastatic urothelial carcinoma (UC)Â ,Phase 2,2024-12-09,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",0.0,262550.8836,24.0934,103.09,103.79,100.06,0.006767234,-0.029832387,0.017501464,0.045185613,1.04058,0.12559,1988.87245,2691,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  3443  2233  2103  1115  5766   110  1104  1103   151
  2428 23313   118 22589  3252  1372  3402  1106  1851   110  1104  1103
  1282  4043  1372  3890   170  2335  2593  1120   127  1808   117  2382
  1382   130   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NKTR,NKTR-255 with BAVENCIO (avelumab) - (JAVELIN),Locally advanced or metastatic urothelial carcinoma (UC)Â ,Phase 2,2024-12-09,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",19.0,186.30286,69.7883,15.29999,15.14999,14.99999,-0.009852303,-0.01980264,0.017501464,0.045185613,2.77922,0.13776,1.17755,2692,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  3443  2233  2103  1115  5766   110  1104  1103   151
  2428 23313   118 22589  3252  1372  3402  1106  1851   110  1104  1103
  1282  4043  1372  3890   170  2335  2593  1120   127  1808   117  2382
  1382   130   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMGN,BLINCYTO (blinatumomab) - (AALL1731),B-cell acute lymphoblastic leukemia (B-ALL)Â ,Phase 3,2024-12-09,"Phase 3 data reported that among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy, noted December 9, 2024.",538.0,149235.2099,24.6373,272.58,277.63,266.5,0.018357143,-0.022557905,0.017501464,0.045185613,1.82413,0.06513,894.65102,2693,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  1621  5833   118 18098  4420   117
   124   118  1214   141 17691  1108  5311   119   126   110  1111  4420
  5165  1114   139  2162 11607  1658  3663 18082  3402  1106  3078   119
   123   110  1111  1343  5165  1114  1178 22572  5521 20939   117  2382
  1382   130   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INCY,Retifanlimab - (POD1UM-304),Non-small cell lung cancer (NSCLC)Â ,Phase 3,2024-12-09,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.",196.0,13892.00946,34.6507,75.92,72.11,69.8,-0.051487423,-0.084046145,0.017501464,0.045185613,3.63131,0.08243,126.77839,2694,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1,neg,"[  101 12278   124  2233  2103  1115  1103  3443  1899  1157  2425  1322
  7587  1104  2905  8115   113 11570   114  1105  1155  3718  1322 21521
   117  2382  1382   130   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MGNX,Retifanlimab - (POD1UM-304),Non-small cell lung cancer (NSCLC)Â ,Phase 3,2024-12-09,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.",63.0,218.4168,83.122,3.5,3.48,3.23,-0.005730675,-0.080280831,0.017501464,0.045185613,8.11795,0.02473,1.16907,2695,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1,neg,"[  101 12278   124  2233  2103  1115  1103  3443  1899  1157  2425  1322
  7587  1104  2905  8115   113 11570   114  1105  1155  3718  1322 21521
   117  2382  1382   130   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRUS,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 1/2,2024-12-09,"Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.",75.0,2994.60141,37.979,44.65,43.74,42.8,-0.020591292,-0.042316205,0.017501464,0.045185613,12.79469,0.08466,52.85253,2696,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2103  1115   170  3659  2905  2593
  2603   113 23066  2069   114  3164   110   117  2382  1382   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GMAB,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 1/2,2024-12-09,"Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.",661.0,99192.69009,24.3986,1549.0,1561.5,1442.5,0.008037336,-0.071231842,0.017501464,0.045185613,0.0,0.06831,132.89146,2697,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  2233  2103  1115   170  3659  2905  2593
  2603   113 23066  2069   114  3164   110   117  2382  1382   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATHA,ATH-1105,Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1,2024-12-09,"Phase 1 data reported that treatment demonstrated neuroprotective activity through the MET receptor; following siRNA-mediated knockdown of MET, the neuroprotective effects of ATH-1105 on neuronal surv",3.0,24.0947,237.778,6.351,6.231,5.774,-0.019075447,-0.0952472,0.017501464,0.045185613,5.72852,0.11625,0.32516,2698,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   122  2233  2103  1115  3252  7160 24928 11955  1643 21020
 13851  3246  1194  1103 22157  1942 10814   132  1378 27466 15654   118
 22060  7466  5455  1104 22157  1942   117  1103 24928 11955  1643 21020
 13851  3154  1104 13020  3048   118  6745  1571  1113 24928 22497  1348
  8910  1964   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JAZZ,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline gliomaÂ ,NDA Filing,2024-12-09,"Pre-NDA meeting with FDA showing clinical data highlighting a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation, noted December 1",60.0,7302.91471,28.9206,122.59,120.8,125.2,-0.014709169,0.021067005,0.017501464,0.045185613,6.31056,0.08934,56.21235,2699,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689   118   151 11392  2309  1114 18762  4000  7300  2233 23201
   170  1743   110  7649  2593  2603   117  3151  2593  9355  1104  1275
   119   125  1808   117  1105  2418  7234  1104  1103  2885  8519 17895
   117  2382  1382   122   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CPIX,Acetadote (N-acetylcysteine for injection) (IV),Prevent or lessen liver injury after toxic quantities of acetaminophen.Â ,Approved,2024-12-09,"FDA approved, noted December 9, 2024.",14.0,17.41246,54.6189,1.235,1.24,2.12,0.00404041,0.540345119,0.017501464,0.045185613,0.63813,0.0109,7.78565,2700,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  4092   117  2382  1382   130   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
FATE,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,2024-12-09,"Phase 1b data presented at ASH showed that all 3 patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained B-cell depletion with favorable sa",115.0,309.79259,92.5725,2.65,2.72,2.0,0.02607224,-0.281412459,0.017501464,0.045185613,9.12148,0.06965,7.42691,2701,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  1830  2233  2756  1120 15278  3048  2799  1115  1155
   124  4420  5165  1107  1148 13753  1884 13252  1204  8318 23896  7858
 23156  1673   118  1714 15851  1105  1437  6099   117  1996   117  1105
  8505   139   118  2765  1260  7136  2116  1114 11169 21718   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMEA,BMF-500 - (COVALENT-103),Acute myeloid leukemia (AML)Â ,Phase 1,2024-12-09,"Phase 1 preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia, noted December 9, 2024.",59.0,209.822,84.0818,6.1,5.79,5.85,-0.05215648,-0.04184711,0.017501464,0.045185613,25.95969,0.01999,5.35064,2702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  9889  2233  6253   139 18586   118  2260   112   188
  3209  1112   170 11303  5838  7606  1111  4420  1114 23485  1942  1495
   182 15012  1906  1231 16046  5591  1137  1231 27476  9363  1183   113
   155   120   155   114 12104  5837 16140  8191   117  2382  1382   130
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NBTX,NBTXR3 (JNJ-1900) - (MD Anderson trial/NANORAY Pancreas),"Non-Small Cell Lung Cancer (NSCLC), Pancreatic cancerÂ ",Phase 1b,2024-12-09,"Phase 1b updated data from investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial, 23 months median Ov",47.0,146.57543,72.6976,3.0,3.0,3.49,0.0,0.151289448,0.017501464,0.045185613,0.0,0.0,1.13417,2703,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   122  1830  8054  2233  1121 17718  4803  1115  1103 11653
  1113  2528 13791  1596 13950 11646  1114   170 11169  3429  6168 13178
  1748 10540  1107   170  7091  2200  3443   117  1695  1808  3151   152
  1964   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTGX,Rusfertide - (REVIVE),Polycythemia veraÂ ,Phase 2,2024-12-09,"Phase 2 final results presented at ASH showed that 54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and impr",62.0,2413.71973,43.622,42.06,40.5,41.46,-0.037795196,-0.014368063,0.017501464,0.045185613,5.53879,0.15447,16.68381,2704,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   123  1509  2686  2756  1120 15278  3048  2799  1115  4335
   110  1104  4420  2541  1167  1190   123   119   126  1201  1104  3840
  9739 23123 10024  1665  7729   113   145  5822   114  1654   113   133
  2532   110   114   117 10558   185  8495 15581 12355  4527  1329   117
  1263   118  1858  1106  2879  6328   117  1105 24034  1197   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IRON,Bitopertin - (BEACON),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,2024-12-09,"Phase 2 data presented at ASH showed that bitopertin significantly reduced protoporphyrin IX (PPIX) at low and high doses and in both adult and adolescent populations, noted December 9, 2024.",34.0,1924.13495,60.6604,64.82,64.66,66.18,-0.002471425,0.020764105,0.017501464,0.045185613,5.52203,0.18755,15.88974,2705,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  2233  2756  1120 15278  3048  2799  1115  2113 19807
  6105  5409  3549  5250  9870  1766 22192  4854 12607   113 27660 19678
   114  1120  1822  1105  1344 24429  1105  1107  1241  4457  1105 25506
  6623   117  2382  1382   130   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IRON,Bitopertin - (HELIOS),Erythropoietic ProtoporphyriaÂ ,Phase 2,2024-12-09,"Phase 2 trial updated analysis presented at ASH showed that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics, noted December 9, 2024.",34.0,1924.13495,60.6604,64.82,64.66,66.18,-0.002471425,0.020764105,0.017501464,0.045185613,5.52203,0.18755,15.88974,2706,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   123  3443  8054  3622  2756  1120 15278  3048  2799  1115
  2113 19807  6105  3549 27660 19678  1107  1155  3073 20080 10294  6202
 23470  1116  1506 17898  1105  2259  2568  5351  5924   117  2382  1382
   130   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRSP,CTX112,Systemic lupus erythematosus (SLE)Â ,Phase 1/2,2024-12-09,"Preliminary data presented at ASH demonstrated that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol, note",90.0,4254.01739,50.3039,52.33,49.84,44.24,-0.048751946,-0.167940463,0.017501464,0.045185613,22.71793,0.16707,102.48744,2707,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1,neg,"[  101 26308  2233  2756  1120 15278  3048  7160  1115 16899  3190 14541
  1477  1144  1103  3209  1106  2194 17119  7300  5257  1114   170  1218
   118 21073  1181  3429  6168  1606   170  2530   181 25698 13040  7136
  2116 11309   117  3805   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RIGL,R289,Myeloid dysplastic syndrome (MDS)Â ,Phase 1,2024-12-09,"Phase 1 initial data presented at ASH demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients",17.0,407.96433,93.9023,25.45,23.16,19.14,-0.09428909,-0.284935357,0.017501464,0.045185613,2.62655,0.15044,6.72166,2708,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  3288  2233  2756  1120 15278  3048  7160  5300  1104
  9889  7300  3246  1107  9808  3777  3073  7877  2913   149  2069   118
  9292  1708  4420   117 24718  1658   118   157  2240   120   145  2240
   118   142 11317  3296  1107  1969   110  1104   174  7501  6718  2165
 15439  4420   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
EDIT,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (RUBY),Sickle Cell DiseaseÂ ,Phase 1/2,2024-12-09,Additional Phase 1/2 data presented at ASH was well-tolerated and continued to demonstrate a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell t,89.0,184.08226,71.2509,2.14,2.23,1.48,0.041195756,-0.368763741,0.017501464,0.045185613,19.26822,0.12166,5.49228,2709,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101  8154 12278   122   120   123  2233  2756  1120 15278  3048  1108
  1218   118 21073  1181  1105  1598  1106 10541   170  3429  6168  8080
  1114  1139 19773  6639 26304  3592 19284  1389 15851  1105 12365 13791
  2285 23123 10024  5674 22331  1596  8175  2765   189   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MGX,MGX-001,Hemophilia AÂ ,Preclinical,2024-12-09,"Preclinical data presented at ASH reported that the mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, no",37.0,156.05773,144.1682,1.85,4.17,3.105,0.812730397,0.517828076,0.017501464,0.045185613,1.18524,0.09766,266.14846,2710,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,pos,"[  101 11689  1665 21472  7867  2233  2756  1120 15278  3048  2103  1115
  1103  1928   143 23314 12738  3246  1104  1808  1492   118  1479   119
   126  1378   149 14576 18463  1158  1108  5729   110   117   128   110
   117  1105  1765   110  3402  1106  1928   143 23314 12738  3246  1104
  1808   124   118   127  1104  5465   110   117   129   110  1105  1476
   110   117  1185   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LYEL,LYL314 (IMPT-314),Large B-cell lymphomaÂ ,Phase 1/2,2024-12-09,"Phase 1/2 trial data from ASH reported an objective response rate (ORR) of 94% and a complete response (CR) rate of 71%, noted December 9, 2024.",19.0,262.94548,117.428,18.084,18.0,13.408,-0.004655812,-0.299176026,0.017501464,0.045185613,3.28733,0.03061,0.61421,2711,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  3443  2233  1121 15278  3048  2103  1126
  7649  2593  2603   113 23066  2069   114  1104  5706   110  1105   170
  2335  2593   113 15531   114  2603  1104  5729   110   117  2382  1382
   130   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ONC,Sonrotoclax (BGB-11417),Chronic lymphocytic leukemia/small lymphocytic leukemiaÂ ,Phase 1b,2024-12-09,"Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.",110.0,22075.50087,40.0044,205.62,207.62,176.33,0.009679681,-0.153672566,0.017501464,0.045185613,0.93994,0.09823,106.51778,2712,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122   120   122  1830  2233  2756  1120 15278  3048  2103
  1115  1103  4612  3890   170  4850   110  2905  2593  2603   113 23066
  2069   114   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ONC,BGB-16673-101 - (CaDAnCe-101),Relapsed or refractory (R/R) CLL/SLLÂ ,Phase 1,2024-12-09,"Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.",110.0,22075.50087,40.0044,205.62,207.62,176.33,0.009679681,-0.153672566,0.017501464,0.045185613,0.93994,0.09823,106.51778,2713,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  2233  2756  1120 15278  3048  2103  1126 23066  2069
  1104  5706   110  1120  1103  2363  1306  1403 13753   117  2382  1382
   130   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KROS,Elritercept with Ruxolitinib - (RESTORE),MyelofibrosisÂ ,Phase 2,2024-12-09,"Phase 2 data presented at ASH reported that 55.2% (n=48/87) of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted December 9, 2024.",40.0,2719.66744,51.0376,70.0,67.14,19.42,-0.04171525,-1.282191779,0.017501464,0.045185613,5.49044,0.0014,41.90738,2714,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   123  2233  2756  1120 15278  3048  2103  1115  3731   119
   123   110   113   183   134  3615   120  5966   114  1104  1103   182
 12150  1942 19598  4420  3890  1126  2905 14044 25669  8167  7874  2593
  1166  1103  1148  1572  2277  1104  3252   117  2382  1382   130   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NRIX,NX-5948,R/R Chronic Lymphocytic Leukemia (CLL)Â ,Phase 1a,2024-12-09,"Phase 1a/1b data presented at ASH reported an 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments, noted December 9, 2024.",76.0,1463.47759,66.3778,21.37,20.66,20.81,-0.033788606,-0.026554429,0.017501464,0.045185613,13.55793,0.08601,20.07047,2715,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101 12278   122  1161   120   122  1830  2233  2756  1120 15278  3048
  2103  1126  3453   119   126   110   152 24380  2109 24187 24442  1134
  2569  1106  5731   119   123   110  1107  4420  1114  1120  1655  1160
  3653 25451   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RXRX,REC-617 - (ELUCIDATE),CDK7 inhibitor; Advanced Solid TumorsÂ ,Phase 1,2024-12-09,"Phase 1 monotherapy safety and PK/PD initial data from the AACR Special Conference reported 1 cPR and 4 SD, noted December 9, 2024.",434.0,2372.15221,80.9701,8.01,8.27,7.44,0.031943748,-0.073819912,0.017501464,0.045185613,22.5121,0.19885,285.16475,2716,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 19863 20939  3429  1105   153  2428   120 27802  3288
  2233  1121  1103 10419 23554  3139  3047  2103   122   172 22861  1105
   125 19416   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
REGN,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,Phase 3,2024-12-09,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.",105.0,84780.55043,25.314,778.0,788.0,724.87,0.012771566,-0.070734196,0.017501464,0.045185613,1.6599,0.14535,809.59278,2717,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2103  1126  7649  2593
  2603   113 23066  2069   114  1104  5840   110  1105  5486   110 15531
  2603   117  2382  1382   130   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ZLAB,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,Phase 3,2024-12-09,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.",109.0,3126.24512,55.1976,27.97,28.91,26.18,0.033055049,-0.066136747,0.017501464,0.045185613,4.51928,0.02846,22.57492,2718,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2103  1126  7649  2593
  2603   113 23066  2069   114  1104  5840   110  1105  5486   110 15531
  2603   117  2382  1382   130   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OMER,Zaltenibart - (OMS906),Paroxysmal nocturnal hemoglobinuria (PNH)Â ,Phase 2,2024-12-09,"Phase 2 proof of concept results presented at ASH showed that clinical data support Phase 3 enrollment to commence in early 2025, noted December 9, 2024.",68.0,659.46827,111.5841,11.61,11.38,7.59,-0.020009367,-0.425035204,0.017501464,0.045185613,18.50758,0.01318,3.63162,2719,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  6777  1104  3400  2686  2756  1120 15278  3048  2799
  1115  7300  2233  1619 12278   124 10803  1106 25824  1107  1346 17881
  1571   117  2382  1382   130   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CRIS,CA-4948 - (Take Aim Leukemia),Acute Myeloid Leukemia / Myelodysplastic Syndromes (MDS)Â ,Phase 1/2,2024-12-09,"Phase 1/2 triplet data presented at ASH reported 10 objective responses (6 CRs, 2 CRi/CRh, and 2 MLFS) among 19 evaluable relapsed/refractory AML patients with FLT3 mutations, treated with the RP2D of",12.0,35.0532,73.7791,3.86,4.14,3.48,0.070028604,-0.10363489,0.017501464,0.045185613,1.91925,0.02959,0.41955,2720,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122   120   123  9225  1204  2233  2756  1120 15278  3048
  2103  1275  7649 11317   113   127 15531  1116   117   123 15531  1182
   120 15531  1324   117  1105   123   150 25470  1708   114  1621  1627
   174  7501  6718  2165  1231 16046  5591   120  1231 27476  9363  1183
  6586  2162  4420  1114 23485  1942  1495 17157   117  5165  1114  1103
   155  2101  1477  2137  1104   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ARTL,ART27.13 - (CAReS),Cancer-Related Anorexia and Weight LossÂ ,Phase 1,2024-12-09,"Phase 1 of CAReS, ART27.13 at one month of treatment, two-thirds of participants showed evidence the drug was impacting their weight loss with either stabilization or reversal of weight loss associate",1.0,3.74413,66.9375,7.35614,6.96,6.36,-0.055355864,-0.145506961,0.017501464,0.045185613,0.67286,0.019,0.2555,2721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1104  8784  2069  1162  1708   117 22133  1942 24458
   119  1492  1120  1141  2370  1104  3252   117  1160   118 12704  1104
  6635  2799  2554  1103  3850  1108  3772  1158  1147  2841  2445  1114
  1719 19428 15100  1137 27183  1104  2841  2445  6500   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SLN,Divesiran (SLN124) - (SANRECO),Polycythemia VeraÂ ,Phase 1,2024-12-09,"Phase 2 dosing commenced and Phase 1 data reported at ASH continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients, noted December 9, 2024.",46.0,377.24648,87.2804,8.52,7.99,6.74,-0.064225581,-0.234356416,0.017501464,0.045185613,0.80795,0.00709,5.91505,2722,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 18463  1158  8042  1105 12278   122  2233  2103  1120
 15278  3048  2760  1106  1437  6432  7234  1107   185  8495 15581 12355
  4527  5625  1105 15405  1104 23123 10024  1665  7729  3001  1107   153
  2559  4420   117  2382  1382   130   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CRBP,CRB-601,Solid tumorsÂ ,Phase 1,2024-12-09,"Phase 1 clinical study initiated, noted December 9, 2024.",12.0,185.61531,155.7959,15.26,15.24,14.28,-0.001311476,-0.066375069,0.017501464,0.045185613,19.71872,0.0061,4.59131,2723,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  7300  2025  7087   117  2382  1382   130   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NAMS,Obicetrapib - (BROADWAY),Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseÂ ,Phase 3,2024-12-10,"Phase 3 study achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction, noted Decem",112.0,2419.58599,74.293,18.52,26.19,26.61,0.346526429,0.362435856,0.013011812,0.037861702,2.80237,0.07731,251.4906,2724,1,0,1,0,0,1,0,0,0,0,0,0,3,0,0,1,pos,"[  101 12278   124  2025  3890  2425  1322  7587  1104   149  1708  1928
  7234  5016  1282  4043  1107   149  2137  2162   118   140  1113  1499
  1104 12477 23984  1193 21073  1181  4764  2386 22015  1158  1103 14543
  1905  1120  1285  5731  1114 11435  1193  2418  7234   117  2382 13063
  5521   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRVO,Neflamapimod - (RewinD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2b,2024-12-10,"Phase 2b topline data did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks, noted December 10, 2024.",9.0,17.82808,243.7278,10.25,2.16,1.94,-1.557169484,-1.664589733,0.013011812,0.037861702,23.20339,0.06014,17.95483,2725,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,neg,"[  101 12278   123  1830  1499  2568  2233  1225  1136 10541 11435  1193
  2418  3154  6055  1282  4043  1113  2425  1105  3718  1322 21521  1120
  1479  2277   117  2382  1382  1275   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
APGE,APG777 + APG333,"Healthy volunteers, Respiratory diseasesÂ ",Preclinical,2024-12-10,"Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD patients, noted December 10, 2024.",59.0,2752.96279,59.9773,49.07,48.38,48.09,-0.014161345,-0.020173595,0.013011812,0.037861702,12.93584,0.06349,58.31851,2726,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101 11689  1665 21472  7867  6777   118  1104   118  3400  3890  1111
 10997  2349  1559  1559  1559   116 10997  2349 23493  1495  4612  1114
  7300  3443  3693 14910  1107  1112  1582  1918  1105 18732 15481  4420
   117  2382  1382  1275   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OLMA,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast CancerÂ ,Phase 2,2024-12-10,"Phase 1b/2 new data presented at SABCS demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability, noted December 10, 2024",68.0,711.10779,67.0893,9.44,9.64,6.14,0.020965128,-0.430131238,0.013011812,0.037861702,13.5771,0.07652,10.71558,2727,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  1830   120   123  1207  2233  2756  1120 13411  9428
  1708  7160 10480  7300  3246   117   170  3429  6168  8080  1114 23298
 13335  1596  2646  1830  1105  1322 13335  8643  7606   117  1105 11169
  1106  2879  6328   117  2382  1382  1275   117 17881  1527   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
QNTM,Lucid-21-302 - (Lucid-MS),"Healthy Volunteers, multiple sclerosisÂ ",Phase 1,2024-12-10,"Phase 1 safety review committee recommends commencing dosing of the second cohort, noted December 10, 2024.",3.0,11.65782,173.0114,5.7,6.05,5.94,0.059592097,0.041242959,0.013011812,0.037861702,0.0,0.01565,0.01057,2728,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  3429  3189  3914 18029  1116  3254  2354  4869 18463
  1158  1104  1103  1248  1884 13252  1204   117  2382  1382  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
QURE,AMT-130,Huntington's diseaseÂ ,Phase 1/2,2024-12-10,"FDA agreed that data from ongoing Phase 1/2 studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval, no",54.0,745.77004,166.0986,7.295,15.3,16.46,0.740663646,0.813744013,0.013011812,0.037861702,6.66977,0.04128,947.50013,2729,0,0,0,0,0,1,1,1,0,0,0,0,3,0,0,1,pos,"[  101 18762  2675  1115  2233  1121  7173 12278   122   120   123  2527
  3402  1106   170  2379  1607  6298  1654  1336  2867  1112  1103  2425
  3142  1111   170   139 19840  8032  4724 24689 22491   113   139 10783
   114  1111   138 19515 11194  5894   138  8661 12316  1348   117  1185
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ACIU,ACI-24 (anti-Abeta vaccine) - (ABATE),Down syndromeÂ ,Phase 1/2,2024-12-10,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug. No cases of amyloid-related imaging abnormalities o,100.0,310.6725,57.6863,3.14,3.14,2.94,0.0,-0.065813219,0.013011812,0.037861702,1.03407,0.03243,0.18561,2730,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0,neg,"[  101 12278   122   120   123  2686  1127  2412  2914  1105  1218 21073
  1181  1107  2833  1114  5245  9318  1114  1185  3021 16798  1958  2272
  1106  1103  2025  3850   119  1302  2740  1104  1821  7777  7874   118
  2272 14377 22832  4233   184   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TAK,ACI-24 (anti-Abeta vaccine) - (ABATE),Down syndromeÂ ,Phase 1/2,2024-12-10,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug. No cases of amyloid-related imaging abnormalities o,0.0,6521432.964,18.2637,13.74,13.46,13.36,-0.020588963,-0.028046119,0.013011812,0.037861702,0.0,0.0,20.64065,2731,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0,neg,"[  101 12278   122   120   123  2686  1127  2412  2914  1105  1218 21073
  1181  1107  2833  1114  5245  9318  1114  1185  3021 16798  1958  2272
  1106  1103  2025  3850   119  1302  2740  1104  1821  7777  7874   118
  2272 14377 22832  4233   184   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INAB,INB-100,"Allogeneic hematopoietic stem cell transplantation (HSCT), leukemias undergoing haploidentical stem cell transplantationÂ ",Phase 1,2024-12-10,Phase 1b data presented at ASH continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease a,4.0,22.10739,150.4975,10.08301,9.15001,8.64001,-0.097096857,-0.154448089,0.013011812,0.037861702,1.18546,0.09661,0.35778,2732,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122  1830  2233  2756  1120 15278  3048  3430  1106 10541
  3840  9739  2335  1231 11234  1116   113 15531   114  1114  1185  1231
 16046  8830  4379  1107  1251 12104  1139 19773  2386  5837 16140  8191
   113  6586  2162   114  4420  1259  1343  1114  1344   118  3187  3653
   170   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVAX,COVID-19 vaccine (NVX-CoV2705),COVID-19-Influenza Combination (CIC) 2024-2025Â ,Phase 3,2024-12-10,"Phase 3 dosing initiated, noted December 10, 2024.",162.0,1404.8224,92.5583,9.07,8.77,9.0,-0.033635458,-0.007747687,0.013011812,0.037861702,24.83551,0.06271,21.91787,2733,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124 18463  1158  7087   117  2382  1382  1275   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATYR,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosisÂ ,Phase 3,2024-12-10,"Phase 3 DSMB recommended that the study continue without any modifications, noted December 10, 2024.",97.0,276.17052,73.3206,3.53,3.29,3.08,-0.070410306,-0.136368274,0.013011812,0.037861702,2.58966,0.0286,2.82015,2734,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124 18448 20660  6315  1115  1103  2025  2760  1443  1251
 13334   117  2382  1382  1275   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LSTA,CENDâ€1 - (CENDIFOX),Solid tumorsÂ ,Phase 1/2,2024-12-10,"Phase 1b/2a all cohorts enrollment completed December 10, 2024.",8.0,23.63165,53.2923,2.64,2.815,2.645,0.064183344,0.001892148,0.013011812,0.037861702,0.17975,0.00626,0.11427,2735,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,pos,"[  101 12278   122  1830   120   123  1161  1155  1884 13252  2145 10803
  2063  1382  1275   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SLS,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML)Â ,Phase 3,2024-12-10,"Phase 3 study reached pre-specified threshold of 60 events (Deaths) initiating the interim analysis, noted December 10, 2024.",105.0,73.19726,62.8266,1.09,1.04,0.8817,-0.046956983,-0.212081113,0.013011812,0.037861702,12.85594,0.0168,3.0295,2736,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2025  1680  3073   118  9467 11810  1104  2539  1958
   113  4735  1116   114  1107 17030  3798  1103 10572  3622   117  2382
  1382  1275   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CLNN,CNM-Au8 - (HEALEY ALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,2024-12-10,Phase 2 FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented find,9.0,39.34005,109.2077,4.75,4.93,4.36,0.03719437,-0.085672561,0.013011812,0.037861702,1.35649,0.00901,2.61272,2737,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 18762 18029  1116  1115   140 11936 24228  2509   151
  8816 10008  8009  1880  3935   113   151  2087  2162   114  2233  1121
  1157  1210 16409 10224  4902 11737 17580  1116   113 23616 17598   114
  1105  1103   145 12420 17516  3663 18589  1708 17742 12819  1106  1619
  2206  2756  1525   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMMP,Eftilagimod alpha (efti) - (TACTI-004),1L Non-small cell lung cancer (NSCLC)Â ,Phase 3,2024-12-10,"Phase 3 initiated, noted December 10, 2024.",147.0,494.78781,83.6359,2.18,2.12,2.13,-0.027908788,-0.023202897,0.013011812,0.037861702,0.0,0.0,0.23341,2738,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  7087   117  2382  1382  1275   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMNN,IMNN-001 - (OVATION 2),Ovarian cancerÂ ,Phase 2,2024-12-10,"Updated Phase 2 data reported that the hazard ratio (HR) decreased from 0.74 to 0.69, with an increase in median overall survival (OS) from 11.1 to 13 months following treatment with IMNN-001 plus sta",2.0,13.03611,207.0059,11.21739,11.72608,11.3113,0.044350168,0.008336973,0.013011812,0.037861702,5.09374,0.03493,0.61549,2739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 17451 12278   123  2233  2103  1115  1103 22699  6022   113   145
  2069   114 10558  1121   121   119  5692  1106   121   119  5691   117
  1114  1126  2773  1107  3151  2905  8115   113 11570   114  1121  1429
   119   122  1106  1492  1808  1378  3252  1114   146  2107  2249  2249
   118  3135  1475  4882   188  1777   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
STRO,Luvelta - (REFRÎ±ME-O1),Platinum-resistant ovarian cancer (PROC)Â ,Phase 2/3,2024-12-10,"Phase 2/3 trial data reported an 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose, noted December 10, 2024.",84.0,193.778,86.5136,2.81,2.35,2.09,-0.178769155,-0.296020417,0.013011812,0.037861702,2.49416,0.18237,8.53272,2740,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   120   124  3443  2233  2103  1126  2724   110  7649
  2593  2603   113 23066  2069   114  1107   174  7501  6718  2165  4420
  1120  1103   126   119   123 17713   120  4023  2547 13753   117  2382
  1382  1275   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TCRX,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignanciesÂ ,Phase 1,2024-12-10,"Phase 1 data presented at ASH reported that event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0",56.0,188.16295,78.6775,4.64,3.33,2.97,-0.331742062,-0.446152413,0.013011812,0.037861702,4.10171,0.04637,6.48532,2741,0,1,1,0,0,1,0,0,0,0,1,0,4,0,0,1,neg,"[  101 12278   122  2233  2756  1120 15278  3048  2103  1115  1856   118
  1714  8115  5473 24208  1103  3252  1981   113   145  2069   134   121
   119  1476   132   185   134   121   119  5129   114   117  1105  3252
   118  1981  4420 10209  2019  2211  9750  1104  1231 16046  2217   113
   145  2069   134   121   119  1743   132   185   134   121   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SPRB,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal HyperplasiaÂ ,Phase 2,2024-12-10,"Phase 2 topline study indicated that higher doses and twice-daily (BID) dosing might improve efficacy, showing trends toward androgen level reduction, Spruce to halt investment in tildacerfont and exp",0.0,22.17954,55.0885,40.4401,40.2751,30.33008,-0.004088455,-0.287681908,0.013011812,0.037861702,0.07427,0.02151,2.50048,2742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1499  2568  2025  4668  1115  2299 24429  1105  3059
   118  3828   113   139  9949   114 18463  1158  1547  4607 23891   117
  4000 14652  1755  1105 26767  1634  7234   117   156 21641  1106  9700
  5151  1107 27216  1810 14840 14467  2227  1105  4252  1643   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SPRB,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control)Â ,Phase 2b,2024-12-10,"Phase 2b study did not meet its primary endpoint of reducing glucocorticoid (GC) usage, with a placebo-adjusted reduction of only 0.7 mg/day. Spruce to halt investment in tildacerfont and explore stra",0.0,22.17954,55.0885,40.4401,40.2751,30.33008,-0.004088455,-0.287681908,0.013011812,0.037861702,0.07427,0.02151,2.50048,2743,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123  1830  2025  1225  1136  2283  1157  2425  1322  7587
  1104  7914   176  7535  2528 19248  2941  7874   113   144  1658   114
  7991   117  1114   170  1282  4043   118 10491  7234  1104  1178   121
   119   128 17713   120  1285   119   156 21641  1106  9700  5151  1107
 27216  1810 14840 14467  2227  1105  8664   188  4487   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SIGA,Tecovirimat - (STOMP),Human Mpox VirusÂ ,Phase 3,2024-12-10,"Phase 3 interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox, noted December 10, 2024.",71.0,461.98821,85.0479,6.94,6.47,6.09,-0.070125666,-0.130653693,0.013011812,0.037861702,5.18753,0.03109,8.57556,2744,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124 10572  3622  2196  1115 21359  2528 25740  8628  1204
  1225  1136  4607  1159  1106  8241  1988  6021  3402  1106  1282  4043
  1107  6323  1114 10496  1106  8828 24904  1563   182 26466   117  2382
  1382  1275   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALMS,izokibep,"Non-infectious, non-anterior uveitisÂ ",Phase 2/3,2024-12-10,"Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance, noted Decemeber 10, 2024. Based on these data, and previously announced g",104.0,456.47747,0.0,8.61,8.39,8.74,-0.025883798,0.014985871,0.013011812,0.037861702,4.46529,0.06304,1.48609,2745,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1,pos,"[  101 12278   123  1830   120   124  3443  1104   178  6112  2293  3962
  1643  1225  1136  2283  2425  1322  7587   132  3718  1322 21521  1145
  1225  1136  5515 11435  7467   117  2382 13063  5521 15581  1200  1275
   117 17881  1527   119  7457  1113  1292  2233   117  1105  2331  1717
   176   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMMX,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosisÂ ,Phase 1/2,2024-12-10,"Phase 1/2 data presented at ASH showed that therapy demonstrated a 94% overall response rate, a favorable safety profile, and no grade 4 cytokine release syndrome or neurotoxicity events, noted Novemb",28.0,60.24173,93.2034,2.54,2.19,2.29,-0.148262537,-0.103612263,0.013011812,0.037861702,1.711,0.14975,0.5906,2746,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   122   120   123  2233  2756  1120 15278  3048  2799  1115
  7606  7160   170  5706   110  2905  2593  2603   117   170 11169  3429
  6168   117  1105  1185  3654   125   172 25669 21420  1673  1836  9318
  1137 24928 11955  2430  8745  9041  1958   117  2382 14152  5521  1830
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
XNCR,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,2024-12-10,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",71.0,1769.84554,52.0906,25.2,25.29,25.04,0.003565066,-0.006369448,0.013011812,0.037861702,6.37487,0.15617,12.52057,2747,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2799  1115  3443  1899
  1157  2425  1322  7587  1104 16147   118  1714  8115   113   153 17691
   114  1105  2501  3718  1322 21521   117  2382  1382  1275   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVS,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,2024-12-10,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",0.0,2178.09011,51.0392,7.15,7.0,7.0,-0.021202208,-0.021202208,0.013011812,0.037861702,0.0,0.00714,0.10973,2748,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2799  1115  3443  1899
  1157  2425  1322  7587  1104 16147   118  1714  8115   113   153 17691
   114  1105  2501  3718  1322 21521   117  2382  1382  1275   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
INCY,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,2024-12-10,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",196.0,13963.29005,34.5163,72.11,72.48,69.4,0.005117931,-0.038305863,0.013011812,0.037861702,3.10726,0.08243,174.44341,2749,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1,neg,"[  101 12278   124  2233  2756  1120 15278  3048  2799  1115  3443  1899
  1157  2425  1322  7587  1104 16147   118  1714  8115   113   153 17691
   114  1105  2501  3718  1322 21521   117  2382  1382  1275   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NXTC,LNCB74,B7-H4 expressing cancersÂ ,IND-Enabling,2024-12-10,"IND cleared by the FDA, noted December 10, 2024.",2.0,31.64755,61.1252,13.92001,13.56001,10.8084,-0.026202353,-0.253003764,0.013011812,0.037861702,0.18009,0.01547,0.09451,2750,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1382  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALXO,Zanidatamab and Evorpacept (ALX148),HER2 Breast cancer and solid tumorsÂ ,Phase 1/2,2024-12-10,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w,53.0,83.3341,114.2088,1.72,1.58,1.79,-0.084899444,0.039891329,0.013011812,0.037861702,13.59677,0.09236,1.988,2751,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122  1830   120   123  2233  1106  1129  2756  1120 13411
  9428  1708  5996  1115   145  9637  1477   118  3112  4420  2133  4182
  1144  1151  3777  3073  7877  2913  1336  5257  1121  2891 24766  1107
 16485  2258   174 12198 12204  6451   112   188  3527  6978  1165  3490
   192   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ZYME,Zanidatamab and Evorpacept (ALX148),HER2 Breast cancer and solid tumorsÂ ,Phase 1/2,2024-12-10,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w,75.0,899.54049,43.6284,13.14,13.06,13.37,-0.006106889,0.017352378,0.013011812,0.037861702,6.72575,0.15698,6.85133,2752,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122  1830   120   123  2233  1106  1129  2756  1120 13411
  9428  1708  5996  1115   145  9637  1477   118  3112  4420  2133  4182
  1144  1151  3777  3073  7877  2913  1336  5257  1121  2891 24766  1107
 16485  2258   174 12198 12204  6451   112   188  3527  6978  1165  3490
   192   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMMX,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL AmyloidosisÂ ,Phase 1/2,2024-12-10,"Phase 1b/2 data reported a 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy, noted De",28.0,60.24173,93.2034,2.54,2.19,2.29,-0.148262537,-0.103612263,0.013011812,0.037861702,1.711,0.14975,0.5906,2753,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830   120   123  2233  2103   170  3453   110   113
  1367   120  1479   114  2335  2593   113 15531   114  2603  4379  1107
  2530  1104  1920   113 23612  1161   118 27688  2064  1766  2137   114
  1231 16046  5591   120  1231 27476  9363  1183 18589  6279  2858 12894
  4863  4420  1114  3151   125  2442  1104  2988  7606   117  2382  3177
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RLYB,RLYB212,Fetal and neonatal alloimmune thrombocytopenia (FNAIT)Â ,Preclinical,2024-12-10,"Preclinical data presented at ASH showed that treatment has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models, noted December 10, 2024.",41.0,49.37023,59.7402,1.16,1.19,1.03,0.025533302,-0.118861203,0.013011812,0.037861702,0.8534,0.01022,0.20601,2754,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101 11689  1665 21472  7867  2233  2756  1120 15278  3048  2799  1115
  3252  1144  1103  3209  1106  1129   170  2914  1105  3903  3843  5838
 20340  1606 10034  1664  1665 21472  7867  3584   117  2382  1382  1275
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RLYB,RLYB332,Iron overloadÂ ,Preclinical,2024-12-10,"Preclinical data presented at ASH demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on pharmacodynamic (PD) parameters, including serum",41.0,49.37023,59.7402,1.16,1.19,1.03,0.025533302,-0.118861203,0.013011812,0.037861702,0.8534,0.01022,0.20601,2755,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101 11689  1665 21472  7867  2233  2756  1120 15278  3048  7160  1115
  1423  1107  4487  7912  2285 14546  1116  1104   155  2162  3663  2064
 23493  1477  1106  1769  2200   143  1665  2069  1179 14105  1125  6099
  1105  8505  3154  1113   185  7111  1918  2528 24662   113 27802   114
 11934   117  1259 23651   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RLAY,RLY-2608 + fulvestrant + ribociclib triplet combination - (ReDiscover),"PIK3CA (PI3KÎ±) mutant tumors, including HR+/HER2- breast cancerÂ ",Phase 1,2024-12-11,"Phase 1 efficacy data shared at SABCS reported a 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D, noted December 11, 2024.",172.0,833.56713,89.2758,4.43,4.98,4.2,0.117030307,-0.053315059,0.033611347,0.079999938,7.12769,0.12209,45.13863,2756,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 23891  2233  3416  1120 13411  9428  1708  2103   170
  3614   110  3659 23066  2069  1506  1155  4420   111  5486   110  1107
  4420  1114 24779 17157  1120   155  2101  1477  2137   117  2382  1382
  1429   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PHAR,Leniolisib - (pediactric),Activated phosphoinositide 3-kinase delta syndrome (APDS)Â ,Phase 3,2024-12-11,"Phase 3 data reported improvement in lymphoproliferation and immunophenotype correction were seen across the four dose levels being investigated, noted December 11, 2024.",68.0,91.76368,48.7655,0.229,0.222,0.21,-0.031044622,-0.086614473,0.033611347,0.079999938,0.0,0.01398,0.00119,2757,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  8331  1107   181 25698  4184 13166 25052
  1891  1105 13280 13601  2728 27801 12512 16726 22590  1127  1562  1506
  1103  1300 13753  3001  1217 10788   117  2382  1382  1429   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CADL,CAN-2409 - (ULYSSES),Prostate Cancer (Active Surveillance)Â ,Phase 3,2024-12-11,Phase 2b clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance showed numerical improvement in time to radical t,54.0,251.68541,105.7908,4.61,7.75,6.53,0.519464986,0.348179086,0.033611347,0.079999938,6.71023,0.00034,780.98909,2758,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1830  7300  3443  1104 19863 20939  8784  2249   118
 11202  1580  1107 11876  4420  1114  1822   118  1106   118  9533  3187
 25813  5250 19596  4182 15819  2327 10900  2799 18294  8331  1107  1159
  1106  8276   189   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CADL,CAN-2409 (aglatimagene besadenovec) combined with Valacyclovir,Prostate cancerÂ ,Phase 2,2024-12-11,"Phase 3 results for CAN-2409 viral immunotherapy in intermediate-to-high-risk localized prostate cancer, achieved its primary endpoint of significantly improved disease-free survival (DFS) when combin",54.0,251.68541,105.7908,4.61,7.75,6.53,0.519464986,0.348179086,0.033611347,0.079999938,6.71023,0.00034,780.98909,2759,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  2686  1111  8784  2249   118 11202  1580 14837 13280
 13601 12512  4679 11478  1183  1107  9533   118  1106   118  1344   118
  3187 25813  5250 19596  4182   117  3890  1157  2425  1322  7587  1104
  5409  4725  3653   118  1714  8115   113   141 17691   114  1165 27481
  1394   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ADCT,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphomaÂ ,Phase 1b,2024-12-11,"Phase 1b data reported a clinically meaningful benefit with 94% best ORR and 72% CR rate, noted December 11, 2024.",112.0,214.65095,127.3844,3.48,2.22,1.91,-0.449525098,-0.599929052,0.033611347,0.079999938,3.11782,0.05734,12.49258,2760,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  2233  2103   170  7300  1193 17119  5257  1114
  5706   110  1436 23066  2069  1105  5117   110 15531  2603   117  2382
  1382  1429   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ARWR,ARO-CFB,Complement Mediated Kidney DiseaseÂ ,Phase 1/2,2024-12-11,"Phase 1/2a data reported dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, noted December 11, 2024.",138.0,2828.39487,63.4606,23.92,22.73,20.36,-0.051029291,-0.161142737,0.033611347,0.079999938,8.09297,0.10278,35.63609,2761,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  1161  2233  2103 13753  7449  7234  1116
  1107 25655 18802  2064  4592  1118  1146  1106  3078   110  1114  3407
  1190   124  1808  9355   117  2382  1382  1429   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CELC,Gedatolisib with Palbociclib and Letrozole,Early-Stage Breast CancerÂ ,Phase 1b,2024-12-11,"Phase 1b trial presented at SABCS showed a median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naÃ¯ve in the advanced setting was 77.3 months, while me",42.0,477.1148,48.9821,12.73,12.85,12.1,0.009382399,-0.05075596,0.033611347,0.079999938,7.73047,0.12608,2.04639,2762,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  3443  2756  1120 13411  9428  1708  2799   170
  3151  2905  8115   113 11570   114  1621  4420  1114   145  2069   116
   117   145  9637  1477   118  3682  7209  4182  1150  1127  3252   118
   100  1107  1103  3682  3545  1108  5581   119   124  1808   117  1229
  1143   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PRLD,PRT2527,Solid tumors and hematological malignanciesÂ ,Phase 1,2024-12-11,"Phase 1 data reported an overall response rate (ORR) of 17.4% (4 of 23), with complete responses (CRs) observed in 3 patients (2 DLBCL, 1 MCL) and 2 partial responses (PRs) observed, noted December 11",56.0,71.31515,130.2163,0.97,0.94,0.9063,-0.031416196,-0.067925694,0.033611347,0.079999938,4.02895,0.00055,0.89254,2763,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1126  2905  2593  2603   113 23066  2069
   114  1104  1542   119   125   110   113   125  1104  1695   114   117
  1114  2335 11317   113 15531  1116   114  4379  1107   124  4420   113
   123 26624  9428  2162   117   122 12029  2162   114  1105   123  7597
 11317   113 11629  1116   114  4379   117  2382  1382  1429   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BPTH,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemiaÂ ,Phase 1,2024-12-11,"Phase 1 study enrollment discontinued, noted December 11, 2024.",8.0,3.07943,93.1923,0.74,0.715,0.669,-0.034367644,-0.100866126,0.033611347,0.079999938,0.71743,0.03037,0.5044,2764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2025 10803  8779   117  2382  1382  1429   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATXS,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteersÂ ",Phase 1/2,2024-12-11,"Phase 1b/2 data results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, noted December 11, 2024.",56.0,592.5593,61.93,10.16,10.5,9.36,0.032916815,-0.082013152,0.033611347,0.079999938,5.57425,0.15108,8.26211,2765,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  1830   120   123  2233  2686  7160  7234  1107  1103
  1928  7868  2035  2603  1104  3078   118  4573   110  1120   127  1808
   117 11169  3429  1105  1106  2879  6328  6168   117  2382  1382  1429
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATXS,STAR-0310,Healthy volunteersÂ ,IND-Enabling,2024-12-11,"IND cleared by the FDA, noted December 10, 2024.",56.0,592.5593,61.93,10.16,10.5,9.36,0.032916815,-0.082013152,0.033611347,0.079999938,5.57425,0.15108,8.26211,2766,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 15969  2137  5323  1118  1103 18762   117  2382  1382  1275   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Preclinical,2024-12-11,"Preclinical data resulted in durable disease eradication up to 150 days post treatment in 20% of mice, noted December 11, 2024.",30.0,7.95502,98.4891,2.31,2.65,1.88,0.137312115,-0.205975748,0.033611347,0.079999938,0.68807,0.03454,0.77999,2767,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  3657  1107  3840  9739  3653  3386
 13923  1146  1106  4214  1552  2112  3252  1107  1406   110  1104 14105
   117  2382  1382  1429   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANRO,ALTO-300,Major Depressive Disorder (MDD)Â ,Preclinical,2024-12-11,"New preclinical data presented at ACNP from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection, noted December 11, 202",27.0,104.91395,188.2551,4.05,3.89,3.64,-0.040307723,-0.106733199,0.033611347,0.079999938,15.11659,0.08357,1.74258,2768,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  1203  3073  1665 21472  7867  2233  2756  1120  9690 14576  1121
   170  7936  5179  2025 17798  1103  5088  1206  1103  6978  1104 18589
 18082   118  3127  1105  1103   142 17020 25128  8519  1200  1215  1111
  5351  4557   117  2382  1382  1429   117 17881   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,CAPLYTA (Lumateperone) - (Study 501),Major depressive disorder (MDD)Â ,Phase 3,2024-12-11,"Phase 3 data reported that response rates for CAPLYTA were 45.6% vs. 24.0% for placebo (p<0.0001) and remission rates were 25.9% vs. 13.6% for placebo, noted December 11, 2024.",0.0,353053.8326,15.1378,149.23,146.64,144.75,-0.017508136,-0.030480623,0.033611347,0.079999938,0.77008,0.00046,1971.81764,2769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  2593  5600  1111  8784 27258  3663
  9159  1127  2532   119   127   110  5016   119  1572   119   121   110
  1111  1282  4043   113   185   133   121   119  1288  1475   114  1105
  1231 11234  5600  1127  1512   119   130   110  5016   119  1492   119
   127   110  1111  1282  4043   117  2382  1382  1429   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JNJ,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD)Â ,Phase 3,2024-12-11,"Phase 3 data reported response rates for CAPLYTA were 40.1% vs. 25.3% for placebo (p<0.01) and remission rates were 25.0% vs. 13.5% for placebo, noted December 11, 2024.",0.0,353053.8326,15.1378,149.23,146.64,144.75,-0.017508136,-0.030480623,0.033611347,0.079999938,0.77008,0.00046,1971.81764,2770,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  2593  5600  1111  8784 27258  3663  9159
  1127  1969   119   122   110  5016   119  1512   119   124   110  1111
  1282  4043   113   185   133   121   119  5187   114  1105  1231 11234
  5600  1127  1512   119   121   110  5016   119  1492   119   126   110
  1111  1282  4043   117  2382  1382  1429   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,2024-12-11,"Phase 2 SABCS data reported a median overall survival (OS) to date of 13.4 months, noted December 11, 2024.",1.0,58.51833,148.2792,161.99992,164.99992,92.39995,0.018349148,-0.561469404,0.033611347,0.079999938,0.0,0.0,10.13496,2771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123 13411  9428  1708  2233  2103   170  3151  2905  8115
   113 11570   114  1106  2236  1104  1492   119   125  1808   117  2382
  1382  1429   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AZN,LYNPARZA (olaparib) - (OlympiA),Early Breast CancerÂ ,Phase 3,2024-12-11,"Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.",0.0,163372.4254,22.1881,105.12,105.38,103.52,0.00247031,-0.015337724,0.033611347,0.079999938,0.0,0.03907,322.25478,2772,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  5966   119   126   110  1104  4420
  5165  1114   149  3663 14576 12426  5301  1592  1127  3534  1120  1565
   118  1201  5016   119  6032   119   123   110  1107  1103  3254 17482
  6579  1981   117  2382  1382  1429   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,LYNPARZA (olaparib) - (OlympiA),Early Breast CancerÂ ,Phase 3,2024-12-11,"Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.",0.0,252331.1556,24.2942,101.0,99.75,98.34,-0.012453461,-0.026689655,0.033611347,0.079999938,1.29616,0.12559,2155.89476,2773,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  2233  2103  1115  5966   119   126   110  1104  4420
  5165  1114   149  3663 14576 12426  5301  1592  1127  3534  1120  1565
   118  1201  5016   119  6032   119   123   110  1107  1103  3254 17482
  6579  1981   117  2382  1382  1429   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CORT,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,2024-12-11,"Phase 2 trial did not meet its primary endpoint, noted December 11, 2024.",105.0,6294.89023,41.8322,58.81,60.08,52.42,0.021365099,-0.115023711,0.033611347,0.079999938,16.27449,0.18646,32.819,2774,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123  3443  1225  1136  2283  1157  2425  1322  7587   117
  2382  1382  1429   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATOS,Z-Endoxifen - (Karisma),"Mammographic breast density (MBD), breast cancerÂ ",Phase 2,2024-12-11,"Phase 2 data showed that the 1 mg dose reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0",129.0,153.47753,57.789,1.26,1.22,0.99,-0.032260862,-0.241162057,0.033611347,0.079999938,9.22338,0.12994,1.28739,2775,0,0,1,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  2233  2799  1115  1103   122 17713 13753  3549 19443
  2137  1118  1542   119   124  6556  1827   117  1229  1103   123 17713
 13753  3890   170  7234  1104  1695   119   126  6556  1827   117  3402
  1106   170 10298  1849  1107  1103  1282  4043  1372  1104   121   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GLUE,MRT-9643,HR-positive/HER2-negative breast cancerÂ ,Preclinical,2024-12-11,"Preclinical data demonstrated that the company has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression, noted December 11, 2024.",61.0,522.82135,132.8884,9.44,8.51,7.03,-0.103714038,-0.294769274,0.033611347,0.079999938,17.99426,0.02311,12.58118,2776,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  7160  1115  1103  1419  1144  7298
  8247  6366  3402  1106  7300   118  2016  2891  2428  1477 27558  1116
  1105 10645 17351 14102  2891  2428  1477 13548 18793   117  2382  1382
  1429   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LLY,Inluriyo (imlunestrant),"ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerÂ ",Phase 3,2024-12-11,"Phase 3 data presented at SABCS significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations, noted December 11, 2024.",0.0,716770.92,33.4221,799.58,796.03,764.71,-0.004449716,-0.044589913,0.033611347,0.079999938,0.64822,0.18857,2794.76421,2777,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124  2233  2756  1120 13411  9428  1708  5409  3549  1103
  3187  1104 16147  1137  1473  1118  3383   110  3402  1106  2530  1322
 13335  8643  7606   113 27269   114  1107  4420  1114   142 16396  1475
 17157   117  2382  1382  1429   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMCR,KIMMTRAK (tebentafusp-tebn) - (ATOM),Uveal melanomaÂ ,Phase 3,2024-12-11,"Phase 3 trial initiated, noted December 11, 2024.",48.0,1539.50833,39.002,31.85,30.77,28.26,-0.034497193,-0.119590005,0.033611347,0.079999938,14.36528,0.15783,9.20014,2778,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  3443  7087   117  2382  1382  1429   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,2024-12-11,"Phase 3 subgroup results from SABCS reported that nearly half (47.1%) of crofelemer group patients were responders through 12 weeks, compared to 33.7% of those on placebo, noted December 11, 2024.",2.0,15.10179,150.3141,24.755,32.0,21.5,0.256708414,-0.140974554,0.033611347,0.079999938,4.36724,0.00605,2.82374,2779,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124 23470  2686  1121 13411  9428  1708  2103  1115  2212
  1544   113  3862   119   122   110   114  1104   172  2180  8124 14183
  1200  1372  4420  1127  6297  1468  1194  1367  2277   117  3402  1106
  3081   119   128   110  1104  1343  1113  1282  4043   117  2382  1382
  1429   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ARVN,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid TumorsÂ ,Phase 1b,2024-12-12,"Phase 1b sub-study data reported a clinical benefit rate: 62.5%; overall response rate: 26.7%, noted December 12, 2024.",73.0,1356.39656,60.0611,22.54,19.74,17.83,-0.132644475,-0.234409077,0.037510307,0.076705325,13.12746,0.05708,49.08758,2780,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  4841   118  2025  2233  2103   170  7300  5257
  2603   131  5073   119   126   110   132  2905  2593  2603   131  1744
   119   128   110   117  2382  1382  1367   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ATOS,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,2024-12-12,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000,129.0,144.67144,58.2001,1.22,1.15,0.98,-0.059088916,-0.219053566,0.037510307,0.076705325,9.22338,0.12994,1.99994,2781,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  2233  1121 13411  9428  1708  2103  1115  1851  3029
  1104  4420   113   124   120   127   114  1107  1103  1372  1115  1460
  2908 17713  1104   113   163   114   118  1322 10649 24603  1179  1114
  1301  6906 24247  1899  1103  4010  6386   118  1352 13441 14759   113
   140  3954   114  1104  2260 28198 28731   789  6087   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LLY,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,2024-12-12,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000,946.0,704453.0096,33.5028,796.03,782.35,757.54,-0.017334663,-0.049560532,0.037510307,0.076705325,0.64822,0.18857,2209.23122,2782,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  2233  1121 13411  9428  1708  2103  1115  1851  3029
  1104  4420   113   124   120   127   114  1107  1103  1372  1115  1460
  2908 17713  1104   113   163   114   118  1322 10649 24603  1179  1114
  1301  6906 24247  1899  1103  4010  6386   118  1352 13441 14759   113
   140  3954   114  1104  2260 28198 28731   789  6087   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KROS,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone lossÂ ,Phase 2,2024-12-12,"Phase 2 trial voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arm due to the unanticipated observation of pericardial effusion adverse events in the trial, noted December 12, 2024.",40.0,746.55155,191.7574,68.65,18.43,16.92,-1.315041361,-1.400524778,0.037510307,0.076705325,5.42443,0.0014,269.91985,2783,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  3443 19446 12919 18463  1158  1107  1103   124   119
   121 17713   120  4023  1105   125   119   126 17713   120  4023  3252
  1981  1496  1106  1103  8362 25711  6617 16963  1181  8310  1104  1679
  4578 16936  1348   174  3101 17268 16798  1958  1107  1103  3443   117
  2382  1382  1367   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GUTS,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D)Â ,Preclinical,2024-12-12,"Preclinical data shared at the WCIRDC was successfully delivered in large animal Yucatan pig models at a low total viral dose, noted on December 12, 2024.",50.0,106.05817,103.6705,2.28,2.205,1.82,-0.033447934,-0.225338942,0.037510307,0.076705325,4.64736,0.11025,0.81579,2784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  3416  1120  1103 16857 18172 15556
  1108  4358  4653  1107  1415  3724 10684 12650  1389 13407  3584  1120
   170  1822  1703 14837 13753   117  2382  1113  1382  1367   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TRVI,Haduvio - (CORAL),Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)Â ,Phase 2b,2024-12-12,"Phase 2b SSRE result reported that it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater, noted December 12, 2024.",121.0,276.71656,82.0595,2.49,3.6,4.15,0.368651135,0.510825624,0.037510307,0.076705325,1.83861,0.00772,229.8707,2785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1830 22916  2036  1871  2103  1115  1122  1108  6315
  1115  1103 18732  9664  2162  3443  1431  2760  1112  2919  1106  4731
  1103  3073   118  9467 21152  1540  1104  2908   110  1137  3407   117
  2382  1382  1367   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ELTX,ELI-002 (AMPLIFY-201),Solid TumorsÂ ,Phase 2,2024-12-12,"Phase 2 data presented include a 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population, noted ESMO-IO on December 12, 2024.",16.0,53.77659,109.263,5.32,4.99,5.075,-0.064037394,-0.047146778,0.037510307,0.076705325,0.55423,0.00768,0.06847,2786,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2756  1511   170  1479   119   124   118  2370
  3151  1231 10182 21629   118  1714  8115   113   182  2069 17691   114
  1105  1743   119   130   118  2370  3151  2905  8115   113   182  9025
   114  1121  1554  2025  1416   117  2382   142 16450  2346   118   146
  2346  1113  1382  1367   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANAB,ANB032 - (ARISE-AD),Atopic dermatitisÂ ,Phase 2b,2024-12-12,"Phase 2b did not meet the primary and secondary endpoints in any of the doses studied in the global, AD trial and all further investment in ANB032 will be discontinued, noted December 12, 2024.",28.0,457.0388,95.5593,15.51,15.02,15.0,-0.032102331,-0.033434776,0.037510307,0.076705325,23.33132,0.10335,12.2313,2787,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1,neg,"[  101 12278   123  1830  1225  1136  2283  1103  2425  1105  3718  1322
 21521  1107  1251  1104  1103 24429  2376  1107  1103  4265   117  5844
  3443  1105  1155  1748  5151  1107 23096  2064  1568 17101  1209  1129
  8779   117  2382  1382  1367   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
APRE,ATRN-119 - (ABOYA-119),Solid tumorsÂ ,Phase 1/2,2024-12-12,"Phase 1/2 dosing commenced, noted December 12, 2024.",5.0,19.12814,73.5815,3.6,3.5195,3.23,-0.022614911,-0.108451708,0.037510307,0.076705325,0.20208,0.02429,0.05387,2788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123 18463  1158  8042   117  2382  1382  1367
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,2024-12-12,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",256.0,119524.4941,23.1811,468.29,464.12,396.64,-0.008944623,-0.166058694,0.037510307,0.076705325,1.42556,0.29269,444.8994,2789,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   122  1830   120   123  1161  2233  2103  1115  1620   110
  1104  4420  3890  1231 11234  1439  1476  1552   117  2382  1382  1367
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,2024-12-12,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",68.0,66.19524,20.6354,7.6,7.6,7.65,0.0,0.006557401,0.037510307,0.076705325,0.0,0.00943,0.0,2790,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12278   122  1830   120   123  1161  2233  2103  1115  1620   110
  1104  4420  3890  1231 11234  1439  1476  1552   117  2382  1382  1367
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PFE,IBRANCE (palbociclib) - (PATINA),"HR+, HER2+ Metastatic Breast CancerÂ ",Phase 3,2024-12-12,Phase 3 data reported that the median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and e,0.0,143771.5372,21.7122,25.23,25.37,25.77,0.005533611,0.021177262,0.037510307,0.076705325,1.59492,0.00061,981.94818,2791,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  2103  1115  1103  3151   153 17691  1108  3140
   119   124  1808   113  4573   110   140  2240   131  2724   119   125
   118  2539   119   130   114  1111  4420  5165  1114   146 26166 14962
 10954  1107  4612  1114  2848   118   145  9637  1477  7606   113   189
  7297  7926 10337  1918  1830  1137   189  7297  7926 10337  1918  1830
  4882  1679  7926 10337  1918  1830   114  1105   174   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMMP,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,2024-12-12,"Phase 2b data presented on ESMO IO reported that the median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls, noted December 12, 2024",147.0,545.72185,84.904,2.36,2.235,2.12,-0.054420391,-0.10724553,0.037510307,0.076705325,0.0,0.0,0.74762,2792,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830  2233  2756  1113   142 16450  2346   146  2346
  2103  1115  1103  3151  2905  8115   113 11570   114  1144  1136  1870
  1151  1680  1105  1103  1367   118  2370 11570  2603  1110  5486   110
   117  1241  1218  1807  3009  7451   117  2382  1382  1367   117 17881
  1527   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ALXO,Evorpacept with zanidatamab,Metastatic breast cancerÂ ,Phase 1/2,2024-12-12,"Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.",53.0,74.89521,114.4824,1.51,1.42,1.48,-0.061452779,-0.020067563,0.037510307,0.076705325,13.59677,0.09236,3.74687,2793,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830   120   123  2233  2103 10480  2848   118 14601
  3246  1114  1126   172  9565  2069  1104  3731   119   127   110   117
  2382  1382  1367   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
JAZZ,Evorpacept with zanidatamab,Metastatic breast cancerÂ ,Phase 1/2,2024-12-12,"Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.",60.0,7472.18757,28.9427,120.72,123.6,122.85,0.023576731,0.017490285,0.037510307,0.076705325,7.03541,0.08934,92.58814,2794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830   120   123  2233  2103 10480  2848   118 14601
  3246  1114  1126   172  9565  2069  1104  3731   119   127   110   117
  2382  1382  1367   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
INTS,INT230-6 - (INVINCIBLE-2),Early stage breast cancerÂ ,Phase 2,2024-12-12,"Phase 2 results in tumors larger than 2 cm showed significant necrosis in 74% of subjects at the time of surgery, noted December 12, 2024.",47.0,31.17765,58.6207,2.35,2.0646,2.0,-0.129478825,-0.161268148,0.037510307,0.076705325,0.25611,0.02398,0.54887,2795,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2686  1107 24309  2610  1190   123  3975  2799  2418
 24928  1665 21556  1107  5692   110  1104  5174  1120  1103  1159  1104
  6059   117  2382  1382  1367   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KRYS,KB408 - (SERPENTINE-1),Alpha-1 antitrypsin deficiency (AATD)Â ,Phase 1,2024-12-12,"Phase 1 data reported a clinically meaningful proportion of conducting airway epithelial cells were transduced following administration of a single dose of KB408, with the percentage of cells positive",28.0,4987.07902,38.7015,187.12,173.4,160.83,-0.076149058,-0.151402216,0.037510307,0.076705325,12.6913,0.13277,82.89092,2796,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103   170  7300  1193 17119 10807  1104  9239
  1586  2787   174 18965 18809  2916  3652  1127 14715 20196  1378  3469
  1104   170  1423 13753  1104   148  2064 12882  1604   117  1114  1103
  6556  1104  3652  3112   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KRYS,KB407 - (CORAL-1),Cystic FibrosisÂ ,Phase 1,2024-12-12,"Phase 1 data reported that no serious adverse events have been reported, noted December 12, 2024.",28.0,4987.07902,38.7015,187.12,173.4,160.83,-0.076149058,-0.151402216,0.037510307,0.076705325,12.6913,0.13277,82.89092,2797,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   122  2233  2103  1115  1185  3021 16798  1958  1138  1151
  2103   117  2382  1382  1367   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BOLD,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplificationsÂ ,Phase 1/2,2024-12-12,"Company will not to continue dose escalation of Part 1 or to proceed into the Part 2 portion of the STARMAP trial, noted December 12, 2024.",22.0,65.78076,100.5225,3.38,2.95,2.52,-0.136070539,-0.293616808,0.037510307,0.076705325,0.81056,0.20982,0.17185,2798,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  1881  1209  1136  1106  2760 13753 13936  7867  1891  1104  4539
   122  1137  1106 10980  1154  1103  4539   123  3849  1104  1103 23676
 12426  8271  2101  3443   117  2382  1382  1367   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CORT,Korlym - (CATALYST),Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control DiabetesÂ ,Phase 3,2024-12-12,"Phase 4 trial met primary endpoint, noted December 12, 2024.",105.0,5901.45959,42.9295,60.08,56.325,51.15,-0.064538521,-0.160914515,0.037510307,0.076705325,16.27449,0.18646,60.15595,2799,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   125  3443  1899  2425  1322  7587   117  2382  1382  1367
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BCYC,Bicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2),Solid tumorsÂ ,Phase 2/3,2024-12-12,"Data presented at SABCS reported an 60% overall response rate, noted December 12, 2024.",69.0,1388.51548,58.0136,21.09,20.11,15.0,-0.047581791,-0.340748793,0.037510307,0.076705325,4.90983,0.08986,6.19173,2800,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,neg,"[  101  7154  2756  1120 13411  9428  1708  2103  1126  2539   110  2905
  2593  2603   117  2382  1382  1367   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KZIA,Paxalisib - (A071701),Brain MetastasesÂ ,Phase 2,2024-12-12,"Phase 2 data presented reported minimal clinical activity, noted December 12, 2024.",1.0,15.98272,251.1149,18.35,18.35,15.15,0.0,-0.191629043,0.037510307,0.076705325,0.511,0.00365,0.113,2801,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2756  2103 10298  7300  3246   117  2382  1382
  1367   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RPTX,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid TumorsÂ ,Phase 1,2024-12-13,"Phase 1 trial achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, noted December 13, 2024.",42.0,75.24395,133.9984,3.97,1.77,1.32,-0.807786548,-1.101134358,-0.005927198,0.031488476,1.35619,0.12353,8.31243,2802,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  3443  3890  1512   119   130   110  2905  2593  2603
   113 23066  2069   114  1107  1322  6758 19091  1348  4182  1105  3413
   119   126   110  1107 11980   118 13676   184  8997  1811  4182   117
  2382  1382  1492   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
FBIO,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC)Â ,Approved,2024-12-13,"Approved December 13, 2024.",29.0,53.55357,77.7319,1.99,1.94,1.72,-0.025446666,-0.145810348,-0.005927198,0.031488476,10.20224,0.04813,1.15238,2803,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1382  1492   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ROIV,Tapinarof Cream 1%,Atopic dermatitis (AD)Â ,Approved,2024-12-16,"Approved December 16, 2024.",682.0,8808.1919,27.5577,11.84,12.1,11.97,0.021721823,0.01091989,-0.012660417,0.016299136,6.56723,0.05566,56.03557,2804,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1479   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
OGN,Tapinarof Cream 1%,Atopic dermatitis (AD)Â ,Approved,2024-12-16,"Approved December 16, 2024.",259.0,3754.9168,35.389,15.3,14.58,14.7,-0.048202102,-0.040005335,-0.012660417,0.016299136,5.31066,0.00748,64.84884,2805,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101   138  8661 16011  1382  1479   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MNKD,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetesÂ ,Phase 3,2024-12-16,Phase 3 data reported that in the intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (,306.0,1729.12614,36.1749,6.54,6.27,7.02,-0.042160811,0.070826053,-0.012660417,0.016299136,15.12491,0.04753,31.56675,2806,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  2233  2103  1115  1107  1103  7676   118  1106   118
  7299  1416   113  9686  1942   114  1276  1115  1103  1206   118  1372
  3719  1107  1928   145  1830  1592  1475  1665  1849  1166  1744  2277
 15582  1103  3073 20080 10294  6202  1664   118 15543  1785  7464  1104
   121   119   125   110   113   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
FHTX,FHD-286,Acute myeloid leukemia (AML)Â ,Phase 1,2024-12-16,"Phase 1 dose escalation trial combination reported that objective clinical responses were observed by standard response criteria. However, the observed response rate did not meet the Company's thresho",56.0,306.31815,89.2537,5.3,5.51,4.93,0.038857803,-0.072367833,-0.012660417,0.016299136,1.59722,0.09491,3.98948,2807,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-1,neg,"[  101 12278   122 13753 13936  7867  1891  3443  4612  2103  1115  7649
  7300 11317  1127  4379  1118  2530  2593  9173   119  1438   117  1103
  4379  2593  2603  1225  1136  2283  1103  1881   112   188 24438 21298
  1186   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PRTC,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF)Â ,Phase 2b,2024-12-16,"Phase 2b topline data reported a strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, noted December 16, 2024.",24.0,407.01623,32.8292,1.628,1.7,1.564,0.043275983,-0.040105625,-0.012660417,0.016299136,0.0,0.04562,3.67089,2808,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1830  1499  2568  2233  2103   170  2012   117  8080
  1105  3840  9739 23891  1114   170  3252  2629  6055  1282  4043  1104
  2908   119   130   110  1114 11169  1106  2879  6328   117  2382  1382
  1479   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,2024-12-16,"Phase 2 data showed sustained increases in tissue frataxin (FXN) levels. Buccal cell FXN increased from 15% of healthy volunteer levels at baseline to 30% by Day 90, and skin cell FXN rose from 16% to",85.0,308.18601,87.4117,6.17,4.83,3.96,-0.24485237,-0.443454813,-0.012660417,0.016299136,6.07745,0.02265,29.44774,2809,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2799  8505  6986  1107  7918   175 15471 16594
   113 27649  2249   114  3001   119   139 21977  7867  2765 27649  2249
  2569  1121  1405   110  1104  8071  8676  3001  1120  2259  2568  1106
  1476   110  1118  2295  3078   117  1105  2241  2765 27649  2249  3152
  1121  1479   110  1106   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MNMD,"MM120 (lysergide D-tartrate, LSD) - (Voyage)",Generalized Anxiety Disorder (GAD)Â ,Phase 3,2024-12-16,"Phase 3 dosing initiated, noted December 16, 2024.",75.0,542.65451,70.9346,7.16,7.4,7.08,0.032970019,-0.011236073,-0.012660417,0.016299136,13.23767,0.0198,9.3566,2810,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   124 18463  1158  7087   117  2382  1382  1479   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNGX,HyBryte - (FLASH2),Cutaneous T-Cell LymphomaÂ ,Phase 3,2024-12-16,"Phase 3 18-week study initiated, noted December 16, 2024.",4.0,7.65422,215.3116,3.1601,3.0501,2.84,-0.035429296,-0.10679962,-0.012660417,0.016299136,1.46197,0.00504,0.32619,2811,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  1407   118  1989  2025  7087   117  2382  1382  1479
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BCAB,Mecbotamab Vedotin (BA3011),Solid TumorsÂ ,Phase 2,2024-12-16,"Phase 2 enrollment completed with a registrational trial planned for 2H 2024. Phase 2 1-year OS was 58% for mKRAS vs. 23% for wtKRAS patients with an ORR of 28.6%, active across 9 mKRAS variants, not",58.0,65.26652,99.3841,1.45,1.35,0.611,-0.071458964,-0.864221876,-0.012660417,0.016299136,8.23806,0.12155,0.8518,2812,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,neg,"[  101 12278   123 10803  2063  1114   170  9630  1348  3443  2919  1111
   123  3048 17881  1527   119 12278   123   122   118  1214 11570  1108
  4650   110  1111   182  2428  9664  1708  5016   119  1695   110  1111
   192  1204  2428  9664  1708  4420  1114  1126 23066  2069  1104  1743
   119   127   110   117  2327  1506   130   182  2428  9664  1708 10317
   117  1136   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ASND,TransCon hGH - (InsiGHTS),Turner SyndromeÂ ,Phase 2,2024-12-16,"Phase 2 topline results reported that all three TransCon hGH starting dose cohort showed a safety and tolerability profile comparable to daily somatropin, noted December 16, 2024.",60.0,8163.27255,44.1011,129.87,136.6,139.7,0.050522997,0.072963316,-0.012660417,0.016299136,6.30403,0.04809,77.7086,2813,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  1499  2568  2686  2103  1115  1155  1210 13809  1658
  1320   177  2349  3048  2547 13753  1884 13252  1204  2799   170  3429
  1105  1106  2879  6328  6168 12763  1106  3828  1177 21943 12736  1394
   117  2382  1382  1479   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
EWTX,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD)Â ,Phase 2,2024-12-16,"Phase 2 trial met its primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to dat",105.0,3095.36762,89.3328,27.62,32.69,29.98,0.168529073,0.081990345,-0.012660417,0.016299136,6.06511,0.17642,125.4298,2814,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  3443  1899  1157  2425  1322  7587  1104  7234  1107
 25655  3001  1104   172 11811 12569 24779   113   140  2428   114   117
   170 25128  8519  1200  2628  1114 23400  6484  3290   117  1107  1103
  2026 16139  9108  1348  3443  1106  5358  1204   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PEPG,PGN-EDO51 - (CONNECT2),Duchenne muscular dystrophy (DMD)Â ,Phase 2,2024-12-16,"Phase 2 trial received a clinical hold notice from the FDA regarding its IND application, noted December 16, 2024.",32.0,147.00677,96.9127,4.68,4.51,3.89,-0.037000956,-0.184888952,-0.012660417,0.016299136,2.3769,0.0878,2.11401,2815,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123  3443  1460   170  7300  2080  4430  1121  1103 18762
  4423  1157 15969  2137  4048   117  2382  1382  1479   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BHVN,BHV-1300,Healthy volunteersÂ ,Phase 1,2024-12-16,"Phase 1 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD, noted December 16, 2024.",105.0,4190.50587,54.3801,38.47,41.44,36.15,0.074367881,-0.062201768,-0.012660417,0.016299136,7.75421,0.12854,87.19594,2816,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   122  3890  1996 15405  1104  9271   146  1403  2349   117
  1114  7234  1116   135  2539   110  1107  1103  6905  4841 12734 13064
 13753  7289  1107  1103  9960  2137   117  2382  1382  1479   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BHVN,Troriluzole (BHV4157-206-RWE),Spinocerebellar AtaxiaÂ ,sNDA Filing,2024-12-16,"sNDA submitted to the FDA, noted December 16, 2024.",105.0,4190.50587,54.3801,38.47,41.44,36.15,0.074367881,-0.062201768,-0.012660417,0.016299136,7.75421,0.12854,87.19594,2817,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101   188 16769  1592  7402  1106  1103 18762   117  2382  1382  1479
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RVPH,Brilaroxazine - (RECOVER),SchizophreniaÂ ,Phase 3,2024-12-16,"Phase 3 long-term topline data from OLE demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year, the treatment generally well-tolerated with low rates of adver",68.0,79.53216,135.0134,2.61,2.3,1.64,-0.126441098,-0.464653979,-0.012660417,0.016299136,17.81521,0.0121,22.22031,2818,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1,neg,"[  101 12278   124  1263   118  1858  1499  2568  2233  1121   152 17516
  7160 11169  1263   118  1858  3429  1105 17351  4728   118 10122 23891
  8505  1166   122   118  1214   117  1103  3252  2412  1218   118 21073
  1181  1114  1822  5600  1104  8050  4121   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNY,MenQuadfi,Meningococcal diseaseÂ ,Approved,2024-12-17,"Approved December 17, 2024.",0.0,115004.5962,22.7225,45.89,48.94,48.29,0.06434783,0.050977271,0.052315789,0.029776217,0.0,0.0,328.29574,2819,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1542   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
SNY,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,2024-12-17,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.",0.0,115004.5962,22.7225,45.89,48.94,48.29,0.06434783,0.050977271,0.052315789,0.029776217,0.0,0.0,328.29574,2820,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   123  1830  1499  2568  2233  2103  1115  1103  3443  1899
  1157  2425  1322 21521   117  2382  1382  1542   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TEVA,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,2024-12-17,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.",0.0,23690.28925,45.4783,16.51,20.88,22.42,0.234825505,0.30598716,0.052315789,0.029776217,1.97495,0.05568,1207.25838,2821,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1,pos,"[  101 12278   123  1830  1499  2568  2233  2103  1115  1103  3443  1899
  1157  2425  1322 21521   117  2382  1382  1542   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,2024-12-17,"Phase 1 data presented at SABCS reported that the best response rates (response only) were, CTC: 88% (7/8), noted December 17, 2024.",99.0,6.30908,87.5461,1.17,1.07,1.08,-0.0893451,-0.080042708,0.052315789,0.029776217,1.93279,0.05666,0.30255,2822,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   122  2233  2756  1120 13411  9428  1708  2103  1115  1103
  1436  2593  5600   113  2593  1178   114  1127   117 16899  1658   131
  5385   110   113   128   120   129   114   117  2382  1382  1542   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNYA,TN-201 - (MyPeak-1),Hypertrophic cardiomyopathy (HCM)Â ,Phase 1/2,2024-12-17,"Phase 1/2 preliminary data from three patients in the first dose cohort of 3E13 vg/kg (Cohort 1) showed that TN-201 was generally well tolerated, with readily detectable vector DNA in the heart, evide",162.0,111.70093,148.4895,2.88,1.41,1.66,-0.71420059,-0.550972692,0.052315789,0.029776217,17.73342,0.14615,59.86532,2823,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122   120   123  9889  2233  1121  1210  4420  1107  1103
  1148 13753  1884 13252  1204  1104   124  2036 17668   191  1403   120
  4023   113  3291 13252  1204   122   114  2799  1115   157  2249   118
 17365  1108  2412  1218 21073  1181   117  1114 12337 11552  1895  9479
  5394  1107  1103  1762   117   174 22650   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,NDA Filing,2024-12-17,"NDA accepted December 17, 2024.",8.0,62.40397,186.7357,53.0,33.39,38.53,-0.46203546,-0.318854755,0.052315789,0.029776217,0.85092,0.03311,340.01815,2824,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   151 11392  3134  1382  1542   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMEA,Icovamenib (BMF-219) - (COVALENT-111),Type 2 DiabetesÂ ,Phase 2,2024-12-17,"Phase 2 study met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population, noted December",59.0,168.14751,83.5268,5.85,4.64,4.01,-0.231727295,-0.37765042,0.052315789,0.029776217,27.36521,0.03017,29.30849,2825,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  2025  1899  1103  2425  1322  7587   117 15959   170
 17119 11435  1193  2418  1282  4043   118 13808  1928  7234  1107   145
  1830  1592  1475  1665  1107  1103  3073 20080 10294  6202  1679 11309
  5351  1416   117  2382  1382   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMMP,IMP761,Autoimmune diseasesÂ ,Phase 1,2024-12-17,"Phase 1 safety data reported no treatment related adverse events to date, noted December 17, 2024.",147.0,494.90046,84.7712,2.08,2.13,1.95,0.023754086,-0.064538521,0.052315789,0.029776217,0.0,0.0,0.14957,2826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  3429  2233  2103  1185  3252  2272 16798  1958  1106
  2236   117  2382  1382  1542   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ACTU,Elraglusib (9-ING-41) - (Actuate-1902),Ewing Sarcoma (Pediatric)Â ,Phase 1,2024-12-17,"Phase 1 met primary endpoint of 1 year survival rate and median overall survival, noted December 17, 2024.",20.0,149.61233,0.0,8.69,7.66,7.53,-0.126160956,-0.143277897,0.052315789,0.029776217,0.19213,0.00211,2.76544,2827,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  1899  2425  1322  7587  1104   122  1214  8115  2603
  1105  3151  2905  8115   117  2382  1382  1542   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
LPCN,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopeniaÂ ",Phase 2,2024-12-17,"Fast track designation granted by the FDA, noted December 17, 2024.",5.0,27.86277,99.2465,4.99,5.21,4.8981,0.043143946,-0.018588535,0.052315789,0.029776217,1.15663,0.00238,0.42104,2828,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 13227  1854  7970  3609  1118  1103 18762   117  2382  1382  1542
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CORT,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,2024-12-17,"Phase 3 long term extension data demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, w",105.0,5777.30105,40.7396,55.43,55.14,52.17,-0.005245558,-0.060613346,0.052315789,0.029776217,16.27449,0.17925,34.06406,2829,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  1263  1858  4973  2233  7160  1115  4420  5165  1114
  1231  1742 19248  8009  2227  4531  7300  1193 17119  1105  3840  9739
  3621  2660 11006  6639 14987  8313  1105  1231  1742 19248  8009  2227
  1108  1218   118 21073  1181   117   192   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SNTI,SN301A (SENTI-301A),Hepatocellular Carcinoma (HCC)Â ,Phase 1,2024-12-17,"Phase 1 dosing commenced in mainland China, noted December 17, 2024.",26.0,23.63152,249.1353,5.11,5.15,4.17,0.00779731,-0.203283368,0.052315789,0.029776217,1.28585,0.03268,0.98138,2830,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 18463  1158  8042  1107  8684  1975   117  2382  1382
  1542   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GPCR,ACCG-2671,ObesityÂ ,Preclinical,2024-12-17,"Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans, noted December 17, 20",57.0,1802.56596,64.1041,31.0,31.48,28.25,0.015365219,-0.092893747,0.052315789,0.029776217,18.42778,0.06346,15.222,2831,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,neg,"[  101 11689  1665 21472  7867  2527  1114 18396  2349   118  1744  1559
  1475 10541 18106  4010  8164   117 17351  2841  2445   117 11169  3429
  6168  1105   153  2428  4625 17847  1104  1517   118  3828 18463  1158
  1107  3612   117  2382  1382  1542   117  1406   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,2024-12-17,"Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.",75.0,3074.01928,37.7655,42.8,44.9,42.41,0.047899692,-0.009153919,0.052315789,0.029776217,12.73779,0.08453,39.90972,2832,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123   152 17516  2942 10294  6163  4182  1884 13252  1204
 18463  1158  8042   117  2382  1382  1542   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,2024-12-17,"Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.",661.0,90680.47717,24.7021,1442.5,1427.5,1485.0,-0.010453057,0.029037053,0.052315789,0.029776217,0.0,0.12409,201.67292,2833,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123   152 17516  2942 10294  6163  4182  1884 13252  1204
 18463  1158  8042   117  2382  1382  1542   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMMX,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosisÂ ,Phase 1/2,2024-12-17,"Phase 1/2 data published at the JCO demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients, noted December 17,",28.0,62.99249,97.0471,1.95,2.29,2.18,0.160722445,0.111495504,0.052315789,0.029776217,1.711,0.13798,0.67116,2834,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122   120   123  2233  1502  1120  1103   147 15678  7160
 18397  7300  3246   117  6099  1105  1996  2335 11317  1107   175 12797
  1105 13676  1231 16046  5591   120  1231 27476  9363  1183 18589  6279
  2858 12894  4863  4420   117  2382  1382  1542   117   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CTNM,PIPE-791,Osteoarthritis and low back painÂ ,Phase 1b,2024-12-17,"Phase 1b commenced, noted December 17, 2024",28.0,362.43577,77.5106,13.66,14.06,14.41,0.028862032,0.053450556,0.052315789,0.029776217,4.02621,0.26052,2.34578,2835,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830  8042   117  2382  1382  1542   117 17881  1527
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
TLSA,Foralumab (Intranasal),Alzheimerâ€™s DiseaseÂ ,Phase 1,2024-12-17,"Phase 1 dosing commenced, noted December 17, 2024.",111.0,107.97323,101.8759,0.9294,0.9898,0.69,0.062963686,-0.297847619,0.052315789,0.029776217,0.19078,0.03705,0.9153,2836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122 18463  1158  8042   117  2382  1382  1542   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MTVA,Vanoglipel (DA-1241),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,2024-12-18,"Phase 2a data reported that DA-1241 (100mg) demonstrated a statistically significant reduction in alanine transaminase (ALT) levels at weeks 4 and 8, with a near statistically significant reduction at",24.0,15.93962,75.2021,2.2486,1.85,1.62,-0.195122161,-0.327881651,0.051855435,0.0279806,0.25298,0.04808,9.03345,2837,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,neg,"[  101 12278   123  1161  2233  2103  1115   141  1592   118 13743  1475
   113  1620  1306  1403   114  7160   170 11435  1193  2418  7234  1107
  2393  7192  1673 14715 11787 13146  1162   113 18589  1942   114  3001
  1120  2277   125  1105   129   117  1114   170  1485 11435  1193  2418
  7234  1120   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CGTX,Zervimesine (CT1812) - (SHIMMER),Dementia with Lewy Bodies (DLB)Â ,Phase 2,2024-12-18,"Phase 2 trial met its primary endpoint, noted December 18, 2024.",73.0,24.09784,134.9202,0.4549,0.58,0.648,0.242950489,0.353813082,0.051855435,0.0279806,6.45953,0.14382,167.85629,2838,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  3443  1899  1157  2425  1322  7587   117  2382  1382
  1407   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CRVS,Soquelitinib - (CPI-818),Moderate to severe atopic dermatitisÂ ,Phase 1,2024-12-18,"Phase 1 data reported that the soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soqueliti",74.0,302.00908,105.1457,7.39,4.7,4.9,-0.452565226,-0.41089253,0.051855435,0.0279806,5.46919,0.03344,66.15086,2839,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  2103  1115  1103  1177 15966 17030  2605  1830
  1928 23616 13882  2794  7234  1108  3731   119   130   110  1120  1743
  1552   113   183   134  1367   114  3402  1106  1928 23616 13882  7234
  1104  1765   119   121   110  1107  1282  4043   119  1335  1285  4650
   117  1598  8331  1107  1103  1177 15966 17030   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
QNRX,QRX003 - (open label),Netherton Syndrome (NS)Â ,Phase 1,2024-12-18,"Phase 1 data from the first subject being dosed twice daily is suggestive of clinical efficacy across a number of measured endpoints after six weeks of dosing with QRX003, which is the midpoint of tes",0.0,2.84046,125.1756,21.09102,19.68752,16.97852,-0.068862425,-0.216898342,0.051855435,0.0279806,1.88423,0.00108,3.29396,2840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  1121  1103  1148  2548  1217 13753  1181  3059
  3828  1110  5996  2109  1104  7300 23891  1506   170  1295  1104  7140
  1322 21521  1170  1565  2277  1104 18463  1158  1114   154  2069  3190
  7629  1495   117  1134  1110  1103  2286  7587  1104 21359  1116   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CHRS,Casdozokitug/toripalimab/bevacizumab,Unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)Â ,Phase 2,2024-12-18,"Phase 2 data reported an objective response rate of 25.3% versus 6.1% in the sorafenib group, a median progression-free survival of 5.8 months, and a median overall survival of 20 months, compared to",116.0,180.88505,108.2226,1.71,1.57,1.47,-0.085417751,-0.15123097,0.051855435,0.0279806,26.66106,0.03588,4.95966,2841,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  2233  2103  1126  7649  2593  2603  1104  1512   119
   124   110  6055   127   119   122   110  1107  1103  1177  1611 13488
 13292  1372   117   170  3151 16147   118  1714  8115  1104   126   119
   129  1808   117  1105   170  3151  2905  8115  1104  1406  1808   117
  3402  1106   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KRYS,KB707 - (KYANITE-1),Solid TumorsÂ ,Phase 1,2024-12-18,"Phase 1 initial data reported an objective response rate (ORR) of 27% and disease control rate (DCR) of 73%, noted December 18, 2024.",28.0,4505.05224,40.7633,169.04,156.64,158.52,-0.076185195,-0.064254605,0.051855435,0.0279806,12.6913,0.13239,56.33432,2842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  3288  2233  2103  1126  7649  2593  2603   113 23066
  2069   114  1104  1765   110  1105  3653  1654  2603   113  5227  2069
   114  1104  5766   110   117  2382  1382  1407   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
VSTM,VS-6766 and LUMAKRAS (Sotorasib) - (RAMP 203),KRAS mutant non-small cell lung cancer (NSCLC)Â ,Phase 1/2,2024-12-18,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.",61.0,189.5978,96.1601,4.6,4.26,3.9,-0.076787143,-0.16507975,0.051855435,0.0279806,4.50276,0.06004,3.36849,2843,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   122   120   123  2233  2103  1185 13753   118 15816 12844
  4233   113 26624  1942  1116   114  1138  1151  4379  1107  1103  9225
  1204  4612   117  2382  1382  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AMGN,VS-6766 and LUMAKRAS (Sotorasib) - (RAMP 203),KRAS mutant non-small cell lung cancer (NSCLC)Â ,Phase 1/2,2024-12-18,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.",538.0,139102.7181,24.7606,265.95,258.78,264.49,-0.027330041,-0.005504878,0.051855435,0.0279806,2.07196,0.0614,1059.3356,2844,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   122   120   123  2233  2103  1185 13753   118 15816 12844
  4233   113 26624  1942  1116   114  1138  1151  4379  1107  1103  9225
  1204  4612   117  2382  1382  1407   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
SVRA,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP)Â ,BLA Filing,2024-12-18,"Rolling BLA submission initiated December 18, 2024.",172.0,632.57157,62.2921,3.22,3.02,3.2,-0.064124528,-0.00623055,0.051855435,0.0279806,5.75939,0.14685,2.0937,2845,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101  8782   139 10783 13455  7087  1382  1407   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NBIX,"CRENESSITY (Crinecerfont) - (CAHtalyst, capsule formulation)",Congenital Adrenal Hyperplasia (CAH)Â ,Approved,2024-12-19,"Approved December 19, 2024.",99.0,13664.28311,40.2637,135.45,134.96,139.03,-0.00362413,0.026087169,-0.014900116,-0.029797363,3.86086,0.05753,132.69416,2846,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1627   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PRTA,Prasinezumab (PRX002) - (PADOVA),Parkinson's diseaseÂ ,Phase 2b,2024-12-19,"Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.",53.0,861.4778,79.7432,11.95,16.01,15.74,0.292482249,0.275473965,-0.014900116,-0.029797363,14.97397,0.06127,52.55444,2847,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,pos,"[  101 12278   123  1830  3443  2604  1106  2283  1157  2425  1322  7587
   117  2382  1382  1627   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MESO,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",Approved,2024-12-19,"Approved December 19, 2024.",128.0,3480.78569,86.4962,12.25,16.76,18.29,0.313469158,0.400828525,-0.014900116,-0.029797363,0.0,0.0,66.81972,2848,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1627   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PLUR,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",Approved,2024-12-19,"Approved December 19, 2024.",8.0,24.45106,71.0927,4.2,4.4,4.6,0.046520016,0.090971778,-0.014900116,-0.029797363,0.15375,0.00591,0.1552,2849,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1627   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VRTX,Suzetrigine,Painful Lumbosacral RadiculopathyÂ ,Phase 2,2024-12-19,"Phase 2 trial met its primary endpoint, noted December 19, 2024.",256.0,102146.4176,29.2005,447.5,396.64,410.65,-0.120647469,-0.085935268,-0.014900116,-0.029797363,1.42556,0.30722,3255.90551,2850,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   123  3443  1899  1157  2425  1322  7587   117  2382  1382
  1627   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRK,Doravirine/Islatravir (DOR/ISL) - (MK-8591A-051),HIV-1 InfectionÂ ,Phase 3,2024-12-19,Phase 3 trial topline srudy demonstrated non-inferiority of DOR/ISL to baseline antiretroviral therapy (bART) andbictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppress,0.0,251749.3394,24.5045,98.34,99.52,99.87,0.011927767,0.015438478,-0.014900116,-0.029797363,1.29616,0.12425,1205.26443,2851,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124  3443  1499  2568   188 25980  1183  7160  1664   118
 15543  1785  1104   141  9565   120 19432  2162  1106  2259  2568  2848
  8127 12316  5132  1233  7606   113   171 12426  1942   114  1105 15421
  1566 14867 25740   120  9712 11048  5168 16405   120  1995 10008  3292
  3161  2393  9823  7076  3080  2007   113   139  9741   120   143  9481
   120   157 12303   114  1107   191  9992  7810  1193 17203   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,2024-12-19,"Phase 1/2 DSMB review noted no serious adverse events, noted December 19, 2024.",292.0,223.70484,71.8422,0.7545,0.7679,0.8142,0.017604238,0.076150758,-0.014900116,-0.029797363,19.56445,0.03106,5.53218,2852,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1,pos,"[  101 12278   122   120   123 18448 20660  3189  2382  1185  3021 16798
  1958   117  2382  1382  1627   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BPTH,BP1001-A (Prexigebersen-A),Obesity in Type 2 diabetes patientsÂ ,Preclinical,2024-12-19,"Preclinical data reported that BP1001-A reduced Grb2 protein expression in myoblast cells, noted December 19, 2024.",8.0,6.41727,145.0869,0.669,1.49,1.35,0.800747339,0.702075811,-0.014900116,-0.029797363,0.71743,0.03109,169.42143,2853,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 11689  1665 21472  7867  2233  2103  1115 21062 20150  1475   118
   138  3549   144 26281  1477  4592  2838  1107  1139 12809 19268  3652
   117  2382  1382  1627   117 17881  1527   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
MRK,Doravirine/Islatravir (DOR/ISL) - (MK-8591A-052),HIV-1 InfectionÂ ,Phase 3,2024-12-19,"Phase 3 met primary efficacy endpoint at Week 48, the study demonstrated to be non-inferior to BIC/FTC/TAF in double-blind trial. The superiority criteria were not met in trial MK-8591A-052. Primary s",0.0,251749.3394,24.5045,98.34,99.52,99.87,0.011927767,0.015438478,-0.014900116,-0.029797363,1.29616,0.12425,1205.26443,2854,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,1,pos,"[  101 12278   124  1899  2425 23891  1322  7587  1120  6237  3615   117
  1103  2025  7160  1106  1129  1664   118 15543  1106   139  9741   120
   143  9481   120   157 12303  1107  2702   118  7198  3443   119  1109
 21378  9173  1127  1136  1899  1107  3443   150  2428   118  4859  1580
  1475  1592   118  4991  1477   119  6933   188   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
REGN,REGN9933 - (ROXI-VTE-I),Venous thromboembolism (VTE)Â ,Phase 2,2024-12-19,"Phase 2 data reported that only 20 of 116 patients has VTE events, noted December 19, 2024.",105.0,76200.28533,26.1552,714.62,708.25,716.68,-0.008953794,0.002878504,-0.014900116,-0.029797363,1.67219,0.1465,769.65315,2855,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2103  1115  1178  1406  1104 13096  4420  1144
   159 12880  1958   117  2382  1382  1627   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ACET,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",Phase 1,2024-12-19,"Phase 1 dosing commenced, noted December 19, 2024.",83.0,78.15507,68.9661,0.8954,0.8603,0.96,-0.03998938,0.069662739,-0.014900116,-0.029797363,3.29356,0.0328,0.8176,2856,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 18463  1158  8042   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
REGN,REGN7508 (ROXI-VTE-II),0,Phase 2,2024-12-19,"Phase 2 data reported that 8 of 113 patients patients with VTE events, noted December 19, 2024.",105.0,76200.28533,26.1552,714.62,708.25,716.68,-0.008953794,0.002878504,-0.014900116,-0.029797363,1.67219,0.1465,769.65315,2857,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123  2233  2103  1115   129  1104 12206  4420  4420  1114
   159 12880  1958   117  2382  1382  1627   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GILD,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,2024-12-19,"Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.",0.0,113522.3569,24.8429,90.69,91.09,94.41,0.004400931,0.040199902,-0.014900116,-0.029797363,1.87869,0.06708,808.54107,2858,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  9889  3429  2233  7160  1126  4725  1106  2879  6328
  6168  1166  3009  2233  1111   187  1324 17656   118  1367   117  1114
  1185 13753   118 15816 12844  4233   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
XLO,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,2024-12-19,"Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.",51.0,41.23267,96.1348,0.8665,0.938,0.975,0.07928784,0.117975362,-0.014900116,-0.029797363,0.39872,0.05764,4.44289,2859,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  9889  3429  2233  7160  1126  4725  1106  2879  6328
  6168  1166  3009  2233  1111   187  1324 17656   118  1367   117  1114
  1185 13753   118 15816 12844  4233   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ARMP,AP-PA02 - (Tailwind),Non-cystic fibrosis bronchiectasis (NCFB)Â ,Phase 2,2024-12-19,"Phase 2 trial results demonstrated that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile, noted December 19, 2024.",36.0,71.64247,77.1137,1.95,1.98,2.02,0.015267472,0.035268139,-0.014900116,-0.029797363,0.00741,0.04578,0.04051,2860,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  3443  2686  7160  1115 16957 10997   118  8544  1568
  1477  2790   170  3840  9739  7234  1104   153  2217 18109 24507  1116
   170  1200  9610  4559  3202  1107  1103 13093   117  1114   170 11169
  3429  1105  1106  2879  6328  6168   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PTN,Bremelanotide - (BREAKOUT),Diabetic Kidney DiseaseÂ ,Phase 2a,2024-12-19,"Phase 2a showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial results for the majority of patients related t",46.0,80.23249,56.1889,0.05,0.049,0.05,-0.020202707,0.0,-0.014900116,-0.029797363,0.0,0.01107,0.07332,2861,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  1161  2799  1115  9304  5521  9945 12512  3269  7606
  1111  1565  1808   117  1107  4420  1114  1628  6902  1563  4267 22377
  2941 24928  7880 12736 23610   117  3657  1107  3112  1105 16250  2686
  1111  1103  2656  1104  4420  2272   189   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,2024-12-19,"Phase 1b demonstrated encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration, noted December 19, 2024.",5.0,1.83608,109.3468,2.51,1.74,2.09,-0.36639764,-0.183118687,-0.014900116,-0.029797363,4.56057,0.11164,10.47054,2862,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830  7160 11653  3429  6168  1107  2518  1884 13252
  1204  1114 13710  1106 13936  7867  2193  1106  1397 13753  6256   117
  2382  1382  1627   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
MRKR,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatmentÂ ,Phase 1,2024-12-19,"Phase 1 showed that 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR), noted December 19, 2024.",12.0,33.28462,110.7572,4.03,3.73,3.37,-0.077358142,-0.178853632,-0.014900116,-0.029797363,0.56135,0.04653,0.44466,2863,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   122  2799  1115  5603   110  1104  4420  3890  7649  2593
  5600   117  1114  3140   119   125   110 15107  2335  2593   113 15531
   114   117  2382  1382  1627   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PTCT,Vatiquinone - (MOVE-FA),Friedreich ataxiaÂ ,NDA Filing,2024-12-19,"NDA submitted to the FDA, noted December 19, 2024.",79.0,3489.91272,57.9092,45.46,45.25,45.84,-0.004630148,0.008324254,-0.014900116,-0.029797363,5.95992,0.24653,26.03825,2864,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101   151 11392  7402  1106  1103 18762   117  2382  1382  1627   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CLDX,Barzolvolimab (CDX-0159),Atopic dermatitis (AD)Â ,Phase 2,2024-12-19,"Phase 2 dosing commenced, noted December 19, 2024.",66.0,1683.81671,58.3092,24.82,25.38,25.65,0.022311683,0.032893792,-0.014900116,-0.029797363,11.60909,0.03326,21.50727,2865,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   123 18463  1158  8042   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMMX,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL AmyloidosisÂ ,Phase 1/2,2024-12-19,"Phase 1b/2 data reported that all four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and th",28.0,61.06695,97.7001,2.1,2.22,2.1,0.055569851,0.0,-0.014900116,-0.029797363,1.711,0.13798,1.00343,2866,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  1830   120   123  2233  2103  1115  1155  1300  4420
  5165  1114   151  3190  1658   118 17365  2999  2200  1147  3653 18004
  1439  1476  1552  1104 18463  1158   117  1104  1134   117  1160  1132
  1640  5667  1112  2335  6297  1468   113 15531   114   117  1105 24438
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OMER,Narsoplimab,Hematopoietic stem cell-associated TMA (HSCT-TMA)Â ,Phase 3,2024-12-19,"Trial met primary endpoint, noted December 19, 2024.",68.0,593.40554,122.3248,7.46,10.24,10.46,0.316746205,0.338003044,-0.014900116,-0.029797363,15.39012,0.01732,61.49483,2867,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,pos,"[  101 12819  1899  2425  1322  7587   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IONS,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Approved,2024-12-19,"Approved December 19, 2024.",159.0,5619.56444,41.0653,36.25,35.59,36.33,-0.018374682,0.002204465,-0.014900116,-0.029797363,6.61723,0.02142,67.42522,2868,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1627   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
RARE,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 3,2024-12-19,"Phase 3 dosing commenced, noted December 19, 2024.",96.0,4011.20925,37.1204,42.94,43.47,43.82,0.012267253,0.020286542,-0.014900116,-0.029797363,3.66192,0.09734,51.10398,2869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   124 18463  1158  8042   117  2382  1382  1627   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ALMS,A-005,Central nervous system (CNS) penetrant TYK2 inhibitorÂ ,Phase 1,2024-12-19,"Phase 1 data demonstrated the ability to cross the human blood-brain barrier to address inflammation within the central nervous system (CNS), noted December 19, 2024.",104.0,469.53523,0.0,8.43,8.63,8.41,0.023447733,-0.002375298,-0.014900116,-0.029797363,4.46529,0.06848,1.96591,2870,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122  2233  7160  1103  2912  1106  2771  1103  1769  1892
   118  3575  9391  1106  4134 24970  1439  1103  2129  5604  1449   113
   140 12412   114   117  2382  1382  1627   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVO,AM833 (CagriSema) - (REDEFINE),ObesityÂ ,Phase 3,2024-12-20,"Phase 3 trial met its primary endpoint, noted December 20, 2024.",0.0,2616837.804,42.8504,103.44,85.0,87.37,-0.196340478,-0.16883976,-0.022895882,-0.017001955,0.0,0.0,4569.80791,2871,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3443  1899  1157  2425  1322  7587   117  2382  1382
  1406   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GSK,Zejula (niraparib) and Jemperli (dostarlimab) - (FIRST-ENGOT-OV44),First line advanced ovarian cancerÂ ,Phase 3,2024-12-20,"Phase 3 trial met primary endpoint, noted December 20, 2024.",0.0,53862.85521,19.0938,13.22,13.2,13.425,-0.001514005,0.015387806,-0.022895882,-0.017001955,0.0,0.07985,184.79789,2872,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  1899  2425  1322  7587   117  2382  1382  1406
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
HUMA,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular TraumaÂ ,Approved,2024-12-20,"Approval announced December 20, 2024.",158.0,597.02177,102.7139,3.46,4.64,5.5,0.293445777,0.463479503,-0.022895882,-0.017001955,15.80334,0.00162,350.27901,2873,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101   138  8661 12316  1348  1717  1382  1406   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
GALT,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosisÂ ,Phase 2/3,2024-12-20,"Phase 2b/3 topline data reported a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo, noted December 20, 2024.",64.0,65.2723,112.2514,2.0,1.04,1.15,-0.653926467,-0.553385238,-0.022895882,-0.017001955,9.33356,0.09276,9.63889,2874,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1,neg,"[  101 12278   123  1830   120   124  1499  2568  2233  2103   170 11435
  1193  2418  7234   113   185   118  2860   133   121   119  4991   114
  1107  1718  1104 13936  4184 19911  1348 15661 18117  1107   123  1306
  1403   120  4023  1884 13252  1204  3402  1106  1282  4043   117  2382
  1382  1406   117 17881  1527   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
RYTM,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old)Â ",Approved,2024-12-20,"Approved December 20, 2024.",66.0,3448.97071,49.4786,55.48,56.12,55.59,0.01146966,0.001980734,-0.022895882,-0.017001955,10.3607,0.21222,85.30386,2875,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1406   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PFE,BRAFTOVI,BRAF V600E-Mutant Metastatic Colorectal CancerÂ ,Approved,2024-12-20,"Approved December 20, 2024.",0.0,149381.8573,22.7368,25.77,26.36,26.62,0.022636685,0.032451788,-0.022895882,-0.017001955,1.59492,2e-05,3066.72432,2876,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,pos,"[  101   138  8661 16011  1382  1406   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VRTX,ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor),Cystic fibrosis (CF) ages 6 years and olderÂ ,Approved,2024-12-20,"FDA approved on December 20, 2024.",256.0,102308.661,29.1688,396.64,397.27,408.76,0.001587082,0.030099118,-0.022895882,-0.017001955,1.42556,0.32439,2464.31785,2877,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762  4092  1113  1382  1406   117 17881  1527   119   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LXRX,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,CRL,2024-12-20,"CRL issued by FDA on December 20, 2024.",363.0,258.35854,107.0384,0.7236,0.7147,0.7734,-0.012375879,0.066557626,-0.022895882,-0.017001955,8.72218,0.07182,5.26482,2878,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1,pos,"[  101 15531  2162  3010  1118 18762  1113  1382  1406   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
LLY,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA)Â ,Approved,2024-12-20,"FDA Approved on December 20, 2024.",946.0,691315.7061,33.4427,757.54,767.76,783.17,0.013400843,0.033273445,-0.022895882,-0.017001955,0.64822,0.24127,7633.29487,2879,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762   138  8661 16011  1113  1382  1406   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
NBIX,CRENESSITY (Crinecerfont) - (oral solution formulation),Classic congenital adrenal hyperplasia (CAH)Â ,Approved,2024-12-20,"FDA Approved on December 20, 2024.",99.0,13710.85669,40.1246,134.96,135.42,139.44,0.003402622,0.032655963,-0.022895882,-0.017001955,3.86086,0.03353,306.80728,2880,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101 18762   138  8661 16011  1113  1382  1406   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
BMY,Sotyktu (deucravacitinib) - (POETYK PsA-1),Psoriatic ArthritisÂ ,Phase 3,2024-12-23,"Phase 3 trial met its primary endpoint, noted December 23, 2024.",0.0,116782.4129,32.1034,57.33,57.58,56.06,0.004351238,-0.022401501,-0.007639457,0.015345005,1.26225,0.00318,543.0899,2881,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3443  1899  1157  2425  1322  7587   117  2382  1382
  1695   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
BMY,Sotyktu (deucravacitinib) - (POETYK PsA-2),Psoriatic ArthritisÂ ,Phase 3,2024-12-23,"Phase 3 trial met its primary endpoint, noted December 23, 2024.",0.0,116782.4129,32.1034,57.33,57.58,56.06,0.004351238,-0.022401501,-0.007639457,0.015345005,1.26225,0.00318,543.0899,2882,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,neg,"[  101 12278   124  3443  1899  1157  2425  1322  7587   117  2382  1382
  1695   117 17881  1527   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
WVE,NHBE GalNAc siRNA (WVE-007) - (INLIGHT),ObesityÂ ,IND-Enabling,2024-12-23,"CTA submitted, noted December 23, 2024.",159.0,2001.05938,121.0172,13.51,13.12,12.41,-0.029292368,-0.084927553,-0.007639457,0.015345005,4.54097,0.07234,11.34166,2883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 16899  1592  7402   117  2382  1382  1695   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
IMCR,IMC-P115C (PRAME-A02 HLE),Solid tumorsÂ ,Phase 1,2024-12-23,"Phase 1 dosing commenced, noted December 23, 2024.",48.0,1407.92215,38.8739,28.325,28.14,29.03,-0.006552755,0.024584971,-0.007639457,0.015345005,14.36528,0.14097,33.185,2884,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122 18463  1158  8042   117  2382  1382  1695   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VYNE,VYN202,Moderate-to-severe plaque psoriasisÂ ,Phase 1a,2024-12-23,"Phase 1a topline results demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitors, no",25.0,37.91118,71.3394,2.5,2.57,3.19,0.027615167,0.243730185,-0.007639457,0.015345005,0.43565,0.13324,0.64029,2885,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1,pos,"[  101 12278   122  1161  1499  2568  2686  7160   170 11169  3429  1105
  1106  2879  6328  6168  1114  1185  3850   118  2272 16798  1958  8528
  2628  1114  2206  3964   117  1750 14930   139 11943 27558  1116   117
  1185   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ARWR,ARO-INHBE,ObesityÂ ,Phase 1/2,2024-12-23,"Phase 1/2a trial initiated, noted December 23, 2024.",138.0,2457.58023,62.4155,19.45,19.75,18.61,0.015306421,-0.044147999,-0.007639457,0.015345005,8.09297,0.10215,27.6356,2886,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   122   120   123  1161  3443  7087   117  2382  1382  1695
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
GKOS,Epioxa (Epi-on),Progressive keratoconusÂ ,NDA Filing,2024-12-23,"NDA filing submitted to the FDA, noted December 23, 2024.",57.0,8176.03489,34.5289,150.88,148.36,149.51,-0.016843066,-0.009121539,-0.007639457,0.015345005,4.83348,0.10755,66.29229,2887,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   151 11392 16504  7402  1106  1103 18762   117  2382  1382  1695
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
XBIT,Natrunix,Rheumatoid ArthritisÂ ,Phase 2,2024-12-23,"Phase 2 trial did not meet its primary endpoint, noted December 23, 2024.",30.0,137.17567,91.3788,6.38,4.5,4.09,-0.349090701,-0.444623127,-0.007639457,0.015345005,2.63668,0.05491,2.13016,2888,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   123  3443  1225  1136  2283  1157  2425  1322  7587   117
  2382  1382  1695   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ASMB,ABI-4334,Hepatitis BÂ ,Phase 1b,2024-12-26,"Phase 1b initial data reported that a mean decline in HBV DNA of 2.9 log10 IU/mL was observed, noted December 26, 2024.",7.0,97.75968,69.2871,14.72,15.38,17.15,0.043860851,0.15279106,0.006872879,0.004904375,0.20952,0.06017,0.6054,2889,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101 12278   122  1830  3288  2233  2103  1115   170  1928  6246  1107
   145  2064  2559  5394  1104   123   119   130  9366 10424   146  2591
   120   182  2162  1108  4379   117  2382  1382  1744   117 17881  1527
   119   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
ONC,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinomaÂ ,Approved,2024-12-27,"FDA Approved on December 27, 2024.",110.0,19365.50563,40.7697,184.68,181.89,180.82,-0.015222489,-0.021122536,0.030242252,0.002593755,1.29179,0.10412,30.87892,2890,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101 18762   138  8661 16011  1113  1382  1765   117 17881  1527   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
PRFX,PRF-110,BunionectomyÂ ,Phase 3,2024-12-27,"Phase 3 trial did not meet the primary 72-hour endpoint due to unresolved data from the final 24-hour period. However, the drug showed statistically significant pain reduction in the first 48 hours, n",1.0,3.06202,334.0346,4.9,3.5,3.32,-0.336472237,-0.389270422,0.030242252,0.002593755,5.42451,9e-05,3.32333,2891,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,-1,neg,"[  101 12278   124  3443  1225  1136  2283  1103  2425  5117   118  2396
  1322  7587  1496  1106  8362  4894  4063  5790  2233  1121  1103  1509
  1572   118  2396  1669   119  1438   117  1103  3850  2799 11435  1193
  2418  2489  7234  1107  1103  1148  3615  2005   117   183   102     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AXSM,AXS-05 (ADVANCE-2),Alzheimer's disease agitationÂ ,Phase 3,2024-12-30,"Phase 3 trial did not demonstrate statistical significance on primary endpoint, noted December 30, 2024.",49.0,4108.64024,35.6041,86.7,84.78,85.13,-0.022394218,-0.018274384,0.014222168,-0.009370302,13.44554,0.03844,299.57395,2892,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  3443  1225  1136 10541 11435  7467  1113  2425  1322
  7587   117  2382  1382  1476   117 17881  1527   119   102     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NRXP,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,NDA Filing,2024-12-30,"NDA initial section filed, noted December 30, 2024.",19.0,18.45296,78.0213,1.51,1.53,3.51,0.013158085,0.843506387,0.014222168,-0.009370302,4.97344,0.0484,1.90266,2893,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101   151 11392  3288  2237  5770   117  2382  1382  1476   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
CORT,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome)Â ,NDA Filing,2024-12-30,"NDA filing submitted December 30, 2024.",105.0,5327.81572,41.6409,52.47,50.85,51.66,-0.031361455,-0.01555779,0.014222168,-0.009370302,14.99953,0.19532,30.32277,2894,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   151 11392 16504  7402  1382  1476   117 17881  1527   119   102
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NVS,Zolgensma Intravenous OAV101 (AVXS-101) - (STEER),Spinal muscular atrophy (SMA) Type 2Â ,Phase 3,2024-12-30,"Phase 3 trial met primary endpoint, noted December 30, 2024.",0.0,2146.97454,47.3646,6.81,6.9,7.42,0.013129291,0.085786937,0.014222168,-0.009370302,0.0,3e-05,0.37732,2895,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   124  3443  1899  2425  1322  7587   117  2382  1382  1476
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PGEN,PAPZIMEOS (zopapogene imadenovec-drba),Recurrent Respiratory Papillomatosis (RRP)Â ,BLA Filing,2024-12-30,"BLA rolling submission completed, noted December 30, 2024. The submission is in the initial 60-day review period, during which time the FDA will decide whether to accept the BLA for further review and",297.0,273.27615,78.8783,0.7263,0.9331,1.27,0.250549224,0.558809027,0.014222168,-0.009370302,6.1053,0.19399,5.24143,2896,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101   139 10783  6362 13455  2063   117  2382  1382  1476   117 17881
  1527   119  1109 13455  1110  1107  1103  3288  2539   118  1285  3189
  1669   117  1219  1134  1159  1103 18762  1209  4958  2480  1106  4392
  1103   139 10783  1111  1748  3189  1105   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
JAZZ,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline gliomaÂ ,NDA Filing,2024-12-30,"NDA submitted to FDA, noted December 30, 2024.",60.0,7434.10118,28.2961,124.6,122.97,121.82,-0.013168183,-0.022564061,0.014222168,-0.009370302,6.94663,0.08564,57.00238,2897,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,neg,"[  101   151 11392  7402  1106 18762   117  2382  1382  1476   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
AXSM,Dextromethorphan-bupropion (AXS-05) - (ACCORD-2),Agitation in patients with Alzheimerâ€™s disease (AD)Â ,Phase 3,2024-12-30,"Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo, noted December 30, 2024.",49.0,4108.64024,35.6041,86.7,84.78,85.13,-0.022394218,-0.018274384,0.014222168,-0.009370302,13.44554,0.03844,299.57395,2898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   124  3443  1107 24278   112   188  3653 26134  5515  1116
  2425  1322  7587  3402  1106  1282  4043   117  2382  1382  1476   117
 17881  1527   119   102     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
NMRA,Navacaprant (NMRA-140) - (KOASTAL-1),Major depressive disorderÂ ,Phase 3,2025-01-02,"Phase 3 KOASTAL-1 data reported that the trial did not meet its primary endpoint with statistical significance, noted January 2, 2025.",161.0,318.2753,245.3232,10.6,1.97,2.37,-1.682820458,-1.497964046,-0.025759083,-0.024676363,6.70534,0.15997,88.41075,2899,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1,neg,"[  101 12278   124   148 23579  9272 12507   118   122  2233  2103  1115
  1103  3443  1225  1136  2283  1157  2425  1322  7587  1114 11435  7467
   117  2382  1356   123   117 17881  1571   119   102     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
ANIP,Prucalopride Tablets - (Motegrity generic),(RLD) Motegrity BiosimilarÂ ,Approved,2025-01-02,"FDA ANDA approved on January 2, 2025.",21.0,1082.45353,39.0241,55.28,55.44,54.16,0.002890175,-0.020468551,-0.025759083,-0.024676363,12.03895,0.07217,8.66982,2900,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,neg,"[  101 18762 16716  1592  4092  1113  1356   123   117 17881  1571   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
KZIA,Paxalisib (GDC-0084) - (GBM AGILE),Glioblastoma multiformeÂ ,Phase 2/3,2025-01-02,"FDA feedback reported that data on OS would generally not be appropriate for accelerated approval, noted January 2, 2025.",1.0,7.59941,262.0674,8.85,8.725,8.45,-0.014224991,-0.046251018,-0.025759083,-0.024676363,0.38538,0.00623,0.42125,2901,1,0,0,0,0,0,0,1,0,0,0,0,2,0,0,1,neg,"[  101 18762 13032  2103  1115  2233  1113 11570  1156  2412  1136  1129
  5806  1111 16112  5684   117  2382  1356   123   117 17881  1571   119
   102     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
COCP,CC-42344,Influenza AÂ ,Phase 2a,2025-01-02,"Phase 2a data reported no SAEs and no drug-related discontinuations by study participants, noted January 2, 2025.",10.0,23.60319,108.5562,2.02,2.32,2.407,0.138469674,0.175283647,-0.025759083,-0.024676363,0.17233,4e-05,0.34266,2902,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  1161  2233  2103  1185 13411 27485  1105  1185  3850
   118  2272 19959 26728 24176  1118  2025  6635   117  2382  1356   123
   117 17881  1571   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
PHIO,RXI-231,HyperpigmentationÂ ,Preclinical,2025-01-02,"Preclinical data reported that RXI-231 significantly reduced tyrosinase mRNA expression, and correspondingly reduced in melanin content in both normal human melanocytes and the 3D human epidermal cult",5.0,3.29158,115.1354,1.8,1.9,1.69,0.054067221,-0.063058136,-0.025759083,-0.024676363,2.29507,0.14382,0.52857,2903,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 11689  1665 21472  7867  2233  2103  1115   155  3190  2240   118
 22154  5409  3549   189 12577  2155 16924  1162   182 15654  2838   117
  1105  7671  1193  3549  1107  1143 21690  1179  3438  1107  1241  2999
  1769  1143  4371 26431  1105  1103  7860  1769   174 25786  1200  7435
  9528   102     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
CAPR,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD)Â ,BLA Filing,2025-01-02,"BLA submission to the FDA completed, noted January 2, 2024.",45.0,680.22982,128.885,13.8,14.96,13.86,0.08071138,0.004338402,-0.025759083,-0.024676363,12.29795,0.01148,18.7839,2904,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,pos,"[  101   139 10783 13455  1106  1103 18762  2063   117  2382  1356   123
   117 17881  1527   119   102     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
KROS,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone lossÂ ,Phase 2,2025-01-05,"Phase 2 trial voluntarily halted all dosing due to new observations of pericardial effusion adverse events, noted January 15, 2025.",40.0,652.16929,191.7289,16.1,16.1,14.56,0.0,-0.100541229,0.002166613,0.032667188,7.46812,0.03251,0.0,2905,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101 12278   123  3443 19446 12919  1155 18463  1158  1496  1106  1207
  9959  1104  1679  4578 16936  1348   174  3101 17268 16798  1958   117
  2382  1356  1405   117 17881  1571   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
OCS,OCS-05 - (ACUITY),Acute optic neuritisÂ ,Phase 2,2025-01-06,"Phase 2 trial met primary safety endpoint, noted January 6, 2025.",43.0,740.3289,42.3619,17.56,17.65,22.38,0.005112195,0.242544115,-0.004965468,0.03613922,0.05245,0.00211,2.98938,2906,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1,pos,"[  101 12278   123  3443  1899  2425  3429  1322  7587   117  2382  1356
   127   117 17881  1571   119   102     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
IMAB,Uliledlimab (TJ004309),Solid tumorsÂ ,Phase 1,2025-01-06,"Development of uliledlimab is being paused, noted January 6, 2025.",81.0,87.94945,75.5089,0.9399,1.08,1.07,0.138942833,0.129640441,-0.004965468,0.03613922,0.84191,0.10754,3.39335,2907,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,pos,"[  101  3273  1104 23449 11908 24891  6639  1110  1217  5162   117  2382
  1356   127   117 17881  1571   119   102     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",1
VYNE,Repibresib Gel (VYN201),VitiligoÂ ,Phase 2b,2025-01-06,"Phase 2b enrollment completed, noted January 6, 2024.",25.0,59.00573,70.7955,3.46,4.0,3.02,0.145025772,-0.136011758,-0.004965468,0.03613922,0.42285,0.10982,1.13926,2908,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1,neg,"[  101 12278   123  1830 10803  2063   117  2382  1356   127   117 17881
  1527   119   102     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
TPST,Amezalpat (TPST-1120) and OPDIVO (nivolumab),"Hepatocellular Carcinoma (HCC), Solid tumorsÂ ",Phase 1/2,2025-01-06,"Orphan Drug Designation granted by the FDA, noted January 6, 2024.",4.0,41.42505,98.0907,12.3747,12.3396,11.9925,-0.002840463,-0.031372611,-0.004965468,0.03613922,7.39012,0.22592,4.42293,2909,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,neg,"[  101  2926 20695  1179 13982  4800  1891  3609  1118  1103 18762   117
  2382  1356   127   117 17881  1527   119   102     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0     0     0     0     0
     0     0     0     0     0     0     0     0]","[0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]","[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]",0
